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17 Abstract / Zusammenfassung 
1 Abstract / Zusammen-
fassung 
The exploration of the structural scope 
of the octahedral coordination mode and 
investigations of defined structural isomers 
regarding their physico-chemical properties 
are of valuable interest for applications in 
the field of catalysis, materials sciences, and 
life sciences. The MEGGERS group establi-
shed a variety of different transition metals 
as structural templates to gain access to 
highly potent and selective kinase inhibitors. 
During this effort, the effectiveness of metal 
complexes as kinase inhibitors with potential 
anticancer properties has repeatedly been 
proven in vitro as well as in vivo. The ambi-
tion to establish metals as structural tem-
plates led from initial half sandwich com-
plexes to highly sophisticated octahedral 
complexes. 
In the current thesis, the challenge to 
selectively synthesise a desired enantiomer 
is presented highlighting the application of 
symmetric polydentate ligands and chiral 
polydentate ligands. 
As a first example, regarding the chem-
ical and biological properties, an N-methyl-
1,4,7-trithiacyclodecan-9-amine based ru-
thenium(II) complex, in context of S6 kinase 
1 (S6K1) inhibition, is presented. Aberrant 
activation of S6K1 is found in many diseas-
es, including diabetes, aging, and cancer. 
The presented ATP competitive organo-
metallic kinase inhibitors were inspired by 
the pan-kinase inhibitor staurosporine, and 
specifically inhibit S6K1, and verify the 
strategy successfully applied previously to 
target other kinases. Furthermore, the ob-
tained biochemical data demonstrate that 
the compounds inhibit S6K1 with an IC50 
value in the low nanomolar range at 100 μM 
ATP. Moreover, the crystal structures of 
S6K1 bound to staurosporine, and two ru-
thenium(II) based inhibitors reveal that the 
compounds bind in the ATP binding site and 
exhibit S6K1-specific contacts, resulting in 
changes to the p-loop, C helix, and D 
helix compared to the staurosporine bound 
structure. In vitro assays reveal inhibited 
S6K phosphorylation in yeast cells. These 
cumulated biological studies demonstrate 
that potent, selective, and cell permeable 
metal based inhibitors can provide a scaffold 
for the future development of compounds 
with possible therapeutic applications. 
However, the so far presented com-
plexes are racemic mixtures. Thus, to apply 
these compounds for the therapeutic use 
the pharmacologic and toxicological charac-
terisation of each present structural isomer 
is obligatory. Therefore, the asymmetric syn-
thesis of desired structural isomers of the 
metal based kinase inhibitors is highly fa-
vourable. 
Thus, controlling the metal centered 
relative stereochemistry represents the key 
to achieve this task. The application of a 
proline based chiral tridentate ligand to de-
cisively influence the coordination sphere of 
an octahedral rhodium(III) complex is de-
scribed as possible solution to face this is-
sue. The mirror-like relationship of synthe-
sised enantiomers and differences between 
diastereomers were investigated. Further-
more, the application of the established pyr-
idocarbazole pharmacophore ligand as part 
                                               

 The term „pharmacophore“ in this thesis is used as a 
structural unit coordinated to the metal core and 
mainly mediating the interactions to the biological 
target. 
The IUPAC definition (1998) of “pharmacophore” is 
given as:  
• A pharmacophore is the ensemble of steric and 
electronic features that is necessary to ensure the 
optimal supramolecular interactions with a specific 
biological target structure and to trigger (or to block) 
its biological response. 
• A pharmacophore does not represent a real molecule 
or a real association of functional groups, but a purely 
abstract concept that accounts for the common mo-
lecular interaction capacities of a group of compounds 
towards their target structure. 
• A pharmacophore can be considered as the largest 
common denominator shared by a set of active mole-
cules. This definition discards a misuse often found in 
the medicinal chemistry literature which consists of 
naming as pharmacophores simple chemical function-
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of the organometallic complexes to obtain 
kinase inhibitors is demonstrated. Moreover, 
the importance of the relative stereochemis-
try at metal in chiral environments like bio-
molecules is highlighted by both, protein 
kinase profiling and competitive inhibition 
studies. The cumulated results confirm that 
the proline based enantiopure rhodium (III) 
complexes differ entirely in their selectivity 
and specificity despite their unmistakably 
mutual origin. 
The successful work using proline as a 
chiral building block inspired to implement 
other chiral amino acids into the ligand de-
sign. For this aim, a versatile set of amino 
acids were elaborated as starting points for 
the ligand synthesis. As highly functional-
ised building blocks, they offer the possibility 
to orient a particular functional group into a 
defined site of the enzyme pocket, overall 
predefined by the chirality-at-metal. Howev-
er, the ambitious attempts were limited by 
the synthetic issues accompanying the im-
plementation of primary amino acids into the 
ligand design due to steric effects influenc-
ing the yields. Nevertheless, the biological 
data evaluating the obtained complexes 
offered valuable hints for the future ligand 
scaffolds. 
                                                                       
alities such as guanidines, sulfonamides or dihy-
droimidazoles (formerly imidazolines), or typical 
structural skeletons such as flavones, phenothiazines, 
prostaglandins or steroids. 
• A pharmacophore is defined by pharmacophoric 
descriptors, including H-bonding, hydrophobic and 
electrostatic interaction sites, defined by atoms, ring 
centers and virtual points 
 
Die Erkundung des dreidimensionalen 
Raumes anhand der Strukturen, welche 
durch die oktaedrische Koordinationssphäre 
ermöglicht werden, führt zu Isomeren, deren 
physiko-chemische Eigenschaften für die 
Forschungsfelder der Katalyse, Material-
wissenschaften und Lebenswissenschaften 
von besonderem Interesse sind. Der Ar-
beitskreis MEGGERS hat hierzu eine Vielzahl 
von unterschiedlichen Übergangsmetallen 
als Strukturtemplate etabliert, um Zugang zu 
hochpotenten, selektiven sowie strukturell 
hochdiversifizierten Kinaseinhibitoren zu 
erhalten. Im Zuge dieser Anstrengungen, 
wurden Kinaseinhibitoren entwickelt, deren 
anitcancerogene Wirkung mehrfach, sowohl 
in vitro als auch in vivo, belegt werden konn-
ten. Hierbei führten die Ambitionen, Metalle 
als Strukturtemplate zu verwenden, über 
anfängliche Halbsandwich-Komplexe zu 
hochdiversifizierten oktaedrischen Komple-
xen. 
In der vorliegenden Arbeit sollen insbe-
sondere die Herausforderungen und die 
Umsetzung der selektiven Synthese von 
angestrebten Enantiomeren anhand von 
mehrzähnigen symmetrischen Liganden 
sowie anhand von mehrzähnigen chiralen 
Liganden verdeutlicht werden. 
Als erstes Beispiel dient hierzu die Be-
trachtung der chemischen und biologischen 
Eigenschaften eines auf N-methyl-1,4,7-tri-
thiacyclodecan-9-amin basierenden Ruthe-
nium(II) Komplexes, im Kontext der S6 
Kinase 1 (S6K1) Inhibierung. Eine gestörte 
Aktivierung von S6K1 wird mit zahlreichen 
Erkrankungen wie z.B.: Diabetes, Krebs und 
Alterungsprozessen in Verbindung gebracht. 
Die vorgestellten ATP kompetitiven metall-
basierten Inhibitoren sind von dem Pan-
Kinaseinhibitor Staurosporin abgeleitet, 
doch inhibieren spezifisch S6K1. Darüber 
hinaus verifizieren sie das Konzept, welches 
bereits erfolgreich bei der Inhibierung ande-
rer Kinasen Anwendung gefunden hat. Die 
erhaltenen biochemischen Daten zeigen, 
dass die Ruthenium(II) basierten Verbin-
dungen S6K1 mit einem IC50 Wert im 
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nanomolaren Bereich inhibieren bei einer 
ATP Konzentration von 100 µM ATP. Zu-
sätzlich konnte anhand der Kristallstrukturen 
von Staurosporin in S6K1 und von zwei Me-
tallkomplexen in S6K1, die Bildung von 
S6K1 spezifischen Kontakten, welche im 
Falle der metallbasierten Inhibitoren im Ver-
gleich zu Staurosporine zu Änderungen in 
der p-Schleife, der C Helix und der D 
Helix führen, gezeigt werden. In vitro Unter-
suchungen zeigten eine inhibierte S6K 
Phosphorylierung in Hefe Zellen. Die Ge-
samtheit der biologischen Studien zeigen, 
dass potente, selektive sowie zellpermeable 
metallbasierte Inhibitoren eine Grundstruktur 
für die Entwicklung von potentiellen Chemo-
therapeutika bereit halten. 
Zu beachten ist, dass die hierbei ge-
zeigten Komplexe in racemischer Form vor-
liegen. Um diese Verbindungen in der The-
rapie einsetzen zu können, müssen somit 
auch die pharmakologischen und die toxiko-
logischen Eigenschaften beider Isomere 
charakterisiert und miteinander verglichen 
werden. In diesem Zusammenhang ist die 
asymmetrische Darstellung eines ge-
wünschten Isomers eines metallbasierten 
Inhibitors sehr erstrebenswert. 
Daher stellt die Kontrolle der relativen 
und absoluten metallzentrierten Stereoche-
mie eine Schlüsselaufgabe zur Realisierung 
dieses Zieles dar. Die Anwendung von pro-
linbasierten dreizähnigen Liganden zur ent-
schiedenen Beeinflussung der Koordinati-
onsphäre von Rhodium(III) Komplexen wird 
daraufhin als mögliche Lösung dieser Her-
ausforderung diskutiert. Die spiegelbildliche 
Beziehung der synthetisierten Enantiomere 
und die Unterschiede zu den entsprechen-
den Diastereomeren werden durchleuchtet. 
Zudem wird die Anwendung des etablierten 
Pyridocarbazole Pharmakophorliganden als 
                                               

 Der Begriff “Pharmakophor“ wird im Rahmen die-
ser Dissertation für eine Struktureinheit verwendet, 
welches als metal-koordinierter Ligand hauptsächlich 
für die Wechselwirkungen mit dem biologischen 
Zielmolekül verantwortlich ist. 
 
Teil des metallbasierten Komplexes zur 
Darstellung von Kinaseinhibitoren demon-
striert. Darüber hinaus, wird die enorme Be-
deutung der relativen Stereochemie am Me-
tallzentrum bei der Wechselwirkung mit 
chiralen Umgebungen wie Biomoleküle 
durch Kinase Profiling Untersuchungen und 
kompetitiven Inhibitionsstudien verdeutlicht. 
Die gesammelten Daten bestätigen, dass 
die unterschiedlichen Rhodium(III) Isomere 
sich gänzlich in Ihrer Selektivität und Spezi-
fität unterscheiden, trotz eines eindeutig 
gemeinsamen Ursprungs. 
Die erfolgreichen Arbeiten mit der Ver-
wendung von Prolin als Gerüstbaustein in-
spirierte folgerichtig zu dem Einsatz weiterer 
Aminosäuren im Ligandendesign. Hierzu 
wurde eine vielseitige Auswahl an Amino-
säuren als Ausgangspunkt für die Liganden-
synthese erarbeitet. Die Arbeiten mit primä-
ren Aminosäuren zeigten deren Potential 
zur Eröffnung von hochdiversifizierten okta-
edrischen Komplexen. Als hochfunktionali-
sierte Gerüstbausteine ermöglichen sie die 
Positionierung von funktionellen Gruppen in 
bestimmte Raumrichtungen einer Enzymta-
sche, welche durch die Chiralität-am-Metall 
vorgegeben wird. Jedoch wird dieses ambi-
tionierte Ziel durch synthetische Schwierig-
keiten bei der Koordination von aminosäu-
renbasierten Liganden, begründet in 
sterischen Effekten und den reduzierten 
Ausbeuten, limitiert. Nichtsdestotrotz, eröff-
nen die erhaltenen biologischen Daten wich-
tige Erkenntnisse für das zukünftige Ligan-
dendesign.  
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21 Introduction 
2 Introduction 
2.1 Kinases 
 
More than 518 different protein kinas-
es have been identified in the human prote-
ome and represent approximately 1.7% of 
the human genome.[1–3] Among these 518 
kinases, 478 are classified as typical kinas-
es, and 40 as atypical, based on the fact 
that the latter still have biochemical kinase 
activity but lack sequence similarity to the 
typical kinases.[1,4,5] The typical kinases are 
further subdivided into two categories de-
pending on the phosphorylated amino acid 
residue: either serine/threonine (388 kinas-
es) or tyrosine (90 kinases).[6,7] 
2.1.1 Classification and Role in Cellular 
Signal Transduction 
 
The eukaryotic protein kinases have 
evolved in a divergent manner than prokar-
yotic protein kinases, that are indeed abun-
dant, but poorly understood.[8,9] However, in 
eukaryotic cells kinases play an inevitable 
role in the majority of cellular signaling 
pathways by regulating the flow of infor-
mation via protein phosphorylation.[10,11] The 
phosphorylation of protein substrates results 
in versatile effects, covering increased or 
decreased enzyme activity of the effector 
proteins, the creation of recognition sites for 
protein assembly or conformational changes 
inducing structure related effects, like con-
traction and relaxation on macro-molecular 
level.[12] 
An overview of the kinase classifica-
tion is provided in Chapter 6.1. Moreover, a 
detailed discussion of kinase classification, 
structural difference, and role in physiologi-
cal processes is out of the scope of this the-
sis. Therefore, further publications are rec-
ommended giving detailed insights in each 
kinase family, see Chapter 6.1. 
 
Figure 1: Dendrogram of the human kinome. AGC: 
named after protein kinase A, G, and C. CAMK: acro-
nym for Ca
2+
/Calmodulin-dependent protein kinases. 
CMGC: acronym based on initials of key members 
CDK, MAPK, GSK, and CDK. RGC: receptor guanyl-
ate cyclase group. TK: tyrosine kinases. TKL: tyrosine 
kinases like group. STE: homologues of yeast Ster-
ile 7, Sterile 11, and Sterile 20 kinases group. CK1: 
casein kinase 1 group.
[1]
 
 
 
Figure 2: Crystal structure of ATP bound to PKA (pdb: 
1ATP). The N-lobe is coloured in blue and the C-lobe 
in yellow. The ATP molecule is showed as red 
spheres and the hinge region is coloured in magenta. 
The manganese ions and the peptide inhibitor IP20 
were omitted for clarity.
[13]
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2.1.2 Structural Properties 
 
Protein kinases themselves are regu-
lated by phosphorylation,[14] among other 
mechanisms, leading either to the active 
conformation or the inactive conform-
ation.[12,15] The active conformation was first 
investigated on the protein kinase A (PKA) 
crystal structure;[16] whereas, the inactive 
conformation was first investigated on the 
crystal structure of cyclin-dependent protein 
kinase 2 (CDK2).[17] Moreover, PKA as one 
of the first reported kinases ever in 1968 by 
WALSH et al.,[18] beside the phosphorylase 
kinase by KREBS and FISCHER in the late 
1950´s,[19] is one of the most characterised 
ones in literature.[16,20–22] Thus, numerous 
structural investigations discussing PKA, an 
AGC kinase,[23] have been performed show-
ing that this is an ideal representative for the 
elucidation of the structural properties of 
protein kinases and their catalytic mecha-
nism. The first crystal structure of PKA was 
obtained with manganese ions instead of 
magnesium and the peptide inhibitor 
IP20.[13] Although, PKA serves as the model 
system, the crucial residues are highly con-
served throughout the kinome.[24,25] 
2.1.2.1 The N-Lobe 
 
Two structurally and functionally dis-
tinct lobes contribute in a unique way to the 
catalytic function and the regulation of a 
kinase, see Figure 2.[23,26] The smaller one, 
the N-lobe, is dominated by five -sheets, 
incorporating two -helical subdomain, 
B-helix and the C-helix, see Figure 3. The 
5-sheet is structurally connected via the 
hinge region to the C-lobe. In contrast, the 
C-helix forms functional contacts to the 
C-lobe. Thus, the 5-sheet and the C-helix, 
are the only two structural elements, which 
interact between the two main 
segments.[27,28] The 1, 2, and 3 strands 
possess two highly conserved sequence 
motifs. The first motif (GxGxxG) is called the 
glycine rich loop (Gly-loop), between 1 and 
2 and the second is the AxK motif in the 3 
strand. 
The Gly-loop is the most flexible part 
of the N-lobe. Its main function is to fold 
over and enclose the nucleotide for the 
proper positioning the -phosphate of aden-
osine triphosphate (ATP) for catalysis.[29] 
Further, it is noteworthy to distinct Gly-loop 
from the P-loop (Walker-A motif, 
(GxxxxGKT/S).[30] Although, both loops an-
chor the phosphonucleotides, their interac-
tion mechanism is different. Whereas, the 
P-loop does not form any contacts to the 
purine moiety, the Gly-rich loop connects 
the 1 and 2-strands enclosing the adenine 
ring, see Figure 3. Highly conserved resi-
dues of the P-loop and the Gly-loop are a 
Ser/Thr binding phosphate and a Val resi-
due (Val57 in PKA) forming hydrophobic 
contacts to the purine base, respectively. 
 
Figure 3: Crystal structure of ATP bound to PKA (pdb: 
1ATP). The -sheet core and the -helical domains of 
the N-lobe are highlighted. The distal N-terminal 
A-helix is shown in blue, further turning into the 1 
sheet (red). The 2-sheet is shown in green followed 
by the 3 sheet in yellow. The Gly-loop is depicted in 
orange. The B-helix is coloured in cyan directly driv-
ing into the C-helix (magenta). The 4-sheet is col-
oured in sienna and the 5 in brown followed by the 
hinge region in wheat. The ATP molecule is coloured 
in white and is covered by the 1, 2 sheet and the 
Gly-loop. The C-lobe, manganese ions, and the pep-
tide inhibitor IP20 were omitted for clarity.
[13]
 
  
23 Introduction 
 
Figure 4:. Crystal structure of ATP bound to PKA 
(pdb: 1ATP). The hinge region connecting the N-lobe 
and the C-lobe is coloured in wheat. The D (ivory), 
E (green), F (blue), G (olive), H (magenta) and 
I (cyan) form the helical core of the C-lobe. The cata-
lytic loop is shown yellow; the phosphate binding site 
containing the DFG-motif is highlighted in red. Moreo-
ver, the activation segment is presented in orange, 
and the 6-9 sheets in white. The ATP molecule is 
shown as white sticks. The C-terminal end is shown in 
light blue. The N-lobe, manganese ions, and the pep-
tide inhibitor were omitted for clarity.
[13]
 
The second important AxK motif, lo-
cated in the 3 strand, fixes the phosphates 
of ATP towards the C-helix (Lys72 in PKA). 
Moreover, the 3 strand further descends 
into the B-helix and then into the C-helix. 
The latter is very dynamic as well as flexible 
and acts as a crucial regulatory element in 
the protein kinase. Although, belonging to 
the N-lobe due to the primary sequence, it 
occupies an important structural position 
functionally connecting many different parts 
of the kinase. Thus, the C-helix serves as 
a ‘‘signal integration motif’’.[22] Whereas, its 
C-terminus is connected via 4 to 5 and 
subsequently to the C-lobe, its N-terminus 
points towards the activation loop for effi-
cient catalysis. The right positioning of the 
C-helix is one of the crucial steps for the 
kinase catalysis defining the open and 
closed conformations.[31] The C-helix con-
tains a highly conserved glutamate residue, 
Glu91 in PKA, which functionally interacts 
with Lys72 in the 3-strand forming a salt 
bridge. The formation of this interaction is an 
indispensable characteristic of the activated 
state of a kinase. Furthermore, this interac-
tion, when the C-helix is bound to the 
-sheet core, induces a conformational 
change moving the entire rigid N-lobe and 
subsequently the Gly-loop, which forms in-
teractions to the triphosphate of ATP.[20] 
2.1.2.2 The C-lobe 
 
The large C-lobe consists mainly of 
helices, see Figure 4. The C-lobe helical 
subdomains are very stable and harbour the 
substrate binding site. Most of the helices 
(D, E, F, and H) backbone amides are ori-
ented away from solvent,[32,33] despite the 
G-helix, which is solvent exposed. Four 
short -strands, 6 to 9, contain most of 
the amino acid residues responsible for the 
catalytic transfer of the phosphate from 
ATP to the protein substrate. Moreover, the 
anchoring of these loops to the helical core 
is mainly mediated by hydrophobic interac-
tions. The catalytic loop is located between 
6 and 7, whereas 8 and 9 flank con-
served Asp-Phe-Gly (DFG) motif. The as-
partate of the DFG motif, Asp184 in PKA, 
offers the chelating carboxyl group, which is 
urgently needed for magnesium ion com-
plexation and subsequent ATP recognition, 
see Figure 8. The activation segment is fol-
lowed by the F-helix, which is the most vari-
able part in sequence and length throughout 
the kinome, offering the possibility to selec-
tively turning a certain kinase off and on 
beside others.[34–36]. Moreover, it anchors 
firmly other motifs in the C-lobe including the 
catalytic loop, the P+1 loop, the activation 
segment, and the H-I loops via hydro-
phobic interactions. The remaining G, H 
and, I helices, often termed as the 
GHI-domain, play an additional role as allo-
steric binding sites for substrate proteins 
and regulatory proteins.[37]  
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2.1.2.3 The ATP Binding Site 
 
The ATP binding site is highly con-
served through the human kinome assuring 
its common recognition. In general, the ac-
tive conformation is defined by several re-
gions contributing to the -phosphate trans-
fer. A flexible loop, the hinge region, 
connects the 5-sheet of the N-lobe with the 
D-helix of the C-lobe. Further, the C-lobe 
includes the activation segment, which is a 
region of a 20 to 35 amino acids covering 
sequences located between a conserved 
Asp-Phe-Gly motif (the DFG motif) and a 
less conserved Ala-Pro-Glu motif (APE mo-
tif).[26,40] The main characteristic of the active 
conformation is the C helix arranged to-
wards the N-terminal lobe, and the aspartate 
of the DFG chelating an Mg2+ ion to preor-
ganise the ATP substrate, “DFG-in”, see 
Figure 8.[41] In opposite, in the inactive con-
formation the phenylalanine residue is 
turned into the ATP binding site, “DFG-out”, 
excluding a Mg2+ coordination. 
The adenine ring forms specific hy-
drogen bonds between N1 and N6 to the 
main chain of the hinge region along with 
nonpolar aliphatic groups providing 
VAN-DER-WAALS contacts to the purine moie-
ty, see Figure 6. Val57 in 2 and Ala70 from 
the AxK-motif in 3 form VAN-DER-WAALS 
contacts to the adenine ring of ATP in the 
same way as Leu173, which is located in 
the middle of 7 and is always flanked by 
two hydrophobic residues, Leu172 and 
Leu174 in PKA.[42] These two residues con-
tact a hydrophobic residue from the 
D-helix, Met128, which in turn is in touch 
with residues of the F-helix (Leu227 and 
Met231). The hydroxyl groups of the ribose 
ring form hydrogen bonds to the side chain 
of Glu127 and the main chain carbonyl oxy-
gen of Glu170, respectively. The triphos-
phate group is directed offside the adeno-
sine pocket for optimal accessibility and 
transfer of the -phosphate to the peptide 
substrate. For the optimised orientation of 
the - and -phosphate groups the Glu91 
residue, within the C helix, and Lys72 as-
 
 
Figure 5: A schematic version of the interacting regions involved in adenosine triphosphate (1) binding to the cata-
lytic site of PKA. The gatekeeper residue R1 is Met120 (dark blue) in PKA excludes large residues via sterical hin-
drances. The purine moiety of ATP forms two hydrogen bonds to the peptide backbone of R2 and R4 of the hinge 
region (sienna); in PKA residues Glu121 and Val123. The highly negatively charged triphosphate group is oriented 
towards the catalytic DFG motif (maroon) and is further enclosed by the glycine rich loop (dark orange). Moreover 
Mg
2+
 ions assist the preorganization of the triphosphate group. The ribose moiety forms polar interactions with the 
sugar binding region (blue). Two hydrophobic regions, the hydrophobic region I (cyan) and the hydrophobic region II 
(yellow) are poorly addressed by ATP.
[38,39]
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sist the coordination. Furthermore, a net-
work of interactions mediated by a magne-
sium ion, fixed by Asp184 of the DFG motif 
and Asn171, ensure correct positioning re-
quired for ATP binding and catalysis. A sec-
ond magnesium ion chelated by Asp184 
coordinates to the - and -phosphate for 
further stability. Moreover, the compensation 
of the negative charges of the triphosphate 
group by the magnesium ions decreases 
electrostatic repulsion and facilitates the 
convergence of a nucleophilic reaction part-
ner.[43] The glycine rich loop further contrib-
utes to the stabilizing effect mediated by the 
interactions formed with the - and 
-phosphate, see Figure 6. 
Moreover, the HRD-motif is of spe-
cial interest for the catalytic mechanism. In 
PKA the histidine of the HRD-motif is substi-
tuted by a tyrosine leading to the residues 
Tyr164, Arg165, and Asp166. Whereas the 
hydrophobic Tyr164 is part of the regulatory 
spine, Arg165 residue forms ionic interac-
tions to the phosphorylated Thr197 mediat-
ing the conformational change of the activa-
tion loop to the rest of the enzyme.[36] 
Furthermore, Asp166 is positioned to act as 
a weak catalytic base deprotonating the 
peptide substrate for eased nucleophilic 
attack.[43,44] 
An additional important role in pro-
tein kinase activation is occupied by the 
‘‘gatekeeper’’ residue, Met120 in PKA, posi-
tioned at the N-terminal side of the hinge 
region, see Figure 6.[45] An investigation of 
the human kinome reveals that 77% of the 
human kinases possess relatively large res-
idues (Leu, Met, Phe) in opposite to 21%, 
mainly tyrosine kinases, bearing smaller 
gatekeeper residues (Thr, Val).[46] The gate-
keeper residue not directly inflicts the ATP 
binding, but mutagenesis of large gatekeep-
ers to smaller residues allows the binding of 
bulky synthetic analogues of ATP, and con-
sequently influences substrate selectivity.[45] 
 
Figure 6: Crystal structure of adenosine triphosphate 
(1) bound to the catalytic site of PKA (pdb: 1ATP); 
three dimensional representation of Figure 5. ATP 
forms tow hydrogen bonds to the hinge region (red 
dashes). The triphosphate group is coordinated by two 
Mg
2+
 ions (red dashes). Carbon atoms of ATP are 
colored in green. Carbon atoms of the gatekeeper 
residue are colored in dark blue. Carbon atoms of the 
hinge region are colored in sienna. Carbon atoms of 
the hydrophobic region I are colored in cyan. Carbon 
atoms of the hydrophobic region II are colored in yel-
low. Carbon atoms of the sugar region are colored in 
blue. Carbon atoms of the catalytic DFG residues are 
colored in maroon. Carbon atoms of the glycine rich 
loop are colored in dark orange. Magnesium ions are 
shown as magenta spheres. Oxygen atoms are col-
ored in red, nitrogen in blue, phosphorus in orange 
and sulfur in yellow. The residual structure of PKA is 
represented as cartoon in grey. The side chains of the 
highlighted regions, except of the gatekeeper residue, 
were omitted for clarity.
[13]
 
2.1.2.4 The Substrate Binding Site 
 
The substrate-binding is mainly me-
diated by the activation segment. Whereas, 
the activation segment of the inactive kinase 
conformation is often partially disordered, 
the catalytically competent active confor-
mation, forming the peptide binding site, is 
triggered in many kinases by phosphoryla-
tion.[12,14,15] For instance, Thr197 of PKA in 
its phosphorylated phosphothreonine state, 
acts as an organizing centre forming hydro-
gen bonds to the side chains of His87, 
Arg165, and Lys189.[16] The resulting con-
formational changes promote closure of the 
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N- and C-lobe inducing the correct confor-
mational arrangement of the activation seg-
ment for substrate binding. Although, the 
phosphorylation of a regulatory residue of-
fers a control mechanism for kinase activa-
tion and many kinases are capable of adopt-
ing the correct activation segment 
conformation without a preceding phosphor-
ylation, i.e.: phosphorylase kinase (PhK),[47] 
epidermal growth factor receptor 
(EGFR),[48,49] cyclin-dependent kinase 5 
(CDK5).[50] In some kinases, additional sec-
ondary structures in the activation segment 
further increase the substrate 
selectivity.[51,52] 
 
Figure 7: Crystal structure of ATP and peptide inhibi-
tor IP20 bound to PKA (pdb: 1ATP). PKA is presented 
in grey with surface. The peptide inhibitor IP20 (green) 
occupies the substrate binding site. Beside the helical 
core of the C-lobe, the activation segment and the 
P+1 loop (orange) is mainly responsible for the pep-
tide substrate binding. The residue of the peptide 
substrate for phosphorylation is oriented towards the 
catalytic region (yellow) and the DFG motif (red) for 
optimal phosphoryl group transfer.
[13]
 
Besides the highly conserved ATP 
binding site, all kinases share in common 
the orientation of the substrate, whereas the 
the hydroxyl group is directed for functional-
ization directly towards the catalytic aspar-
tate, Asp166 in case of PKA. In serine/thre-
onine kinases, a lysine residue two residues 
next to the catalytic aspartate contacts the 
-phosphate and is assumed to stabilise the 
developing negative charge during 
catalysis.[43] In tyrosine kinases, the stabiliz-
ing amino acid is four residues away and is 
an arginine instead of a lysine offering more 
space for the larger tyrosine residue.[53] 
Moreover, two additional chains of con-
served hydrophobic residues, termed the 
catalytic and regulatory spines, which as-
semble as a response to changes within the 
catalytic site due to kinase activation and 
conduct those changes to the rest of the 
domain.[34,35,54] The regulatory spine de-
scribes an assembly of interactions of resi-
dues located in the N- and C-terminal lobes 
and promoted by the conformational chang-
es of the activation segment.[40] Thus in turn, 
is responsive to peptide binding. Whereas, 
active kinases share a common catalytically 
competent conformation, the inactive kinas-
es are structurally diverse especially in the 
conformation of the hydrophobic regulatory 
spine.[55] This diversity is based on the 
abundance of catalytic requirements and 
constrains missing in the inactive state, al-
lowing the different conformations.[15,26,39,54] 
Although common structural themes across 
the kinome for the inactive form are existing, 
the possible conformations differ more ex-
tensively than the conformations of the ac-
tive form. Therefore, addressing the inactive 
form offers possibilities to selectively ad-
dress single kinases among others, see 
Chapter 2.1.5. 
2.1.3 The Catalytic Mechanism of Phos-
phate Group Transfer 
 
Protein kinases catalyse the transfer 
of the the -phosphate from ATP to the hy-
droxyl group of serine, threonine, or tyrosine 
residues in protein substrates and recognise 
local regions around the site of phosphoryla-
tion. They usually phosphorylate sites of 
less ordered parts of the protein substrate 
exposed on the surface.[56] This preference 
allows the kinase to induce an extended 
conformational change to the substrate pro-
tein fitting the catalytic site and allowing the 
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localization of specificity determining resi-
dues.[57] Moreover in numerous kinases, 
remote docking sites located either offside 
the catalytic domain, i.e.: the mitogen-
activated protein kinases (MAPKs),[58] or on 
separate domains or subunits, i.e.: the 
Cdk2/cyclin complexes,[59] contribute to an 
additional mechanism of target recognition 
and selectivity. 
 The chemical principle of the phos-
phorylate transfer step is simple and de-
pends on the correct orientation of the two 
substrates. The -phosphate of ATP and the 
hydroxyl group of the serine, threonine, or 
tyrosine residue to be phosphorylated must 
be orientated in the right fashion based on 
the structural properties of the kinase, see 
Chapter 2.1. Kinetic studies using 
a) 
 
b) 
               
Figure 8: a) Mechanistic details of the -phosphate group transfer in the PKA binding site.
[7,43]
 Left: The triphosphate 
is preorganised for the catalytic reaction by a network of interactions. One magnesium ion (magenta) coordinates the 
- and -phosphate, and is itself anchored by Asn171 and Asp184, whereas the second ion coordinates to the - and 
-phosphate anchored by Asp184. Further, the Lys72 and Lys168 side chains form hydrogen bonds to the - and 
-phosphate, and to the -phosphate, respectively. Asp166 assists the deprotonation of the substrate hydroxyl group 
for phosphorylate group transfer. Middle: -phosphate in a trigonal-bipyramidal transition state. Right: phosphate 
transferred to the substrate hydroxyl function. Oxygen atoms of the triphosphate group and the substrate are high-
lighted in red; magnesium ions in magenta, phosphor atoms in orange, the substrate carbons in green, and the sub-
strate hydrogen in blue. Ad = Adenosine. b) Crystal structures of the phosphorylate group transfer from ATP to a 
substrate inhibitor molecule, reflecting the principles of a) in the PKA binding site. Left: The triphosphate group is 
preorganised as described above. Note that the peptide inhibitor IP20 has no serine residue being capable of accept-
ing the phosphate, thus bearing an alanine instead at this position for the crystallisation of ATP in the binding site, 
(pdb: 4DH3).
[60]
 Middle: AlF3 is crystallised as a transition state mimic of the trigonal-bipyramidal form of the 
-phosphate during catalytic transfer together with ADP and magnesium ions in the ATP binding site of PKA, (pdb: 
1L3R).
[29]
 In this, and the third case, the peptide inhibitor molecule offers a serine residue at the proper position. Right: 
The -phosphate group has been transferred to the substrate molecule SP20, (pdb: 4IAD).
[61]
 Carbon atoms of ATP 
and ADP are represented in green, phosphor atoms in orange, oxygen in red, nitrogen in blue. The peptide inhibitor 
IP20 and SP20 are shown as cartoon in green. PKA is shown as cartoon in grey as well as the carbon atoms of the 
highlighted residues. 
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[-32P]-ATP or radiolabelled peptide sub-
strate with PKA indicate that both substrates 
have unrestricted access to the catalytic 
site.[62] Moreover, the binding of one sub-
strate does not exclude the other, although 
at high ATP concentrations, which are typi-
cal in the cellular media, there is a prefer-
ence for sequenced binding with ATP 
first.[62] 
 Thereafter, the phosphorylate group 
transfer reaction proceeds attacking the hy-
droxyl group of the substrate in a trajectory 
opposite and in line to the leaving 
-phosphate group, leading to the Walden-
inversion at the phosphorus atom of the 
phosphate, indicating the absence of a 
phosphorylated kinase intermediate. This 
postulated geometry was supported by 
structural studies of PKA co-crystallised with 
the transition state analogue aluminium tri-
fluoride, see Figure 8.[29] Furthermore, the 
reaction mechanism highlights the im-
portance of the coordinated magnesium ions 
stabilising the significant amount of negative 
charges and aiding the controlled release of 
ADP.[43] 
The transition state intermediate is 
discussed to be either dissociative, where 
the bond to the leaving group is broken be-
fore the new bond is formed, or associative, 
where the reaction proceeds through a pen-
tavalent phosphorane intermediate with 
bond formation first by the attacking group 
or at least at the same time as bond break-
ing by the leaving group.[63] Beside the 
phosphorylate group transfer mechanism, a 
base catalysis from the catalytic aspartate 
deprotonating the attacking hydroxyl group 
followed by a subsequent transfer of the 
proton to the reaction product facilitates the 
entire reaction cascade, see Figure 8 a).[64]  
Nevertheless, deprotonation of the nucleo-
philic hydroxyl group in the early stages of 
the reaction is not a rate-limiting step.[65] 
Once the substrates have been correctly 
oriented, the rate-limiting step is the release 
of products.[62,64,66,67] 
2.1.4 Kinases Related Disorders 
 
The regulating mechanisms of protein 
kinases is based on the inhibition or activa-
tion of assembling protein partners,[68] their 
phosphorylation,[14,26,69,70] their cellular ex-
pression and localization,[71] the limitation of 
substrates and activating cofactors, and 
their degradation.[72–74] The dysregulation of 
protein kinase activity mediated by muta-
tions leading to constitutively active forms, 
the loss of down-regulating mechanisms, or 
chromosomal rearrangements are associat-
ed with numerous disorders including can-
cer,[75,76] neurodegenerative,[77,78] neuro-
logic,[79] or cardiovascular disorders.[80] 
Moreover, a detailed physiological and 
pathophysiological role of the investigated 
kinases during this work will be discussed in 
the results section in detail. Nonetheless, 
since the first description of protein kinases, 
they achieved special interest as drug tar-
gets, confirmed today by the numerous FDA 
approved small molecule compounds suc-
cessfully applied in therapy.[81] The increas-
ing insights of the structural properties of the 
protein kinases had a significant impact on 
the development of selective and specific 
inhibitors. 
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                           a)                                                      b)                       
 
                                                          c) 
 
                                   d)                                               e) 
 
Figure 9: Comparison of different types of kinase inhibition mediated by small molecules. a) The irreversible inhibitor 
afatinib (2a) binds to a similar active conformation of EGFR (pdb: 4G5P) as observed for type I inhibitors.
[82]
 b) Type I 
inhibitors like dasatinib (3) bind to the active conformation of the target kinase, here BCR-ABL (pdb: 2GQG),
[83]
 with 
the DFG in motif. c) Type II inhibitors like imatinib (4) bind to the inactive DFG out conformation of the target kinase 
BCR-ABL (pdb: 1IEP).
[84]
 Moreover, the P+1 loop contributing to peptide substrate recognition is disordered. d) Type 
III inhibitors like TAK-733 (6) bind to an adjacent allosteric pocket next to the ATP binding site and still allow the bind-
ing of ATP (1) to target kinase, here MEK1 (pdb: 3PP1).
[85]
 e) Finally, type IV inhibitors like GNF-2 (7) (blue spheres) 
bind to an allosteric site remote the ATP binding site of BCR-ABL (pdb: 3K5V) occupied by imatinib (4) in the inactive 
conformation.
[86]
 All inhibitors binding to or next to the ATP binding site are presented as red spheres; ATP is present-
ed as sticks with the carbon atoms in green. The hinge region is coloured green, the catalytic loop in yellow, the activa-
tion loop with the DFG motif in red, and the P+1 loop in orange. All kinases are represented as cartoon in grey with the 
surface in grey. 
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2.1.5 Mechanisms of Kinase Inhibition 
 
Small-molecule kinase inhibitors rep-
resent useful tools to investigate and evalu-
ate kinase functions in numerous cellular 
activities. Nevertheless, due to the highly 
conserved domains targeting selectively 
single kinases among others was assumed 
to be an unconvertible challenge, unless the 
first selective kinase inhibitors against the 
epidermal growth factor receptor (EGFR) 
were reported in the late 1980s.[87,88] This 
incidence as a starting point, led to a large 
number of kinase inhibitors with various 
structural scaffolds and selectivity profiles 
aiding to elucidate the molecular recognition 
of kinase/inhibitor interactions.[89,90] 
The majority of kinase inhibitors tar-
get the ATP binding site, which is formed 
between the N- and C-lobe, to perturb the 
ATP fixation; see also Chapter 2.1.2.3. The 
flexible activation loop containing the DFG 
motif controls the access to the active site, 
see Figure 4.[91] In principle the developed 
kinase inhibitors can be divided into two 
classes covering the irreversible and re-
versible ones. The former ones bind cova-
lently with a reactive nucleophilic cysteine 
residue adjacent to the ATP binding site 
resulting in a permanent irreversible extru-
sion of ATP. In opposite, reversible inhibi-
tors compete with ATP and do not form 
permanent covalent modifications with the 
target kinase. Moreover, they are subdivided 
into four main types based on the confor-
mation of the kinase occupied during bind-
ing, see Figure 9.[92,93] Nevertheless, a strict 
discrimination into the classes are not al-
ways appropriate since some kinase inhibi-
tors, i.e.: bi-substrates and bivalent inhibi-
tors (type V),[94] exhibit more than one of the 
mentioned binding modes. 
Most of the clinically approved ki-
nase inhibitors are tyrosine kinase 
inhibitors,[95] a few are serine/threonine ki-
nase inhibitors, and only one is a lipid ki-
nase inhibitor.[96] Mechanistically, 26 are 
reversible inhibitors and only two are irre-
versible inhibitors. Moreover, only one type 
III inhibitor is approved so far, although sev-
eral promising allosteric kinase inhibitors are 
being currently in clinical trials at different 
stages.[81] Detailed review discussing FDA 
approved small molecule kinase inhibitors 
are provided in literature.[81] 
 
Figure 10: Chemical structure of afatinib (2a) and 
ibrutinib (2b). In both inhibitors a MICHEAL acceptor 
moiety highlighted in red covalentely connetcs the 
compounds to their corresponding target kinases. In 
case of afatinib, the residues interacting with specific 
regions of the ATP binding site are coloured according 
to Figure 5. The quinazoline core occupies the ade-
nine region, whereas the 3-chloro-4-fluoro-aniline 
residue is steered to the hydrophobic region I. The 
quinazoline ring forms a hydrogen bond to the hinge 
region (red dashed arrow). The N,N-(dimethylamino)-
but-2-enamide residue contains the MICHAEL acceptor 
moiety forming the covalent bond to the Cys797 side 
chain of EGFR. 
2.1.5.1 Irreversible Kinase Inhibitors 
 
Currently, two irreversible kinase in-
hibitors are approved by the FDA, first the 
EGFR inhibitor afatinib (2a), followed shortly 
by the Bruton´s tyrosine kinase (BTK) inhibi-
tor ibrutinib (2b).[97,98] Both of them incorpo-
rate a MICHAEL acceptor moiety in their scaf-
fold forming a covalent bond with a reactive 
cysteine residue in the active site of the ap-
propriate target kinase. Despite the achie-
ved specificity and potency, concerns re-
garding potential toxicities have to be 
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considered during the design of irreversible 
inhibitors to avoid unspecific covalent modi-
fication of off-targets.[99] Nevertheless, the 
success of these two examples of kinase 
inhibitors, i.e.: ibrutinib is expected to reach 
US$ 9 billion in 2020,[100] should emphasise 
further drug design endeavours to consider 
irreversible inhibitors as a true alternative to 
develop inhibitors with increased selectivity 
and potency profile. 
 
Figure 11: Crystal structure of afatinib (2a) bound to 
the active site of EGFR (pdb: 4G5P). The quinazoline 
moiety forms a hydrogen bond with the main chain of 
the hinge region residue Met793 (red dashes). The 
reactive cysteine residue of Cys797 forms a covalent 
C–S bond with the MICHAEL acceptor enone group at 
the edge of the active site in the C-lobe. The carbon 
atoms of afatinib are presented in green. Nitrogen 
atoms are shown in blue, oxygen atoms in red, chlo-
rine in green, fluorine in light cyan, and sulfur in yel-
low. EGFR is presented as cartoon with the surface in 
grey and the hinge region as sticks.
[82]
 
However, the detailed mechanism of 
irreversible inhibitor interaction is best high-
lighted on the example of afatinib (2a). The 
crystal structure of afatinib bound covalently 
to the wild type EGFR is shown, see Figure 
11. It is noteworthy, that afatinib shows ap-
parently a type I binding, very similar to oth-
er approved reversible EGFR inhibitors due 
to the same common anilinoquinazoline 
core. For instance, a conserved hydrogen 
bond is formed between hinge residue 
Met793 and the quinazoline moiety of the 
aromatic ring system. The reactive cysteine 
residue Cys797 forms the covalent C–S 
bond with the MICHAEL acceptor enone 
group at the edge of the active site in the 
C-lobe.[82] 
 
Figure 12: Chemical structure of dasatinib (3). The 
residues interacting with specific regions of the ATP 
binding site are coloured according to Figure 5. The 
thiazole core occupies the adenine region, whereas 
the 2-chloro-6-methylaniline residue is steered to the 
hydrophobic region I. The piperazine moiety with the 
attached hydroxyethylene residue is solvent exposed. 
The thiazole core forms two hydrogen bonds hinge 
region region, and the aniline residue forms one addi-
tional hydrogen bond to the gatekeeper residue 
Thr315 (red dashed arrows). 
2.1.5.2 Type I Kinase Inhibitors 
 
Type I inhibitors are ATP competitive 
inhibitors binding to the active conformation 
of the target kinase with the aspartate resi-
due of the DFG motif oriented into the active 
site. For instance, dasatinib (3), as a type I 
inhibitor, binds to BCR-ABL with the fully 
extended activation loop ready for substrate 
binding. In case of dasatinib, see Figure 13, 
the nitrogen of the heteroaromatic thiazole 
core and the adjacent bridging amino group 
form hydrogen bonds with the amid back-
bone of the hinge residue Met318. The ali-
phatic hydroxyethylpiperazinyl residue is 
solvent exposed, whereas the terminal 
2-chloro-6-methyl aniline group is oriented 
towards the hydrophobic pocket I. The latter 
further interacts via the bridging amide with 
the gatekeeper by hydrogen bond formation. 
All compounds addressing the hydrophobic 
region I are affected by mutation-related 
drug resistance often mediated by a T315I 
mutation leading to steric shielding of this 
important grove, see Chapter 2.1.5.3.[101] 
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Figure 13: Crystal structure of dasatinib (3) bound to 
the active site BCR-ABL (pdb: 2GQG). The thiazole 
core forms two hydrogen bond with the main chain of 
the hinge region residue Met318; an additional hydro-
gen bond is formed between the aniline residues and 
Thr318 (red dashes). The carbon atoms of dasatinib 
are presented in green. Nitrogen atoms are shown in 
blue, oxygen atoms in red, chlorine in green, and 
sulfur in yellow. BCR-ABL is presented as cartoon with 
the surface in grey and the hinge region as sticks.
[83]
 
2.1.5.3 Type II Kinase Inhibitors 
 
In contrast to the type I inhibitors, the 
type II inhibitors bind to the inactive forms of 
the target kinase where the aspartate resi-
due of the DFG motif is oriented outwards of 
the ATP binding. Moreover, kinases differ in 
their inactive conformations more extensive-
ly then in their active conformation and sub-
sequently offering more differentiable inter-
action sites, see Chapter 2.1.2.3. Thus, the 
type II inhibitors exploiting these specific 
pockets adjacent to the ATP-binding site 
offer the potential for increased selectivity. 
However, BCR-ABL was the first ki-
nase, which was addressed by the first suc-
cessfully approved small-molecule inhibitor 
imatinib (4).[102] Beside the revolutionary 
success for the treatment of patients suffer-
ing on chronic myeloid leukemia (CML),[103] 
imatinib induced a “gold fever” in the inhibi-
tor development of kinases as druggable 
therapy targets. Numerous SAR studies 
using imatinib led to the design of whole 
classes of second generation inhibitors and 
provided a deeper understanding of the in-
hibition mechanism.[104,105] Thus, the acting 
mechanism of type II inhibitors is best high-
lighted using imatinib as a model. 
 
Figure 14: Chemical structure of imatinib (4). The 
residues interacting with specific regions of the ATP 
binding site are coloured according to Figure 5. The 
pyridinylprimidine residue occupies the adenine re-
gion, whereas the 4-methylbenzene-1,3-diamine core 
is steered to the hydrophobic region I. The piperazine 
moiety binds to an allosteric pocket formed by the 
DFG out motif (olive). Hydrogen bonds were formed 
mainly by the 4-methylbenzene-1,3-diamine and the 
pyridine residue (red dashed arrows). 
Imatinib binds to the inactive BCR-
ABL with the DFG motif occupying the ‘out’ 
conformation by addressing three different 
binding pockets, see Figure 14. The 4-(py-
ridin-3-yl)pyrimidine moiety of imatinib forms 
a conserved hydrogen bond to the back-
bone of the hinge residue Met318. The 
bridging 4-methylbenzene-1,3-diaminyl core 
occupies the hydrophobic pocket I, whereas 
the adjacent amine, connecting the 4-(py-
ridin-3-yl)pyrimidine moiety group, forms a 
hydrogen bond with the side chain of the 
gatekeeper residue Thr315. Moreover, the 
terminal 4-((4-methylpiperazin-1-yl)methyl) 
benzoic acid, connected via an amide group 
to the 4-methylbenzene-1,3-diaminyl core, 
binds to an allosteric pocket, which is 
formed by DFG out conformation. Further-
more, bidentate ionic interactions with 
His361 and Ile360 are formed by the methyl 
piperazinyl group. Closing, the set of molec-
ular interactions is completed by hydrogen 
bonds formed by the amide group and both 
the Glu286 and Asp381, see Figure 15.[84] 
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Figure 15: Crystal structure of imatinib (4) bound to 
the active site BCR-ABL (pdb: 1IEP). The pyridinyl-
primidine moiety forms a hydrogen bond to the main 
chain of Met318 (red dashes). The 4-methylbenzene-
1,3-diamine core forms two hydrogen bond with the 
side chain residues of Thr315 and Glu286, whereas 
the carbonyl oxygen of the amide group forms a hy-
drogen bond to the main chain of Asp381. The 4-((4-
methylpiperazin-1-yl)methyl) benzoic acid residue of 
imatinib occupies an allosteric binding region only 
accessible due to the DFG out conformation of BCR-
ABL. Beside the hydrophobic interactions, ionic inter-
actions (magenta dashes) between the terminal ter-
tiary nitrogen of the piperazine with His361 and Ile360 
complete the set of attracting interactions. The carbon 
atoms of imatinib are presented in green. Nitrogen 
atoms are shown in blue, oxygen atoms in red, and 
sulfur in yellow. BCR-ABL is presented as cartoon with 
the surface in grey and the hinge region as sticks.
[84]
 
Despite high efficacy and limited tox-
icity compared to traditional chemo-
therapeutic drugs, point mutations, in the 
kinase domain of BCR-ABL, especially of 
the gatekeeper residue, led to the develop-
ment of drug resistance against imatinib.[106–
108] Several potential explanations of this 
resistance have been discussed; however, a 
mutation towards larger gatekeeper resi-
dues stabilises the R-spine more efficiently 
than threonine, subsequently shifting the 
equilibrium to the active conformation in-
stead of the imatinib recognised inactive 
conformation.[109] Such a stabilization, in 
combination with simple steric blocking of 
the binding site,[110] prevents the binding of 
imatinib, and inevitably creates a constitu-
tively active oncogenic kinase. To overcome 
these resistance mechanisms a proceeding 
development of next generation compounds 
is necessary to ensure a fast substitutional 
therapy.[111] Indeed, next-generation drugs 
like nilotinib,[112] dasatinib,[113] or ponatinib[114] 
were developed overcoming drug resistance 
towards imatinib, and the latter even toler-
ates the gatekeeper mutation.[115] 
 
Figure 16: Chemical structure of trametinib (5) and 
TAK-733 (6). Specific regions of the ATP binding site 
are coloured according to Figure 5. TAK-733 as a 
trametinib derivative crystallised in MEK1 acts as a 
surrogate to elucidate the molecular interactions of 
type III kinase inhibitors. The pyridopyrimidine core of 
TAK-733 interacts with an allosteric pocket (olive) 
adjacent to the ATP binding site, whereas the halo-
genated phenylaminyl substituent occupies a MEK 
selective hydrophobic pocket I (cyan). Moreover, hy-
drogen bonds are formed between the dihydroxypro-
pyl group and the ATP phosphate as well as Lys97, 
between the carbonyl group of the pyrimidine moiety 
and Lys97, and between the oxygen in the pyridine 
moiety to Val211 and Ser212 (red dashed arrows). 
2.1.5.4 Type III Kinase Inhibitors 
 
The type III inhibitors bind exclusive-
ly in an allosteric pocket adjacent to the ATP 
binding site. The only FDA approved type III 
kinase inhibitor so far is trametinib targeting 
MEK1 and MEK2. It was developed based 
on a high-throughput screening (HTS) hit 
and subsequent SAR studies, driven by 
growth inhibitory activity against cancer cell 
lines,[116] guided by the structural features of 
established MEK inhibitors.[117] 
 
34 Introduction 
 
Figure 17: Crystal structure of TAK-733 (6) and ATP 
(1) bound to the allosteric and the MEK specific hy-
drophobic pocket I (pdb: 3PP1). The pyridopyrimidine 
core of TAK-733 interacts with the allosteric pocket 
adjacent to the ATP binding site, whereas the halo-
genated phenylaminyl substituent is steered to the 
MEK selective hydrophobic pocket I. The dihydroxy-
propyl group and the ATP phosphate as well as 
Lys97, the carbonyl group of the pyrimidine moiety 
and Lys97, as well as the oxygen in the pyridine moie-
ty and Val211 and Ser212 form hydrogen bonds (red 
dashes). The carbon atoms of TAK-733 are presented 
in green. The carbon atoms of ATP are presented in 
wheat. Nitrogen atoms are shown in blue, oxygen 
atoms in red, sulfur in yellow, and the magnesium ion 
as magenta sphere. MEK1 is presented as cartoon 
with the surface in grey and the hinge region as 
sticks.
[85]
 
Although the co-crystal structure of 
MEK1 or MEK2 with trametinib could not be 
achieved by now, an analogue of trametinib, 
TAK-733, was crystallised successfully in 
complex with MEK1, see Figure 17, which 
also showed a type III binding mode and is 
therefore discussed as a surrogate. The 
pyridopyrimidinedione core occupies an al-
losteric pocket in direct proximity to the ATP 
binding site with hydrogen bond formations 
of both the oxygen on the pyridine moiety to 
Val211 and Ser212, as well as the oxygen 
of the pyrimidine moiety to Lys97. The at-
tached 2-fluoro-4-iodoaniline moiety acts as 
a MEK-selective recognition motif for the 
hydrophobic pocket I. The terminal dihy-
droxypropyl chain forms hydrogen bonds 
with both hydroxyl functions to the ATP 
-phosphate and Lys97 respectively.[85] 
Type III inhibitors, like trametinib, are valua-
ble tools to modify kinase activity distinct to 
type I or type II inhibitors, and as in case for 
the combination strategy along with the 
B-Raf inhibitor dabrafenib, they offer diverse 
possibilities to overcome resistance mecha-
nism.[118,119] 
2.1.5.5 Type IV Kinase Inhibitors 
 
The type IV inhibitors bind to an allo-
steric site completely offside the ATP bind-
ing pocket.[120] Currently, they are no FDA 
approved type IV kinase inhibitors in use; 
although several candidates are in different 
clinical stages.[121–124] For instance, GNF-2 is 
a highly selective non-ATP competitive in-
hibitor of BCR–ABL (IC50 = 0.14 mM).
[125] 
The allosteric myristoyl pocket located near 
the carboxyl terminus of the ABL kinase 
domain was discovered as the precise bind-
ing site of GNF-2 to the BCR-ABL fusion 
protein by both NMR and X-ray experi-
ments.[126–128] GNF-2 replaces the myristoy-
lated peptide occupying an extended con-
formation with the trifluoromethyl group 
buried at the same cleft as originally occu-
pied by the final two carbons of the 
myristate ligand, see Figure 19. Moreover, a 
favourable, but probably weak, polar interac-
tion between one fluorine atom and the main 
chain of Leu340 can be described, along 
with water-mediated hydrogen bonds. No 
direct hydrogen bonds with the protein can 
be observed, thus confirms the binding me-
diated mainly by hydrophobic interactions. 
 
Figure 18: Chemical structure of GNF-2 (7). GNF-2 
binds to the myristate binding site of BCR-ABL remote 
the ATP binding site and the catalytic cleft. The mo-
lecular interactions are mainly driven by hydrophobic 
interactions, although a weak polar interaction be-
tween one fluorine atom and Leu340 can be assumed 
(red dashed arrow). 
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Figure 19: Crystal structure of GNF-2 (7) bound to the 
myristate binding site of BCR-ABL remote the ATP 
binding site (pdb: 3K5V). The 4-trifluoromethoxy-
phenylaminyl residue is steered deep into the C-ter-
minal -helices, whereas the benzamide moiety is 
solvent exposed. The carbon atoms of GNF-2 are pre-
sented in green. Nitrogen atoms are shown in blue, 
oxygen atoms in red, and fluorine in light cyan. 
BCR-ABL is presented as cartoon with the surface in 
grey.
[86]
 
Nevertheless, allosteric inhibitors are 
likewise affected by resistance 
mechanisms.[86] For instance, mutation of 
three residues near the entrance of the 
myristate-binding site (C464Y, P465S and 
V506L) is found to evoke GNF-2 resistance, 
presumably caused by steric reasons. How-
ever, as described for type III inhibitors, a 
combination of inhibitors, acting according to 
different mechanisms, lead to increased 
selection pressure on oncogenic kinases. 
Therefore, the likeliness of a kinase suc-
cessfully handling two distinct binding sites 
to overcome inhibition by alterations via mu-
tagenesis is significantly decreased. For 
instance, the simultaneous binding of a 
myristoyl mimic and an ATP-competitive 
inhibitor results in the inhibition of both the 
wild-type and the T315I BCR-ABL kinase 
activity and cell growth.[86] 
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2.2 Metal Complexes as Kinase In-
hibitors 
 
The MEGGERS group established a va-
riety of different transition metals as struc-
tural templates to gain access to highly so-
phisticated organometallic complexes 
serving as catalysts for asymmetric reac-
tions,[129–132] as DNA intercalators and bind-
ers,[133–135] biorthogonal catalysts,[136,137] pho-
tosensitiser,[138,139] or as highly potent and 
selective kinase inhibitors.[140–142] 
Remarkably, the MEGGERS group es-
tablished the pyridocarbazole pharma-
cophore ligand, derived from staurosporine, 
as a bidentate ligand for metal complex-
ation, which proved to be part of highly se-
lective and specific kinase inhibitors with 
potential anticancer effects, see Figure 
21.[143–145] However, the initial ruthenium 
based kinase inhibitors elaborated in the 
MEGGERS group were half-sandwich com-
plexes coordinated to a cyclopentadienyl 
ligand beside the mentioned pyridocarba-
zole pharmacophore and a monodentate 
ligand completing the coordination 
sphere.[146] 
 
Figure 20: Superimposed crystal structures of stauro-
sporine (8) bound GSK-3 (pdb: 1Q3D) and organo-
metallic inhibitor (R)-10 bound GSK-3 (pdb: 2JLD). 
An almost identic position of the indolocarbazole 
moiety of staurosporine and the pyridocarbazole lig-
and of (R)-10 in the ATP binding site can be observed 
forming identical hydrogen bonds to the main chain of 
Tyr134. The carbon atoms of staurosporine are pre-
sented in green and the carbon atoms of (R)-10 are 
presented in cyan. Nitrogen atoms are shown in blue, 
oxygen atoms in red, fluorine in light cyan, and the 
ruthenium core in teal. GSK-3 is presented as car-
toon and the hinge region as sticks with the surface in 
grey.
[146]
 
 
 
 
Figure 21: Staurosporine (8) serves as a lead structure for metal based kinase inhibitors. The bidentate pyrido-
carbazole pharmacophore ligand mimics the indolocarbazole moiety of staurosporine and mediates hydrogen 
bonds to the hinge region as it is true for staurosporine. 
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Subsequent developments led to 
modifications of the cyclopentadienyl ligand, 
of the pyridocarbazole ligand, and of the 
monodentate ligand, see Figure 22.[147–149] 
Moreover, the metal core of the kinase in-
hibitors itself was substituted by a variety of 
transition metals covering platinum, rhodi-
um, rhenium, osmium, or iridium.[138,150–153] 
However, the ambition to establish metals 
as structural templates lead from initial half 
sandwich complexes to highly sophisticated 
octahedral complexes by establishing a va-
riety of ligand scaffolds as part of metal 
based kinase inhibitors.[140,143–145,152,154] 
Indeed, it is an obvious fact that a 
tetravalent carbon with its possible two en-
antiomers is no comparison in its complexity 
to a hexavalent metal ion with 30 possible 
structural isomers in case of six distinguish-
able monodentate ligands, see Figure 
23.[155] But on the other hand, this enormous 
number of possible stereoisomers has a 
high demand of well elaborated methods to 
selectively synthesise the desired structures 
over the undesired ones. This bidentate pyr-
idocarbazole pharmacophore ligand as a 
prerequisite for the mentioned purpose of 
the organometallic compounds, influences 
the number of possible structural isomers. 
Whereas, half-sandwich complexes, con-
taining at least one bidentate ligand, form 
only two enantiomers, octahedral complexes 
can reach up to 24 different structural iso-
mers using four distinguishable monoden-
tate ligands.[147,156] Moreover, introducing 
multidentate ligands into the organometallic 
complex scaffold further alter the possible 
number of structural isomers. Since, initially 
octahedral complexes were designed con-
taining C2-symmetric ligands, like 1,4,7-tri-
thiacyclononane in complex 11, simplifying 
the mentioned challenge, more and more 
sophisticated modified ligands were devel-
oped addressing unexplored chemical 
space, like -12.[157] 
The specificity and selectivity of or-
ganometallic compounds against their target 
kinases of the human kinome are highly 
dependent on the globular shape and the 
ligand sphere which is built by the coordi-
nated ligands.[140,158] Therefore, the conse-
quent development of these organometallic 
compounds as kinase inhibitors from half-
sandwich complexes to octahedral ones is 
accompanied by the increase of the chanc-
es as well as the challenges of the feasibility 
of particular structural isomers.[159,160] As the 
target interaction structures are biomole-
cules consisting of chiral building blocks, 
they create a chiral environment which rec-
ognises sensitively complementary struc-
tures and excludes mismatching ones.[161] 
Therefore, methods for the asymmetric syn-
thesis of octahedral organometallic com-
plexes to obtain certain desired structural 
scaffolds, ideally designed to a correspond-
 
Figure 22: The development of metal based kinase inhibitors led from initial half-sandwich complexes to highly 
sophisticated octahedral complexes with increasing structural diversity. The shown isomers of (R)-9, (R)-10 and 
-12, are the more potent ones, whereas 11 is as racemic mixture of two enantiomers both existing as thiocyanate 
and isothiocyanate.
[147–149]
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ing binding site of a target biomolecule, are 
highly appreciated,[140,152,159,161] and many 
articles report about the structural potential 
disclosed by multivalent organometallic 
complexes and the associated challen-
ges.[155,162–167] 
2.3 Octahedral Complexes – Taming 
the Structural Scope 
 
Many ways to control the metal cen-
tered relative and absolute stereochemistry 
have been published with different ad-
vantages and disadvantages. In principle, 
the approaches can be clustered in several 
groups controlling the relative and absolute 
stereochemistry via chiral ligands, chiral 
anions, chiral auxiliaries, or even via catalyt-
ic asymmetric synthesis.[132,162,168–177] How-
ever, the approach of these methods must 
be correlated to the requirements of an or-
ganometallic compound being capable of 
acting as a kinase inhibitor simultaneously. 
Structural restrictions of the ligands 
inevitably lead to the discrimination of cer-
tain structures over others. These structural 
restrictions are mostly represented by chiral-
ity introduced into the ligand system; either 
in the scaffold in direct proximity of the co-
ordinating atoms of a multidentate ligand or 
via sophisticated linkers which preorganise 
the ligand for complexation.[171,172,178–181] For 
instance, the binaphtyl core of the (S)-2,2'-
(1,1'-binaphthyl-2,2'-diyl)bis(7-tert-butylqui-
nolin-8-ol) ligand (S)-13 incorporates an 
axial chirality into the tetradentate ligand 
subsequently leading to chirality transfer to 
the metal core favouring the shown confor-
mation of cis---(S)-14, Scheme 1. In op-
posite, the (S, S)-[4,5]-chiragen-[6] ligand 15 
projects its chiral information to the metal 
centre via the aliphatic linker. Both dime-
thylbicyclo[3.1.1] heptane moieties of 15 act 
as conformative anchors restricting the pos-
sible coordination patterns of the peripheral 
bipyridinyl residues mediated by the linker. 
Although, the coordination leads to signifi-
cant loss of the number of degrees of free-
dom for the spacious ligand 15 resulting in 
 
Figure 23: a) Staurosporine (8) serves as a lead structure for metal based kinase inhibitors. Depending on the 
design and connectivity of the residual ligands a diversity of different stereoisomers can be achieved. From two 
stereoisomers regarding half sandwich complexes to up to 24 regarding octahedral complexes in case of A ≠ B ≠ 
C ≠ D. M: a diversity of transition metals. b) The number of possible stereoisomers can be reduced by connecting 
monodentate ligands to polydentate ligands. 
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the low yields observed for the formation of 
-17, Scheme 1.[182] In contrast, 
2,6-bis((((S)-2-phenyl-4,5-dihydrooxazol-4-
yl)methylthio)methyl) pyridine ligand 18, 
which is C2-symmetric, results in the shown 
conformation of -19 based on both, the 
incorporated chirality of the oxazoline moie-
ties and the ligand design itself. The corre-
sponding -19 complex would be less fa-
voured, because the peripheral phenyl 
groups of the oxazolines would be placed 
above and below the ligand backbone lead-
ing to steric repulsions, Scheme 1.[183] 
Due to the restricted space offered 
by the active site of a kinase, the strategy 
using large linking systems is not suitable to 
transfer the ligand chirality onto the metal for 
octahedral organometallic compounds with 
the purpose of kinase inhibition.[182,184] The 
same is true for ligands based on axial chi-
rality which often leads to bulky coordination 
spheres.[185] And as the pyridocarbazole is a 
mandatory prerequisite, the dentity of possi-
ble ligands to form an octahedral scaffold 
cannot exceed the number of four making 
many successful approaches with multiden-
tate ligands inapplicable for this case.  
 
Scheme 1: The axial chirality of (S)-13 results into chirality transfer to the metal core leading to cis---(S)-14. The 
chiral information of 15 is mainly projected via the aliphatic linker. In contrast, the C2-symmetric ligand 18 medi-
ates chirality to the metal centre based on the oxazoline moieties and the ligand design itself. 
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Scheme 2: The TRISPHAT ligand 22 can be ap-
plied as auxiliary for the synthesis and separation of 
enantiomers via extraction forming an ion pair.
[169]
 
Moreover, the approach of using chiral 
anions to form certain octahedral scaffolds 
presupposes a matching charge in the de-
sired organometallic complex.[169,176,177] For 
example, the chiral tris(tetrachlorobenzene-
diolato)phosphate(V) anion can be obtained 
either as  or  form.[169] Moreover, this 
compound can be used as an auxiliary in 
the asymmetric synthesis of organometallic 
complexes and for the selective extraction of 
a particular enantiomer via ion pair for-
mation, see Scheme 2.[176,187] However, the 
design of a kinase inhibitor in contrast 
claims ideally for a neutral compound, which 
is suitable to pass the lipid bilayer of a cell 
membrane via passive diffusion.[188] 
High inertness of the complex as well 
as a high persistence of the absolute stere-
ochemistry are desirable features for organ-
ometallic compounds interacting with biolog-
ical structures to avoid unspecific binding or 
unintended release of the metal 
core.[152,189,190] Coordination compounds of 
the d6 metals like RuII, OsII, RhIII, and IrIII 
fulfill these criteria.[167] But at the same time 
this characteristic poses significant chal-
lenges for the asymmetric synthesis using 
auxiliaries coordinating to the metal centre 
compared to anion mediated asymmetric 
synthesis. The harsh conditions to coordi-
nate and to substitute the chirality inducing 
auxiliary by the final ligand limit available 
methods via this strategy.[167] After intensive 
research and experience on this area, the 
MEGGERS group reported innovative strate-
gies to overcome this issue like using 
switchable auxiliaries, which can possess 
different coordination preferences by trigger-
 
 
Scheme 3: The (S)-Salox ligand 24, an auxiliary in asymmetric synthesis, can be labilised by protonation followed 
by the substitution of other ligands under sustained stereoconfiguration.
[186]
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ing a recognition group e.g. via protonation 
or reduction.[131,132,191–194] For instance, the 
(S)-Salox ligand 24, utilised as auxiliary in 
asymmetric synthesis, can be labilised by 
protonation followed by the substitution of 
other coordinating ligands under sustained 
stereoconfiguration, Scheme 3.[186] It is 
noteworthy, that the proper choice of the 
appropriate solvent is crucial for stereo-
chemical outcome of the reaction: only co-
ordinating solvents, like acetonitrile or tetra-
hydrofuran (THF) are capable of 
suppressing racemization at the applied 
reaction temperature.[195] 
The smart optimization of reaction con-
ditions can further develop a former auxiliar 
into a true catalyst. The reaction of 27 
300 mM in ethylene glycol using 0.2 eq. of 
(S)-28 in the presence of TFA and bipyridine 
result in -[Ru(bpy)3]
2+ with a yield of 93 % 
and an er of 8.0:1.0, whereas the chiral 
compounds 27 acts as true catalyst with 
turnover numbers of more than three, 
Scheme 4.[132] Although, the feasibility of 
catalytic asymmetric coordination chemistry 
has been demonstrated, the broad applica-
tion must be established in future. 
Considering all restrictions, being in-
evitable for a metal based kinase inhibitor, 
ends up to following characteristics ideally 
united in one single compound: enantiopure, 
neutral, low molecular weight, inert complex, 
and persistent stereoconfiguration. In this 
work, ways to fulfill these requirements in a 
metal compound were elaborated and com-
pared to established ligand systems. More-
over, the chemical modification of the pre-
sented ligand systems to improve selectivity 
and specificity as well as pharmacological 
properties will be discussed. Closing, sruc-
tural inspirations guided by computer aided 
design will be introduced as a potential use-
ful tool.  
 
Scheme 4: A former auxiliar (S)-28 acts as a true catalyst under specialised conditions. The achiral starting material 
27 is converted to enantiomerically pure Δ-[Ru(bpy)3]
2+
 in an asymmetric catalysis.
[132] 
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3 Results and Discussion 
3.1 The Pyridocarbazole Pharmaco-
phore Ligand 
 
Figure 24: Superimposed crystal structures of pyrido-
carbazole-based complex (R)-9 (pdb: 2BZH)
[196]
 and 
an organoruthenium complex based on the pharma-
cophore ligand 34 (pdb: 4AS0),
[154]
 both bound to 
PIM-1. Both pharmacophore ligands mediate the 
complex binding into the ATP binding site of the target 
kinase. However, the residual ligand sphere is signifi-
cantly shifted in relation to each other, resulting in 
different selectivity and specificity. The carbon atoms 
of (R)-9 are presented in green and the carbon atoms 
of the 34 based organoruthenium complex are pre-
sented in cyan. Nitrogen atoms are shown in blue, 
oxygen atoms in red, sulfur in yellow and the rutheni-
um cores in teal. PIM-1 is presented as cartoon in 
grey. 
The pyridocarbazole pharmacophore 
ligand was established in the MEGGERS 
group as a bidentate ligand for metal com-
plexation mimicking the indolocarbazole 
moiety of staurosporine (8).[149] As depicted 
in Figure 21 the pyridocarbazole pharmaco-
phore ligand steers the entire coordination 
sphere into the kinase hinge region and is 
therefore the major mediator of target 
recognition. Nevertheless, additional phar-
macophore ligands with modified scaffolds 
have been successfully designed in the 
MEGGERS group to enlarge the set of organ-
ometallic compounds with new structures 
addressing the kinome with diverse affinity 
and selectivity profiles.[190,197] 
However, the pyridocarbazole ligand 
(31) serves as the standard pharmacophore 
ligand for the complexation reactions in this 
work. The convergent synthetic route starts 
with 1H-pyrrole-2,5-dione (35) which is re-
acted with bromine in an electrophilic addi-
tion for 18 h under reflux conditions and cat-
alysed by aluminium trichloride, see 
Scheme 5. The resulting 3,4-dibromofuran-
2,5-dione (36) in a yield of 47% serves as 
starting point for different maleimides. 36 
can be processed using either benzyl amine 
or methyl ammonium chloride to obtain 1-
benzyl-3,4-dibromo-1H-pyrrole-2,5-dione 
(37) (87%) or 3,4-dibromo-1-methyl-1H-
pyrrole-2,5-dione (38) (55%), respectively. 
Both reactions were performed in acetic acid 
at 130 °C for 16 h. These two modified ma-
leimides can be used directly for the photo-
cyclisation reaction resulting in modified 
pyridocarbazoles. A sufficient protection 
group must be applied to obtain an unsubsti-
tuted maleimide moiety in the final pyrido-
carbazole pharmacophore ligand. 
 
Figure 25: The pyridocarbazole 31 as the first pharmacophore ligand derived from the indolocarbazole moiety of 
staurosporine served as lead structure for several new pharmacophore ligand scaffolds like 32, 33, 34 shifting the 
position of the coordination sphere and subsequently leading to organometallic kinase inhibitors with diverse affini-
ty and selectivity profiles.
[190,197]
 The coordinating atoms have been indicated by dashed arrows. 
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Scheme 6: FISCHER indole synthesis of 2-(pyridin-2-
yl)-1H-indole (46). 
Therefore, 3,4-dibromo-1H-pyrrole-
2,5-dione (39) obtained under the same re-
action conditions as 37 and 38 in 54% yield 
must be protected with the tert-butyldi-
methylsilyl protection group using tert-
butyl(1-methoxyvinyloxy)dimethylsilane (41) 
(54%) in acetonitrile under reflux conditions 
for 5 h followed by stirring for 8 h at ambient 
temperature. Methyl acetate (40) was react-
ed with lithium diisopropylamine, which was 
generated first in situ, 1,3-dimethyl-tetra-
hydropyrimidin-2(1H)-one (DMPU), and tert-
butyldimethylsilyl triflate in THF over 3 h 
from -78 °C to ambient temperature to ob-
tain 41 in 51% yield. 3,4-dibromo-1-(tert-
butyldimethylsilyl)-1H-pyrrole-2,5-dione (42) 
as the resulting intermediate can then be 
applied for the photocyclisation in analogue 
to 37 and 38. 
The second component for the pho-
tocyclisation reaction is 2-(pyridin-2-yl)-1H-
indole (46) or its modified derivatives. The 
unsubstituted 46 can be obtained in a 
FISCHER indole synthesis by reacting phe-
nylhydrazine (43) and 2-methyl-pyridyl-
ketone (44) in ethanol under slow heating to 
80 °C over a period of 15 min and reflux 
conditions for 45 min, see Scheme 6. The 
resulting 2-(1-(2-phenylhydrazono)ethyl) 
pyridine (45) (98%) is then further reacted to 
46 (94%) by the sequential addition of small 
portions into polyphosphoric acid and heat-
ing at 95 °C under firm stirring for 4 h. 
In contrast to the general reaction 
conditions applicable for maleimide deriva-
tives described above, the FISCHER indole 
synthesis cannot be applied universally to 
obtain modified pyridylindoles due to the 
harsh conditions of the reaction and the re-
action mechanisms itself, which bears the 
potential leading to rearrangements or the 
loss of attached groups.[198] 
 
Scheme 5: The synthesis of maleimide derivatives 37, 38, and 42. 
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Therefore, to synthesise modified 
pyridylindoles a synthetic route applying the 
Suzuki coupling was established, see 
Scheme 7.[149] First, the indole has to be 
protected with the tert-butyl carboxylate 
group using di-tert-butyl dicarbonate. The 
protection group masks the indole nitrogen 
and hinders potential interferences during 
the synthetic route. Moreover, it supports 
the deprotonation of the indole at the 2 posi-
tion for the formation of the boronic acid. 
Therefore, indole (47) was reacted with 
di-tert-butyl-dicarbonate and dimethylamino-
pyridine in THF at 4 °C for 16 h to afford 
tert-butyl 1H-indole-1-carboxylate (51) in 
quantitative yield. The same reaction condi-
tions were applied to obtain tert-butyl-5-(tert-
butyldimethylsilyl)-1H-indole-1-carboxylate 
(52) (93%), tert-butyl-5-benzyl-1H-indole-1-
carboxylate (53) (92%), and tert-butyl-5-
methoxy-1H-indole-1-carboxylate (54) 
(98%). 
All protected indole derivatives were 
then transformed into the appropriate bo-
ronic acids for the SUZUKI coupling using in 
situ generated lithium diisopropylamide and 
triisopropyl borate in THF in almost quantita-
tive yields. Nevertheless, the resulting bo-
ronic acids must be processed promptly due 
to the limited stability of the intermediates, 
see Scheme 8. As coupling partner, a selec-
tion of modified pyridines, 59 to 63, were 
used and combined with the synthesised 
boronic acids 55 to 58. The reaction was 
performed using tetrakis(triphenylphos-
phine) palladium(0) and sodium carbonate 
in a dimethoxyethane : water (4:1) mixture 
under reflux conditions for 16 h. The yields 
of the synthesised pyridylindoles 64 to 70 
varied from 47% to 79%. 
However, due to investigational find-
ings achieved during this work, only three 
different pyridylindoles 46, 71, and 72 were 
processed to the appropriate pyridoc-
arbazoles. Prior to the use of the pyridyl-
indoles for the monobromide synthesis and 
the following photocyclisation step, the 
deprotection of the tert-butyl-carboxylate 
group must be performed. Soaking the 
compounds 64 and 70 on silica gel under 
heating at 80 °C in vacuo for 16 h afforded 
the unprotected pyridylindoles 71 and 72 in 
quantitative and 93% yield, respectively. 
 
Scheme 7: The synthesis of the boronic acids 55 to 58 as coupling partners for the SUZUKI reaction. 
 
Scheme 8: The SUZUKI coupling using different boronic acids in combination with different pyridine derivatives led to 
the formation of a set of protected pyridylindoles 64 to 70. Two derivatives were further proceeded and deprotected. 
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The pyridylindoles 46, 71, and 72 
were reacted with the maleimides 37, 38, or 
42 in a MICHAEL reaction using lithium 
bis(trimethylsilyl)amide as base in THF to 
obtain the monobromides 73 to 76 in varying 
yields from 54% to 71%, see Scheme 9. 
These intermediates had to be converted 
immediately into the corresponding pyrido-
carbazoles due to their instability. The pho-
tocyclisation itself was performed in toluene 
under continuous water cooling. For this 
purpose, the compounds were irradiated 
with an iron iodide endowed mercury UV 
lamp of 700 W power and a wavelength of 
max = 350 nm. The finished pyridocarba-
zoles 77 to 80 were obtained in yields vary-
ing from 53% to 80%. The pyridocarbazoles 
77 to 80 were then used for the complexa-
tion reactions discussed in this work. More-
over, the pyridocarbazole derivatives 81 to 
84 from the internal compound library of the 
MEGGERS group have been used to synthe-
sise novel complexes with diverse inhibition 
profiles, see Figure 26. 
The established pyridocarbazole 
synthesis, offers many possibilities to intro-
duce additional functional groups. Especial-
ly, the convergent synthetic route increases 
the general flexibility and the quick access 
to a plethora of different structures. Never-
theless, the multistep synthesis is a disad-
vantage. One of the major tasks of the alter-
natively established compounds 32, 33, and 
34, beside the development of new scaf-
folds, was to decrease the number of syn-
thetic steps.[190,197] However, the pyrido-
carbazole ligand itself serves as reference 
pharma-cophore ligand to investigate the 
complementarily coordinating ligands pre-
sented in this work. 
 
Figure 26: Pyridocarbazole derivatives retrieved from 
the MEGGERS group internal compound library. 
   
 
Scheme 9: The monobromide synthesis and the following photocyclisation reaction affording the pyridocarbazole 
pharmacophore ligand. 
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3.2 Development of S6K1 Inhibitors 
3.2.1 Target Synopsis and Aim 
 
 
 
Figure 27: Growth factors, hormones, and amino 
acids, as proliferation and anabolism mediators, acti-
vate the downstream located mTORC1. This complex 
consecutively phosphorylates Thr389 in the hydro-
phobic motif of S6K, providing a docking site for 
PDK1, which then phosphorylates Thr229 in the acti-
vation segment, converting S6K into its active form.
[23]
 
S6 kinases (S6K) are members of 
the AGC serine/threonine kinases which 
belong to the RSK family. The catalytic do-
main is highly conserved and the phos-
phorylation of Thr-389 within the activation 
loop triggers the kinase induced by the 
phosphoinositide-dependent kinase-1 
(PDK1), see Figure 27.[199,200] The S6 kinas-
es act downstream of the phosphatidyl-
inositide-3-kinase (PI3K) pathway. Beside 
PDK1, mTOR is also involved in the activa-
tion of S6K1.[199–201] Whereas yeast contains 
one S6K kinase, called sch9, the human 
kinome covers two isoforms called S6K1 
and S6K2. S6 kinases are associated with 
many cellular processes, including protein 
synthesis, mRNA processing, cell growth, 
and cell survival mainly based on the phos-
phorylation of glycogen synthase kinase 3 
(GSK3) and the ribosomal S6 protein.[202,203] 
Both isoforms of S6K phosphorylate and 
activate the 40S ribosomal protein S6, which 
promotes protein synthesis through an in-
creased rate of mRNA transcription.[204] 
S6K1 also regulates cell proliferation 
through the cell cycle, in addition to promot-
ing cell survival by inactivating the pro-
apoptotic protein BAD.[205–207] 
Whereas S6 kinases are involved in 
indispensable cellular processes, a per-
turbed activation leads to severe diseases. 
Alterations in S6 kinase activity have been 
shown to play a critical role in many patho-
logic incidences, including diabetes, obesity, 
aging, and cancer.[208–210] Many melanoma 
cells exhibit constitutive activation of the 
PI3K-AKT pathway, which results in AKT 
phosphorylation and leads to an amplifica-
tion of the downstream targets mTOR and 
S6K1.[211] This increase in phosphorylation 
of ribosomal S6 by S6K1 results in in-
creased protein translation and cell growth. 
This effect can be abolished by the treat-
ment with rapamycin, an allosteric mTOR 
inhibitor, causing a significant dephosphory-
lation of S6K1 and consequently to a de-
creased cell growth.[212] However, the treat-
ment with rapamycin is accompanied by 
drawbacks, mainly reasoned in the abroga-
tion of feedback inhibitions of other path-
ways.[213] This cross-talk perturbance leads 
to side effects such as hyperglycaemia, hy-
percholesterolemia, and hyperlipidaemia.[214] 
Therefore, inhibition of S6K1 represents an 
alternative therapeutic strategy that may 
bypass the disadvantages of mTOR inhibi-
tion. Recent studies reveal S6K as being a 
critical node linking HER-family and PI3K 
pathway signaling, making it an effective 
target for single-agent therapy.[215]  
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3.2.2 Synthesis and Structural Investi-
gations of Organoruthenium(II) 
Complexes 
 
 
Figure 28: Octahedral organoruthenium complexes 
inhibiting S6K1. 
Highly sophisticated octahedral 
complexes were realised by an extensive 
screening of potential ligands suiting the 
requirements of a hexavalent metal 
centre.[143–145,152] The tridentate 1,4,7-trithia-
cyclononane ligand is capable of both, being 
a synthetically quickly accessible com-
pound, and fitting in numerous binding sites 
as a part of organometallic inhi-
bitors.[140,151,152,154] 85 and 86, which were 
synthesised during former studies in the 
MEGGERS group, also contain this motif and 
turned to be selective and potent S6K1 in-
hibitors, beside 87, see Figure 28.[216] But, 
the ligand is only capable of forming hydro-
phobic VAN-DER-WAALS contacts and offers 
no additional functional groups to either form 
hydrogen bonds or to enhance physico-
chemical properties, e.g.: solubility. There-
fore, ligands offering modification sites to 
improve biomolecular recognition as well as 
physico-chemical parameters for the conse-
quent development of octahedral organome-
tallic complexes are highly desirable. 
Keeping the sulfur atoms for com-
plexation sustained, we introduced a meth-
ylene group into the cyclic ring system to 
include a secondary amine function. This 
additional group is known to act as both, a 
hydrogen bond acceptor and hydrogen bond 
donor.[217–219] Moreover, a secondary amine 
influences the protonation state of the com-
plex at different pH levels and subsequently 
the potential membrane permeability.[220–222] 
 
 
Scheme 10: Synthesis of complex precursor 95. The key steps are the formation of the medium-sized ring 90 by a 
nucleophilic substitution, the functional group interconversion by a reductive amination to 91. Prior to the complexa-
tion a potential cross-coordination has to be avoided by protecting the secondary amine group by allyl chlo-
roformiate. To obtain the reactive precursor 95, a substitution of all monodentate ligands towards acetonitrile as 
better leaving group for the pyridocarbazole introduction is necessary. 
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The synthesis of the modified ligand 
is similar to the published one of 
1,4,7-trithiacyclononane, according to Blow-
er et al.,[223] with slight modifications, see 
Scheme 10. First, the ten-membered ring 
has to be formed. For this reason, caesium 
carbonate was suspended in dimethyl-
formamide (DMF) and heated to 60 °C. 
Caesium carbonate acts as a base, depro-
tonating the thiol groups of the 2,2'-thio-
diethanethiol (89) and increasing their nu-
cleophilic character. The use of caesium 
carbonate at this step is substantial, due to 
the size of the caesium ion preorganizing 89 
for the nucleophilic substitution reac-
tion.[223,224] Furthermore, this preorganisation 
reduces the competing polymerisation reac-
tion beside the intended cyclisation. 
1,3-dichloracetone 88 was pre-diluted in 
DMF and added drop wise to the reaction 
mixture. The drop wise addition of the reac-
tants was performed over a time period of 
9 h followed by an additional 9 h of stirring 
at 60 °C. The low concentration (38 mmol/L) 
of both reaction partners is crucial to avoid 
the mentioned polymerisation. This fact lim-
its the amount of reactants applicable in a 
single reaction batch. The yield of 46% is 
low but not unusual for medium-sized ring 
synthesis.[225]
 The resulting 1,4,7-trithiacyclodecan-
9-one (90) was then processed in a reduc-
tive amination using potassium carbonate 
and methyl ammonium chloride to form the 
imine intermediate in situ. The reaction was 
performed in methanol at 34 °C for 2 hours. 
Sodium cyanoborohydride was used as a 
reducing agent and the reaction mixture was 
stirred over night at 34 °C. The N-methyl-
1,4,7-trithiacyclodecan-9-amine (91) ligand 
was obtained at 36% yield. It is noteworthy 
that the sp2-carbon centre of 90 turned into 
a prochiral sp3-carbon during this reaction 
procedure. Due to the symmetric character 
of the ligand, this fact has no further influ-
ence on the synthesis, unless it is coordi-
nated to the metal centre, see Chapter 
3.2.4. 
Prior to complexation, the secondary 
amine of 91 had to be protected to avoid 
competing cross-coordination towards a 
second metal ion. The most suitable protec-
tion group for this purpose is the al-
lyloxycarbonyl group, which can be cleaved 
under mild orthogonal conditions after com-
plexation. Therefore, 91 in methylene chlo-
ride was reacted with allyl chloroformiate 
(92), pyridine, and 4-dimethylaminopyridine 
at 0 °C according to standard protection 
procedure.[226] The allyl methyl (1,4,7-tri-
thiacyclodecan-9-yl) carbamate ligand (93) 
was obtained in a yield of 70% and was fur-
ther processed in the complexation reaction. 
 
Scheme 11: Synthesis of ruthenium(II) complex 87. The acetonitrile ligands of the reactive precursor 95 were 
sequentially substituted by the pyridocarbazole ligand 78 and sodium thiocyanate. The deprotection step of the 
allyloxycarbonyl using tetrakis(triphenylphosphine) palladium(0) results in the final complex 87. 
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Dichlorotetrakis(dimethylsulfoxide) 
ruthenium(II) as a standard precursor was 
used to coordinate (93). The reaction was 
performed in chloroform under reflux condi-
tions for 5 h. The preliminary resulting com-
plex 94 was directly processed to ligand 
exchange by precipitating the chlorido lig-
ands using silver trifluoromethanesulfonate 
in acetonitrile under reflux conditions for 6 h. 
95 could be obtained in 87%. It is notewor-
thy that the prochiral carbon centre of 91 
turns into a stereogenic centre during the 
complexation reaction. Due to the high 
moisture sensibility of this compound, a di-
rect continuance into the complex synthesis 
is necessary. 
Therefore, the pharmacophore lig-
and 78 was reacted with the ruthenium pre-
cursor 95 using potassium carbonate as a 
base, in DMF at 85 °C under microwave 
irradiation for 40 min, followed by addition of 
sodium thiocyanate as the residual mono-
dentate ligand, see Scheme 11. After an 
additional 40 min at 85 °C and column 
chromatography, the organometallic com-
plex 96 was obtained as a racemic mixture 
in 59% yield. The crystal structure of 96 re-
veals the coordination pattern of the ligands 
towards the ruthenium metal centre, see 
Figure 29. The tridentate ligand forms two 
five-membered and one six-membered 
metallacycles. The six-membered metalla-
cycle aligns in a chair conformation as ob-
served for aliphatic rings. It must be high-
lighted, that the secondary amine function is 
oriented in equatorial position minimising the 
steric hindrance of the bulky allyloxycarbon-
yl protection group with the residual coordi-
nation sphere. The isothiocyanate ligand is 
observed to be coordinated in the N-bound 
form. 
To obtain the final complex 87, the 
allyloxycarbonyl protection group was 
cleaved using tetrakis(triphenylphosphine) 
palladium(0) in methylene chloride for 14 h 
and allowing the reaction mixture to warm 
from 0 °C to ambient temperature. The reac-
tion was quenched using sodium hydrogen 
carbonate, and after column chromatog-
raphy, the metal complex 87 was obtained 
in 47% yield. 
 
 
Figure 29:  Crystal structure of 96. Solvent Molecules were omitted for clarity. ORTEP drawing with 50% probabil-
ity of thermal ellipsoids. Selected bond lengths [Å] for 96: Ru1-N1 = 2.1411(18), Ru1-N4 = 2.124(2), 
Ru1-N36 = 2.061(2), Ru1-S1 = 2.2862(7), Ru1-S2 = 2.2802(6), Ru1-S3 = 2.3029(6). 
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3.2.3 Biological Investigations 
3.2.3.1 Screening and IC50 Determination 
 
A screening set of ten different stau-
rosporine-inspired organometallic ruthenium 
complexes against a diverse panel of 283 
protein kinases by Millipore (Kinase Profil-
erTM) led to the identification of 85 as a po-
tential inhibitor of S6K1, with 7% activity at a 
concentration of 100 nM in the presence of 
10 µM ATP. 86 has an almost identical 
chemical structure, differing only in the ex-
change of the substituted isothiocyanate 
towards an isocyanate, see Figure 28, lead-
ing to significantly less, only 54%, activity 
under the same conditions. In the kinase 
panel, the inhibitor 85 inhibited only 41 ki-
nases (16%) to less than 10% activity, in-
cluding S6K1 and the related S6K family 
members RSK1, RSK2, RSK3, and RSK4. 
To characterise the preliminary hits, 
biological investigations were performed in 
the MARMORSTEIN group. For this purpose, a 
radioactive kinase assays were performed 
to determine the activity of S6K1 protein 
constructs prepared in baculovirus-infected 
insect cells, in order to identify a construct 
that would be suitable for inhibitor testing. 
The construct preparation and the radio-
active kinase assays were performed by JIE 
QIN and JULIE S. BARBER-ROTENBERG. Initial 
tests revealed, that the full-length -I iso-
form of S6K1, S6K (1-525), and the isolated 
kinase domain, S6K (84-384), had low ki-
nase activity, although the full-length kinase 
showed more activity than the kinase do-
main, see Figure 30. The S6K1 protein con-
structs had low kinase activity because the 
full-length kinase contained the C-terminal 
auto-inhibitory domain. To address this is-
sue and express a more active kinase for 
further inhibitor studies, a S6K1 (1-421) 
construct was prepared, including both the 
Thr-252 and Thr-412 phosphorylation sites, 
based on previous data from Keshwani et 
al.[227] The results indicate that the catalytic 
domain of the S6K1aII isoform (residues 1-
398) is analogous to S6K1 (1-421) of the -I 
isoform. To further enhance the catalytic 
activity of S6K1 (1-421), the T412E mutant 
was prepared to mimic phosphorylation at 
this position and was co-expressed with 
PDK1 to promote phosphorylation of T252. 
Preparation of the S6K1 (1-421, T412E, 
PDK1 activated) protein resulted in a highly 
active kinase that was suitable for further 
inhibition studies in vitro, Figure 30. 
 
Figure 30: Radioactive kinase assays performed by 
JIE QIN and JULIE S. BARBER-ROTENBERG were used to 
determine the activity of five different protein con-
structs of S6K1. Only the S6K1 (1-421, T412E, PDK1 
activated) construct (cyan) resulted in a highly active 
kinase, which was suitable for further radioactive 
competition studies in vitro. 
 Both organoruthenium metal com-
plexes were assayed against the construct 
S6K1 (1-421, T412E, PDK1 activated) in a 
radioactivity-based kinase assay by JULIE S. 
BARBER-ROTENBERG to determine the IC50 
values of 33.9 nM for 85 and 23.5 µM for 86, 
respectively, at an ATP concentration of 
100 µM, see Figure 32. As a control, the IC50 
value of the unselective kinase inhibitor 
staurosporine was determined resulting in 
64.1 nM under the same conditions. Moreo-
ver, the S6K1 inhibitor PF-4708671 (97) was 
tested against S6K1 under the same condi-
tions as a literature known specific S6K1 
inhibitor, see Figure 31. An IC50 value of 
142.8 nM was determined for PF-4708671, 
consistent with published results.[228] 
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Given the apparent specificity and 
potency of 85, it became the lead structure 
for the development of second-generation 
organometallic S6K1 inhibitors covering 
charged and neutral octahedral organo-
ruthenium and organorhodium complexes. 
 
Figure 31: S6K1 inhibitor PF 4708671 (97).
[83] 
 
 
Figure 32: 85 (33.9 nM), 86 (23.5 µM), 87 (7.3 nM), 
Staurosporine (64.1 nM), and PF-4708671 (97) 
(142.8 nM) were assayed by JULIE S. BARBER-
ROTENBERG against the construct S6K1 (1−421, 
T412E, PDK1 activated) in a radioactive kinase assay 
using 100 μM ATP and 2 nM of enzyme. Data points 
represent mean values calculated from triplicates. 
3.2.3.2 Crystallisation Studies of 85 
 
To investigate the binding mecha-
nisms the crystallisation and structure deter-
mination of 85 bound in the ATP binding 
pocket of S6K1 were performed. In this con-
text, the crystal growth, preparation, and 
compound soaking was performed by JIE 
QIN and the structure was solved by JOHN 
DOSMIC. These studies revealed an unusual 
binding conformation. Whereas, initial trials 
to co-crystallise the S6K1 kinase domain 
(S6K1KD, residues 84-384) bound to 85, 
using several factorial screens, failed, the 
reproduction of the crystals of the S6K1 ki-
nase domain in complex with staurosporine, 
according to SUNAMI et al. were 
successful.[229] Thereafter, soaking of these 
crystals with high concentrations of 85, for 
the exchange of staurosporine by the or-
ganoruthenium inhibitor, led to crystals 
which diffracted to about 2.5 Å resolution 
and formed in space group P21 with two 
molecules per asymmetric unit. The struc-
ture was refined to Rwork and Rfree values of 
19.15% and 22.21%, respectively, with ex-
cellent geometry, see Table 13. Closing, the 
inhibitors were modelled after the full re-
finement of the protein. 
 
Figure 33: 85 bound to the active site of one of two 
S6K1 kinase molecules in the asymmetric unit 
(pdb: 4RLO). The -sheet rich N-lobe and the -helix 
rich C-lobe enclose the ATP-binding site. The protein 
surface discloses the substrate binding groove per-
fectly occupied by the organometallic inhibitor. Oxy-
gen atoms are depicted in red, nitrogen in blue, fluo-
rine in light blue, and sulfur in yellow. Carbon atoms of 
85 are depicted in grey. S6K1 is represented as car-
toon in cyan. 
 In accordance to the published struc-
tures of the S6K1 kinase domain, the kinase 
domain is bilobal, consisting of an sheet 
rich N-lobe and a -helix rich C-lobe.[229,230] 
The crystal structure revealed that only one 
staurosporine molecule could be substituted 
by 85 of the two protein molecules in the 
asymmetric unit. This is an additional proof 
that 85 is indeed an ATP-competitive inhibi-
tor, displacing staurosporine from the active 
site. Both, the staurosporine as well as the 
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85-bound protein molecules in the asymmet-
ric units are similar to each other with an 
overall r.m.s.d. of 0.68 Å for the shared at-
oms. 
 
Figure 34: Staurosporine bound to the active site of 
one of two S6K1 kinase molecules in the asymmetric 
unit (pdb: 4RLO). The -lactam ring of staurosporine 
forms two hydrogen bonds (red dashes). The back-
bone nitrogen of Leu-175 interacts with the lactam 
oxygen and the backbone oxygen of Glu-173 with the 
lactam nitrogen. The methylamine group of stauro-
sporine forms a third hydrogen bond (red dashes) to 
the backbone oxygen of Glu-222. Additional amino 
acid residues involved in VAN-DER-WAALS contacts are 
highlighted and labelled. Oxygen atoms are depicted 
in red, nitrogen in blue, and sulfur in yellow. S6K1 is 
depicted as cartoon with carbon atoms in cyan and 
carbon atoms of staurosporine are depicted in orange. 
 Although both molecules bind in the 
ATP binding pocket, the increased S6K1 
potency of the organoruthenium complex is 
caused by extensive interaction compared 
to staurosporine. The latter forms hydrogen 
bonds to S6K1 via the backbone oxygen of 
Glu-222 of the kinase with the nitrogen of 
the methylamine residue of the aliphatic ring 
system of staurosporine. Furthermore, the 
pyrrolidine ring of the aromatic indolocarba-
zole moiety of staurosporine forms hydrogen 
bonds to the backbone nitrogen of Leu-175 
and the backbone oxygen of Glu-173 of the 
kinase hinge region via the oxygen and ni-
trogen atom, respectively. Beside the hy-
drogen bonds VAN-DER-WAALS contacts are 
formed by Leu-97, Lys-99, Gly-98, Val-105, 
Ala-121, Tyr-174, Glu-179, and Met-225, 
see Figure 34. 
 
Figure 35: 85 bound to the active site of one of two 
S6K1 kinase molecules in the asymmetric unit (pdb: 
4RLO). The maleimide moiety of the pyridocarbazole 
ligand forms two hydrogen bonds (red dashes). The 
backbone nitrogen of Leu-175 interacts with the ma-
leimide oxygen and the backbone oxygen of Glu-173 
with the maleimide nitrogen. Additional amino acid 
residues involved in VAN-DER-WAALS contacts are 
labelled. Oxygen atoms are depicted in red, nitrogen 
in blue, fluorine in light blue, and sulfur in yellow. 
S6K1 is depicted as cartoon with carbon atoms in 
green and carbon atoms of 85 are depicted in grey. 
 Compared to staurosporine, 85 re-
tains two hydrogen bonds between the 
backbone atoms of the hinge residues 
(Glu-173 and Leu-175) and the maleimide 
ring of 85, as well as all of the 
VAN-DER-WAALS interactions, but forms addi-
tional interactions between the ruthenium 
coordination sphere and the protein, as 
shown in Figure 35. In particular, the isothi-
ocyanate group of 85 leads to VAN-DER-
WAALS interactions with Gly-100 and 
Val-105 of the kinase p-loop. The 1,4,7-tri-
thiacyclononane ligand forms VAN-DER-
WAALS contacts to Gly-100 of the p-loop, 
Glu-179 and Glu-222 across from the 
p-loop, where the protein substrate is likely 
to bind, as well as to Thr-235 and Asp-236 
of the activation loop. Comparing the stau-
rosprine bound S6K1 structure to the 85 
bound S6K1 structure of the asymmetric unit 
indicate a dramatic movement of these ami-
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no acid residues towards 85, see Figure 36. 
The binding of 85 to S6K1 also introduces 
significant structural changes in the kinase 
relative to the staurosporine complex. These 
structural changes appear to be indirectly 
caused by the 1,4,7-trithiacyclononane lig-
and of 85. The D-helix of the staurosporine 
complex is about two turns longer at its 
N-terminus than the corresponding helix of 
the 85 complex, where the corresponding 
segment takes on a -strand conformation. 
This structural differrence appears to be 
driven by the interaction of the tridentate 
ligand of 85 with Glu-179. 
 
Figure 36: Superimposed structures of S6K1 bound to 
staurosporine and bound to 85. Glu-179, Glu-222, 
Thr-235 and Asp-236 undergo a dramatic movement 
comparing the staurosporine bound conformation to 
the 85 bound conformation (red arrows) (pdb: 4RLO). 
The tridentate 1,4,7-trithiacyclononane ligand of 85 
seems to cause these drastic alterations in the secon-
dary structure, whereas the D-helix of the stauro-
sporine complex is nearly two turns longer at its N-ter-
minus than the corresponding helix in the 85 bound 
form possessing a -sheet conformation instead. 
Oxygen atoms are depicted in red, nitrogen in blue, 
fluorine in light blue, and sulfur in yellow. S6K1 bound 
to 85 depicted as cartoon with carbon atoms in green 
and carbon atoms of 85 in grey; S6K1 bound to stau-
rosporine is depicted as cartoon with carbon atoms 
cyan and carbon atoms of staurosporine in orange. 
On the opposite side of the inhibitor, 
the staurosporine complex has an activation 
loop folded towards the ATP active site in an 
inactive conformation without an ordered 
C-helix, as previously reported.[230] Striking-
ly, the 85 complex contains a well-defined 
C-helix of about 2 turns. The different 
alignment of the C-helix in the two struc-
tures appears to be centred around the 
N-terminal region of the activation loop that 
undergoes about a 6 Å movement towards 
85 compared to staurosporine. The move-
ment of the activation segment towards the 
85 inhibitor appears to be mediated by the 
VAN-DER-WAALS interactions between 
Thr-235 and Asp-236 with the 1,4,7-trithia-
cyclononane ligand, see Figure 36. This in 
turn, provides enough space for the C-helix 
to be formed and being stabilised by VAN-
DER-WAALS contacts between Phe-237 of 
the activation loop and Leu-147 of the 
C-helix as well as a hydrogen bond be-
tween Lys-123 of the small domain and 
Glu-143 of the C-helix, see Figure 37. In-
terestingly, these interactions are character-
istics of the active conformations of kinases, 
even though the activation segment is in an 
inactive conformation. 
 
Figure 37: The αC-helix (magenta) is more ordered in 
the 85-bound S6K1 structure. This conformation is 
based on hydrophobic interactions between Phe-237 
and Leu-147, and a hydrogen bond between Lys-123 
and Glu-143 (pdb: 4RLO). Oxygen atoms are depicted 
in red, nitrogen in blue, fluorine in light blue. S6K1 
bound to 85 is depicted as cartoon with carbon atoms 
in green and carbon atoms of 85 are depicted in grey. 
In contrast, the activation loop is is 
turned outwards in case of the staurosporine 
bound S6K1 placing Phe-237 and Asp-236 
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in sterically hindered positions to form the 
C-helix, see Figure 36. Concluding, 
whereas staurosporine bound to S6K1 in-
duces the inactive conformation, the 
S6K1/85 complex has characteristics of 
both, the inactive and active kinase, confor-
mations. 
3.2.3.3 Development of Second Genera-
tion Organometallic Ruthenium In-
hibitors 
 
85 offered an IC50 value in the mid-
nanomolar range and the co-crystal struc-
ture confirmed that it is a competitive inhibi-
tor binding in the ATP-pocket of the S6K1. 
Therefore, 85 was a promising lead struc-
ture for the design of second generation 
S6K1 inhibitors. The organometallic com-
pounds offer plenty of possible positions for 
modifications regarding e.g.: the pyrido-
carbazole moiety or the different coordi-
nated ligands. As previous work proved, 
modifications in the coordination sphere can 
have significant effects on binding affinities 
and kinase selectivity.[140,149,231] Moreover, 
the crystal structure of 85 bound to S6K1 
indicated several positions suitable for 
chemical elaboration to improve specificity 
for the kinase. A series of 64 derivatives of 
85 were synthesised by the MEGGERS group 
with modifications at the pyridocarbazole 
and the remaining ligand sphere. Then, they 
were tested for inhibition of S6K1 activity 
using both a radioactive kinase assay and 
an ADP-Glo assay with 1 µM of compound, 
by the MARMORSTEIN group.[232] Twenty-five 
of these inhibitors were further screened 
using 250 nM of compound. The eight com-
pounds that inhibited S6K1 to less than 25% 
activity, were assayed to determine their 
IC50 values (at 100 µM ATP). This analysis 
produced several compounds that inhibited 
S6K1 similarly or more potently than 85 with 
compound 87 (Figure 28) as the most potent 
one with an IC50 of 7.3 nM, using 100 µM of 
ATP and 2 nM of enzyme, see Figure 32. 
 
Figure 38: 87 was analysed by JULIE S. BARBER-
ROTENBERG against the construct S6K1 (1−421, 
T412E, PDK1 activated) in a radioactive kinase assay 
using varying concentrations of ATP and 2 nM of en-
zyme. The determined IC50 values are: 3.61 nM (1 µM 
ATP), 4.46 nM (10 µM ATP), 6.90 nM (100 µM ATP), 
11.23 nM (250 µM ATP), and 18.86 nM (500 µM ATP). 
Data points represent mean values calculated from 
triplicates. 
3.2.3.4 Characterisation of 87 
 
The radioactive kinase assays, using 
either S6K1 or S6K2 as target molecule, 
resulting to the following IC50 values were 
performed by JULIE S. BARBER-ROTENBERG. 
Testing the inhibitor 87 at a range of con-
centrations from 1 µM ATP to 500 µM ATP 
resulted in an expected increase of the IC50 
value concurrent with the increasing ATP 
concentrations from 3.61 nM at 1 µM ATP to 
18.86 nM at 500 µM ATP, confirming that 87 
is an ATP competitive inhibitor, see Figure 
38. The increase in IC50 values between 
1 µM and 500 µM ATP is quite modest com-
pared to the range published before, indicat-
ing that the inhibitor binds very tightly within 
the ATP binding site.[232] 
To further prove the specificity of 87 
for the S6K1 isoform, the compound was 
also analysed against recombinant S6K2, 
which resulted in an IC50 value of 11.2 nM, 
which is in the same range as the IC50 value 
for S6K1, see Figure 39. Thus, leads to no 
significant prevalence of 87 for any S6K 
isoform. Indeed, S6K1 and S6K2 share 83% 
sequence identity in the catalytic domain.[233] 
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Figure 39: Radioactive kinase assay of 87 (11.2 nM) 
against S6K2 using 100 µM of ATP and 2 nM of en-
zyme; performed by JULIE S. BARBER-ROTENBERG. 
To establish the kinase selectivity 
profile of 87, the compound was submitted 
at a concentration of 100 nM to the Discov-
eRx KINOMEscanTM performed by 
LeadHunter Discovery Services. 87 was 
tested against 456 kinases. The results for 
primary screen binding interactions are re-
ported as percent of control ('% Ctrl', 
(POC)), where lower numbers indicate 
stronger hits and larger red circles in the 
dendrogram, see Figure 40. Empiric investi-
gations proved that binding constants (Kd) 
are correlated with primary screening re-
sults, whereas lower POC values correlate 
with low Kd values (higher affinity interac-
tions). Moreover, the selectivity score (SS) 
is a quantitative measure of compound se-
lectivity. It is calculated by based on the 
number of kinases bound by the compound 
divided by the total number of distinct kinas-
es tested, excluding variants. Furthermore, 
this score value can be calculated for differ-
ent selectivity levels using POC as a poten-
cy threshold, e.g. below 35% or 10%. These 
SS clustered in different selectivity score 
types (SST) provide a quantitative method 
of describing compound selectivity and allow 
a facilitated comparison of different com-
pounds among each other. 
87 demonstrated a high degree of 
kinase selectivity. Only 10 kinases (2.2%) 
showed less than 10% activity (SST(10)) 
and only 26 kinases (5.7%) showed less 
than 35% (SST(35)). In analogue to 85, 87 
showed characteristic inhibition of the CAM, 
DAP, FLT, PIM, and RSK family member 
kinases. Unexpectedly, S6K1 itself had a 
residual activity of 71% in the DiscoveRx 
KINOMEscanTM with 70 kinases (15.3%) 
showing a higher degree of inhibition than 
S6K1. The potency of 87 seems to be 
greater against the S6K1 prepared by our 
protocol than the preparation performed by 
Lead Hunter Discovery Services. The differ-
ent S6K1 kinase preparation and/or phos-
phorylation state, used by Lead Hunter Dis-
covery Services, may have led to the 
different 87 potencies measured for S6K1. 
Nevertheless, taking together the analysis of 
87 against S6K1 and the kinase profiling 
results led to the conclusion, that 87 exhibits 
a high degree of kinase selectivity. 
 
 
Figure 40: Kinase profiling of 87. The complex was 
tested against 456 human kinases at 100 nM by an 
active-site-directed affinity screening (KINOMEscan
TM
, 
DiscoveRx, LeadHunter Discovery Services). The 
dendrograms show the remaining POC levels of the 
kinases in percent to the control depicted as red cir-
cles. The selectivity score type (SST), the number of 
hits (NH) as well as the selectivity score (SS) of 87 
are: SST(35) NH(20) SS(0.051); SST(10) NH(10) 
SS(0.025); SST(1) NH(2) SS(0.005). 
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3.2.3.5 Crystallisation Studies with 87 
 
To investigate the molecular mecha-
nisms for the increased potency of 87 over 
85, the X-ray crystal structure of 87 in com-
plex with S6K1 to 2.7 Å resolution was de-
termined, see Table 13. In this context, the 
crystal preparation and growth was per-
formed by JIE QIN, the compound soaking 
was performed by JEMILAT SALAMI, and the 
structure was solved by JOHN DOSMIC. The 
overall structure for the 87-bound S6K1 
(pdb: 4RLP) is very similar to the 85-bound 
structure (pdb: 4RLO), with an r.m.s.d. of 
0.54 Å for all atoms. Especially the p- and 
activation-loops, the D, and the C-helices 
take an almost identical conformations, alt-
hough the C-helix is about one turn shorter 
at its N-terminal end, see Figure 41. 
 
Figure 41: Superimposed structures of S6K1 bound 
to 85 (green) (pdb: 4RLO) and bound to 87 (blue) 
(pdb: 4RLP). The αC-helix of S6K1 (red circle) is one 
turn shorter at its N-terminal end of the 87-bound 
structure compared to the 85-bound structure. Oxygen 
atoms are depicted in red, nitrogen in blue, fluorine in 
light blue. S6K1 bound to 85 is depicted as cartoon 
with carbon atoms in green and carbon atoms of 85 in 
grey. S6K1 bound to 87 is depicted as cartoon with 
carbon atoms in navy and carbon atoms of 87 in apri-
cot. 
87 retains all interactions made by 
85, covering some additional interactions 
including a hydrogen bond between the 
backbone carbonyl of Lys-99 of the kinase 
p-loop with the amine ligand of the 
N-methyl-1,4,7-trithiacyclodecan-9-amine 
ligand. The methoxy group of the pyrido-
carbazole moiety forms VAN-DER-WAALS 
interactions with Tyr-174 of the kinase hinge 
region, see Figure 42. These additional in-
teractions of 87 likely contribute to the in-
creased potency of 87 over 85. The protru-
sion of the amine ligand into the region 
where protein substrate binds for phos-
phorylation probably also contributes to the 
increased inhibitor potency. 
 
Figure 42: 87 forms more interactions with the ATP 
binding site of S6K1 compared to 85 (pdb: 4RLP). An 
additional hydrogen bond between the methylamine 
group and Lys-99 can be observed. The methoxy 
group of the pyridocarbazole pharmacophore ligand 
increases VAN-DER-WAALS contacts especially to 
Tyr-174. Oxygen atoms are depicted in red, nitrogen 
in blue, fluorine in light blue. S6K1 bound to 87 is 
depicted as cartoon with carbon atoms in navy and 
carbon atoms of 87 in apricot. 
3.2.3.6 Cellular Properties of 87 
 
After establishing that 87 functions 
as a potent ATP competitive S6K1 inhibitor 
in vitro, studies to characterise the cellular 
activity have been performed by PATRICIA 
REYES-URIBE. 87 was first tested for overall 
cell cytotoxicity and downregulation of 
phosphorylation of S6 in the 451Lu 
(BRAFV600E mutant) and 451Lu-MR 
(BRAF/MEK-inhibitor resistant) melanoma 
cell lines. Cells were treated with inhibitor 
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ranging from 0.001 µM to 10 µM for 22 h, 
see Figure 43. Neither the 451Lu or 451Lu-
MR cell lines showed a significant decrease 
in S6 phosphorylation, nor a decrease in cell 
viability as indicated by the absence of 
cleaved PARP. There was also no change 
in total S6 or peEF2K levels, indicating that 
mTOR was not targeted by 87. 
 
Figure 43: Western Blot of human cells treated with 
87. 451Lu (BRAFV600E mutant) and 451Lu-MR 
(BRAF/MEK-inhibitor resistant) melanoma cells were 
treated with increasing concentrations of 87 for 22 h. 
Cells were lysed and blotted for pS6 and other down-
stream effectors of S6K1. Neither the 451Lu or 
451Lu-MR cell lines showed a significant decrease in 
S6 phosphorylation. The absence of cleaved PARP 
indicates unaffected cell viability. No change in total 
S6 or peEF2K levels indicate that mTOR was not 
affected by 87. The experiment was performed by 
PATRICIA REYES-URIBE. 
 
Figure 44: AZD8055, an ATP-competitive dual 
mTORC1 and mTORC2 inhibitor.
[234,235]
 
 Furthermore, the effect of 87 in 293T 
cells, at both 3 h and 16 h of treatment, was 
investigated, see Figure 46. As controls, 
AZD8055 (98), PF-4708671 (97), and 99 
were measured in parallel. AZD8055 is an 
ATP-competitive dual mTORC1 and 
mTORC2 inhibitor that inhibits their phos-
phorylation and consequently the phos-
phorylation of the substrates S6K1 and 
4EBP1 as mTORC1 substrates, as well as 
the phosphorylation of AKT, which is the 
downstream target of mTORC2.[234,235] 
PF-4708671 is a reported S6K1 inhibitor 
that does not affect the phosphorylation of 
AKT. 99 is an 87 analogue with an IC50 of 
11 nM towards S6K1. In 99 the fluorine of 85 
is substituted by a hydroxymethyl group and 
the thiocyanate ligand by selenocyanate. 
 
Figure 45: Second generation S6K1 inhibitor 99. 
Previous studies using 97 demon-
strated a significant reduction in S6 phos-
phorylation in 293T cells within 30 
minutes.[228] Therefore, both a short time 
point of 3 h and long-time point of 16 h for 
treatment were evaluated. As expected, the 
98 mTOR inhibitor showed a significant de-
crease in downstream target levels of pS6 at 
both the S235 and S240 sites, along with a 
decrease in pAKT at T308 and S473. The 
97 compound showed a modest decrease in 
phosphorylation of S6 at the 3 h time point, 
but this phosphorylation returned to near 
basal levels by the 16 h time point. No effect 
on the phosphorylation of AKT was ob-
served. Notably, neither 87 nor 99 inhibited 
phosphorylation of S6 or AKT. Therefore, 87 
either has poor cell membrane permeability 
or the inhibition of S6K1 in cells does not 
significantly reduce S6 phosphorylation. The 
latter possibility is consistent with the fact 
that the structurally unrelated compound 97 
also shows poor inhibition of S6 phosphory-
lation in cells. 
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Figure 46: Western Blot of 293T cells treated with 
AZD8055 (98) (dual mTORC1 and mTORC2 inhibitor), 
PF-671 (4708671) (97), 87, or 99 for 3 or 16 h. 
AZD8055 shows a significant decrease of pS6 at the 
S235 and S240 sites and a decrease of pAKT at T308 
and S473. PF-4708671 shows a modest decrease in 
phosphorylation of S6 after 3 h, but almost basal lev-
els after 16 h, and no effect on the phosphorylation of 
AKT. Neither 87 nor 99 inhibit phosphorylation of S6 
or AKT. The experiment was performed by PATRICIA 
REYES-URIBE. 
Moreover, S6K2 is also capable of 
S6 phosphorylation and could circumvent an 
S6K1 inhibition in a cellular system.[236] To 
verify if 87 is able to inhibit S6 phos-
phorylation in a setting excluding S6K2, its 
inhibition potency of S6 phosphorylation in 
budding yeast was investigated by HAIYING 
LIU, where only a single kinase, sch9, is 
orthologous to human S6K1. In this system, 
the treatment of wild-type budding yeast 
cells (BY4742) with 87 significantly de-
creased the level of phosphorylated S6 in a 
dose dependent manner, see Figure 47. At 
the highest dosage, S6 phosphorylation was 
reduced to a level similar to the sch9 
knockout strain. This control experiment 
suggests that 87 functions as an inhibitor of 
S6 kinases in vivo in a yeast cellular system. 
 
Figure 47: Western Blot of BY4742 budding yeast 
cells treated with 87 for 4 h. They were then lysed and 
blotted for pS6. 87 significantly decreased the level of 
phosphorylated S6 in a dose-dependent manner. At 
1 µM dosage, S6 phosphorylation level is similar to the 
sch9 knockout strain. Quantitative Western blot sig-
nals were detected by Li-Cor, and the relative pS6 
levels were calculated by normalizing raw pS6 meas-
urements to GAPDH signals. (∗) p< 0.05 (two-tailed 
student-t test, n = 3). The experiment was performed 
by HAIYING LIU. 
3.2.4 Interpretation 
 
The Millipore Kinase Profiler and ra-
dioactivity-based kinase assays proved 85 
as a selective and potent S6K1 inhibitor with 
an IC50 of 100 nM and inhibiting 93% of 
S6K1 activity and only 16% of 283 kinases 
by less than 90%. Furthermore, it served as 
a lead compound for a second generation of 
potent and selective S6K1 inhibitors. 86, an 
analogue in which an isocyanate group re-
places the monodentate isothiocyanate is 
about 1000-fold less potent, implying that 
potency and specificity could be further op-
timised. The crystal structure of 85 bound to 
S6K1 provided important molecular insights 
for the development of 87, a compound con-
taining a novel ligand scaffold and an IC50 in 
the single digit nanomolar range for S6K1. 
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Moreover, the crystal structure of 87 bound 
to S6K1 revealed the molecular basis for the 
compound’s potency and selectivity to 
S6K1. 
 To investigate the efficacy of 87 in 
living cells, the inhibitor was evaluated in 
both human 293T and BRAFV600E mutant 
melanoma cells and in budding yeast. 87 
was only able to inhibit S6 phosphorylation 
in yeast cells. This results may be evoked 
by the following suggested incidences: ei-
ther the compound is unable to enter human 
cells, a significant shift in the IC50 of the 
compound occurs in the presence of physio-
logical levels of ATP, or the uninhibited 
S6K2 isoform in human cells, is still capable 
of maintaining S6 phosphorylation. Regard-
ing that 87 had previously been used to 
successfully target MST1, PAK1, and PI3K 
in cells, the second possibility seems to be 
plausible.[159,188,231]  
The setting of the radioactive kinase 
assay prohibits measurements at physio-
logical levels of ATP. Nevertheless, the ac-
tivity of 87 against S6K1 using an ATP 
range from 10 µM to 500 µM and the subse-
quent increase of IC50 values with increasing 
ATP concentrations, is consistent with 87 
binding competitively to ATP in the ATP 
binding site. Moreover, this conclusion is 
further confirmed by the crystal structure of 
the S6K1/87 complex. Interestingly, the IC50 
ranged from 3.91 nM at 10 µM ATP to only 
25.79 nM at 500 µM ATP (a 6-fold increase), 
suggesting that S6K1 binds ATP relatively 
loosely. Therefore, it is likely that 87 is able 
to displace ATP even at the higher physio-
logical concentration. Based on this accu-
mulated data, 87 is supposed of being una-
ble to inhibit S6 phosphorylation in human 
cells because S6 is still phosphorylated by 
the uninhibited S6K2. 
 S6K1 and S6K2 share 83% 
sequence identity in the catalytic domain.[233] 
A study involving S6K1/2 knockdown in 
mice suggests that both S6K1 and S6K2 are 
required for full phosphorylation of S6, but 
S6K2 may be the more important one for the 
phosphorylation of S6.[236] The MEK inhibitor 
AZD6244 (100) showed additive effects on 
decreasing the phosphorylation of S6 in 
vitro, when treated in combination with 
siRNA inhibition of both S6K1 and S6K2, 
indicating the importance of S6K2 in the 
phosphorylation of S6.[237] Furthermore, 
while pathologically inconspicuous tissues 
often express low levels of S6K2, over-
expression of S6K2 in cancer cells is 
observed more commonly than an over-
expression of S6K1.[238–241] Concluding, 
targeting S6K2 either alone or in 
combination with S6K1 may be a more 
promising option for direct S6 inhibition in 
melanoma cells and potentially other cancer 
forms. 
 
Figure 48: Structure of the MEK inhibitor Selumetinib 
(AZD6244) (100).
[242]
 
 Despite the similarities in the catalyt-
ic domain, homology modelling between 
S6K1 and S6K2 indicates an important dif-
ference in residue Tyr-174 which is crucial 
for binding of 87 and is exchanges for a cys-
teine in S6K2.[243] This residue is located in 
the hinge region of S6K1 and forms an im-
portant VAN-DER-WAALS contact with the 
methyl group of the secondary amine, which 
cannot be formed with a cysteine residue. 
This circumstance suggests that 87 may not 
be a potent inhibitor for S6K2. However, the 
cumulated data show no significant preva-
lence of 87 towards S6K2. The perinatal 
lethality of S6K1-/-/S6K2-/- knockout mice 
implies that S6K2 targeting may need to be 
selective for therapeutic value.[236] Up to 
now, no commercially available S6K2-
selective inhibitors are reported, indicating a 
potential target for the next series of organ-
ometallic inhibitors. 
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Taken together, 87 is a potent and 
selective S6K1 inhibitor that should be use-
ful to probe S6K1 function and could act as 
a starting point for the development of effi-
cacious S6K inhibitors for therapeutic use. 
Although, to realise the selective targeting of 
S6K2, especially the structural challenges of 
the metal based inhibitor had to be solved. 
In particular, 87 is based on the 85 lead 
structure, but it differs by a methoxy group 
instead of the hydroxyl group at the pyrido-
carbazole moiety and the ten-membered 
thioether-containing tridentate ligand instead 
of the nine-membered ring. Especially the 
substitution of the nine-membered ring from 
the symmetrical 1,4,7-trithiacyclononane 
ligand to a prochiral 1,4,7-trithiacyclodecane 
bearing a basic N-methylamine group at the 
9-position significantly increased the struc-
tural complexity of the inhibitor, which is 
exemplified by the number of possible ste-
reoisomers. This prochiral stereogenic cen-
tre becomes a true stereocentre after the 
complexation reaction compared to the tri-
dentate ligand in the uncoordinated state. 
Therefore, the coordination must be 
controlled to obtain the desired complex 
which directs the hydrogen bond accepting 
as well as donating N-methylamine group in 
the ATP binding site of S6K1 in optimised 
fashion. The orientation of the N-methyl-
amine functionality coordinated to the metal 
centre underlies several synthetic principles, 
which can be utilised by a smart reaction 
procedure. Therefore, a detailed analysis of 
the stereogenic effects during complexation 
must be considered to transfer and improve 
the concepts to design future complexes 
with desired structure. 
During this synthetic route, the al-
lyloxycarbonyl group was chosen to protect 
the N-methylamine functionality combining 
several favourable advantages at once. The 
most important reason is to avoid the for-
mation of possible side products during the 
complexation reaction itself due to the 
cross-coordination of the N-methylamine 
group to a second metal ion. Further, the 
synthetically orthogonal deprotection of the 
allyloxycarbonyl group can be performed 
under mild conditions using tetrakis(tri-
phenylphosphine)palladium. Nevertheless, 
due to its bulkiness, the allyloxycarbonyl 
group is an ideal modification to implement 
a large residue to the N-methyl-1,4,7-tri-
thiacyclodecan-9-amine ligand leading to a 
substrate based stereocontrol during the 
complexation reaction. The ruthenium pre-
cursor has two different possibilities to coor-
dinate to the tridentate ligand resulting in 
different orientations of the allyloxycarbonyl 
protected N-methylamine functionality, see 
Figure 49. Both, the coordination from the 
front side and from the back side, lead to a 
six membered ring with the metal ion at one 
end, highlighted in red. This cyclic six mem-
bered metallacycle can be assumed to act 
similarly to cyclohexane with the corre-
sponding sterical and conformational princi-
ples. Therefore, the coordination of the met-
al ion from the front side leading to a six 
membered metallacycle in a stable chair 
conformation as well as setting the allyloxy-
carbonyl protected N-methylamine group 
into an equatorial position is highly favoured 
in contrast to all other possible structural 
isomers. 
The final exchange of the three 
monodentate ligands by the pyridocarbazole 
and the isothiocyanate also underlies mainly 
steric effects forced by the coordinated al-
lyl-N-methyl-(1,4,7-trithiacyclodecan-9-yl) 
carbamate. The bulky pyridocarbazole lig-
and coordinates as far as possible from the 
tridentate ligand and coordinates therefore 
at the opposite positions to the sulfur atoms 
of the six-membered metallacycle, leaving 
only one residual position for the isothiocya-
nate. Furthermore, the described principles 
could be assured by the obtained crystal 
structure of the allyloxycarbonyl protected 
precursor of 87, see Figure 29. Since the 
coordination positions for the two nitrogen 
atoms of the pyridocarbazole ligand towards 
the metal centre are both equal but the pyri-
docarbazole itself is asymmetric, a 180° flip 
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of the pharmacophore ligand leads exactly 
to the enantiomer, which is the bioactive 
one, see Figure 42. 
The stereocontrol of the coordination 
sphere induced by the bulky allyloxycarbon-
yl-group is comparable to the concept intro-
duced in Chapter 2.3. Even though the in-
fluence of the protection group during 
synthesis is valuable, its presence in the 
final inhibitor would be a disadvantage due 
to steric hindrances in the binding site of 
target kinases. For the purpose of inhibitor 
design with predefined structural scaffold, 
large persisting groups controlling the coor-
dination sphere via steric effects cannot be 
applied for future development. Moreover, 
cleavable groups claim for additional syn-
thetic steps, dramatically increasing the ef-
fort of the entire workflow. Nevertheless, the 
chirality-at-metal itself was not affected by 
the N-methyl 1,4,7-trithiacyclodecan-9-
amine ligand due to its intrinsic symmetry. 
Therefore, the investigated complex 87 was 
obtained as a racemic mixture. However, 
the investigation of single enantiomers is 
standard for chiral organic compounds in 
biological context. To make organometallic 
compounds more and more adequate to the 
requirements of drug-like molecules, meth-
ods have to be developed to obtain a partic-
ular isomer in an enantiopure fashion. 
Several concepts could be pursued 
to achieve this goal based on different ap-
proaches. To avoid a racemic mixture the 
synthesis of organometallic kinase inhibitors 
must avoid the formation of enantiomers, 
e.g.: by forming separable diastereomers 
during the complexation, or forming only one 
possible coordination product in analogue to 
organic meso-compounds. Whereas the first 
approach could be achieved using chiral 
ligands transmitting the chiral information 
into the metal complex, the latter one could 
be achieved via highly symmetric ligands. 
Both concepts were investigated and the 
advantages and disadvantages will be dis-
cussed in the following Chapters. 
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Figure 49: Interpretation of steric effects leading to the observed conformation and configuration of 94. 
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3.3 Enantiopure Organorhodium(III) 
Complexes 
3.3.1 Target Synopsis and Aim 
3.3.1.1 PIM Kinases 
 
The proviral insertion in murine (PIM) 
lymphoma protein genes were first identified 
as oncogenes in mouse models in the 
1980s.[244] They are constitutively active and 
the regulation of activity is mainly regulated 
at the transcriptional and translational level 
induced by diverse signals depending on the 
cell type.[245,246] PIM kinases are expressed 
in haematopoietic,[247–249] neuronal,[250,251] 
vascular smooth muscle,[252] cardio-
myocyte,[253] endothelial,[254] and epithelial 
cell lineages.[255,256] Moreover, they are al-
ready expressed in early progenitors of 
some of these cells types,[257,258] and in em-
bryonic stem cells.[248,254,259] 
PIM kinases, covering PIM-1, PIM-2, 
and PIM-3, play important physiological 
roles evidenced by knock-out mice experi-
ments. For instance, PIM-1 deficient mice 
had a specific defect in IL-7 driven growth of 
pre-B cells, as well as IL-3 dependent 
growth of bone marrow-derived mast 
cells.[248,257] PIM-2 deficient mice had re-
duced T cell activation and expansion in the 
presence of the serine/threonine protein 
kinase mTOR inhibitor rapamycin;[260] PIM-3 
deficient mice had an increased glucose 
tolerance.[261] 
However, the physiological activities 
of the PIM kinase family is mediated through 
the phosphorylation of a broad range of cel-
lular effectors subdivided in different clas-
ses, i.e.: transcriptional regulators such as 
Myc,[262] Myb,[263] RUNX1 and RUNX3;[264]  
cell cycle regulators such as p21,[256,265] 
CDKN1B,[266] Cdc25A,[267] Cdc25C;[268] sig-
nalling intermediates such as Socs-1,[269] 
Socs-3,[270] and MAP3K5;[271] protein transla-
tion regulators such as eIF4B,[272] 
eIF4EBP1;[245] and apoptosis regulators 
such as BAD.[245,273–275] 
 
Figure 50: BAD has strong pro-apoptotic activity by 
binding to and neutralizing anti-apoptotic Bcl-2 part-
ners.
[276]
 Moreover, BAD regulates glucose-dependent 
mitochondrial respiration in hepatocytes and pancreat-
ic β-cells by activating glucokinase (GCK) via dimeri-
zation.
[276]
 The regulatory phosphorylation sites of 
BAD are Ser112, Ser135 and Ser155,
[276]
 phosphory-
lation of Ser112 and Ser135 lead to the binding of 
14-3-3
[274,276,277]
 required for phosphorylation on 
Ser155. The Ser155 phosphorylation is the rate-
limiting step for the dissociation from BCL-2 and 
BCL2L1.
[276]
 Several survival kinases like AKT, PIM, 
S6K1, PKA, RSK1 have been found to phosphorylate 
BAD, leading consequently to increased cell 
survival.
[274,276,278]
 
Due to the manifold interaction part-
ners and substrates, and their role in cell 
signaling, PIM kinases are potent onco-
genes overexpressed in a range of hemato-
poietic malignancies and solid cancers. PIM 
kinases are often overexpressed in the con-
text of increased Myc levels,[279] where the 
overexpression of PIM-1 has been observed 
to counteract Myc-induced apoptosis.[280] In 
addition, PIM kinases prevent cells from 
apoptosis by the phosphorylation of the 
proapoptotic BCL-2–associated agonist of 
cell death (BAD), which abolishes the bind-
ing with the anti-apoptotic protein BCL-2, 
leading consequently to increased cell sur-
vival, see Figure 50.[274] Moreover, they are 
involved in the cell proliferation through the 
phosphorylation of the cyclin-dependent 
kinase inhibitors p21.[266] Due to their digres-
sive expression in several human tumors, 
they could be important contributors in the 
pathogenesis of neoplasias including lym-
phomas, gastric, colorectal and prostate 
cancers.[281–283] PIM kinase expression is 
correlated with poor prognosis in most hem-
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atopoietic malignancies.[284–287] A similar 
association was observed in pancreatic duc-
tal carcinoma,[288] non-small-cell lung can-
cer,[289] in gastric cancer,[290] and squamous 
cell carcinoma of the head and neck.[291] The 
cumulated findings make PIM kinases to 
appealing targets for specific treatment of 
cancer and autoimmune diseases.[278,292,293] 
3.3.1.2 FLT-3 
 
The FMS-like tyrosine kinase 3 
(FLT-3) is a 993 amino acid long membrane 
bound receptor tyrosine kinase (RTK) of the 
subclass III family. It is composed of five 
immunoglobulin-like extracellular domains, a 
transmembrane domain, a juxtamembrane 
domain and two intracellular tyrosine kinase 
domains linked by a kinase-insert 
domain.[294] Two forms of human FLT-3 have 
been described: a 158–160-kDa membrane 
bound protein glycosylated at the extracellu-
lar N-terminus and an unglycosylated cyto-
solic 130–143-kDa protein.[295,296] In the inac-
tive state, the conformation of the receptor 
might result in steric inhibition of dimeriza-
tion and to the exposure of phosphorylate 
acceptor sites in the tyrosine kinase domain 
by the juxtamembrane domain. This occurs 
to be a general inhibition mechanism also 
found in other families of tyrosine 
kinases.[297] Thus, after ligand binding, the 
membrane-bound FLT-3 changes its con-
formation, forming a homodimer and expos-
ing phosphorylate acceptor sites in the tyro-
sine kinase domain.[298] The dimerization 
leads to a stabilizing conformational change, 
further increasing the activation of the re-
ceptor.[299] In contrast, the receptor inactiva-
tion is mainly driven by receptor internaliza-
tion and degradation.[298] 
 
Figure 51: FLT-3 signalling cascade has not been 
entirely characterised. However, the binding of FLT-3 
ligand (L) to FLT-3 activates the Akt/mTOR and 
Ras-Raf pathways resulting in increased cell prolifera-
tion and the inhibition of apoptosis.
[300–302]
 
FLT-3, triggers both the Ras-Raf-
MEK signaling pathway via the activation of 
the growth factor receptor-bound protein 2 
(Grb2)[303,304] and the Akt/mTOR signaling 
pathway mediated by Gab, Ship, Cbl, which 
subsequently activate the phosphatidyl-
inositol-3-kinase (PI3K),[303,305,306] see Figure 
51.[301,302] These interactions lead to the 
phosphorylation of associated proteins and 
the activation of downstream effectors in-
volved in haematopoiesis.[301,302] Moreover, 
the FLT-3 receptor was found to be associ-
ated with SH2-domain-containing inositol 
phosphatase (Ship) activity.[307] Beside the 
primary role of Ship in phospholipid metabo-
lism, it also acts as a negative regulator of 
cell proliferation mediated by the competitive 
binding of phosphorylated SHC proteins, 
which would otherwise activate the Ras–
Raf–Mek–Erk pathway.[303] However, FLT-3 
pathways seem to be highly species and 
tissue specific;[301,303,306] whereas, in healthy 
state, FLT-3 is expressed mainly in early 
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myeloid and lymphoid progenitors,[308] but 
not in erythroid cells,[309] megakary-
ocytes,[310] or mast cells.[311] 
As all members of the RTK class III, 
FLT-3 plays an important role in the early 
hematopoiesis, being involved in pro-
liferation, differentiation and apoptosis.[300,312] 
Moreover, its increased expression was re-
ported in 70-90% cases of acute myeloid 
leukemia and acute lymphoblastic 
leukemia,[296,308,313–315] but not in chronic my-
eloid leukemia (CML) and chronic lympho-
cytic leukemia (CLL) above all possessing a 
common progenitor stem cell.[316] Despite 
the widespread expression of FLT-3 and its 
role in signaling pathways, it is surprising 
that flt-3-knockout mice had relatively incon-
spicuous haematopoiesis without severe 
morphological changes in the bone 
marrow.[317] However, mice with both, kit and 
flt-3 knockouts, developed lethal haemato-
poietic deficiencies indicating a conjunction 
of FLT-3 with other growth factor receptors 
to promote the proliferation and differentia-
tion of myeloid and lymphoid cells. [317] 
These findings suggest a significant 
but not absolute role of FLT-3 in healthy 
haematopoiesis and thus indicate selective 
FLT-3 inhibition as a treatment option to 
block inappropriate FLT-3 activation in leu-
kaemia cells avoiding severe haematopoiet-
ic side-effects. Moreover, considering the 
high frequency of activating FLT-3 mutations 
in patients with AML, FLT-3 and its down-
stream pathway members are attractive tar-
gets for directed inhibition.[300,318] 
3.3.1.3 Aurora Kinases 
 
The serine/threonine Aurora kinases, 
play important roles in the control of the cen-
trosome and nuclear cycles, and have es-
sential functions in mitotic processes cover-
ing the chromosome condensation, spindle 
dynamics, kinetochore-microtubule interac-
tions, chromosome orientation and estab-
lishment of the metaphase plate.[319–325] 
Moreover, they are also involved in cytoki-
nesis. Due to the first description of Aurora 
A in the spindle pole regions, it was named 
after the polar lights.[322] However the family 
consist of Aurora A, B, and C whereas hu-
man Aurora A and B share 71% 
identity.[326,327] Nevertheless, the main differ-
ences are located in the amino-terminal do-
main.[328,329] Especially Aurora A and B are 
of high interest in research, whereas little is 
known about Aurora C.[326,327] 
Aurora A associates with the sepa-
rating centrosomes during late S/early G2, 
which is directed independently by the ami-
no-terminal region as well as the carboxy-
terminal catalytic domain.[330] But the catalyt-
ic kinase activity is not necessarily required 
for the association. Thereafter TPX2 has 
been found to mediate Aurora-A activation 
and localization to the spindle microtubules, 
but not to the spindle poles.[331] During cell 
maturation the absence of Aurora A, has 
significant adverse effects on the recruit-
ment of several components of the pericen-
triolar material, like -tubulin, to the centro-
some and downstream effectors leading to a 
decreased microtubule mass of spindles by 
about 60%.[332–334] Moreover, Aurora A was 
identified as a component of the progester-
one signalling pathway.[335] Its activation is 
an early event after progesterone induced 
signal transduction resulting in the activation 
of the ERK/MAPK pathway. 
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The regulation of Aurora A is com-
plex and involves phosphorylation and 
dephosphorylation as well as protein degra-
dation.[336] Aurora A has three phosphoryla-
tion sites, Ser53, Thr288, Ser349, whereas 
the first two sites are important for kinase 
regulation, the third is not essential for cata-
lytic activity but structural stability.[336] The 
degradation of Aurora A occurs in the late 
mitosis/early G1 by the APC/C.[73,74] 
Human Aurora B is a chromosomal 
passenger protein with full expression peak 
at the G2–M transition state, and maximal 
kinase activity during mitosis.[328,337] Where-
as the protein exchanges continuously with 
the surrounding cytoplasmic pool, the kinase 
association with central spindle microtubules 
during anaphase is highly reduced.[338] Auro-
ra B also seems to have an important role in 
the regulation of kinetochore–microtubule 
interactions in higher eukaryotes, whereas 
perturbance of its activity causes defects in 
chromosome congression.[339–342] Moreover, 
Aurora-B kinases are important for the 
phosphorylation of histone H3.[343] 
To date, most interest has focused 
on Aurora A, due to its high potential as on-
cogene and its amplified expression in a 
number of cancer cell lines and primary tu-
mours.[328,344,345] Moreover, malfunction of 
Aurora A, as well as the overexpression of 
Aurora B or Plk1, cause cytokinesis failure 
and perturbed centrosome duplication.[346,347] 
Remarkably, even catalytically inactive ki-
nase forms induce cytokinesis failure and 
centrosome amplification.[347] Aurora in-
duced mitotic abnormalities are exacerbated 
in cells that lack p53 due to its inactivating 
influence on the kinase function.[347,348] Nev-
ertheless, Aurora B has also been implicat-
ed in cancer reasoned in the elevated levels 
of phosphorylated histone H3 and defects in 
chromosome segregation and cyto-
kinesis.[349] The resulting cells are aneuploid 
and can produce aggressive tumours as 
observed in human colorectal tumour cell 
lines.[349] Taking all together, the important 
role of Aurora kinases in cell cycle progres-
sion and their role as oncogene in several 
tumor types revealed them as potential new 
target for cancer treatment, i.e.: of the 
treatment of prostate cancer.[350–352] Further 
information is provided in literature.[320,353–355] 
 
Figure 52: Starting from G1 phase, the expression of 
Aurora kinase A (green boxes) and Aurora B (red 
circles) increases turning into the prophase. Aurora A 
is mainly concentrated around the centrosomes. In 
opposite, Aurora B associated nuclear. During meta-
phase, Aurora A is attached to the microtubules adja-
cent to the spindle poles, whereas Aurora B is fixed to 
the inner centromere. In the next cell cycle phase, the 
anaphase, Aurora A is mainly located on the polar 
microtubules, although some might also be located in 
the spindle midzone. In contrast, Aurora B is exclu-
sively concentrated in the area of spindle midzone and 
at the appropriate cell cortex at the site of cleavage-
furrow ingression. In cytokinesis, both kinases are 
concentrated in the midbody.
[320]
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3.3.2 Synthesis and Structural Investi-
gations 
 
One strategy to control relative and 
absolute configuration of a metal centre is 
the use of chiral multidentate ligands, see 
Chapter 2.3. Along these lines, during previ-
ous work of the MEGGERS group, a chiral 
tridentate proline-containing ligand as being 
part of a cyclometalated rhodium(III) com-
plex with the pharmacophore ligand 32 led 
to enantiopure metal complexes. [197] This 
promising initial work inspired us to investi-
gate this chiral ligand in the context of the 
established metallo-pyridocarbazole kinase 
inhibitors. 
3.3.2.1 Synthesis of Enantiopure Prolinato 
Organorhodium(III) Complexes 
 
Starting with either enantiopure (R) 
or (S)-pyrrolidine-2-carboxylic acid ((R)-101 
and (S)-101) first the protection of the car-
boxyl group to methyl ester was performed 
by suspending the starting material in meth-
anol and adding thionylchloride drop wise at 
0 °C, followed by a slow warm up to ambient 
temperature over 16 h, see Scheme 12. The 
methyl pyrrolidine-2-carboxylate hydrochlo-
ride product was obtained in quantitative 
yield for (R)-102 and 96% for (S)-102. 
After the protection of the carboxyl 
group, a reductive amination using picolin-
aldehyde (103) was performed to attach a 
pyridine ring to (R)-102 and (S)-102, respec-
tively. Hence, palladium on carbon 
(10 wt. %) was suspended in methanol, pic-
olinaldehyde, and sodium acetate were 
added at 0 °C. After addition of (R)-102 or 
(S)-102, the reaction mixture was stirred for 
1 h and the nitrogen atmosphere was com-
pletely substituted by hydrogen in three 
turns. The reaction was continued for 16 h 
allowing the mixture to warm up to ambient 
temperature. After chromatographic puri-
fication, 61% of (R)-104 and 58% of (S)-104 
were obtained. Prior to the complexation 
reaction the methyl ester must be cleaved to 
reveal the carboxyl group. Therefore, both 
compounds were dissolved in sodium hy-
droxide (1 M, aq.) and reacted for 16 h at 
ambient temperature. (R)-105 was obtained 
in 91% and (S)-105 in quantitative yields. 
The rhodium(III) complexes were 
synthesised in a one-pot reaction under ni-
trogen atmosphere in sealed vessels, see 
Scheme 13. Accordingly, the pyridocarba-
zole ligand 79 was reacted first in a sequen-
tial addition to a suspension of RhCl3∙3H2O 
in an ethanol/water mixture at 90 °C for 3 h 
followed by addition of the chiral tridentate 
ligand (R)-105 or (S)-105. Reacting the mix-
tures at 90 °C for 16 h led to the formation of 
the two diastereomers -(R)-106 (22%) plus 
-(R)-107 (15%) starting from (R)-105, and 
-(S)-106 (24%) plus -(S)-107 (14%) start-
ing from (S)-105. Note that the absolute 
configuration of the chiral ligand controls the 
absolute metal centred configuration with 
R-ligand leading to -metal and S-ligand to 
-metal so that in the course of each reac-
tion only two diastereomers are generated. 
These two diastereomers could be separat-
ed by silica gel chromatography with meth-
ylene chloride/methanol 20:1 to 10:1 fol-
lowed by a preparative TLC for each single 
 
Scheme 12: Synthesis of enantiopure chiral tridentate ligand (R)-105 and (S)-105. 
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compound using methylene chloride/me-
thanol 15:1. The tert-butyl-dimethyl silyl pro-
tection group of ligand 79 was cleaved un-
der the reaction conditions. Additional 
isomers were not detected which can be 
rationalised with the restricted possible con-
formations of the proline-based ligand. The 
low yields of this reaction may arise from the 
usage of RhCl3∙3H2O as staring material. 
Indeed, rhodium(III) complexes typically 
react very slowly.[356] Moreover, the labilizing 
trans effect of chloride is greater than that of 
the aqua ligand leading among others to a 
fac-[RhCl3(H2O)3] configuration possessing 
all aqua ligands in opposite positions to the 
chloride ligands.[356] This fac-[RhCl3(H2O)3] 
configuration is inert to further aquation and 
thus may also be adverse for the ligand ex-
change by i.e. ligand 79, (R)-105, or (S)-105 
respectively. The formation of 
fac-[RhCl3(H2O)3] is promoted by free chlo-
ride ions which are inevitably released dur-
ing the coordination of 79 to the metal cen-
tre of already reacted RhCl3∙3H2O. 
Therefore, scavenging free chloride ions in 
solution or pre-activating RhCl3∙3H2O into 
precursors with labilised ligands like 
[Rh(C4H8S)3Cl3] may improve the product 
yield.[151] 
3.3.2.2 Assignment of The Relative Stere-
oconfiguration 
 
The assignment of the stereo-
configuration in case of the presented com-
plexes -(R)-106, -(R)-107, -(S)-106 and 
-(S)-107 is not trivial. Thus, a short ab-
stract of the operations leading the nomen-
clature is mandatory. To describe the abso-
lute configuration, and to distinguish the 
enantiomers of coordination compounds, 
two major, but fundamentally different, sys-
tems have been elaborated and docu-
mented by the IUPAC in the Red Book.[357] 
Although, a short overview is indispensable: 
The first is based on the chemical 
constitution of the compound and is related 
to the R/S convention established by Cahn-
Ingold-Prelog (CIP) and is applied to de-
scribe tetrahedral centres. In contrast, the 
closely related C/A (C = clockwise, A = anti-
clockwise) convention was established for 
other polyhedral coordination spheres. The 
R/S and C/A conventions use the priority 
sequencing according to Cahn-Ingold-
Prelog, where the atomic number and the 
substituents of the coordinating atoms have 
to be respected to assign a priority, see Fig-
ure 53 a) and b).[358,359] This system is often 
also applied to describe the configuration of 
 
Scheme 13: Asymmetric synthesis of organorhodium complexes -(R)-106, -(R)-107, -(S)-106 and -(S)-107. 
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coordinated ligands beside the tetrahedral 
metal centres. Moreover, in case of pseudo-
tetrahedral organometallic complexes, i.e.: a 
cyclopentadienyl ligand, the π-ligands were 
treated as monodentate ligands of highest 
priority, as it is true for (R)-9, see Figure 53 
a). To assign the correct chirality symbol to 
an octahedral complex according to the C/A 
nomenclature the reference axis has to be 
identified: the coordinating atom of the high-
est CIP priority and the trans coordinated 
atom of lowest possible CIP priority form the 
reference axis. The reference axis is then 
oriented pointing the highest CIP priority 
ligand upwards and the residual coordina-
tion plane aligned perpendicular to the ref-
erence axis. Thereafter, the orientation of 
the ligands and their sequence of CIP priori-
ty numbers are compared, see Figure 53 b). 
Closing, a sequence readable in clockwise 
orientation is assigned by the symbol C, and 
a sequence readable in anticlockwise orien-
tation is assigned by the symbol A. 
The second nomenclature principle 
is based on the geometry of the molecule 
and is based on the skew-lines convention. 
[357] This principle is mainly established to 
describe octahedral complexes and the two 
enantiomers are identified by the symbols  
and , Figure 53 c). A chiral enantiomeric 
pair of octahedral complexes in three-
dimensional space corresponds unambi-
guously to a screw (or often referred as a 
helix) and is either right-handed leading to 
the  isomer or left-handed leading to the  
isomer. 
To describe the absolute configura-
tions of octahedral complexes, both, the / 
system or the C/A system can be applied, 
but the first is used more commonly. Never-
theless, the C/A system is more general and 
probably used for most complexes. Moreo-
ver, the / system is only applicable to 
tris(bidentate), bis(bidentate) and closely 
related systems. 
 
Figure 53: Assigning the relative stereoconfiguration 
of metal complexes. a) Tetraedic metal centres can be 
assigned analogously to the Cahn-Ingold-Prelog (CIP) 
nomenclature established for organic compounds. 
[358,359]
 The same priority rules are valid. However, 
π-ligands were treated as monodentate ligands of 
highest priority as in case of (R)-9. b) The coordinating 
atom of the highest CIP priority defines the reference 
axis. The highest CIP priority ligand is oriented up-
wards and the residual coordination plane is oriented 
perpendicular to the reference axis. The clockwise (C) 
or anticlockwise (A) oriented sequence of ligands 
leads to the appropriate chirality symbol. c) A chiral 
enantiomeric pair of octahedral complexes in three-
dimensional space forms a screw beeing right-handed 
() or left-handed ( isomer. d) The -nomen-
clature is also applicable to bis(bidentate) and other 
related systems as illustrated for -12. 
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Figure 54: The terminal edge convention (TEC) sim-
plifies polydentate ligands coordinated to octahedral 
complexes to apply the -nomenclature. a) Only the 
edges of polydentate ligands were taken to account, 
whereas the connections inbewteen were disrespect-
ed.
[360]
 The simplification via the TEC operation results 
in model complexes suitable for the  system. b) 
The TEC operation results not in a doubtless assign-
ment of  or  configuration in case of octahedral 
complexes containing both a bidentate and a triden-
tate ligand. 
To transfer the /-nomenclature on 
complexes of higher polydentate ligands 
additional rules are required and some solu-
tions have been suggested in literature, i.e: 
the terminal edges convention (TEC). [360] 
However, they were not aimed as general 
nomenclature proposal, see Figure 54, and 
consequently the possible solutions to fit 
polydentate ligands to the /-nomenclature 
have not been adopted by the IUPAC to a 
general recommendation by now.[357] 
However, as the aim of this work is 
the clean comparison of enantiomers of oc-
tahedral complexes and their biological ac-
tivities, the unambiguous definition of the 
stereoconfiguration according to the 
/-nomenclature is highly appreciable. 
Moreover, this would offer a quick correla-
tion of the newly synthesised complexes to 
former ones based on tris(bidentate) or 
bis(bidentate) scaffolds as -12. Unfortu-
nately, the mentioned TEC fails considering 
octahedral complexes containing both bi-
dentate and tridentate ligands as it is true for 
-(R)-106, -(R)-107, -(S)-106 and 
-(S)-107; there is simply no terminal edge 
in a tridentate ligand, see Figure 54 b). 
Thus, to assign the stereocon-
figuration of the newly synthesized com-
plexes an additional stereodescription step 
was introduced based on the already esta-
blished conventions, see Figure 55. First, 
the priority of all coordinating atoms were 
determined according to CIP. Then, the lig-
and with the highest priority was assigned 
as reference ligand and oriented upwards in 
the vertical lane according to the established 
procedure of the C/A nomenclature. At this 
point, the assignment of chirality symbols 
according to the C/A nomenclature is possi-
ble as recommended by the IUPAC. How-
ever, as the aim is to apply the  nomen-
clature for these octahedral complexes, the 
stereodescriptive operation “reference lig-
and expansion” (RLE) was introduced. In 
this operation the reference ligand is virtual-
ly connected to the tridentate ligand. The 
virtual connection has to be performed be-
tween the coordinating atom of the triden-
tate ligand with highest priority and the ref-
erence ligand. Furthermore, the coordinating 
atom of the tridentate ligand has to be in the 
plane which is oriented perpendicular to the 
vertical lane of the reference ligand. This 
operation converts the tridentate ligand into 
a virtual tetradentate ligand, which is now 
suitable for the TEC operation, see Figure 
55. The additional stereodescriptive RLE 
operation turns octahedral complexes con-
taining both bidentate and tridentate ligands 
into models suitable to apply the 
nomenclature. All further complexes 
with these specifications, presented in this 
thesis, have been processed analogously. 
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Figure 55: Assignment of stereoconfiguration -(S)-106 (a), -(S)-107 (b), -(R)-106 (c), and -(R)-107 (d) accord-
ing to the -nomenclature. In the second column the assignment according to the C/A-nomenclature is demon-
strated. The reference ligand expansion (RLE) adds a virtual connection form the ligand of highest priority to the 
tridentate ligand shown in the third column. The connection is formed to the atom of highest Cahn-Ingold-Prelog 
(CIP) priority located in the perpendicular plane of the tridentate ligand. After this virtual operation the terminal edg-
es convention can be applied as reported in literature to fit the complex to the  system.
[360]
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Figure 56: 2D-spectra of -(R)-107 as an example for the determination of the stereoconfiguration (500 MHz, 
(CD3)2SO). (a) H-H-COSY spectrum of -(R)-107 of the aromatic protons. (b) HSQC spectrum of -(R)-107 of the 
aliphatic protons and carbons. (c) HSQC spectrum of -(R)-107 of the aromatic protons and carbons. 
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3.3.2.3 Determination of The Relative Ste-
reoconfiguration 
 
To determine the relative stereo-
configuration the unambiguous assignment 
of the protons and carbons of the obtained 
complexes was necessary. For this purpose, 
several 2D-NMR techniques were applied to 
elucidate the structural properties of the 
compounds. As a model -(R)-107 is pre-
sented in Figure 56, whereas -(R)-106, 
-(S)-106, and -(S)-107 were processed 
analogously. The assignment of all aromatic 
protons by a proton-proton correlation spec-
troscopy experiment (H,H-COSY) revealed 
a significant upfield shift of the hydrogen 
atom at position 11 of the pyridocarbazole in 
-(R)-107 to a chemical shift of  = 5.7 ppm, 
see Figure 56 a) and Figure 58 a). Further-
more, the assignment of the carbon atoms 
bearing the investigated protons via an het-
eronuclear single quantum coherence ex-
periment (HSQC) revealed that also an up-
field shift of the C-11 is observed to a 
chemical shift of  = 112.23 ppm, see Figure 
56 c). The aliphatic proton signals were 
identified also via the HSQC experiment, 
whereas the DMSO-d6 solvent signal over-
lays one proton of the prolinato ligand (H), 
see Figure 56 b). After the assignment of 
proton and carbon atoms via H,H-COSY 
and HSQC experiments, the bridging carbon 
atoms of the compound were assigned via 
an heteronuclear multiple bond correlation 
(HMBC) experiment. Figure 57 illustrates 
the assignment of C-5, C-7, C-7a and C-4b 
via the HMBC signals of H-6. This proce-
dure was repeated in case of the protons 
H-4, H-8, and H-11 to identify the proximal 
carbon atoms. Closing, the remaining brid-
ging carbon atoms were assigned correla-
ting their observed chemical shifts in the 
13C-NMR spectrum to their chemical envi-
ronment. 
As both, the H,H-COSY and HSQC 
experiments, in case of -(R)-107, unambi-
guously correlated the previously described 
signals  = 5.7 ppm to H-11 and 
 = 112.23 ppm to C-11, structural 
properties had to be considered leading to 
the signifycant upfield shift. Due to the 
characteristics of the pyridocarbazole and 
the applied tridentate ligand, certain 
structural features can be exploited to distin-
guish the stereoisomers and explaining the 
observed spectral incidences highlighted by 
the comparison of the diastereomers 
-(R)-106 and -(R)-107. Correlating their 
1H-NMR spectra reveals that the H-11 
proton of -(R)-106 posses a chemical shift 
 
Figure 57: HMBC spectrum of H-6 of -(R)-107 to determine the bridging carbon atoms (500 MHz, (CD3)2SO). 
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of  = 7.8 ppm which is located 2.1 ppm 
lowfield than the H-11 signal of -(R)-107. 
This is based on the aromatic ring current 
induced by the cis-coordinated pyridine ring, 
see Figure 58. The H-11 proton positioned 
inside the aromatic ring of the pyridine ring 
moiety of the tridentate ligand experiences a 
shielding effect. This effect can only be 
observed when the pyridine ring of either 
(R)-105 or (S)-105 is coordinated cis and 
almost perpendicular to the indole moiety of 
the pyridocarbazole ligand as it is the case 
for -(R)-107 and -(S)-107. This effect has 
been described also previously in context of 
other complexes synthesised in the 
MEGGERS group with related structures and 
therefore support the concluded stereo-
configuration.[361] 
 
 
Figure 58: 
1
H-NMR spectra of the diastereomers -(R)-107 and -(R)-106 (500 MHz, (CD3)2SO). The proton H-11 
(red circle) of -(R)-107 (a) is upfield shifted by 2.1 ppm compared to -(R)-106 (b) and allows to assign its relative 
configuration. (in b) additional solvent signal of methylene chloride) 
 
Figure 59:  Crystal structures of -(R)-106 and -(S)-106. Solvent Molecules were omitted for clarity. ORTEP 
drawing with 50% probability of thermal ellipsoids. Selected bond lengths [Å] for -(R)-106: Rh1-O35 = 2.004(4), 
Rh1-N21 = 2.032(4), Rh1-N4 = 2.032(4), Rh1-N28 = 2.057(5), Rh1-N1 = 2.071(5), Rh1-Cl1 = 2.3399(16). Selected 
bond lengths [Ǻ] for -(S)-106: N1-Rh1 = 2.076(3), N4-Rh1 = 2.036(3), N21-Rh1 = 2.043(3), N28-Rh1 = 2.058(3), 
O34-Rh1 = 2.004(3), Cl1-Rh1 = 2.3440(11). 
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The crystal structures of -(R)-106 
and -(S)-106 lead to the determination of 
their relative stereoconfiguration and sup-
ported the conclusions resulted from the 
NMR experiments, see Figure 59. The com-
parison of the crystal structures of both iso-
mers demonstrates that they are enantio-
mers and diastereomeric towards -(R)-107 
and -(S)-107. This relationship between 
the structural isomers was further investi-
gated via CD-spectroscopy as shown in 
Figure 61, revealing the enantiomeric char-
acter of -(R)-106 compared to -(S)-106; 
the same is true for -(R)-107 and 
-(S)-107. 
 
Figure 60: Stability of rhodium complexes in 
DMSO-d6/D2O 9:1 (5 mM) in the presence of 
mercaptoethanol (5 mM) determined by ELISABETH 
MARTIN. Excerpts of the 
1
H-NMR spectra of the dia-
stereomers -(R)-106 and -(R)-107 are shown after 
30 min (red), 6 h (kaki), 24 h (green), and 48 h (blue) 
at 25 °C as well as 24 h (purple) at 37 °C. 
 
Figure 61: CD-spectra of the rhodium(III) complexes 
in dimethylsulfoxide (DMSO) at a concentration of 
0.25 mM. The direct correlation of -(S)-106 to 
-(R)-106 as well as -(S)-107 to -(R)-107 reveals a 
mirror-inverted relationship of CD-light refraction be-
tween the corresponding enantiomers. 
3.3.2.4 Stablity of Enantiopure Prolinato 
Organorhodium(III) Complexes 
 
The time dependent complex stability 
was performed by ELISABETH MARTIN. Thus, 
-(R)-106 and -(R)-107 were dissolved in 
DMSO-d6/D2O (9:1) at a final concentration 
of 5 mM. In addtion, to investigate the com-
plex inertness towards free nucleophiles, 
mercaptoethanol at a final concentration 
of 5 mM was added. Indeed, during the in-
vestigated time period covering either up to 
48 h at 25 °C or 24 h at 37 °C no alterations 
in the 1H-NMR spectra could be observed. 
This confirms the complex stability in the 
presence of free thiol groups which are 
ubiquitous in biological environments, see 
Figure 60. 
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3.3.3 Kinome Profiling and Biological 
Investigations 
 
To investigate the potential kinase 
inhibition properties of the four stereo-
isomeric rhodium complexes, they were 
tested for their protein kinase binding affinity 
profile against in the DiscoveRx 
KINOMEscanTM by LeadHunter Discovery 
Services. This was accomplished by an 
active-site-directed affinity screening against 
456 human protein kinases.[362,363] The com-
pounds were screened at 1 µM and results 
for primary screen binding interactions are 
reported as “percent of control” (POC), 
where lower numbers indicate stronger 
interactions, correlating with larger red 
circles in the dendrogram, see Figure 62. 
Empiric investigations demonstrated that 
binding constants (Kd) are correlated with 
such primary screening results, where lower 
POC values are associated with low Kd 
values (higher affinity interactions). 
Moreover, the selectivity score (SS) is a 
quantitative measure of compound 
selectivity. It is calculated by dividing the 
number of kinases that compounds bind to, 
by the total number of distinct kinases 
tested, excluding mutant variants. Further, 
this score value can be calculated for 
different selectivity levels using POC as a 
potency threshold, e.g. below 35% or 10%. 
These SS clustered in different selectivity 
score types (SST) provide a quantitative 
method of describing compound selectivity 
and allow a facilitated comparison of 
different compounds among each other. 
Depending on using L- or D-proline 
as the starting point for the ligand synthesis 
of (S)-105 or (R)-105, the derived complex-
es differ entirely in their biological proper-
ties. Whereas complexes (R)-107, 
-(S)-107, and -(S)-106 act as kinase in-
hibitors, complex -(R)-106 is almost inef-
fective against the tested kinase panel. 
 This is evidenced by the different 
selectivity scores of the individual com-
pounds. Indeed, -(R)-107 possesses a 
selectivity score of 0.041 at a SST of 35% 
and 0.013 at a SST of 10%; -(S)-107 pos-
sesses a selectivity score of 0.025 at a SST 
of 35% and 0.005 at a SST of 10%; 
-(S)-106 possesses a selectivity score of 
0.076 at a SST of 35% and 0.025 at a SST 
of 10%. In opposite, -(R)-106 didn’t hit any 
kinase at the SST level of 35%, 10%, or 
even 1% in the tested concentration of 1 µM. 
None of the four compounds inhibited a ki-
nase in the tested panel at a POC lower 
than 1%, see Figure 62. These remarkable 
differences of the tested compounds, not 
only regarding the selectivity across the 
whole kinome but also the preference to 
distinct kinase subfamilies addressed by 
them, indicate the importance of the relative 
configuration around the rhodium metal cen-
tre. 
To further verify the primary hits of 
the kinome profiling, all four compounds 
were tested in competitive studies using 
[33P]-ATP. Therefore, one target kinase for 
each compound with a POC lower than 10% 
was selected. Three kinases were chosen 
regarding their commercial availability and 
role in human pathogenesis: FLT-3 (4.9%) 
addressed by -(S)-107, Aurora A (2.4%) 
addressed by -(S)-106, and PIM-1 (1.8%) 
addressed by -(R)-107. The [-33P]-ATP 
competitive studies confirmed the primary 
results of the KINOMEscanTM. As expected, 
the target kinases were inhibited profoundly 
by the compound identified in the kinome 
profiling, see Figure 62 and Figure 63. 
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Figure 62: Kinase profiling of -(R)-106, -(R)-107, -(S)-107, and -(S)-106. All complexes were tested against 456 
human kinases at a concentration of 1 µM by an active-site-directed affinity screening (KINOMEscan
TM
, DiscoveRx, 
LeadHunter Discovery Services). The dendrograms show the remaining POC levels of the kinases depicted as red 
circles. The selectivity score type (SST), the number of hits (NH) as well as the selectivity score (SS) of the single 
enantiomers are: -(R)-107: SST(35) NH(16) SS(0.041); SST(10) NH(5) SS(0.013). -(S)-107: SST(35) NH(10) 
SS(0.025); SST(10) NH(2) SS(0.005). -(S)-106: SST(35) NH(30) SS(0.076); SST(10) NH(10) SS(0.025). 
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Figure 63: One single target kinase for each com-
pound with a POC lower than 10% was selected for 
[-
33
P]-ATP competitive assays with an ATP concen-
tration of 10 µM (double determination). -(R)-106 
(purple triangle), -(R)-107 (blue triangle), -(S)-107 
(black squares), and -(S)-106 (red circle). a) FLT-3: 
-(R)-106 = 8.47 µM, -(R)-107 = 1.2 µM, -(S)-107 = 
137 nM, and -(S)-106 = 8.26 µM. b) Aurora A: 
-(R)-106 = 164 µM, -(R)-107 = 39 µM, -(S)-107 = 
35 µM, and -(S)-106 = 121 nM. c) PIM-1: -(R)-106 = 
1.99 µM, -(R)-107 = 15 nM-(S)-107 = 1.03 µM, and 
-(S)-106 = 0.88 µM. 
Indeed, -(R)-107 inhibited PIM-1 
with an IC50 of 15 nM, -(S)-107 inhibited 
FLT-3 with an IC50 of 137 nM, and -(S)-106 
Aurora A with an IC50 of 121 nM. Further, 
other structural isomers of the rhodium(III) 
complexes differ significantly in their IC50 
values towards the non-target kinases. For 
instance, -(R)-106 (8.47 µM), -(R)-107 
(1.2 µM), and -(S)-106 (8.26 µM) are signif-
icantly less affine towards FLT-3 than 
-(S)-107. The same is true for Aurora A: 
-(R)-106 (164 µM), -(R)-107 (39 µM), and 
-(S)-107 (35 µM) in opposite to -(S)-106; 
as well as for PIM-1: -(R)-106 (1.99 µM), 
-(S)-107 (1.03 µM), and -(S)-106 
(0.88 µM) in opposite to the original screen-
ing hit -(R)-107. Moreover, it is noteworthy, 
that -(R)-106 is the weakest inhibitor to-
wards all tested kinases. All gathered results 
of the [-33P]-ATP competitive studies are in 
very good congruence to the results of the 
kinome profiling highlighting the importance 
of the stereochemistry at the metal centre 
for metal based kinase inhibitors. 
3.3.4 Interpretation 
 
The pros and cons comparing classic 
organic kinase inhibitors to organometallic 
complexes have been discussed intensively 
in literature.[152,159–161,189,190,364–368] The PIM 
kinase family have been described above to 
possess oncogenic and survival promoting 
properties, see Chapter 3.3.1.1.[266,274,281–
283,287,292,369–371] Therefore, targeting mem-
bers of the PIM kinase family offers potential 
treatment options, i.e.: various 
leukemias,[372] mantle cell lymphoma,[287] 
and diffuse large B-cell lymphoma.[369] An 
actual example of a phase I clinical trial PIM 
kinase inhibitor is AZD1208 (108) by Astra-
Zeneca.[370] AZD1208 inhibits the kinase 
activity of all three PIM kinases with an IC50 
of 0.4 nM (PIM-1), 5.0 nM (PIM-2), and 
1.9 nM (PIM-3).[371] Moreover, the organic 
inhibitor AZD1208 was evaluated by the 
KINOMEscanTM (DiscoveRx) using a panel 
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of 442 kinases, whereas only 16 kinases 
had an residual activity of less than 50%, 
including all three PIM kinases.[371] In com-
parison, the kinase profiling of -(R)-107 
against 456 kinases revealed 23 kinases 
with an residual activity of less than 50%. 
Moreover, PIM-2 with an POC of exactly 
50% was not adequately addressed by 
-(R)-107 as PIM-1 or PIM-3, both 1.8%. 
This example shows that -(R)-107 with its 
low nanomolar IC50 of 15 nM against PIM-1 
and its selectivity profile is quite comparable 
to literature known fully organic kinase inhib-
itors, although the exact selectivity profile 
inevitably differ. 
 
Figure 64: Chemical Structure of AZD1208 (108).
[370] 
Though, differences in the selectivity 
profiles comparing classic organic inhibitors 
with metal based complex inhibitors are like-
ly to expect, similarities like in case of FLT-3 
confirm a related mode of action. For in-
stance, FLT-3 inhibitors often affect other 
members of the type III receptor tyrosine 
kinases including KIT and PDGFR due to 
their close structural relationship.[373] This is 
true for i.e. SU11248 (109) (Sunitinib, 
Pfizer)[374] approved for the treatment of re-
nal cell carcinoma (RCC) and imatinib-
resistant gastrointestinal stromal tumor 
(GIST). Beside also affecting other type III 
receptor tyrosine kinases like KIT and 
PDGFR in the kinome profiling, the rhodi-
um(III) inhibitor -(S)-107 possesses an 
determined IC50 of 137 nM for FLT-3 which 
is in the same range as the IC50 of SU11248 
(250 nM).[373] 
 
Figure 65: Chemical structure of SU11248 (109).
[374]
 
Closing, many inhibitors targeting the 
Aurora kinases have been reported before 
and some are evoking increasing focus in 
clinical trials.[353,355,375] For instance, AT9283 
developed by Astex Therapeutics is current-
ly in several Phase II studies under the 
Cancer Research UK.[376] It is a multi-target 
tyrosine kinase inhibitor, including Aurora A 
(IC50 = 3 nM) and B (IC50 = 3 nM), JAK (IC50 
= 1.2 nM), and T315I ABL (IC50 = 4 nM).
[377] 
In opposite, -(S)-106 inhibits Aurora A in 
the medium range of an IC50 of 121 nM. 
Moreover, the kinase profile does not un-
doubtedly support the mentioned targets of 
AT9283 as additional targets for -(S)-106, 
see Figure 62. 
 
Figure 66: Chemical structure of AT9283 (110).
[377]
 
Despite the short provided framing of 
the presented rhodium(III) complexes into 
the context of classic organic kinase inhibi-
tors, it is noteworthy that the obtained re-
sults reflect just the beginning of enanti-
opure metal based kinase inhibitor design. 
Further improvements of target selectivity 
and potency are achievable by modifying i.e. 
the pyridocarbazole pharmacophore ligand 
79[149] or attaching additional functional 
groups to the tridentate ligands (R)-105, or 
(S)-105, as described in the following Chap-
ters. 
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3.3.5 Scanning the Binding Pocket - 
Further Development of Tridentate 
Chiral Ligands 
 
The successful synthesis of prolinato 
organorhodium(III) complexes and the sub-
sequent conclusion of the ligand character-
istics leading to the enantiopure kinase in-
hibitors resulted into new modified ligands. 
They were able to act both, as tools to 
asymmetrically synthesise organometallic 
complexes and being part of highly sophis-
ticated kinase inhibitors. 
Many synthetically accessible proline 
derivatives have been reported.[378–382] Nev-
ertheless, prior to start, a multistep ligand 
synthesis with different substitution patterns, 
slight modifications to explore the available 
chemical space in the ATP binding site of 
the target kinases must be evaluated first. 
Moreover, the transferability of the ligand 
requirements must be verfied. Thus, a small 
set of comercially available proline deriva-
tives like (S)-methyl-proline (S)-111, 
(2S, 4R)-hydroxyproline (115), and pipe-
colinic acid ((S)-120 and (R)-120) were se-
lected, see Scheme 14. In general, the es-
tablished synthetic route was applied to the 
single compounds in analogy to (R)-105 and 
(S)-105. 
 
 
Scheme 15: Cleavage of the ester function of 
(S, R)-118. 
The methyl esters of the correspond-
ing amino acid building blocks were formed 
by reacting them with thionylchloride in 
methanol at 0 °C during the drop wise addi-
tion, followed by 16 h of stirring the reaction 
mixture at ambient temperature. The methyl 
esters were obtained as pure hydrochloride 
salts after repeated co-evaporation of ex-
cessive thionylchloride. The protected amino 
acid building blocks were obtained in quant. 
yields in case of (S)-112, (S, R)-116, and 
(R)-121; in case of (S)-121 the ester for-
mation led to a yield of 97%. 
The methyl esters were then pro-
cessed to the reductive amination reaction 
using 103 in methanol. The reaction mix-
tures were stirred for 72 h at 0 °C under 
hydrogen atmosphere and using palladium 
on carbon as catalyst. During this period the 
reaction mixture was allowed to warm up to 
ambient temperature. After the separation of 
the heterogeneous catalyst via filtration over 
CELITE, the intermediates could be purified 
by flash chromatography using methylene 
chloride : methanol. Unexpectedly, the re-
 
Scheme 14: Synthesis of enantiopure chiral tridentate proline derived ligands (I). 
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ductive amination reactions were performed 
with decreased yields as compared to the 
synthesis of (R)-105 and (S)-105. The yields 
of 38% in case of (S)-113 and 40% in case 
of (S, R)-117 led to the counteraction of ap-
plying a substitutional reaction using 2-(chlo-
romethyl)pyridine hydrochloride (122) in-
stead of the established reductive ami-
nation. This alternative route was applied in 
the synthesis of (S)-1-(pyridin-2-ylmethyl)pi-
peridine-2-carboxylic acid ((S)-124) and 
(R)-1-(pyridin-2-ylmethyl) piperidine-2-car-
boxylic acid ((R)-124). Therefore, (R)-methyl 
piperidine-2-carboxylate ((R)-121), or the 
corresponding (S) enantiomer ((S)-121), 
was reacted with 122 in DMF at 50 °C for 
36 h using sodium carbonate and sodium 
iodide. This alternative synthetis with 81% 
yield outperformed the reductive amination, 
see Scheme 16. 
Finally, after basic ester cleavage, 
using 1 M sodium hydroxide at ambient tem-
perature for 16 h, the finished tridentate lig-
ands were obtained in 93% ((S)-114), 81% 
(S, R)-119, and quant. yields ((R)-124 and 
(S)-124), respectively. Additional functional 
groups, like in case of (S, R)-117, were pro-
tected to avoid a potential cross coordina-
tion with a second metal ion during the 
complexation reaction, see Scheme 14. The 
attached tert-butyl-dimethylsilyl protection 
group at the hydroxyl residue fulfills this 
function, which was attached using diiso-
propylethylamine (DIPEA) and tert-butyl-
dimethylsilyl triflate in DMF. 
3.3.6 Synthesis and Structural Investi-
gations 
 
The newly designed ligands for 
chemical space exploration and asymmetric 
organorhodium(III) complexation were re-
acted under the same conditions applied for 
the synthesis of -(R)-106, -(S)-106, 
-(R)-107 and -(S)-107, see Chapter 3.3.2. 
Thus, makes the reactions comparable, 
Scheme 17. As observed before the reac-
tion mixtures led to the formation of two dia-
stereomers for each used ligand, like for the 
ligands (R)-105 and (S)-105. 
 
Scheme 16: Synthesis of enantiopure chiral tridentate proline derived ligands (II). 
 
Scheme 17: Asymmetric synthesis of organorhodium complexes -(S, R)-125 and -(S, R)-126. 
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In analoguous way, the diastereo-
mers could be separated by flash column 
chromatography using methylene chlo-
ride : methanol (20:1  10:1) followed by a 
preparative TLC for each single compound 
using methylene chloride : methanol 15:1 for 
further purification. Like observed before, 
the tert-butyl-dimethylsilyl protection group 
of ligand 79 was cleaved, see Scheme 17 
and Scheme 18. Moreover, the tert-butyl-
dimethyl silyl protection group of (S, R)-119 
was also cleaved under the reaction condi-
tions, see Scheme 17. All second genera-
tion organorhodium(III) complexes were 
obtained in comparable yields to the proline 
based progenitors: (S, R)-119 derived 
-(S, R)-125 (23%) and -(S, R)-126 (17%); 
(S)-124 derived -(S)-127 (21%) and 
-(S)-128 (15%); as well as (R)-124 derived 
-(R)-127 (24%) and -(R)-128 (16%). 
The relative stereoconfiguration of 
-(S)-125 and -(R)-127 was determined 
via X-ray crystallography, see Figure 67 and 
Figure 68, respectively. Moreover, corre-
lating all physico-chemical properties to the 
obtained data of -(R)-106, -(R)-107, 
-(S)-106, and -(S)-107 covering crystal 
structures and the 1H-NMR shift of the H-11 
proton of the coordinated pyridocarbazole 
for allowed a doubtless assignment of the 
relative stereoconfiguration of each second 
generation organorhodium(III) complex as 
depicted. 
 
Figure 67: Crystal structure of -(S,R)-125. Solvent 
molecules were omitted for clarity. ORTEP drawing 
with 50% probability of thermal ellipsoids. Selected 
bond lengths [Å] for -(S,R)-125: Rh1-N1 = 2.055(3), 
Rh1-N4 = 2.038(3), Rh1-N23 = 2.073(4), Rh1-N26 
= 2.039(4), Rh1-O1 = 2.010(3), Rh1-Cl1 = 2.3256(10). 
 
 
Figure 68: Crystal structure of -(R)-127. Solvent 
molecules were omitted for clarity. ORTEP drawing 
with 50% probability of thermal ellipsoids. Selected 
bond lengths [Å] for -(R)-127: Rh1-N1 = 2.069(3), 
Rh1-N4 = 2.043(2), Rh1-N23 = 2.080(2), Rh1-N30 
= 2.044(2), Rh1-O1 = 2.009(2), Rh1-Cl1 = 2.3417(7). 
  
 
Scheme 18: Asymmetric synthesis of organorhodium complexes -(R)-127, -(R)-128, -(S)-127 and -(S)-128. 
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Additionally, beside exploring the ligand 
sphere using modified chiral tridentate lig-
ands, the monodentate chlorine ligand of the 
enantiopure organorhodium complexes was 
also substituted by bromine, see Scheme 
19. For this purpose, the established syn-
thetic procedure was applied using 
RhBr3∙xH2O (24% Rh) instead of 
RhCl3∙3H2O. 79 was reacted in a sequential 
addition to a suspension of RhBr3∙xH2O in 
an ethanol/water mixture at 90 °C for 3 h 
followed by the chiral tridentate ligand 
(R)-105. Reacting the mixture at 90 °C for 
16 h led to the formation of two diastere-
omers, which were separated by silica gel 
chromatography with methylene chlo-
ride : methanol 20:1 to 10:1 followed by a 
preparative TLC for each single compound 
using methylene chloride : methanol 15:1. 
The complex -(R)-129 was obtained in 
16% yield and -(R)-130 in 10%. 
3.3.7 Biological Investigations 
 
To further investigate the biological 
properties and kinase inhibition potentials of 
selected second generation organo-
rhodium(III) complexes, they were tested in 
competitive assays against PIM-1, FLT-3, 
and Aurora A. Therefore, each investigated 
structural isomer was correlated to the ap-
propriate prolinato progenitor against its 
primary target kinase. 
FLT-3 was inhibited by -(S, R)-126 
with an IC50 of 780 nM which is 5.7-fold 
higher than the IC50 of 137 nM for -(S)-107 
as the appropriate progenitor. A similar rela-
tion can be observed for Aurora A. 
-(S)-106 inhibited Aurora A with an IC50 
value of 121 nM, whereas the IC50 value of 
12.5 µM of -(S, R)-125 is about 100-fold 
higher. These two examples demonstrate 
that the substitution of (S)-105 towards 
(S, R)-119 introducing an additional hydroxyl 
group significantly impairs the affinity of the 
resulting inhibitors. The same is true for the 
enlargement of the aliphatic ring size from a 
five-membered ring in case of using (R)-105 
to a six-membered ring using (R)-124. The 
resulting -(R)-128 inhibits PIM-1 with an 
IC50 of 206 nM which is almost 14-fold higher 
compared to the IC50 of 15 nM in case of 
-(R)-107. The enlarged ring size and the 
subsequent conformational changes of the 
ligand sphere significantly decrease the af-
finity of the second generation organorhodi-
um(III) complex. In contrast, the substitution 
of the monodentate ligand to bromine in-
stead of chlorine has only little influence on 
the affinity as confirmed by the IC50 of 32 nM 
of -(R)-130, which is quite comparable to 
the value obtained for -(R)-107. Moreover, 
as PIM-1 offers a relatively large 
ATP-binding site for interactions, the com-
plexes -(R)-129 (735 nM) and -(R)-127 
(3.76 µM) were also tested for their affinity. 
However, the obtained values for them con-
firmed the primary expectations. 
 
Scheme 19: Asymmetric synthesis of organorhodium complexes -(R)-129, -(R)-130. 
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Figure 69: The target kinases of the prolinato or-
ganorhodium(III) complexes were tested using the 
second generation enantiopure organorhodium(III) 
complexes in [-
33
P]-ATP competitive assays with an 
ATP concentration of 10 µM. The data points repre-
sent mean values of double determinations and an 
independent verification assay under same conditions. 
Additionally, the most potent prolinato organorhodi-
um(III) inhibitor is sown for comparison. a) FLT-3: 
-(S)-107 (black squares) IC50 = 137 nM, -(S, R)-126 
(green triangle) IC50 = 780 nM. b) Aurora A: -(S)-106 
(red circles) IC50 = 121 nM; -(S, R)-125 (orange trian-
gle) IC50 = 12.5 µM. c) PIM-1: -(R)-107 (blue trian-
gles) IC50 = 15 nM, -(R)-130 (yellow circles) 
IC50 = 32 nM, -(R)-128 (grey rhombi) IC50 = 206 nM, 
-(R)-129 (green hexagons) IC50 = 735 nM, -(R)-127 
(brown triangles) IC50 = 3.76 µM. 
 
 
Figure 70: Superimposed crystal structures of organ-
ometallic inhibitor (R)-10 (pdb: 2JLD) and -12 (pdb: 
3PUP) bound GSK-3. The binding pose of both pyri-
docarbazole pharmacophore ligands are flipped by 
180° in relation to each other. The pyridocarbazole 
carbon atoms of (R)-10 are presented in cyan and the 
pyridocarbazole carbon atoms of -12 in green. Nitro-
gen atoms are shown in blue, oxygen atoms in red, 
and fluorine in light cyan. GSK-3 as well as the re-
sidual coordination sphere is presented as cartoon or 
sticks in white for clarity.
[146]
 
3.3.8 Interpretation 
 
The initial modifications of the proline 
core of the chiral tridentate ligands signifi-
cantly influenced the inhibition profiles of the 
resulting organorhodium(III) complexes 
compared to the corresponding structural 
isomers of the prolinato rhodium(III) com-
plex progenitors. In case of the additional 
hydroxyl function of (S, R)-119 or enlarging 
the ring size as in case of (R)-124 led to 
decreased affinities towards the kinase tar-
gets indicating sterical hindrances induced 
by these groups. Due to the findings of the 
complexes -(S, R)-125, -(S, R)-126, 
-(R)-127, and -(R)-128 the (S)-124 de-
rived complexes -(S)-127, and -(S)-128 
were not further investigated regarding their 
inhibitory potential. Moreover, scanning the 
binding pocket of PIM-1 revealed the tolera-
tion of a larger monodentate ligand like 
bromine instead of chlorine. Indeed, PIM-1 
has been reported to possess a relatively 
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large ATP binding site compared to other 
kinases.[140,147,231,292] Thus, PIM-1 is often hit 
as a target in metal based complex inhibitor 
investigations examined by the MEGGERS 
group.[140,147,231] 
Moreover, due to the symmetry of the 
maleimide moiety of the pyridocarbazole 
pharmacophore ligand, the residual coordi-
nation sphere has an important influence on 
the binding pose of the entire complex. For 
instance, superimposing the crystal struc-
tures of (R)-10 and -12 in the binding 
pocket of GSK-3 reveals a 180 ° flip of both 
pyridocarbazole ligands in relation to each 
other, one occupying the same chemical 
space with its indole moiety whereas the 
other with its pyridine moiety and vice versa, 
see Figure 70. The different binding poses 
of the pyridocarbazole ligands in relation to 
each other are mainly driven by the mono-
dentate carbonyl ligands, which point to-
wards the glycine rich loop, and the addi-
tional substituents at the pyridocarbazoles 
picking up different molecular interactions. 
However, it is noteworthy, that the dia-
stereomers obtained in a single reaction, 
using the chiral tridentate ligands presented 
so far, arise from a 180 ° flipped coordina-
tion of the pyridocarbazole. Therefore, the 
ligand sphere of two diastereomers can be 
superimposed, whereas the pyridocarbazole 
ligands of each complex is inverted com-
pared to the other. Keeping this fact in mind, 
modifications in the ligand sphere or intro-
ducing additional functional groups at the 
pyridocarbazole could completely change 
the preferred binding poses of the resulting 
isomers. 
Therefore, this effect has been investi-
gated in the case of PIM-1 and both, 
-(R)-127 and -(R)-128, have been tested 
in competitive assays. In case of PIM-1, 
despite offering the mentioned large binding 
site, the results of the IC50 determinations 
show the same trends as observed for 
-(R)-106 and -(R)-107. Although, the de-
scribed assumption was not confirmed in 
this case, the possibility, that modifications 
leading to new complexes might also result 
into distinct binding poses compared to the 
cooresponding progenitor, has to be consid-
ered for future investigations to prevent mis-
interpretations and undisclosed conclusions. 
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3.3.9 Scanning the Binding Pocket – 
Modifications of the Pyrido-
carbazole Pharmacophore 
 
After the results scanning the binding 
pockets with modified tridentate chiral lig-
ands, additional functional groups to the 
pyridocarbazole pharmacophore ligand itself 
were attached to investigate their influences 
on the inhibition profile. Therefore, different 
pyridocarbazoles were reacted according to 
the established synthetic route, see Chapter 
3.3.2. Accordingly, the pyridocarbazole lig-
ands 78, 81, 82, and 83 were reacted in a 
sequential addition to a suspension of 
RhCl3∙3H2O in an ethanol/water mixture at 
90 °C for 3 h followed by addition of the chi-
ral tridentate ligand (S)-105 or (R)-105, see 
Scheme 20 and Scheme 21. Reacting the 
mixtures at 90 °C for 16 h led to the for-
mation of the two diastereomers for each 
pharmacophore ligand as observed before 
for 79. The diastereomers of each single 
reaction could be separated by silica gel 
chromatography followed by a preparative 
TLC for each single compound resulting in 
purple complexes. Moreover, the general 
loss of tert-butyl-dimethylsilyl protection 
groups of the ligands, not only at the malei-
mide moiety but also at the hydroxyl groups, 
was observed. 
The yields of the obtained complexes 
are quite comparable to the initial reactions, 
see Chapter 3.3.2. Although, the disad-
vantage of protection group cleavage seems 
to affect the solubility of the ligands and 
subsequently impairs the yield of the reac-
tion. However, screening of different solvent 
systems and reaction temperatures failed to 
form the intended reaction products. Fur-
thermore, the established synthetic route 
was still applied as a reference procedure to 
compare the influences of the ligand modifi-
cations. 
 
Scheme 20: Asymmetric synthesis of organorhodium complexes with modified pyridocarbazole ligands (I). 
 
Scheme 21: Asymmetric synthesis of organorhodium complexes with modified pyridocarbazole ligands (II). 
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3.3.10 Biological Investigations 
 
Closing, the obtained complexes of 
the pyridocarbazole modifications were test-
ed according to the IC50 determination to-
wards the target kinases FLT-3, Aurora A, 
and PIM-1, as described in Chapter 3.3.3. 
FLT-3 was inhibited by -(S)-132 
(474 nM), -(S)-134 (51 nM), -(S)-136 
(622 nM), but not by -(S)-138 (5.85 µM). 
Moreover, -(S)-134 outperforms the IC50 of 
137 nM for -(S)-107. -(S)-106 inhibited 
Aurora A with an IC50 value of 121 nM, 
whereas -(S)-131 (6.95 µM), -(S)-133 
(12.5 µM), -(S)-135 (7.71 µM), and 
-(S)-137 (9.46 µM) are significantly worse 
inhibitors. PIM-1 was inhibited by -(R)-107 
with an IC50 of 15 nM, whereas the inhibitors 
-(R)-134 (19 nM), and -(R)-136 (32 nM) 
inhibit the kinase at comparable concentra-
tions. Nevertheless, -(R)-132 (326 nM) and 
-(R)-138 (1.29 µM) possess a decreased 
affinity to the PIM-1 kinase than the original 
structural progenitor. 
3.3.11 Interpretation 
 
Modifying the chiral tridentate pro-
linato ligands showed, that the investigated 
target kinases do not tolerate additional 
groups on this side of the complex. Moreo-
ver, Aurora A excludes simultaneous modifi-
cations on the indole as well as on the pyri-
dine moiety of the pyridocarbazole ligand. 
Nevertheless, in some cases modifications 
of the pyridocarbazole ligand led to the for-
mation of inhibitors with increased affinity, 
i.e.: -(S)-134. However, these functional 
groups may offer an additional adjusting 
point to increase solubility and lipophilic 
properties to modulate and improve ADME 
properties. 
 
 
 
Figure 71: IC50 determination by [-
33
P]-ATP competi-
tive assays with an ATP concentration of 10 µM. The 
data points represent mean values of double determi-
nations and an independent verification assay under 
same conditions. a) FLT-3: -(S)-132 (474 nM), 
-(S)-134 (51 nM), -(S)-136 (622 nM), and -(S)-138 
(4.31 µM). b) Aurora A: -(S)-131 (6.95 µM), -(S)-133 
(12.5 µM), -(S)-135 (7.71 µM), and -(S)-137 
(9.46 µM). c) PIM-1: -(R)-132 (326 nM), -(R)-134 
(19 nM), -(R)-136 (32 nM), and -(R)-138 (1.29 µM). 
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3.4 Design of Phosphatidylinositol-
3-Kinases (PI3K) Inhibitors 
3.4.1 Target Synopsis and Aim (III) 
 
The phosphatidylinositol-3-kinases 
(PI3K) belong to the family of lipid kinases. 
In opposite to the regular protein kinases, 
membrane bound lipids are the phosphory-
lation targets of PI3Ks acting as subsequent 
second messenger.[383] The phosphorylation 
products play important roles for the regula-
tion of cellular processes like gene expres-
sion, carbohydrate metabolism, or apopto-
sis.[383,384] Moreover, some members are key 
players of pathologic processes involved in 
diseases like diabetes, cancer, cardiovascu-
lar diseases and autoimmune defi-
ciencies.[384,385] Therefore, PI3Ks are inter-
esting targets for the pharmaceutical 
research.[386–388] 
The PI3Ks consist of a regulatory 
domain (p85 or p101) and a catalytic do-
main (p110). Thus, they were clustered into 
three different classes covering class I, II, 
and III, due to their structural differences 
and substrate specificity.[389,390] The class I is 
further subdivided into two groups, IA and IB 
based on their different structure and activa-
tor recruitment. Both result into the phos-
phorylation of phosphatidylinositol-4,5-bis-
phosphate (PIP2) to phosphatidylinositol-
3,4,5-trisphosphate (PIP3). In contrast, 
phosphatase and tensin homologue (PTEN) 
acts as the cellular counterpart of the PI3Ks 
class I cleaving the attached phosphorylate 
group.[391] PIP3 as the second messenger 
activates various effectors via the pleckstrin 
homology domain (PH), i.e.: PDK1 and 
mTORC2. Further, it regulates the PIP3 acti-
vated protein kinase B (AKT), which itself 
regulates a plenty of downstream effectors 
covering p53, and BAD, see Figure 
73.[389,392] 
Class IA PI3Ks are heterodimers 
consisting of a regulatory p85 binding do-
main isoform (for p110, p110 and p110), 
a Ras binding domain, a protein kinase C 
homology domain 2 (C2), a PI3Ka domain, 
and a catalytic PI3Kc domain.[389,390] The 
different binding domains lead to the three 
isoforms , , and . The extracellular do-
main of an attached membrane bound re-
ceptor tyrosine kinase activated by growth 
factors, and insulin among others, phos-
phorylates the regulatory domain of the 
PI3Ks. This leads to an activated state of 
the catalytic domain.[383] Nevertheless, also 
synergistic effects of G and RTKs depend-
ent activation have been reported.[393–395] 
Class IB PI3Ks are also heterodi-
mers. However, in contrast to class IA the 
regulatory domain (p101) offers an adaptor 
binding site (AdB).[383,389] Only one isoform of 
class IB, PI3K was identified by now.[389,390] 
Moreover, the activation is mediated by a 
Gi/o-protein coupled receptor 
(GPCR).[384,394,396] It is noteworthy, that in 
opposite to the usual activation of effectors 
by the G subunit, the G subunit activates 
PI3K beside other effectors. Thus acceler-
ates the whole signal transduction event 
faster than the class IA mediated signal 
cascade.[388] 
Whereas the PI3K and PI3K are 
expressed ubiquitous in all cell types, the 
isoforms PI3K and PI3K are mainly ex-
pressed in cells of the native and adaptive 
immune system, the blood pressure regula-
tion, and the blood coagulation.[385,397] More-
over, PI3K is often expressed for a cooper-
ative activation of other receptors and 
effector proteins, i.e.: PI3K.[388] Chemo-
kines, pro-inflammatory lipids, and bacterial 
products represent extracellular ligands for 
PI3K activation in immune cells.[385] The 
activation subsequently increases the effi-
ciency of neutrophils by accelerated excre-
tion of proteases, reactive oxygen species, 
and antimicrobial substances.[398] Moreover, 
PI3K and PI3K mediated cellular events 
leads to the enhanced recruitment of mac-
rophages and monocytes to the inflamma-
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tion site.[398,399] PI3KandPI3K coopera-
tion is responsible for the ADP dependent 
platelet coagulation.[388] Moreover, PI3K 
seems to be involved in myocardial muscle 
cell contraction.[400] A direct binding to the 
cAMP-phosphodiesterase and the subse-
quent reduction of the cAMP level leading to 
reduced muscle contraction is discussed as 
the mechanism of action.[400] 
However, the class II PI3Ks lack the 
p85 domain but offer a C-terminal Phox do-
main and an additional C2 domain. In con-
trast, the class III are reduced to the rudi-
mentary structural properties responsible for 
phosphatidylinositol binding and catalysis, 
see Figure 72.[389] 
The described important roles of 
PI3Ks in physiological processes and patho-
logical events turn them to interesting tar-
gets for the treatment of hypertonia, auto-
immune diseases, and cancer.[385] Beneficial 
effects targeting PI3Ks have been observed 
in mouse models for rheumatoid arthritis 
and systemic lupus.[397,401] 
 
Figure 72: PI3Ks are divided into three classes. All 
PI3K catalytic subunits consist of a C2 domain, a 
helical PI3Ka domain and a catalytic PI3Kc domain. 
Class IA PI3Ks exist in complex with a regulatory p85 
subunit isoform. Class II lack the regulatory subunits 
but have amino- and carboxy-terminal extensions to 
the PI3K core structure. Class III are structurally re-
duced to the rudimentary PI3K core.
[389]
 
 
 
Figure 73: PI3K pathway is initialised by RTKs recruit resulting in increased phosphatidylinositol-3,4,5-tris-
phosphate (PIP3) levels. PIP3 subsequently concentrates many effector proteins to the membrane via their pleck-
strin homology (PH) domains including AKT, PDK1, PHLPP. Furthermore, PDK1 and mTORC2 activate AKT, 
whereas the inactivation is mediated via the dephosphorylation by PHLPP. Activated AKT phosphorylates various 
substrates, influencing effectors of cellular growth, survival, and proliferation. However, an AKT-independent acti-
vation of downstream targets, such as RAC1/CDC42, by PI3K is also possible.
[391]
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3.4.2 Organometallic Inhibitor Design 
 
The cumulated results obtained for 
the investigations described for chiral triden-
tate ligands claim for a more efficient way to 
design and anticipate ligand modifications 
increasing the binding affinity. Scanning a 
kinase binding pocket by the subsequent 
introduction of additional functional groups 
into the ligand scaffold inevitably increases 
the number of synthetic steps. Moreover, a 
beneficial effect is not guaranteed turning 
some elaborated synthetic routes into super-
fluous efforts. Thus, to avoid the dissipation 
of time and resources a more sophisticated 
way to design new organometallic inhibitors 
has to be elaborated. To face this issue, 
initial efforts were spent to apply methods 
established for the molecular modelling of 
pure organic inhibitors onto the concept of 
organometallic inhibitors. 
The challenge of synthesising enan-
tiopure organometallic complexes has been 
discussed previously, see Chapter 2.3., and 
appropriate possible solutions have been 
presented, see Chapter 3.3.2 and Chapter 
3.3.5. Nevertheless, the importance and the 
need of such systems for the asymmetric 
synthesis of octahedral complexes is high-
lighted once again in the context of PI3K 
inhibition. The complex 139 synthesised by 
STEFAN MOLLIN in the MEGGERS group was 
only obtained as a racemic mixture consist-
ing of -139 and 139. 139. The racemic 
mixture was found to inhibit PI3K. Although, 
a crystal structure of 139 bound to PI3K 
was obtained by JIE QIN in the MARMOR-
STEIN group, the correct assignment of the 
eutomer in congruence to the measured 
electron density was not unambiguously 
possible. Moreover, a complicated separa-
tion of the enantiomers was not performed 
during the former investigations, see Figure 
75. 
 
Figure 74: Single enantiomers of /-139, which was 
used as racemic PI3K inhibitor. 
 
Figure 75: PI3K in complex with organoruthenium(II) 
complex 139 (internal data from MEGGERS group). The 
map is the fofc.map at 2  level. The crystals were 
recorded for 8 h and the resolution was 2.55 Å. The 
electron density do not allow an accurate assignment 
of the eutomer. The chemical structure of -139 is 
shown as sticks with the carbon atoms in green. Nitro-
gen atoms are shown in blue, oxygen atoms in red, 
sulfur in yellow, and the ruthenium core in purple. 
PI3Kis presented as cartoon in white. 
To circumvent these problems, the 
elaborated concepts to synthesise enanti-
opure metal based inhibitors could be ap-
plied to develop a PI3K selective inhibitor. 
Moreover, computer aided design could as-
sist the development of new complexes 
avoiding superfluous synthetic efforts. 
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3.4.3 Hot Spot Analysis – a First Clue to 
Address the Right Sites 
 
The next generation complexes of 
PI3K inhibitors were intended to be de-
signed as octahedral complexes. To assist 
these attempts a hot spot analysis was ap-
plied first to achieve a first clue, if there are 
favourable interactions present. Thus, two 
different programs, FCONV and HOTSPOTSX 
developed by GERD NEUDERT, were applied 
in collaboration with TOBIAS CRAAN to design 
the new scaffold. 
 
Figure 76: Representative atoms (highlighted in red) 
assigned according to the internal annotation of 
FCONV. The annotation includes element symbol, 
chemical environment, hybridisation state, bonding 
state and interaction group. 
3.4.3.1 FCONV – a program for format con-
version, manipulation and feature 
computation of molecular data 
 
FCONV is applicable for molecule data 
handling and data parsing problems.[402] This 
program assignes internal predefined atom 
types to the atoms of an input structure. The 
internal atom type classification considers 
the element itself, the hybridisation state, 
and the intermolecular interaction of the ap-
propriate functional group, see Figure 76 for 
representatives; i.e.: the oxygen of an hy-
droxyl group is assigned by the descriptors 
O for oxygen, 3 for sp3 hybridisation, and oh 
as the oxygen is bound to an hydrogen atom 
beside the alkyl residue. On one hand, the 
hydroxyl group could form hydrogen bonds 
providing its own hydrogen atom; on the 
other, it could provide one of its lone pairs 
for hydrogen bond formation. In the first 
case the hydroxyl group acts as a donor and 
in the second as an acceptor. Therefore, the 
O.3oh atom type belongs to the doneptor 
group. In opposite, an oxygen of an alkyloxy 
Table 1: Overview of the internal atom types of FCONV clustered by their physico-chemical properties. Acceptor 
(Acc), doneptor (AnD), aromatic (Aro), donor (Don) and hydrophobic (Hyd) properties. 
 
Doneptors Aromatic Donor Hydrophobic
O.carb O.co2 O.3oh C.ar6 N.guh C.1s
N.ar2 O.2po N.r3 C.ar6x N.ar6p C.2r3
N.1 O.2so N.gu1 C.arp N.arp C.3r3
N.oh O.2p N.gu2 C.arx N.ar3h C.1p
N.aas3 O.2so N.mi1 C.ar N.ohac C.2p
N.aat3 O.3po N.mi2 N.ar6 N.ims C.2s
N.2n O.3so N.aap N.ar3 N.amp C.2t
N.2s O.o N.2p O.ar N.ams C.et
N.3t O.3es N.3n S.ar N.samp C.ohp
O.r3 O.3eta N.3p N.sams C.ohs
O.n O.3eta N.3s N.mih C.oht
O.2co2 S.r3 O.h2o N.4H C.3p
O.2es S.thi O.noh C.3s
O.2hal S.2 O.3ac C.3t
O.am O.ph C.3q
S.sh
S.s
S.3
15 9 12 18
Acceptors
29
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group assigned by the descriptors O.3eta (O 
for oxygen, 3 for sp3 hybridisation, and eta 
for ether) can not act as a donor and thus 
belongs solely to the acceptor group. 
In total, 157 different atom types were 
considered and clustered into five different 
groups considering their main generic phys-
icochemical properties: acceptor (29), 
doneptor (15), aromatic (9), donor (12), and 
hydrophobic (18), see Table 1. The atom 
types that can not be accounted to any of 
the described groups were defined as X 
(74). Thus, by correlating and assigning 
each atom of a molecule by FCONV, enables 
a description of the local chemical environ-
ment, hybridisation, and bonding state. 
3.4.3.2 HotSpotsX – a program to generate 
contour maps and hot spots 
 
The second applied program during 
these investigations was HOTSPOTSX. This 
program is applicable to predict interaction 
fields, expressed by contour maps, for the 
previously defined atom types of an input 
structure. If the input structure is i.e.: a pro-
tein structure, contour maps for the catalytic 
center, an allosteric binding site, any other 
binding site, or a protein surface of interest 
can be predicted. The predictions are 
knowledge based.[403,404] 
First, atoms of functional groups and 
structural motifs were assigned and clus-
tered by FCONV as described before. These 
process was performed not only for the 
structure of interest, but also for a reference 
data set like entries from the Cambridge 
Structural Database (CSD) or the Protein 
Data Bank (PDB). Then, the experimentally 
determined distances and angles, deposited 
in the reference data set, for a predefined 
atom type and its appropriate interaction 
partner were correlated by HOTSPOTSX. 
Here, contour maps for each predefined 
atom types were calculated expressing the 
ideal coordinates for the matching interac-
tion partner. The coordinates with high oc-
curance frequencies in the databases, re-
garding distance and angle were represent-
ed by high propensity and subsequently 
result into hot spots. 
The contour maps can be represented 
at different map levels, which will be ex-
plained by the example of hydrogen bonds 
below. The length of hydrogen bonds vary 
between approximately 1.6 Å and 2.0 Å. It 
depends on different factors like bond 
strength, temperature, and pressure.[405,406] 
Moreover, the bond strength in turn is de-
pendent on temperature, pressure, bond 
angle, and the individual environment of the 
interacting molecules.[405,406] Thus, i.e.: the 
FCONV atom type N.3p, a primary amine 
could form an hydrogen bond with a certain 
partner, i.e.: O.carb (carbonyl oxygen) under 
a particular distance and a particular angle 
in one entry of the PDB reference set, see 
Figure 77 a). However, in a second entry, 
the hydrogen bond between the same atom 
types differ slightly due to the environment 
of the entry in the reference set, see Figure 
77 b). Thus, evaluating all N.3p – O.carb 
pairs of the reference set inevitably leads to 
a scattering of the ideal coordinates of N.3p 
around a certain mean value for the dis-
tance of interest, see Figure 77 c). The 
same observation is true for varying dis-
tances retaining a particular angle. 
Therefore, a single coordinate for the 
ideal position of N.3p related to O.carb can 
not be provided. Moreover, plenty of combi-
nations of distances and angles of the hy-
drogen bonds are possible. However, all 
converge an ideal distance and angle. Thus, 
leads to a three dimensional scattering and 
results subsequently into the mentioned 
contour maps. Three-dimensional areas with 
high propensity of N.3p coordinates result 
into a hot spot for this doneptor group. 
Moreover, by altering the grade of propensi-
ty subsequent contour map levels can be 
examined. 
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Figure 77: The general principle of countour map 
calculation by HOTSPOTSX highlighted on an example 
with altering angles and fixed hydrogen bond distance. 
a) The coordinates of an interaction pair forming hy-
drogen bonds like N.3p and O.carb were determined. 
Their coordinates are crucially influenced by the hy-
drogen bond length and the angle. b) In a second 
N.3p – O.carb interaction pair the individual environ-
ment of the molecules force a slight difference in the 
angle of the hydrogen bond by retaining the hydrogen 
bond length. This entry of the reference data set leads 
to slightly altered coordinates for the N.3p atom type 
related to the O.carb atom type as shown in a). c) 
With increasing number of compared N.3p – O.carb 
interaction pairs the coordinates for N.3p scatter 
around a certain mean value. However, plenty of 
combinations of lengths and angles of the hydrogen 
bonds are possible. Thus, leads to a three dimension-
al scattering. This subsequently results into a contour 
map rather than a single ideal coordinate. Three-
dimensional areas with high propensity of N.3p coor-
dinates result into a hot spot for this doneptor group. 
The same described procedure was 
applied for any combination of atom type 
pairs, which form intermolecular interac-
tions, i.e.: acceptor – donor, acceptor – 
doneptor, hydrophobic – hydrophobic, aro-
matic - aromatic, etc. The combined contour 
maps of all FCONV atom types, which belong 
to a distinct group of physico-chemical inter-
action, represent the contour map of the 
interaction group itself. For instance, the 
combined contour maps of all 15 single at-
om types of the doneptor group represent 
the contour map of the doneptor group itself, 
see Table 1. However, some atom types like 
N.guh, a protonated guanidinium nitrogen, 
posses less entries in the reference set then 
other like O.3oh. Thus, the absolute levels 
for each generic physicochemical interaction 
group inevitably differ and negative values 
are favorable values. However, a relative 
comparison is more appropriate to compare 
different interaction types than a correlation 
of the absolute contour map level. There-
fore, the percentage above the minimal map 
level was considered for each physicochem-
ical interaction group for comparison. High 
percentages are based on high propensities 
for certain interaction types representing 
more accurate hot spot. 
However, the main focus of the investi-
gations performed during this work was not 
the evaluation of every single FCONV atom 
type of PI3K to a particular interating atom 
type via HOTSPOTSX as described in previ-
ous studies.[407] A general comparison of the 
different generic physicochemical interaction 
groups was sufficient to achieve a first clue. 
These impulses could be implemented in 
the ligand scaffold. Thus initial hints could 
significantly inspire the future metal complex 
design. 
3.4.3.3 PI3K as investigation target for the 
hot spot analysis 
 
As a three dimensional structure of 
the target protein is necessary to perform 
the hot spot analysis, the crystal structure of 
140 in complex with PI3K (pdb: 3CST) was 
selected as template.[188] The metal based 
half sandwich inhibitor is composed of a 
modified pyridocarbazole ligand, a mono-
dentate carbonyl ligand and a modified cy-
clopentadienyl ligand. Nevertheless, only 
the structural information of the kinase was 
accounted for the analysis. 
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Figure 78: PI3K inhibitor 140 (pdb: 3CST). 
 
Figure 79: Contour map of the physicochemical inter-
action type donor (blue) at contour map level of 69% 
above minimal map level. The carbon atoms of the 
organometallic complex 140 are depicted in green, the 
oxygen atoms in red, the nitrogen atoms in blue, the 
fluorine in light cyan, and ruthenium in purple. The 
surface of the PI3K binding site is shown in white. 
The hot spot analysis, applying the in-
troduced programs FCONV and HOTSPOTSX, 
in case of PI3K was performed for each of 
the five generic physicochemical interaction 
types: acceptor, donor, doneptor, hydro-
phobic and aromatic. The donor contour 
map at a level of 69% is shown in Figure 79 
and the acceptor contour map at a level of 
46% in Figure 80, both for the PI3K binding 
site.  
Figure 79 already reveals a coincidence 
of the hydroxyl group of the pyridocarbazole 
ligand of 140 and the donor contour map. 
Moreover, one of the two hydroxyl groups of 
the 2-amino-2-methylpropane-1,3-diol resi-
due of 140 is oriented towards but not cov-
ered by the donor contour map. However, 
the surface of PI3K suggests that this bind-
ing site area is of limited accessibility. 
In Figure 80 the monodentate carbonyl 
ligand is close to be covered by the acceptor 
contour map. However, the carbonyl ligand 
can not be considered as a true hydrogen 
bond acceptor. Thus, a metal coordinating 
ligand acting as a true acceptor could im-
prove the affinity. This hypothesis remains 
to be proven. However, these examples 
confirm the worthiness of the hot spot anal-
ysis for future drug design. 
 
Figure 80: Contour map of the physicochemical inter-
action type acceptor (red) at contour map level of 46% 
above the minimal map level. The carbon atoms of the 
organometallic complex 140 are depicted in green, the 
oxygen atoms in red, the nitrogen atoms in blue, the 
fluorine in light cyan, and ruthenium in purple. The 
surface of the PI3K binding site is shown in white. 
The separate inspection of already 
these two contour maps of the PI3K binding 
site suggests, that a simultaneous compari-
son of all five physicochemical interation 
types would rapidly lead into a confusing 
overall picture for visual evaluation. There-
fore, the contour maps of the investigated 
physicochemical interaction types were con-
verted into discrete spheres by MICHAEL 
BETZ. These spheres represent a contour 
map at a certain map level, but allow to se-
lectively hide spheres of disinterest for clari-
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ty as shown for the acceptor contour map in 
Figure 81. 
The hot spots are depicted as spheres 
with ideal positions for hydrogen bond ac-
ceptors (red), hydrogen bond donors (blue), 
doneptors (purple), hydrophobic groups 
(white) and aromatic groups (yellow). They 
were selected by visual inspection according 
to their relevance for prediction, verification, 
and guidance for synthetic modifications, 
see Figure 82. The size of the spheres re-
flect their appropriate contour maps at a 
certain map level. 
 
Figure 81: Conversion of the acceptor contour map to 
corresponding spheres offers the possibility to selec-
tively omit spheres of disinterest for clarity. In this 
example, three spheres adjacent to the pyridine moie-
ty of the pyridocarbazole ligand of 140 are displayed 
and others were hided. The contour map level is 40% 
above the minimal map level. The carbon atoms of the 
organometallic complex 140 are depicted in green, the 
oxygen atoms in red, the nitrogen atoms in blue, the 
fluorine in light cyan, and ruthenium in purple. The 
surface of the PI3K binding site is shown in white. 
Regarding the hot spots in the binding 
site reveals that the pyridocarbazole ligand 
of 140 exactly occupies the ideal position for 
a hydrophobic interaction partner with its 
maleimide moiety. The hot spot represents 
the contour map at 82% above minimal map 
level. This indicates that the hydrophobic 
interaction might be of major importance for 
the overall ligand-protein interaction. This 
observation is in good congruence to the 
fact, that the pyridocarbazole ligand faces 
an aromatic amino acid residue (Tyr-867) in 
the PI3K binding site, see also Figure 83. 
This residue, along with others in the bind-
ing site, indeed favours an hydrophobic in-
teraction partner. 
 
Figure 82: PI3K in complex with 140 (pdb: 3CST). 
The five interaction groups are depicted as spheres: 
hydrogen bond acceptor (red, 46%), hydrogen bond 
donor (blue, 69%), doneptors (purple, 52%), hydro-
phobic (white, 82%) and aromatic (yellow, 80%). 140 
is presented as sticks with the carbon atoms in green. 
Nitrogen atoms are shown in blue, oxygen atoms in 
red, fluorine in light cyan, and the ruthenium core in 
purple. PI3Kis presented as cartoon in white, 
whereas the only the ATP binding site is shown for 
clarity. 
Moreover, the hydroxyl function of the 
pyridocarbazole ligand almost occupies the 
predicted ideal position for a donor interac-
tion type. The hot spot represents the con-
tour map at 72% percent above the minimal 
map level. Thus, a hydrogen bond donor at 
this area of the binding site might result into 
a beneficial contribution to the ligand-protein 
interaction. A predicted hot spot for a donep-
tor is in a 2.67 Å distance to the carbonyl 
group of the maleimide function represent-
ing the contour map at 52% above the min-
imal map level. However, the pyrido-
carbazole does not meet this potential 
interaction. A selective modification of the 
pharmacophore ligand on this moiety is diffi-
cult, although synthetically possible and re-
alised in former studies.[408] 
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Furthermore, a hot spot for a hydrogen 
bond acceptor was identified 3.62 Å away of 
the fluorine atom of the pyridocarbazole re-
flecting the corresponding contour map at 
46% above the minimal map level. However, 
addressing this potential interaction could be 
quite challenging due to its location in a cleft 
of the binding pocket, which is difficult to 
reach from the inhibitor binding site. 
Closing, the hot spot for an aromatic 
group (82% above minimal map level) and 
the hot spot for a hydrogen bond donor 
(80% above the minimal map level) are both 
located next to the indole moiety of 140. 
Although, 140 does not address these inter-
actions, suitable functional groups could be 
elaborated to address both simultaneously. 
The hot spot analysis has not resulted in 
favourable interactions covered by the cy-
clopentadienyl ligand of 140 at arguable 
map levels. In addition, potential adjacent 
favourable donor interactions, as indicated 
by the contour map, might be difficult to 
meet, see Figure 81. 
However, the hot spots for the acceptor, 
doneptor, and the donor interaction types 
are all representing their corresponding con-
tour maps at a map level below 69%. This 
fact should evaluated critically, as valuable 
hot spots for ligand design should aspire 
map levels of about 90% or even 
higher.[407,409,410] However, the hydrophobic 
and the aromatic interaction types, both 
above 80% above minimal map level, seem 
to be the main contributing interactions for 
the binding of 140. This observation is of 
very good congruence to the characteristics 
of complex 140 as its pyridocarbazole ligand 
is methylated at the maleimide moiety. This, 
significantyl turns it into a hydrophobic com-
plex compared to the unmodified ones. 
It is noteworthy, that the hot spot analy-
sis was performed only for the binding site 
itself leading to results only for the ATP 
binding site. Indeed, different sites of PI3K 
may offer much favourable positions for 
these interaction types and may reveal po-
tential allosteric binding sites. However, no 
further favourable functional groups or struc-
tural moieties have to be respected for the 
ligand design using 140 as a starting point. 
Thus, the ligand design can be entirely fo-
cused to face the enantiopure complex syn-
thesis. 
 
Figure 83: PI3K in complex with 140 (pdb: 
3CST).
[188]
 The hydroxyl group forms two hydrogen 
bonds to Val882 and Asp884 (red dashes). Tyr-867 
forms hydrophobic interactions to the pyridocarbazole 
ligand of 140. 140 is presented as sticks with the car-
bon atoms in green. Nitrogen atoms are shown in 
blue, oxygen atoms in red, fluorine in light cyan, and 
the ruthenium core in purple. PI3Kis presented as 
cartoon in white and the main chain of the hinge re-
gion is depicted additionally as sticks. 
The results of the hot spot analysis 
are over all in a very good congruence to 
the experimentally determined results; es-
pecially, comparing them to the crystal 
structure of 140 in complex with PI3K, see 
Figure 83. First, the hydroxyl group of the 
pyridocarbazole forms two hydrogen bonds 
with Val882 and Asp884 and simultaneously 
occupies the space adjacent to the predict-
ed hot spot for a hydrogen bond donor. 
Nevertheless, as the hydroxyl group acts as 
a doneptor, in this case a doneptor hot spot 
should have been identified at this position. 
Second, the Tyr-867 determines the corre-
sponding interaction partner and the pyrido-
carbazole ligand fulfillls these requirements 
ideally occupying the hydrophobic hot spot. 
This position was assigned as a hydropho-
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bic hot spot due to the clustering of the atom 
types into the different pysico-chemical in-
teraction types. However, the atom types 
assigned to either aromatic or hydrophobic 
hot spots are related to each other regarding 
their chemical properties. Therefore, the 
discrimination is not strict and both interac-
tion types can be addressed by related 
structures. 
However, discrepancies in the posi-
tioning should not be overrated. The flexibil-
ity of the protein leads to a subsequent shift 
of the hot spots, which can not be respected 
in an analysis based on a rigid model. How-
ever, further verification experiments for the 
hot spot analysis could help to improve its 
accuracy and the effect of preliminary prep-
aration procedures. For instance, the influ-
ence of the scope of the input structure, 
considering binding site versus the use of 
the entire protein domain could be investi-
gated. Nervertheless, the hot spot analysis 
on this example indicated its beneficial po-
tential to the future design of PI3K inhibi-
tors.  
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3.4.4 Elaborating the Ligand Scaffold 
3.4.4.1 Tetradentate C2-Symmetric Lig-
ands 
 
As the hot spot analysis has not re-
vealed favourable interactions ideally to ad-
dress by the residual ligands offside the pyr-
idocarbazole, the focus was set on the 
synthesis of enantiopure metal based PI3K 
inhibitors. Different ways to achieve this goal 
were pursued. The first approach was the 
use of C2-symmetric ligands to avoid the 
formation of diastereomers during a single 
complexation reaction. Ligands like 2,5,8-tri-
thia-{9}(2,6)pyridinophane (144), 2,11-di-
thia[3.3](2,6)pyridinophane (146), and 
1,4,7,10-tetrathiacyclododecane (151) fulfill 
the requirements of being symmetric and 
offering coordinating atoms for metal com-
plexation. 
The synthesis of the pyridinophane de-
rivatives 144 and 146 starts from the com-
mon precursor 2,6-bis(bromomethyl) pyri-
dine 142, see Scheme 22. 142 can be syn-
thesised in 98% yield starting from 2,6-py-
ridinedimethanol (141) in melted phosphoryl 
bromide at 60 °C. 142 was extracted and 
dried in vacuo to obtain white needles. 
Then, different cyclisation conditions result 
into the related compounds 144 and 146. 
Caesium carbonate suspended in DMF at 
60 °C for 20 h reacting a homogenous solu-
tion of 142 with 2,2-Bis(2-mercaptoethyl)sul-
fide (143) leads to the formation of 144 in 
28% yield. It is noteworthy, that a drop wise 
addition of the reactants via a syringe pump 
is mandatory to form the medium size ring 
and to avoid polymerisation to side prod-
ucts. Reacting 142 with thioacetamide (145) 
and lithium carbonate in DMF at 55 °C for 
3 h result to the formation of 146. After ex-
traction and column chromatography the 
product was obtained as yellow, highly vis-
cous oil. 
In opposite 2,2'-(ethane-1,2-diylbis (sul-
fanediyl))diethanol (147) was refluxed with 
thiourea (148) in hydroboric acid (47% aq.) 
for 8 h followed by the addition of sodium 
hydroxide and an additional 16 h of reflux 
condition. After extraction the intermediate 
 
Scheme 22: Synthesis of C2-symmetric tetradentate ligands. 
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2,2'-(ethane-1,2-diylbis(sulfanediyl))diethan-
ethiol (149) was obtained as highly viscous 
pale oil in 42% yield. The cyclisation was 
then performed using caesium carbonate 
suspended in DMF heated to 50 °C and the 
addition of a homogenous solution of 149 
and 1,2-dibromoethane (150) drop wise over 
a period of 12 h via a syringe pump. The 
reaction was continued for an additional 2 h. 
The crude material was extracted and the 
product was recrystallised from chloroform 
to obtain 151 as white crystals in 10% yield. 
Ligand 151 and subsequent precursor were 
synthesised by the research intern SOPHIE 
FRANZ. 
For the synthesis of the medium sized 
rings, the general problem is the low yields 
observed for all three examples. Although, 
the ligands were synthesised successfully, 
the complexation to the intended complexes 
were not pursued during this work as these 
complexes would have been positively 
charged. This incidence could be adverse 
for the passive diffusion for targeting PI3K 
or other kinases, in a cellular model. There-
fore, tetradentate C2 symmetric ligands do 
not offer a suitable solution to synthesise 
enantiopure metal based kinase inhibitors 
from the pharmacokinetic point of view. 
Meanwhile, the success of the chiral pro-
linato ligand concept in combination with 
rhodium as the metal centre was applied for 
PI3K inhibitor synthesis leading to pro-
mising results. Thus, the tetradentate ligand 
project was stopped despite the potential of 
obtaining interesting compounds, due to the 
lack of time. Nevertheless, the concept itself 
offers the possibility to achieve access to 
novel enantiopure octahedral metal com-
plexes. Therefore, they should be consid-
ered for future enantiopure complexes with 
a distinct aim. 
3.4.4.2 Amino Acids as Building Blocks for 
Chiral Multidentate Ligands 
 
The successful work using proline in ei-
ther L- or D-configuration as a building block 
for chiral multidentate ligand synthesis in-
spired to apply the residual proteinogenic 
amino acids in a similar way to control the 
stereochemistry of the complexes. 
A. STRECKER had synthesised metal 
based complexes based on amino acids 
already in 1850, and many successful appli-
cations have been reported in literature by 
now.[411–415] Crucial for the use of amino ac-
ids in metal complexation is the proper han-
dling of the present side chain.[416] The dif-
ferent functional groups can be either 
applied as steric effectors, coordinating 
structural motifs, or interaction partners for 
other molecules influencing physico-
chemical, biological, and toxicological ef-
fects.[416] 
 
Figure 84: The incorporation of chiral primary amino 
acids into the design of tridentate ligands lead to the 
formation of four diastereomers a)-d) assuming a 
fac-coordination. 
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Transferred to the principles of octahe-
dral metal complexes observed for prolinato 
ligands, the incorporation of chiral primary 
amino acids into the synthetic route should 
result into several changed characteristics of 
the expected complexes, see Figure 84: 
1. The rigid structure of proline led to 
the formation of only two dia-
stereomers during the complexation; 
using primary amino acids should re-
sult into four, if the tridentate ligand 
still occupies a fac-coordination and 
the pyridine ring remains in the same 
plain as the pyridocarbazole. 
2. If enantiopure amino acids are uti-
lised, all resulting four structural iso-
mers of a complexation reaction are 
diastereomers as the C chirality 
centre of the amino acid breaks 
symmetry. 
3. All resulting four diastereomers 
should differ in their physico-
chemical properties and therefore a 
standard purification should be appli-
cable. 
However, as there is a large set of 
commercially available amino acids, both in 
(S) as well as (R) configuration, a rational 
selection of suitable ones has to be elabo-
rated. The resulting coordination spheres 
using distinct amino acids result in a differ-
ent steric demand of the complexes. Mo-
rover, the different functional groups of the 
amino acid residues may interact with the 
kinase binding site. In addition, applicability 
to the synthetic route has to be considered. 
These aspects have to be weighed wisely to 
reduce the synthetic effort and the con-
sumption of resources. 
3.4.5 The Selection of Amino Acids for 
the Ligand Design 
3.4.5.1 General Strategy 
 
First, the tridentate ligand was retrosyn-
thetically separated into his two main com-
ponents, see Figure 85. The general ligand 
design 152 was simplified to two fragments 
resulting in 2-methylpyridine (153) and the 
amino acid fragment (154). 153 remains 
unmodified in the intended ligands and the 
focus was set onto the amino acids and their 
residues. Thus, to solve the introduced is-
sues, see chapter 3.4.4.2, the relevant ami-
no acids were compared regarding their 
distinct characteristics. Moreover, the pyri-
docarbazole ligand and the metal core were 
defined as structural anchors remaining un-
touched. 
 
 
Figure 85: Fragmentation of the tridentate ligand 
scaffold. 
 
 
102 Results and Discussion 
3.4.5.2 Selection Criteria 
 
The estimated accessible space in the 
binding site of PI3K has to be assessed to 
obtain a first hint for the ligand design. Thus, 
coordinates for the pyridocarbazole ligand 
and the metal core were extracted from the 
PI3K (pdb: 3CST) crystal structure and 
predefined as template structures. All amino 
acids of the primary sequence of PI3K in 
4 Å distance to the pyridocarbazole and the 
metal core were identified and respected as 
binding site of the pyridocarbazole moiety. 
Two different anchor points were de-
fined as A1 and A2. The coordinates of 
these two anchor points were extrapolated 
from the crystal structure of -(S)-106, see 
Figure 59, as an octahedral template in op-
posite to 140. These anchor points occupy 
approximately the same positions as the 
corresponding coordinating atoms of the 
tridentate proline-based ligand of -(S)-106. 
The distance was set to 2 Å, in congruence 
to -(S)-106, and the anchor points are in 
the same plane as the pyridocarbazole lig-
and. Thus, the anchor points A1 and A2 
represent the positions, where the coordi-
nating atoms of the intended ligands should 
be located. Then, the centre Z1 was de-
fined, whereas A1 is located 2 Å away from 
Z1, which in turn is located 4 Å away from 
the metal core; all three of them form a line. 
The same is true for Z2 and A2 related to 
the metal core, see Figure 86 a). The exact 
coordinates can be extrapolated by vector 
calculations based on the coordinates for 
the coordinating nitrogen atoms of the pyri-
docarbazole and the ruthenium metal core. 
The spheres of Z1 and Z2 were defined with 
5 Å diameter, see Figure 86 b). These hypo-
thetic spheres represent guidance volumes, 
which should not be exceeded by the in-
tended amino acids. Indeed, a sphere of 5 Å 
seems to be a proper limit avoiding steric 
hindrances. 
a) 
 
b) 
 
Figure 86: a) Overview of the anchor points A1 to A4 
and the two centres Z1 and Z2. A1, Z1, the metal 
core, as well as the nitrogen atom of the pyridine moi-
ety of the pyridocarbazole are all in line. The distance 
Z1-metal core is 4 Å, the distance A1-metal core is 
2 Å. The same is true for Z2 in correspondence to A2 
and the metal centre. A1, A2, Z1 and Z2 as well as the 
pyridocarbazole and the ruthenium core are all located 
in the same plane. A3 and A4 mark the residual ideal 
positions for coordinating atoms. b) The zones around 
Z1 and Z2 include the space within 5 Å and represent 
an hypothetic guidance volume. This volume should 
not be exceeded by the intended amino acids for the 
tridentate ligand synthesis. The PI3Kstructure as 
well as the pyridocarbazole structure are derived from 
the data set pdb: 3CST.
[188]
 The pyridocarbazole lig-
and is presented as sticks with the carbon atoms in 
green. Nitrogen atoms are shown in blue, oxygen 
atoms in red, fluorine in light cyan, and the ruthenium 
core in purple. PI3Kis presented as cartoon in 
wheat. 
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For a further definition of the desired 
complex structure two additional anchor 
points A3 and A4, see Figure 86 a), were 
defined, which are derived from the residual 
coordinating atoms in -(S)-106. They de-
scribe favourable positions to form an octa-
hedral complex. Therefore, ideal poses of 
the fragments 153 and 154 should adress 
the anchorpoints A1 and A2, occupying the 
zones around Z1 and Z2, but not A3 and A4. 
This is congruent with a presumed fac-coor-
dination. Thus, an estimated space of 65.45 
Å3 (represented by the spheres around Z1 
and Z2 with a diameter of 5 Å) should be 
accessible and therefore considered as 
guidance for the amino acid selection. 
However, it is also important which 
sphere, around Z1 or Z2, is occupied either 
by the amino acid fragment 154 or the 
2-mehylpyridine moiety 153, see Figure 86. 
As the two spheres, in a chiral environment, 
like the binding site of PI3K, are not equal. 
The different fragments will experience dif-
ferent interactions, when located either in 
the sphere of Z1 or Z2. For instance, a bulky 
amino acid residue, like phenylalanine, tyro-
sine, or tryptophane, could hypothetically 
lead to steric hindrances, when occupying 
the sphere of Z2. In opposite, the offered 
space occupying the sphere of Z1 could be 
sufficient for the mentioned bulky amino 
acids.[417–419] In contrast, a polar charged 
amino acid, could experience high attraction 
in Z2 by forming a salt bridge or could expe-
rience high repulsion due to adverse hydro-
phobic interactions or charges of the same 
polarity.[418–420] 
Further, the chirality at the C of the 
amino acid influences significantly the 
globular shape of the entire complex, see 
also Figure 84. The C atom crucially de-
fines the three dimensional space, which is 
occupied by the corresponding functional 
group of the amino acid fragment. Thus, 
whereas a complex based on a (S)-confi-
gurated amino acid could hypothetically fit 
into the binding site, the complex based on 
the corresponding (R)-configurated amino 
acid could experience steric hindrances and 
a subsequent repulsion. 
Moreover, desolvatation effects of the 
amino acid residues have to be considered. 
Thus, stripping off the hydrate shell of 
charged or polar groups could significantly 
decrease the binding affinity towards PI3K, 
if the polar or ionic group is not captured by 
a sufficient counterpart inside the binding 
pocket.[421] Analogous principles are true for 
hydrophobic side chains and aromatic side 
chains. [417–419] In contrast, if they find a suf-
ficient grove to displace water molecules 
and to meet hydrophobic or aromatic inter-
actions a valuable contribution to the binding 
affinity could be achieved. However, amino 
acids with large hydrophobic and aromatic 
residues result into bulky complexes, which 
in turn possess decreased water 
solubility.[140,156,157,422] They require an in-
creased amount of solvation mediators like 
dimethylsulfoxid for in vitro assays. Howev-
er, an excessive use of dimethylsulfoxid 
influences the structural integrity of proteins 
on secondary, tertiary and quartery level 
leading to falsified assay results.[423] 
 
Figure 87: Possible placements of the fragments 153 (a) or 154 (b) into the sphere around Z1. a) 153 occupying 
the sphere of Z1 as a rigid fragment experiences different interactions in a chiral environment like the binding site 
of PI3K as occupying the sphere of Z2. b) the same is true for 154. For both fragments the placement into the 
sphere of Z1 is shown but the examples are analogously true for the placement into sphere of Z2. 
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Thus, a simple selection on steric crite-
ria of the amino acids compared to the ac-
cessible space of the binding site is ac-
ceptable but not entirely sufficient. In 
addition, functionalised side chains of amino 
acids require the application of protection 
group chemistry to avoid interfering coordi-
nation during the complexation 
reaction.[416,424] These protection groups 
have to be planed orthogonal to the residual 
reaction sequence to ensure a cleavage 
after a certain planned step. 
Therefore, a first generation set of ami-
no acids with distinct characteristics to cover 
the mentioned aspects were selected. 
Moreover, both positive and negative con-
trols were covered, see also Table 2. These 
amino acids should ideally act as represent-
atives for related ones, i.e.: phenylalanine 
as representative for aromatic amino acids. 
In addition, to minimise protection group 
chemistry, amino acids with ideally ortho-
gonal protectable functional groups regard-
ing the complex synthesis were preferred. 
Thus, the first representative amino acid 
group consisted of L-alanine ((S)-155), 
D-alanine ((R)-155), and L-serine ((S)-159) 
as small sized ones. These amino acids, 
regarding their VAN-DER-WAALS volume, 
should hypothetically fit into the binding site. 
This is only true if the estimated accessible 
volume of approximately 65.45 Å3 of Z2 
complies to the existing conditions of the 
PI3K binding site. Moreover, the influence 
of the C stereoconfiguration, during these 
investigations, should be covered comparing 
both L-alanine ((S)-155) and D-alanine 
((R)-155). 
The second group was represented by 
L-phenylalanine ((S)-156), L-leucine 
((S)-158), and L-valine ((S)-160). These 
large unpolar amino acids should result into 
bulky complexes experiencing steric hin-
drances. Thus, they should subsequently 
possess a reduced affinity towards the 
PI3K binding site. Due to the rotation 
around the C and the C bond, the bulky 
residues of the members of this group could 
potentially avoid steric clashes. To investi-
gate the elimination of this rotational free-
dom D-phenylglycine ((R)-179) as a non-
coded amino acid was added to this group. 
As a third group L-histidine ((S)-157) 
and L-tyrosine ((S)-161) were selected rep-
resenting large aromatic but simultaneously 
polar amino acids. As for the second selec-
tion group, the resulting complexes should 
hypothetically be excluded from the binding 
site by steric hindrance. Thus, the resulting 
complexes should also represent negative 
controls. 
As the last group, L-proline ((S)-101) as 
well as D-proline ((R)-101) were applied 
again as established ligand systems due to 
their successful former application, see 
Chapter 3.3.2. 
Table 2: Amino Acid Characteristics 
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Alanine aliphatic neutral apolar 67 1.8
Arginine aliphatic basic polar 148 -4.5
Asparagine aliphatic neutral polar 96 -3.5
Aspartate aliphatic acidic polar 91 -3.5
Cysteine aliphatic neutral polar 86 2.5
Glutamate aliphatic acidic polar 109 -3.5
Glutamine aliphatic neutral polar 114 -3.5
Glycine aliphatic neutral apolar 48 -0.4
Histidine aromatic basic polar 118 -3.2
Isoleucine aliphatic neutral apolar 124 4.5
Leucine aliphatic neutral apolar 124 3.8
Lysine aliphatic basic polar 135 -3.9
Methionine aliphatic neutral apolar 124 1.9
Phenylalanine aromatic neutral apolar 135 2.8
Proline heterocyclic neutral apolar 90 -1.6
Serine aliphatic neutral polar 73 -0.8
Threonine aliphatic neutral polar 93 -0.7
Tryptophan aromatic neutral apolar 163 -0.9
Tyrosine aromatic neutral polar 141 -1.3
Valine aliphatic neutral apolar 105 4.2
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3.5 Proof of Concept 
3.5.1 Subsequent Synthesis of Selected 
Amino Acid 
 
The synthetic route described for the 
synthesis of (R)-105 and (S)-105 was ap-
plied analogously to synthesise the amino 
acid derived tridentate ligands, see Chapter 
3.3.2. The amino acids (1 eq.) were suspen-
ded in methanol and thionylchloride (1.1 eq.) 
was added drop wise at 0 °C. The reaction 
mixture was refluxed for 16 h. Thereafter, 
the solvent was removed under reduced 
pressure, the residue resolved in methanol 
and then concentrated. This procedure was 
repeated three times to afford the meth-
ylesters as white solids. The yields for the 
ester formation were excellent as observed 
before. (S)-162 to (S)-168 were obtained in 
quantitative yields except of (S)-164 and 
(S)-165, both in 98% yield. The same is true 
for (S)-168, (R)-162, and (R)-180 all ob-
tained in quantitative yields. Ligand (S)-178 
and subsequent precursor were synthesised 
by the research intern OLIVER BORN. 
Esters derived from amino acids with 
unfunctionalised side chains like (R)-155, 
(S)-155, (S)-156, (S)-158, (S)-160, and 
(R)-179 could be processed straight for-
ward. In contrast, functionalised amino acids 
(S)-157, (S)-159, and (S)-161 had to be pro-
tected at different stages of the ligand syn-
thesis to become compatible to the com-
plexation conditions, see Scheme 25, 
Scheme 26, and Scheme 27. A reductive 
amination as described for (R)-104 and 
(S)-104, see Chapter 3.3.2, was preferred 
over a nucleophilic substitution as described 
for (R)-123 and (S)-123, see Chapter 3.3.5, 
to avoid side product formation. In general, 
palladium on carbon (3%) was suspended in 
methanol and picolinaldehyde (103) 
(1.2 eq.) was added at 0 °C. Sodium acetate 
(2 eq.) was added to the reaction mixture. 
Then, the methylester of the appropriate 
amino acid (1 eq.) was dissolved in metha-
nol and added to the reaction mixture. The 
reaction mixture was stirred for 1 h and the 
nitrogen atmosphere was completely substi-
tuted by hydrogen in three turns during this 
time. The reaction was continued for 15 h 
allowing the mixture to warm up to ambient 
temperature. The reaction mixture was fil-
trated over CELITE to separate the palladium 
 
Scheme 23: Synthesis of tridentate chiral ligands based on L-amino acids. 
 
Scheme 24: Synthesis of tridentate chiral ligands based on D-amino acids. 
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on carbon and the crude material was sub-
jected to column chromatography using 
methylene chloride : methanol. The reduc-
tive amination products were obtained as 
yellow oil in modest to good yields, see 
Scheme 23 and Scheme 24. 
The L-histidine derived methylester 
(S)-164 afforded a special preparation due 
to the imidazole ring in the side chain. The 
side chain had to be protected to avoid inter-
ferring effects during complexation. For this 
purpose a sequential protection and selec-
tive deprotection procedure according to 
published methods was pursued.[179,425] 
Therefore, (S)-164 (15.4 g, 63.7 mmol) 
was dissolved in methanol (70.0 mL) and di-
tert-butyl dicarbonate (27.8 g, 127 mmol) 
presolved in methanol (10.0 mL) was added 
drop wise. Then, triethylamine was added 
drop wise under extensive stirring at 0 °C for 
1 h. The reaction was proceeded for 16 h 
and warmed up to ambient temperature. 
The entire reaction mixture was poured into 
water (100 mL) and then extracted with 
methylene chloride (3 x 100 mL). The com-
bined organic layer was dried over sodium 
sulfate, filtrated and concentrated under 
reduced pressure. (S)-183 was purified by 
column chromatography using dieth-
yl ether : ethyl acetate (3:1  ethyl acetate) 
to obtain it as a white solid (16.6 g, 
45.1 mmol, 70.7%). Due to protonation and 
deprotonation effects, determined by 
1H-NMR, a second fraction of the product 
was obtained as colourless oil (3.45 g, 
8.50 mmol, 13.4%). 
To cleave the tert-butyloxycarbonyl-
protection group at the imidazole ring moiety 
(S)-183 (16.6 g, 44.7 mmol) was dissolved 
in methanol (65.0 mL) and potassium car-
bonate (617 mg, 4.47 mmol) was added. 
The reaction mixture was refluxed and the 
reaction was finished after 2 h. The entire 
mixture was cooled to ambient temperature 
and poured into water (80 mL) and extracted 
with ethyl acetate (3 x 80 mL). The com-
bined organic layer was dried over sodium 
sulfate, filtrated and concentrated under 
reduced pressure. The product (S)-184 was 
obtained as a white solid (10.1 g, 
37.5 mmol, 84.1%). Ligand (S)-184 and 
subsequent precursor were synthesised by 
the research intern KHANG NGO. 
The hydroxyl group of the L-tyrosine de-
rived intermediate (S)-174 can be protected 
in a late step of the ligand synthesis. There-
fore, (S)-174 (2.00 g, 6.98 mmol) was dis-
solved in DMF (60 mL) and cooled to 0 °C. 
Then, DIPEA (6.0 mL, 34.90 mmol) was 
added drop wise over a period of 2 h fol-
lowed by the dropwise addition of tert-
butyldimethylsilyl trifluoromethanesulfonate 
(2.1 mL, 7.81 mmol) over a period of 1 h. 
The reaction was continued for 45 h and 
allowed to warm up to ambient temperature. 
Ammonium acetate (60 mL, 1 M aq.) was 
added and the reaction mixture was extract-
ed with ethyl acetate (3 x 60 mL). The com-
bined organic layer was washed with BRINE, 
dried over sodium sulfate, filtrated and con-
centrated under reduced pressure. After 
purification by column chromatography us-
ing methylene chloride : methanol (35:1) the 
product (S)-187 was obtained as yellow oil 
(2.77 g, 6.92 mmol, 99%). Ligand (S)-187 
and subsequent precursor were synthesised 
by the research intern GEORG RENNAR. 
 
Scheme 25: Introduction of protection groups to mask the imidazole moiety of L-histidine derived (S)-164. 
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Scheme 26: Protection of the hydroxyl group. 
The protection of the hydroxyl func-
tion of the L-serine derived (S)-172 interme-
diate was performed next to the reductive 
amination. Thus, to prevent a cross coordi-
nation of the hydroxyl group a cyclisation to 
an oxazolidine in analogy to Schöllkopf et 
al.[426] was performed. This published meth-
od was preferred over a more common pro-
tection with 2,2-dimethoxypropane due to 
concerns of the resulting dimethyl meth-
ylene group adjacent to the nitrogen atom 
potentially perturbing the ligand complexa-
tion to the metal centre. For this purpose, 
(S)-172 (1.00 g, 4.75 mmol) was dissolved 
in methylene chloride (45 mL) at 0 °C and 
trifluoroacetic acid (366 µL, 4.75 mmol, 
0.1 N) was added drop wise followed by the 
dropwise addition of water (45 mL). Under 
extensive stirring formaldehyde (705 µL, 
7.12 mmol, 37% aq.) was added drop wise 
to the reaction mixture. The reaction was 
performed for a total period of 16 h at ambi-
ent temperature. The solvent was evapo-
rated under reduced pressure and the crude 
material subjected to column chromato-
graphy using methylene chloride : methanol 
(35:1). After drying in vacuo (S)-185 was 
obtained as yellow oil (760 mg, 3.72 mmol, 
72%). The cleavage of the ester function 
was performed as established for the previ-
ous amino acids suspending (S)-185 
(760 mg, 3.42 mmol) in sodium hydroxide 
(4.50 mL, 1 M) at 0 °C for 16 h. The reaction 
mixture was washed with methylene chlo-
ride (3 x 20 ml) to separate organic side 
products. The combined aqueous layer was 
neutralised to pH 7 with hydrochloric acid 
(1 M) and solvent removed under reduced 
pressure. The residue was suspended in 
ethanol (5.00 mL) and filtrated via a syringe 
filter. After drying in vacuo (S)-186 was ob-
tain as a white solid (705 mg, 3.39 mmol, 
quant.). 
Beside the chiral amino acids, addi-
tional achiral glycine derived tridentate lig-
ands 188 and 189, from the MEGGERS group 
intern compound library were applied for 
complex synthesis. These ligands were al-
ready applied in former studies and could 
therefore act as reference ligands for the 
complexation conditions.[197] 
 
 
Figure 88: Glycine derived achiral tridentate ligands. 
 
Scheme 27: Protection of the hydroxyl group of (S)-173 via oxazolidine formation and subsequent ester cleavage. 
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3.5.2 Complex Synthesis 
 
The new amino acid derived ligands 
were processed to rhodium(III) complexes 
according to the same conditions applied for 
the synthesis of -(R)-106, -(S)-106, 
-(R)-107 and -(S)-107, see Chapter 3.3.2, 
thus making the reactions comparable. 
However, using primary amino acid derived 
ligands, the formation of four diastereomers 
were expected, see Chapter 3.4.4.2. 
Moreover, the diastereomers pos-
sessing the pyridine ring of the tridentate 
ligands in cis-coordination to the indole moi-
ety of the pyridocarbazole ligand were ex-
pected to be identified via the 1H-NMR spec-
tra in analogy to the described procedure of 
-(R)-107, see Figure 58. Nevertheless, the 
orientation of the coordinating amino group, 
either towards A3 or A4 of the hypothetical 
complex had to be identified. For this pur-
pose, complexes of the L-valine derived lig-
and (S)-178 were synthesised using the 
N-benzylated pyridocarbazole 80, see 
Scheme 28. In former studies, organo-
metallic complexes using the ligand 80 were 
successfully applied as model systems to 
investigate their structural properties, as the 
resulting complexes had an increased crys-
tallisation tendency.[140,156,157,422] The subse-
quent studies, solving the chemical structure 
via X-ray experiments and correlating the 
retention times of each isomer of the 
N-benzyl pyridocarbazole complexes to the 
ones obtained using other pyridocarbazoles 
with distinct modification patterns, led to 
correct conclusions of their structural con-
figuration.[140,156,157,422] 
However, after the complexation reac-
tion and subsequent column chroma-
tography using methylene chloride : meth-
anol (15:1), only -(S)-191 (Rf value: 0.45) 
could be obtained as pure compound in 7% 
yield, synthesised by the research intern 
OLIVER BORN. The successful crystallisation 
of -(S)-191 allowed to solve its relative ste-
reoconfiguration, see Figure 89. Moreover, 
only one additional spot via TLC analysis 
was observed (Rf = 0.19). Despite eva-
luating different solvent systems and pre-
parative TLC conditions, to assign correct 
yields, the second compound could not be 
purified indicating the major disadvantage of 
the complex synthesis. On one hand, a sin-
 
Scheme 28: Synthesis of rhodium(III) complexes -(S)-190, -(S)-191. The expected -(S)-192 and -(S)-193 
were not observed (n.o.). -(S)-190 could not be characterised (n.c.). 
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gle complexation reaction should have re-
sulted in four different compounds to explore 
the chemical space; on the other, the com-
plex purification seems to significantly limit 
the applicability of this concept. 
 
Figure 89: Crystal structures of -(S)-191. Solvent 
Molecules were omitted for clarity. ORTEP drawing 
with 50% probability of thermal ellipsoids. Selected 
bond lengths [Å] for -(S)-191: Rh1-N1 = 2.065(4), 
Rh1-N4 = 2.041(5), Rh1-N27 = 2.044(4), Rh1-N30 
= 2.032(5), Rh1-O1 = 2.013(3), Rh1-Cl1 = 2.3575(13). 
Despite the good crystallization ten-
dency of pyridocarbazole 80 and resulting 
complexes, also adverse solubility charac-
teristics and agglomeration effects were 
reported.[140,156,157,422] These effects in com-
bination with the increased number of pos-
sible isomers probably hindered the purifica-
tion. These effects could be circumvented 
using pyridocarbazole ligands with distinct 
substitution patterns as intended for the de-
velopment of PI3K selective inhibitors. Es-
pecially, pyridocarbazole 77 was identified 
as a pharmacophore ligand addressing 
metal based kinase inhibitors towards 
PI3K.[188] 
 
Figure 90: Crystal structure of -(S)-195. Solvent 
Molecules were omitted for clarity. ORTEP drawing 
with 50% probability of thermal ellipsoids. Selected 
bond lengths [Å] for -(S)-195: Rh1-N1 = 2.0284(17), 
Rh1-N4 = 2.0580(17), Rh1-N22 = 2.0436(17), 
Rh1-N25 = 2.0200(17), Rh1-O31 = 2.0320(14), 
Rh1-Cl1 = 2.3429(5). 
Further, to synthesise biologically active 
PI3K inhibitors, the pyridocarbazole 77 was 
applied in the complexation reaction instead 
of 80, see Scheme 29. Interestingly, the 
complexation reaction resulted in a single 
product formation observed by TLC control 
prohibiting comparisons between the reten-
tion times as intended by the model system 
using 80. Thus, the relative stereoconfigura-
tion of the purified complex -(S)-194 (18%) 
could not be assigned or concluded by the 
comparison to the former results. Neverthe-
less, the relative position of the pyridine ring 
of the tridentate ligand could be determined 
due to the upfield shift of the pyridocarba-
zole H-11 proton in the 1H-NMR spectra of 
-(S)-194 in analogy to -(R)-107.
 
Scheme 29: Synthesis of rhodium(III) based inhibitor -(S)-194. 
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A similar effect was observed using 
(R)-182 as chiral tridentate ligand, see 
Scheme 30. Again, only one spot during the 
complexation reaction was detected via TLC 
control during the synthesis performed by 
the research intern KHANG NGO. Moreover, 
the pyridine ring of the (R)-182 was again 
coordinated cis to the indole moiety of the 
pyridocarbazole 77 in the resulting complex, 
as observed for -(S)-194, verified by the 
1H-NMR spectra. Attempts to determine the 
relative stereoconfiguration of the (R)-182 
derived complex via crystallisation were 
successful. However, beside the expected 
-(R)-195 the corresponding enantiomer 
-(S)-195 was formed as a racemic mixture 
in 9% yield, see Figure 90. As the optical 
rotation of (R)-182 was  20D  = -16.3, the 
racemisation must have been occurred dur-
ing the complexation reaction itself, whereas 
the exact mechanism of this observation 
remains unclear. Perhaps, due to protona-
tion and deprotonation effects at the carb-
oxylate group, during the complexation reac-
tion, a conjugated vinylogue double bond is 
formed, which subsequently eliminates the 
chiral information at the C atom of the 
D-phenylglycine derived ligand (R)-182. 
Due to the unexpected difficulties during 
complexation and purification, a further app-
lication of the primary chiral amino acid de-
rived ligands had to be discarded and sev-
eral ligands were not finished as initially 
intended. The unreproducible reaction out-
come excluded an adequate investigation of 
the possible isomers, because neither the 
intended directed formation or the proper 
purification could be handled. 
Nevertheless, to generate as much 
different structural scaffolds as possible, the 
achiral ligand 189, as well as the chiral pro-
line derived ligands (R)-105 and (S)-105, 
due to their former successful application, 
were processed to the complexation reac-
tion, Scheme 33. Moreover, chlorine was 
substituted by bromine to validate the influ-
ence of the monodentate ligand size, keep-
 
Scheme 30: Synthesis of rhodium(III) based inhibitors -(R)-195 and -(S)-195 obtained as racemic mixture. 
 
Scheme 31: Synthesis of rhodium(III) based inhibitor -196 as racemic mixture. 
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ing the established reaction conditions un-
touched but using RhBr3 instead of RhCl3. 
Interestingly, using the achiral ligand 
189, only the racemic mixture of /-196, 
where the pyridine ring of the tridentate lig-
and is coordinated cis to the pyrido-
carbazole moiety, could be obtained in 17% 
yield. In opposite, using RhBr3 both ex-
pected diastereomers were obtained as ra-
cemic mixtures /-197 and /-198 in 19% 
and 10% yield, respectively. 
The use of (R)-105 and (S)-105 re-
sulted in enantiopure complexes with de-
fined relative stereoconfiguration using pyri-
docarbazole ligand 79, see Chapter 3.3.2. 
Moreover, due to the cumulated results, a 
 
Scheme 32: Synthesis of rhodium(III) based inhibitors -197 and -198, both as racemic mixtures. 
 
Scheme 33: Synthesis of rhodium(III) based inhibitors -(R)-199, -(R)-200, -(S)-199,-(S)-200, -(S)-201, and 
(S)-202 as enantiopure compounds. 
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correct assignment of the stereoconfigura-
tion is possible. The complexes -(R)-199 
(21%), -(S)-199 (23%), (R)-200 (13%), 
and -(S)-200 (16%) were obtained in ex-
pected yields. The same is true for 
(S)-201 (19%) and -(S)-202 (12%), both 
with a substituted monodentate ligand from 
chlorine to bromine compared to (S)-199 
and -(S)-200, see Scheme 33. 
3.5.3 Biological Investigations and Tar-
get Selectivity 
 
All synthesised PI3K inhibitors were 
tested in Kinase Glo-Assays performed by 
JASNA MAKSIMOSKA. Moreover, to achieve a 
first insight into the compounds selectivity 
among the PI3K isoforms, PI3K was tested 
in parallel as target molecule, see Figure 91. 
Table 3: Determined IC50 values against PI3K and 
PI3K. The single values for -(R/S)-195 were out of 
specification (OOS), as an intra- and interassay repro-
ducibility at low inhibitor concentrations were not giv-
en, and thus an accurate calculation of the IC50 value 
was not possible. Experiments were performed by 
JASNA MAKSIMOSKA. The data points for curve fitting 
were determined in triplicates and the experiments 
were repeated independently, the shown data points 
represent mean values. 
 
Regarding PI3K (Figure 91 c) and 
d)) the tested compounds possess following 
IC50 values: -(S)-194 (21.5 µM), -196 
(130.8 µM), -197 (30.0 µM), -198 
(26.3 µM), -(S)-199 (6.5 µM), -(R)-199 
(14.5 µM), -(S)-200 (2.6 µM), -(R)-200 
(7.7 µM), -(S)-201 (3.6 µM), -(S)-202 
(4.4 µM). The obtained data for 
-(R/S)-195 in case of PI3K were out of 
specification as the data points at low con-
centrations scattered irregularly. Thus, an 
accurate fit was not possible, see Table 3. 
Regarding PI3K (Figure 91 a) and 
b)) the tested compounds possess following 
IC50 values: -(S)-194 (14.2 µM), 
-(R/S)-195 (23.2 µM), -196 (67.6 µM), 
-197 (4.8 µM), -198 (3.2 µM), 
-(S)-199 (13.5 µM), -(R)-199 (1.4 µM), 
-(S)-200 (3.2 µM), -(R)-200 (2.7 µM), 
-(S)-201 (19.6 µM), -(S)-202 (4.1 µM), see 
Table 3. 
3.5.4 Interpretation 
 
The biological investigations deter-
mining the IC50 of each compound against 
the primary target PI3K as well as the se-
lectivity check against PI3K, revealed 
mostly compounds inhibiting both with al-
most similar IC50. However, some preferred 
either PI3K or PI3K. Aligning the protein 
sequences of PI3K (UniProt Code: 
P48736.3) and PI3K (UniProt Code: 
P42336.2) via BLAST identified 358 identical 
amino acids of 997 compared ones reflect-
ing 36% sequence homology, and 536 
chemically similar amino acids of 997 com-
pared ones reflecting 53% sequence similar-
ity. Moreover, an E-value of 1e-177 reflects a 
high relationship of both sequences.[427,428] 
A comparison of the three dimen-
sional structure of PI3K (3CST) with the 
entire deposited entries in the PDB was per-
formed using the program VAST. VAST is the 
acronym for Vector Alignment Search Tool, 
and is a open source computer algorithm 
developed at NCBI. This algorithm can be 
used to identify similar protein three dimen-
sional structures by purely geometric criteria 
to identify distant homologues that cannot 
be recognized by sequence comparison.[429] 
Complex IC50 PI3K  [µM] IC50 PI3K  [µM]
-(S )-194 21.5 14.2
-(R /S )-195 OOS 23.2
-196 130.8 67.6
-197 30.0 4.8
-198 26.3 3.2
-(S )-199 6.5 13.5
-(R )-199 14.5 1.4
-(S )-200 2.6 3.2
-(R )-200 7.7 2.7
-(S )-201 3.6 19.6
-(S )-202 4.4 4.1
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The VAST search resulted in 13 
neighbours applying the three-dimensional 
structure of PI3K (pdb: 3CST) as query 
starting point. These are representatives 
from the medium redundancy subset, mean-
ing that they posses a BLAST p value of 
10e-40 to each other. In Figure 91 the red 
regions are aligned segments forming three-
dimensional structures compared and dis-
played on primary sequence level. The 
structure deposited under the pdb code 
4OVU reveals several three-dimensional 
motifs related to the query starting structure 
3CST. Indeed, the structure 4OVU belongs 
to the crystal structure of PI3K.[430] 
Moreover, comparing the ATP bind-
ing site of both PI3K (pdb: 3CST) and 
PI3K (pdb: 4OVU) reveals many identical 
amino acids on important motifs for ligand 
binding like the hinge region, the hydropho-
bic region I, or the catalytic region, see Fig-
ure 92. 
 
Figure 92: Alignment of the crystal structures of PI3K 
(pdb: 3CST) and PI3K (pdb: 4OVU). The comparison 
of the ATP-binding site of both isoform reveals highly 
conserved amino acids among these two isoforms. 
The amino acids of the hinge region, the hydrophobic 
region I, and the catalytic region, all depicted as 
sticks, indicate a related primary sequence. All struc-
tural motifs except the ATP binding site were omitted 
for clarity. PI3K is shown as cartoon in white. PI3K 
is shown as cartoon in green. Nitrogen atoms are 
shown in blue, oxygen in red, and sulfur in yellow. 
 
 
 
Figure 91: Results of the VAST search over the entire primary sequence. 13 neighbours were found for the three-
dimensional structure of PI3K (pdb: 3CST) as starting point. 13 representatives from the medium redundancy 
subset are displayed, meaning that they posses a BLAST p value of 10e
-40
 to each other. The red regions are 
aligned segments, where a corresponding comparison of three-dimensional structures can be visualised on prima-
ry sequence level. Especially the structure deposited under the pdb code 4OVU reveals several three-dimensional 
motifs similar to the query 3CST. Indeed, the structure 4OVU belongs to the crystal structure of PI3K.
[430]
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In addition, the sequence alignment 
and comparison of especially the ATP bind-
ing site reveals several identical amino ac-
ids, see Figure 93. For example, the hinge 
region represented by the residues 877 to 
882 on the primary sequence of PI3K (pdb 
4OVU) posses 3 identical amino acids to the 
primary sequence compared to PI3K. 
Moreover, both isoforms have the identical 
gatekeeper residue isoleucine. The similari-
ties in the catalytic loop starting from 957 to 
964 on the primary sequence of PI3K 
compared to PI3K are much more impres-
sive, as every amino acid residue of the 8 
considered ones are identical. 
Much more structural motifs could be 
investigated in detail as described above. 
However, the focus set on the hinge region, 
hydrophobic region I, and the catalytic loop 
already highlights the similarities between 
the two isoforms at the ATP binding site. 
Therefore, selectively binding compounds 
are valuable tools not only for target inhibi-
tion for pharmacologic purpose, but also for 
systemic biological investigations. 
However, a clear selectivity tendency 
for one of the two investigated PI3K 
isoforms by any of the tested complexes 
could not be identified. Moreover, it is note-
worthy, that the complexes -196, 
-197, -198 were tested as racemic 
mixtures. Thus, a correct assignment which 
enantiomer mediates the inhibition remains 
unclear. Using a racemic mixture, the affini-
ties of the eutomer to the non-binding enan-
tiomer may differ significantly. Therefore, the 
apparent IC50 value of the racemic mixture is 
not representative for the true conditions. 
The compounds -196 (1.93-fold), 
-197 (6.25-fold), -198 (8.21-fold), 
-(R)-199 (10.35-fold), and -(R)-200 (2.85-
fold) showed a modest tendency of in-
creased PI3K inhibition compared to 
PI3K. In opposite, the compounds 
-(S)-199 (2.07-fold) and -(S)-201 (5.44-
fold) offered an increased tendency towards 
PI3K compared to PI3K. The compounds 
-(S)-200 (1.2-fold) and -(S)-202 
(1.07-fold) showed no preferences and can 
be considered as unselective among the 
investigated kinases. Nevertheless, none of 
the compounds showed an IC50 in the na-
nomolar range indicating structural potential 
to increase affinity. In contrast, former inves-
tigated half sandwich complexes targeting 
PI3K showed IC50 values in the nanomolar 
range. This might be a hint of adverse steric 
effects for the octahedron itself.[188] 
A closer look on the obtained IC50 val-
ues targeting PI3K could help to under-
stand a potential correlation between the 
structure of the compounds and their corre-
sponding activity. Potential hints could help 
to synthesise a second generation of PI3K 
 
Figure 93: Comparison of the primary sequence of PI3K (VS82, an VAST query annotation) and PI3K (pdb: 
4OVU). Identical amino acids in aligned sequences are highlighted in red. The hinge region (residues 877 to 882 
on 4OVU) posses 3 identical amino acids between both isoforms. The catalytic loop from 957 to 964 on the primary 
sequence of PI3K consists of 8 identical amino acids. 
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inhibitors with enhanced selectivity profiles 
and affinities. However, the iterpretation can 
only represent a conservative evaluation as 
for true structure-activity relationhips the 
compounds must to be ultrapure to avoid 
misinterpretation. However, Figure 95 high-
lightes the stereoconfigurations of -(R)-200 
and -(R)-199 and correlates them to the 
binding areas, which could be hypothetically 
occupied as introduced in Figure 86. 
-(R)-200 possesses the tridentate lig-
and in fac-coordination with the pyridine ring 
cis to the indole moiety of the pyridocarba-
zole. This leads to an hypothetical occupa-
tion of the binding sphere Z1. Subsequently, 
the chlorine is oriented towards A4. In the 
PI3K binding site, it is the area next to the 
C-termial domain of PI3K. Closing, the ni-
trogen of the amino group is oriented to-
wards A3 converging to the N-terminal do-
main of PI3K. -(R)-200 possesses an IC50 
of 2.7 µM against PI3K and is one of the 
best inhibitors investigated during these 
studies. 
However, the best investigated PI3K 
inhibitor is -(R)-199 (1.4 µM). This complex 
possesses the pyridine ring of the 
fac-coordinated tridentate ligand cis to the 
pyridine moiety of the pyridocarbazole. 
Thus, this moiety should occupy the binding 
sphere of Z2. Subsequently, the monoden-
tate chlorine ligand is oriented towards A3. 
The proline moiety of complex -(R)-199 is 
coordinated towards A4. 
Thus, in case of PI3K the structural ar-
rangement of the tridentate proline ligand, 
has little influence on the selectivity. The 
same is true for PI3KMoreover, as the 
other two proline based complexes, 
-(S)-199 und -(S)-200 are also single 
isomers with defined stereoconfigurations, 
their structural properties were analoguously 
    
     
Figure 94: IC50 values of metal based compounds against PI3K (a) and b)) and PI3K (c) and d)). The IC50 val-
ues of the synthesised inhibitors were determined using a Kinase-Glo Assay (Promega
®
) at 10 µM ATP. Samples 
with 2% DMSO in absence of kinase served as 100% control and the corresponding signals were related to them. 
Each measuring point was determined in triplicates and the experiments were repeated independently, the shown 
data points represent mean values. Experiments were performed by JASNA MAKSIMOSKA. The sigmoidal dose re-
sponse curve fitting was processed using Origin8. 
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investigated as described for -(R)-199 to 
-(R)-200. However, again a clear correla-
tion can not be elaborated. For instance, the 
conclusion that an orientation of the pyridine 
moiety of the tridentate ligand in the binding 
sphere of Z1 of PI3K is superior to an ori-
entation towards the binding sphere of Z2 or 
vice versa is not legitime. These observa-
tions again confirm, that the octahedral 
shape itself could be adverse for the inhibi-
tion of PI3K as former investigated half 
sandwich complexes showed IC50 values in 
the nanomolar range.[188] 
Closing, to investigate the influence of 
the monodentate ligand the demand of 
space from chlorine to bromine was com-
pared. Interestingly, the obtained complexes 
-(S)-201 (19.6 µM) and -(S)-202 (4.1 µM) 
resulted in the same inhibition tendencies 
against PI3K as their chlorine counterparts 
-(S)-199 (13.5 µM) und -(S)-200 (3.2 µM). 
Thus, in this case the enlarged monodentate 
ligand seems to have little influence and had 
not resulted into significant alterations. 
Unfortunately, the difficulties during the 
synthesis of rhodium(III) complexes derived 
from chiral primary amino acids resulted 
only into the complexes -(S)-194 and 
-(R/S)-195. Moreover, as the stereo-
configuration of -(S)-194 was not entirely 
solved and -(R/S)-195 was tested as 
racemic mixture, their value for structural 
interpreations compared to their affinites are 
limited. Nevertheless, both complexes inhibit 
PI3K and L-valine incorporated in -(S)-194 
was identified as a suitable building block. In 
case of -(R/S)-195 a final statement 
which one, either -(S)-195 or -(R)-195, is 
the eutomer could not be verified with the 
investigations performed during this work. 
Closing, a detailed interpretation reflect-
ing the difficulties during the synthesis of 
primary chiral amino acid derived rhodi-
um(III) complexes is mandatory to elucidate 
the basic principles. During the synthetic 
procedure, despite the expectation of four 
possible diastereomers, not all possible 
structural isomers were obtained. 
The most likely reason could be steric 
effects, which have been overlooked during 
the conceptual planning of this project, see 
Figure 96. Introducing residues in the back-
bone of the tridentate ligand results in steric 
conflicts as highlighted by the methyl group 
of L-alanine in this example. The most im-
portant fact is that the tridentate ligand loses 
degrees of rotational freedom of at least four 
bonds during the coordination step. Moreo-
ver, the coordination to the metal forces the 
 
Figure 95: Comparison of the stereoconfiguration of -(R)-199 and (R)-200 and the resulting affinities towards 
PI3K and PI3K. a) In fac coordination the pyridine ring of the tridentate ligand could be either coordinated cis 
(shown in a)) or trans to the indole moiety of the pyridocarbazole occupying either zone Z1 (as shown in a)) or Z2 (red 
shaded circles). The amino acid moiety is then subsequently fac-coordinated in cis position to the pyridine moiety of 
the pyridocarbazole occupying the binding sphere of Z2 (red shaded circle). The nitrogen of the amino acid building 
block could be coordinated to the metal centre occupying A3 (yellow shaded circle). Thus, it would be oriented to-
wards the N-terminal domain of the kinase. The monodentate chlorine ligand could be coordinated to the metal centre 
occupying anchor point A4 (green shaded circle). Thus, it would be oriented towards the C-terminal domain of the 
kinase. b) (R)-200 reflect the situation described in a). c) (R)-199 orientates the pyridine moiety towards binding 
sphere Z2, the carboxyl moiety towards binding sphere Z1, the coordinating amino acid towards A4, and the 
mondentate chlorido ligand towards the A3. 
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tridentate ligand into sterically disfavoured 
conformations, as depicted in case of Figure 
96 b) and c). In this coordination pattern, the 
methylene hydrogens adjacent to the pyri-
dine ring of the tridentate ligand and the 
hydrogen atoms of the methyl residue of the 
amino acid experience a high steric repul-
sion. Moreover, the rigid structure of the 
complex offers no possibility for these resi-
dues to circumvent these repulsions by a 
conformational change. This is also true for 
any other amino acid as they possess larger 
residues than alanine. Moreover, the ob-
tained crystal structures of -(S)-191 and 
-(S)-195 support the described hypothesis 
of steric hindrance. 
 
Figure 96: The incorporation of chiral primary amino 
acids into the design of tridentate ligands may cause 
adverse steric effects in at least two of the four possi-
ble diastereomers, b) and c) assuming a fac-coor-
dination. 
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4 Conclusion and Outlook 
We here reported our progress in de-
veloping structurally complicated and at the 
same time stereochemically defined organ-
ometallic protein kinase inhibitors. Multiden-
tate prochiral ligands, tridentate chiral pro-
line-based ligands and the attempts to 
introduce amino acids as building blocks for 
the ligand design represented the line-up. 
In the first study, the development of an 
organometallic ruthenium compound and 
the structural comparison to other modified 
complexes inhibiting S6K1 were elucidated. 
The Millipore Kinase Profiler and radioactive 
kinase assays identified 85 as lead com-
pound. The potent and selective inhibitor 85 
using 100 nM inhibited 93% of S6K1 activity 
and only 16% of 283 kinases by less than 
90%. The compound 86 possessing an iso-
cyanate group instead of an isothiocyanate 
is about 1000-fold less potent. This indicat-
ed the importance of already slight differ-
ences in the coordination sphere and high-
lighted the potential for further potency and 
specificity optimisation. 
Valuable insights for the complex de-
sign were gathered by the crystal structure 
of 85 bound to S6K1 lead to the develop-
ment of 87. The novel ligand scaffold of 87 
resulted in an IC50 in the single digit nano-
molar range targeting S6K1. Moreover, the 
crystal structure of 87 bound to S6K1 re-
vealed the molecular basis for the com-
pounds potency and selectivity. The subse-
quent in vivo testing of the compounds also 
lead to valuable insights. The cell permeabil-
ity and effects on signaling pathways could 
be elaborated. 
Taking all gathered data together also 
lead to the suggestion, that targeting S6K2 
either alone or in combination with S6K1 
inhibition could be a better option for direct 
S6 inhibition in melanoma and potentially 
other cancer cells. However, to date there 
are no commercially available S6K2 selec-
tive inhibitors. Thus, S6K2 could be target 
for the next series of organometallic inhibi-
tors. 
However, the development of S6K1 se-
lective metal based inhibitors also highlight-
ed the issues arising with complicated coor-
dinating ligands resulting in increased 
numbers of potential structural isomers. 
Thus, the enantiopure rhodium(III) complex-
es presented in this work highlight the im-
portance to access defined structural iso-
mers. The have unique properties regarding 
molecular recognition with chiral interaction 
partners like proteins. The remarkable dif-
ferences in target specificity and affinity are 
an additional example for the potential of 
octahedral metal based compounds as ki-
nase inhibitors. Moreover, we paired these 
benefits with the possibility to investigate 
single enantiomers, as it is standard for chi-
ral organic compounds in the biological con-
text. These possibilities turn organometallic 
compounds more and more adequate to the 
requirements of drug-like molecules and 
suitable for appropriate investigations. 
Moreover, different structural isomers 
may not only possess different kinase inhibi-
tion effects, but also different toxicity pro-
files. They may based on changes in the 
overall physico-chemical properties of each 
isomer. Finally, the scaffold offers plenty of 
possibilities to introduce additional functional 
groups in order to improve target specificity 
and affinity or to enhance pharmacological 
properties, as it is the subject of current in-
vestigations.  
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5 Experimental 
5.1 General Information 
 
All reactions were carried out under ni-
trogen atmosphere with magnetic stirring. 
The glass vessels were heated up and 
chilled down to ambient temperature for at 
least three times. HPLC-Grade solvents 
were used for reactions and distilled under 
nitrogen and dried using calcium hydride 
(CH3CN, CH2Cl2, CHCl3, DMF), sodium/ben-
zophenone (THF, EtO2), or magnesium 
shavings (MeOH) prior usage. All reagents, 
if not declared otherwise, were purchased 
from commercial suppliers and used without 
further purification. 
Flash column chromatography was 
performed with distilled solvents using silica 
gel 60 M from Macherey–Nagel (irregular 
shape, 230–400 mesh, pH 6.8, pore volume: 
0.81 mL/g, mean pore size: 66 Å, specific 
surface: 492 m2/g, particle size distribution: 
0.5% < 25 m and 1.7% > 71 m, water 
content: 1.6 %). 
1H-NMR and proton decoupled 
13C-NMR spectra were measured using ei-
ther Avance 300 A (1H-NMR: 300 MHz, 
13C-NMR: 75 MHz), Avance 300 B (1H-NMR 
300 MHz, 13C-NMR: 75 MHz), DRX 400 
(1H-NMR: 400 MHz, 13C-NMR: 100 MHz), or 
a DRX 500 (1H-NMR: 500 MHz, 13C-NMR: 
125 MHz) spectrometer from Bruker at am-
bient temperature. The NMR data were 
evaluated using MestReNova 6.0.2-5475 
(Mestrelab Research S.L.). NMR standards 
were used as follows: 1H-NMR spectrosco-
py: δ = 7.26 ppm (residual CDCl3), δ = 
2.50 ppm (residual (CH3)2SO), δ = 2.05 ppm 
(residual (CH3)2CO), δ = 1.94 ppm (residual 
CD3CN). 
13C{1H}-NMR spectroscopy: δ = 
77.16 ppm (residual CDCl3), δ = 39.52 ppm 
(residual (CH3)2SO), δ = 29.84 ppm (residu-
al (CH3)2CO), δ = 1.32 ppm (residual 
CD3CN). 
IR spectra were measured using a 
Bruker Alpha FT-IR spectrophotometer. IR 
spectra were evaluated using OPUS 6.5 
(Bruker Optik GmbH). 
High-resolution mass spectra were 
measured using a LTQ-FT Ultra mass spec-
trometer (Thermo Fischer Scientific) using 
ESI technique. 
Crystals were measured on a 'STOE 
IPDS2 Image Plate' or on a 'Bruker D8 
QUEST area detector' diffractometer. The 
temperature was kept at 100.15 K during 
data collection. Using Olex2, the structure 
was solved with the SIR2011 structure solu-
tion program using Direct Methods and re-
fined with the XLMP refinement package 
using Least Squares minimisation. The cell 
refinement software SAINT V8.27B (Bruker 
AXS Inc., 2012) and the data reduction 
software SAINT V8.27B (Bruker AXS Inc., 
2012) as well as SAINT V8.30C (Bruker 
AXS Inc., 2013) and SAINT V8.30C (Bruker 
AXS Inc., 2013) were used. The programs 
applied for solution and refinement were 
SHELXS-97 (Sheldrick, 2008), 
SHELXL-2013 (Sheldrick, 2013), and DIA-
MOND (Crystal Impact) as well as XS 
(Sheldrick, 2008), SHELXL-2013 (Sheldrick, 
2013) and DIAMOND (Crystal Impact). The 
programs used for visualization are either 
Pymol Molecular Graphics System, v0.99 
(DeLano Scientific LLC) or ORTEP-III v1.0.3 
(C.K. Johnson and M.N. Burnett). 
CD spectra were recorded on a JAS-
CO J-810 CD spectropolarimeter with cu-
vettes of 1 mm diameter. 
The counts per minute (CPM) per-
forming radioactive kinase assays were 
measured using a Beckmann Coulter 
LS6500 multipurpose scintillation counter 
and corrected by the background CPM. 
PyMOL Molecular Graphics System 
DeLano Secientific LLC, Version 1.1, was 
used to visualize the protein crystal-
structures.[431]  
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5.2 Synthetic Procedures 
5.2.1 Synthesis of pyridocarbazoles and 
related intermediates 
5.2.1.1 3,4-dibromofuran-2,5-dione (36) 
 
 
1H-pyrrole-2,5-dione (40.0 g, 
408 mmol), and aluminium trichloride 
(832 mg, 6.3 mmol) were suspended in 
bromine (42.0 mL, 810 mmol) and refluxed 
at 130 °C for 18 h. The resulting solid crude 
material was recrystallised from a mixture of 
toluene : ethylacetate (70 mL, 6:1). The pre-
cipitate was washed with hexane and dried 
in vacuo. The product 36 was obtained as 
beige solid (27.74 g, 108 mmol, 27%). After 
concentration of the filtrate and a second 
recrystallisation procedure under same con-
ditions, additional product was obtained 
(20.72 g, 81 mmol, 20%). 13C-NMR 
(75 MHz, CDCl3): δ(ppm) 157.9 (2xCO), 
131.1 (2xCBr). IR (film): v (cm-1) 3081, 3000, 
2649, 2520, 1699, 1584, 1417, 1389, 1268, 
1224, 1181, 1136, 1056, 944, 906, 809, 761, 
688. 
5.2.1.2 1-benzyl-3,4-dibromo-1H-pyrrole-
2,5-dione (37) 
 
 
36 (17.0 g, 66.3 mmol) and benzyl 
amine (10.7 g, 99.5 mmol) were dissolved in 
acetic acid (150 mL) and heated to 130 °C 
for 16 h. The solvent was removed under 
reduced pressure and residual acetic acid 
was coevaporated using toluene 
(3 x 40 mL). The dark crude material was 
subjected to column chromatography using 
hexane : ethylacetate (10:1) and dried in 
vacuo. The product 37 was obtained as 
beige solid (17.84 g, 51.7 mmol, 78%). 
Rf = 0.33 (hexane : ethylacetate 10:1). 
1H-NMR (300 MHz, CDCl3): δ(ppm) 7.40–
7.29 (m, 5H, Har), 4.75 (s, 2H, Hbenzyl). 
13C-NMR (75 MHz, CDCl3): δ(ppm) 163.76 
(2xCO), 135.37 (Car), 129.66 (2xCBr), 
129.02 (2xCar), 128.93 (2xCar), 128.48 (Car), 
43.41 (Cbenzyl). IR (film): v (cm
-1) 1781, 1709, 
1592, 1519, 1491, 1432, 1388, 1336, 1233, 
1158, 1100, 1060, 906, 851, 812, 752, 722, 
695, 626, 583. 
5.2.1.3 3,4-dibromo-1-methyl-1H-pyrrole-
2,5-dione (38) 
 
 
36 (5.0 g, 19.5 mmol) and methyl 
ammonium chloride (2.02 g, 29.9 mmol) 
were dissolved in acetic acid (50 mL) and 
heated to 130 °C for 16 h. The solvent was 
removed under reduced pressure and resid-
ual acetic acid was coevaporated using tol-
uene (3 x 30 mL). The dark crude material 
was subjected to column chromatography 
using hexane : ethylacetate (3:1) and dried 
in vacuo. The product 38 was obtained as 
beige solid (2.85 g, 10.6 mmol, 55%). 
Rf = 0.46 (CHCl3). 
1H-NMR (300 MHz, 
CDCl3): δ(ppm) 3.13 (t, J = 2.1 Hz, 3H, 
CH3).
13C-NMR (75 MHz, CDCl3): δ(ppm) 
164.1 (2xCO), 129.5 (2xCBr), 25.6 (CH3). IR 
(film): v (cm-1) 2951, 2853, 1772, 1705, 
1599, 1465, 1304, 1258, 1164, 1066, 1026, 
848, 819, 790, 744, 706, 678. 
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5.2.1.4 3,4-dibromo-1H-pyrrole-2,5-dione 
(39) 
 
 
36 (20.0 g, 78.2 mmol) and ammoni-
um acetate (9.04 g, 117.2 mmol) were dis-
solved in acetic acid (250 mL) and heated to 
130 °C for 16 h. The solvent was removed 
under reduced pressure and residual acetic 
acid was coevaporated using toluene 
(3 x 50 mL). The dark crude material was 
subjected to column chromatography using 
hexane : ethylacetate (5:1  2:1) and dried 
in vacuo. The product 39 was obtained as 
beige solid (10.81 g, 42.4 mmol, 54%). 
Rf = 0.16 (hexane : ethylacetate 8:1). 
1H-NMR (300 MHz, (CD3)2SO): δ(ppm) 11.7 
(bs, 1H, NH). 13C-NMR (75 MHz, (CD3)2SO): 
δ(ppm) 165.15 (2xCO), 129.72 (2xCBr). IR 
(film): v (cm-1) 3231, 3071, 1776, 1704, 
1576, 1408, 1323, 1271, 1197, 1170, 1129, 
1026, 994, 910, 872, 826, 788, 725. 
5.2.1.5 tert-butyl(1-methoxyvinyloxy) di-
methylsilane (41) 
 
 
Diisopropylamine (22.4 mL, 
159.6 mmol) were dissolved in THF 
(134 mL) and cooled to 0 °C. n-butyl lithium 
(58.5 mL, 146 mmol, 2.5 M in hexane) was 
added over a period of 30 min at -78 °C fol-
lowed by the drop wise sequential addition 
of methylacetate (10.58 mL, 133 mmol), 
DMPU (24.1 mL, 199 mmol) over a period of 
40 min. Tert-buytldimethylsilylchloride (20 g, 
133 mmol) was dissolved in THF (32 mL) 
and added to the reaction mixture. The reac-
tion was continued for 1 h at -78 °C. The 
solvent was evaporated under reduced 
pressure and the crude material was solved 
in pentane (400 mL). The organic layer was 
washed with water (3 x 50 mL), saturated 
cupper sulfate solution (3 x 50 mL) and sat-
urated sodium carbonate solution 
(3 x 50 mL). The combined aqueous layer 
was extracted with pentane (4 x 50 mL). The 
combined organic layer was dried over so-
dium sulfate. The solvent was removed un-
der reduced pressure and the crude material 
was subjected to bulb to bulb distillation 
(50 °C, 8 mbar). The product 41 was ob-
tained as colourless oil (15 g, 68.7 mmol, 
51%). Rf = 0.48 (hexane : ethylacetate 8:1). 
1H-NMR (300 MHz, CDCl3): δ(ppm) 3.53 (s, 
3H, OCH3), 3.23 (d, J = 2.6 Hz, 1H, 
CvinylHH), 3.10 (d, J = 2.6 Hz, 1H, CvinylHH), 
0.93 (s, 9H, Cq(CH3)3), 0.17 (s, 6H, 
Si(CH3)2). 
13C-NMR (75 MHz, CDCl3): 
δ(ppm) 162.49 (Ccarbonyl), 60.26 (CvinylH2), 
55.15 (OCH3), 25.75 (3xCq(CH3)3), 18.26 
(Cq(CH3)3), -4.57 (Si(CH3)2). 
5.2.1.6 3,4-dibromo-1-(tert-butyldimethyl-
silyl)-1H-pyrrole-2,5-dione (42) 
 
 
39 (10.7 g, 42 mmol) were dissolved 
in acetonitrile (100 mL) and stirred at ambi-
ent temperature. 41 (10 mL, 46 mmol) were 
added dropwise and the reaction was then 
refluxed for 5 h. The reaction mixture was 
cooled down to ambient temperature over a 
period of 8 h. The solvent was evaporated 
under reduced pressure and the crude ma-
terial was subjected to column chromatog-
raphy using hexane : ethyl acetate (9:1  
3:1). The product was 42 was obtained as 
white solid (8.38 g, 22.65 mmol, 54%). 
Rf = 0.67 (hexane : ethylacetate 8:1). 
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1H-NMR (300 MHz, CDCl3): δ(ppm) 0.94 (s, 
9H, Cq(CH3)3), 0.46 (s, 6H, Si(CH3)2). 
13C-NMR (75 MHz, CDCl3): δ(ppm) 168.87 
(2xCO), 131.72 (2xCBr), 26.24 
(3xCq(CH3)3), 19.02 (Cq(CH3)3), -4.44 
(Si(CH3)2). 
5.2.1.7 (E)-2-(1-(2-phenylhydrazono) 
ethyl)pyridine (45) 
 
 
2-Methyl-pyridylketone (3.70 mL, 
33.0 mmol) and phenylhydrazine (3.35 mL, 
34.1 mmol) were dissolved in ethanol 
(10 mL, abs.) under nitrogen atmosphere. 
The reaction mixture was heated up slowly 
to 80 °C over a period of 15 min and re-
fluxed for another 45 min until a yellow pre-
cipitate was formed. The reaction mixture 
was cooled down to 0 °C and filtrated. The 
yellow precipitate was washed with cooled 
ethanol (150 mL, abs.) and dried in vacuo. 
The residual filtrate was concentrated and 
cooled to 0 °C to precipitate additional crude 
material which was filtrated and washed with 
cooled ethanol (100 mL, abs.) and dried in 
vacuo as the first product fraction. The com-
bined product fractions led to the product 45 
as a yellow solid (6.84 g, 32.4 mmol, 98%). 
Rf = 0.55 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, CDCl3): δ(ppm) 
8.58 (d, J = 4.7 Hz, 1H, Har), 8.19-8.15 (m, 
1H, Har), 7.73-7.68 (m, 1H, Har), 7.33-7.18 
(m, 5H, Har), 6.93-6.88 (m, 1H, Har), 2.41 (s, 
3H, CH3). 
13C-NMR (75 MHz, CDCl3): 
δ(ppm) 148.0, 144.7, 136.5, 129.4, 122.4, 
120.9, 120.2, 113.6, 10.1 (CH3). IR (film): v 
(cm-1) 3204, 3171, 3019, 2939, 1596, 1564, 
1470, 1427, 1289, 1246, 1149, 1110, 1077, 
1048, 993, 967, 892, 781, 748, 695, 652, 
636, 549, 508, 411. HRMS calculated for 
C13H13N3H (M + H
+) 212.1188 found 
(M + H+) 212.1183. 
5.2.1.8 2-(pyridin-2-yl)-1H-indole (46) 
 
 
Polyphosphoric acid (34.0 g, 1.1 g 
per mmol of educt) were heated to 95 °C 
and firm stirring. 45 (6.50 g, 30.8 mmol) was 
added sequentially in small portions to the 
clear viscose reaction mixture. After 4 h the 
reaction mixture was cooled down to ambi-
ent temperature and sodium hydroxide solu-
tion (20%) was added until pH 9 was set. A 
crude material precipitated as yellow solid. 
The reaction mixture was extracted with 
methylene chloride (3 x 150 mL). The com-
bined organic layer was washed with BRINE 
(4 x 25 mL) dried over sodium sulfate, fil-
trated and dried in vacuo. The product 46 
was obtained as yellow solid (5.63 g, 
29.0 mmol, 94%). Rf = 0.71 (hex-
ane : ethylacetate 10:1). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 9.76 (s, 1H, NH), 8.57(dt, J 
= 5.0 Hz, J = 1.1 Hz, 1H, CHar), 7.83 (dt, J = 
8.0 Hz, J = 1.0 Hz, 1H, CHar), 7.75 (td, J = 
7.7 Hz, J = 1.4 Hz, 1H, CHar), 7.66 (d, J = 
7.9 Hz, 1H, CHar-10), 7.44 (dd, J = 8.1 Hz, J 
= 0.7 Hz, 1H, CHar), 7.24-7.17 (m, 2H, CHar), 
7.14-7.09 (m, 1H, CHar), 7.05 (dd, J = 2.1 
Hz, J = 0.7 Hz, 1H, CHar). IR (film): v (cm
-1) 
3114, 2968, 1591, 1557, 1439, 1408, 1337, 
1299, 1255, 1143, 994, 776, 741, 616, 602, 
563, 520, 493, 427, 400. HRMS calculated 
for C13H10N2Na (M + Na
+) 217.0742 found 
(M + Na+) 217.0740. 
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5.2.1.9 5-(tert-butyldimethylsilyloxy)-1H-
indole (48) 
 
 
5-(benzyloxy)-1H-indole (5.00 g, 
22.39 mmol) were dissolved in 200 mL 
ethylacetate in a 1 L reaction flask. Pd/C 
(3.95 g, 3.81 mmol, 10% v/w) were sus-
pended and the nitrogen atmosphere was 
completely substituted by hydrogen in three 
turns. The mixture was reacted at ambient 
temperature for 16 h under intensive stirring. 
The suspension was filtrated over CELITE 
and the filtrate was dried in vacuo. The resi-
due was dissolved in 80 mL DMF and 
cooled to 4 °C. Over a period of 10 min di-
isopropylethylamine (19.4 mL, 111.95 mmol) 
were added drop wise. Then, tert-butyl-
dimethylsilyltriflate (6.1 mL, 22.39 mmol) 
was added drop wise over 16 h and the re-
action mixture was warmed up to ambient 
temperature simultaneously. The orange 
coloured reaction mixture was quenched 
with ammonium acetate (200 mL, 1 M) and 
then diluted with of water (100 mL). The 
mixture was then extracted with ethylacetate 
(4 x 200 mL), the organic layer was sepa-
rated, washed with BRINE (3 x 50 mL), and 
dried over sodium sulfate. The crude mate-
rial was dried in vacuo and subjected to sili-
ca gel chromatography hexane : ethyl-
acetate (9:1). The product 48 was obtained 
as pale oil (3.78 g, 15.28 mmol, 68% over 
two steps). Rf = 0.57 (hexane : ethylacetate 
3:1). 1H-NMR (300 MHz, CDCl3): δ(ppm) 
8.03 (s, 1H, NH), 7.23 (d, J = 8.7 Hz, 1H, 
CHar-7), 7.18-7.15 (m, 1H, CHar-2), 7.07 (d, 
J = 2.3 Hz, 1H, CHar-4), 6.76 (dd, J = 8.7, 
2.3, 1H, CHar-6), 6.44 (m, 1H, CHar-3), 1.01 
(s, 9H, Cq(CH3)3), 0.20 (s, 6H, Si(CH3)2). 
13C-NMR (75 MHz, CDCl3): δ(ppm) 149.53 
(Car-5), 131.59 (Car-7a), 128.71 (Car-3a), 
124.95 (Car-2), 116.48 (Car-6), 111.33 (Car-
7), 110.23 (Car-4), 102.42 (Car-3), 25.97 
(3xCq(CH3)3), 18.39 (Cq(CH3)3), -4.26 
(Si(CH3)2), -4.45 (Si(CH3)2). HRMS calculat-
ed for C14H21NOSiNa (M + Na
+) 270.1285, 
found (M + Na+) 270.1285. 
5.2.1.10 tert-butyl 1H-indole-1-carboxylate 
(51) 
 
 
Indole (10.0 g, 85.4 mmol) was dis-
solved in THF (25 mL) and cooled to 4 °C. 
Di-tert-butyl-dicarbonate (18.6 g, 85.4 mmol) 
was presolved in THF (25 mL) and added to 
the reaction mixture. Dimethylaminopyridine 
(DMAP, 15.7 g, 128 mmol) was added slow-
ly. The reaction mixture was stirred for 16 h 
and warmed up to ambient temperature. 
The reaction mixture was cooled to 4 °C and 
hydrochloric acid (60 mL, 1 M) was added 
followed by 15 min of stirring. The organic 
layer was separated. The aqueous layer 
was extracted with ethylacetate (5 x 50 mL). 
The combined organic layer was washed 
with BRINE (3 x 50 mL), and dried over sodi-
um sulfate. The solvent was evaporated 
under reduced pressure and the crude ma-
terial was subjected to column chromatog-
raphy using hexane : ethylacetate (8:1). The 
product 51 was obtained as colourless oil 
(18.34 g, 84.5 mmol, quant.). Rf = 0.37 (hex-
ane : ethylacetate 8:1). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 8.11 (d, J = 8.1 Hz, 1H, 
CHar-7), 7.55 (d, J = 3.7 Hz, 1H, CHar-2), 
7.51 (ddd, J = 7.6, 1.3, 0.8 Hz, 1H, CHar-4), 
7.26 (ddd, J = 8.4, 7.3, 1.4 Hz, 1H, CHar-6), 
7.21–7.14 (m, 1H, CHar-5), 6.51 (dd, J = 3.7, 
0.7 Hz, 1H, CHar-3), 1.62 (s, 9H, 
OCq(CH3)3). 
13C-NMR (75 MHz, CDCl3): 
δ(ppm) 149.92 (Ccarbonyl), 135.35 (Car-7a), 
130.71 (Car-3a), 125.98, 124.29, 122.74, 
121.03, 115.28, 107.38, 83.70 (Cq(CH3)3), 
28.31 (Cq(CH3)3). IR (film): v (cm
-1) 2978, 
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2933, 1728, 1604, 1535, 1450, 1375, 1333, 
1248, 1208, 1152, 1114, 1076, 1018, 935, 
881, 850. 
5.2.1.11 tert-butyl 5-(tert-butyldimethylsilyl-
oxy)-1H-indole-1-carboxylate (52) 
 
 
48 (3.78 g, 15.28 mmol) was dis-
solved in THF (12 mL) and cooled to 4 °C. 
Di-tert-butyl-dicarbonate (4.20 g, 
19.32 mmol) was presolved in THF (3 mL) 
and added to the reaction mixture. Dime-
thylaminopyridine (DMAP, 2.35 g, 
19.22 mmol) was added slowly. The reac-
tion mixture was stirred for 16 h and turned 
from orange to green while warming to am-
bient temperature. The reaction mixture was 
cooled to 4 °C and hydrochloric acid (11 mL, 
1 M) was added followed by 5 min of stirring. 
The organic layer was separated. The 
aqueous layer was extracted with 
ethylacetate (4 x 50 mL). The combined 
organic layer was washed with BRINE 
(3 x 50 mL), and dried over sodium sulfate. 
The solvent was removed in vacuo and the 
crude material subjected to column chroma-
tography hexane : ethylacetate (20:1). The 
product 52 was obtained as colourless oil 
(4.95 g, 14.24 mmol, 93%). Rf = 0.63 (hex-
ane : ethylacetate 10:1). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 7.96 (d, J = 8.6 Hz, 1H, 
CHar-7), 7.55 (d, J = 3.6, 1H, CHar-2), 6.99 
(d, J = 2.4 Hz, 1H, CHar-4), 6.84 (dd, J = 8.9, 
2.4, 1H, CHar-6), 6.46 (d, J = 3.7, 1H, CHar-
3), 1.66 (s, 9H, OCq(CH3)3), 1.00 (s, 9H, 
SiCq(CH3)3), 0.20 (s, 6H, Si(CH3)2). 
13C-NMR 
(75 MHz, CDCl3): δ(ppm) 151.53 (Ccarbonyl), 
131.66 (Car-7a), 130.54 (Car-3a), 126.61, 
117.74, 115.70, 111.12, 107.16, 83.55 
(OCq(CH3)3), 28.39 (OCq(CH3)3), 25.92 
(SiCq(CH3)3), 18.40 (SiCq(CH3)3), -4.27 
(Si(CH3)2). IR (film): v (cm
-1) 2956, 2932, 
2892, 2858, 1731, 1614, 1580, 1462, 1372, 
1274, 1218, 1149, 1118, 1081, 1022, 966, 
878, 840, 811, 770. HRMS calculated for 
C19H29NO3SiNa (M + Na
+) 370.1809, found 
(M + Na+) 370.1811. 
5.2.1.12 tert-butyl 5-(benzyloxy)-1H-indole-
1-carboxylate (53) 
 
 
5-(benzyloxy)-1H-indole (49) (3.8 g, 
17.1 mmol) was dissolved in THF (12.5 mL) 
and cooled to 4 °C. Di-tert-butyl-dicarbonate 
(3.9 g, 17.9 mmol) was presolved in THF 
(3 mL) and added to the reaction mixture. 
Dimethylaminopyridine (DMAP, 3.2 g, 
25.6 mmol) was added slowly. The reaction 
mixture became solid and was fluidised by 
heating to 50 °C for 5 min. The reaction mix-
ture was then stirred for 16 h at ambient 
temperature. The reaction mixture was 
cooled to 4 °C and hydrochloric acid (12 mL, 
1 M) was added followed by 10 min of stir-
ring. The organic layer was separated. The 
aqueous layer was extracted with 
ethylacetate (3 x 20 mL). The combined 
organic layer was washed with BRINE 
(3 x 50 mL), and dried over sodium sulfate. 
The solvent was evaporated under reduced 
pressure and the crude material was sub-
jected to column chromatography using 
hexane : ethylacetate (15:1). The product 53 
was obtained as colourless oil (5.08 g, 
145.71 mmol, 92%). Rf = 0.59 (hex-
ane : ethylacetate 8:1). 1H-NMR (300 MHz, 
(CD3)2SO): δ(ppm) 7.93 (d, J = 9.1 Hz, 1H, 
CHar-7), 7.63 (d, J = 3.7 Hz, 1H, CHar-2), 
7.48 (d, J = 1.7 Hz, 1H, CHar-o), 7.45 (d, J = 
1.2 Hz, 1H, CHar-o), 7.43–7.29 (m, 3H, 
CHar-p, CHar-m), 7.23 (d, J = 2.5 Hz, 1H, 
CHar-4), 7.01 (dd, J = 9.0, 2.5 Hz, 1H, 
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CHar-6), 6.62 (d, J = 4.3 Hz, 1H, CHar-3), 
5.13 (s, 2H, CH2benzyl), 1.61 (s, 9H, 
OCq(CH3)3). 
5.2.1.13 tert-butyl 5-methoxy-1H-indole-1-
carboxylate (54) 
 
 
5-methoxy-1H-indole (50) (5.0 g, 
33.9 mmol) was dissolved in THF (15 mL) 
and cooled to 4 °C. Di-tert-butyl-dicarbonate 
(7.5 g, 34 mmol) was presolved in THF 
(3 mL) and added to the reaction mixture. 
Dimethylaminopyridine (DMAP, 6.11 g, 
50 mmol) was added slowly. The reaction 
mixture became solid and was fluidised by 
heating to 50 °C for 5 min. The reaction mix-
ture was then stirred for 16 h at ambient 
temperature. The reaction mixture was 
cooled to 4 °C and hydrochloric acid (30 mL, 
1 M) was added followed by 15 min of stir-
ring. The organic layer was separated. The 
aqueous layer was extracted with 
ethylacetate (4 x 50 mL). The combined 
organic layer was washed with BRINE 
(3 x 50 mL), and dried over sodium sulfate. 
The solvent was evaporated under reduced 
pressure and the crude material was sub-
jected to column chromatography using 
hexane : ethylacetate (10:1). The product 54 
was obtained as white solid (8.2 g, 
33.2 mmol, 98%). Rf = 0.54 (hex-
ane : ethylacetate 8:1). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 8.01 (d, J = 8.0 Hz, 1H, 
CHar-7), 7.56 (d, J = 3.5 Hz, 1H, CHar-2), 
7.03 (d, J = 2.5 Hz, 1H, CHar-4), 6.92 (dd, J 
= 9.0, 2.5 Hz, 1H, CHar-6), 6.50 (d, J = 3.7 
Hz, 1H, CHar-3), 3.85 (s, 3H, OCH3), 1.66 (s, 
9H, OCq(CH3)3). 
13C-NMR (75 MHz, CDCl3): 
δ(ppm) 155.98 (Car-5), 149.83 (Ccarbonyl), 
131.49 (Car-7a), 130.08 (Car-3a) 126.58, 
115.91, 113.07, 107.21, 103.66, 83.53 
(OCq(CH3)3), 55.74 (OCH3), 28.28 
(OCq(CH3)3). IR (film): v (cm
-1) 2978, 2937, 
1726, 1614, 1585, 1471, 1443, 1373, 1342, 
1260, 1152, 1117, 1081, 1019, 937, 842, 
805, 761, 720, 627. 
5.2.1.14 1-(tert-butoxycarbonyl)-1H-indol-2-
ylboronic acid (55) 
 
 
Diisopropylamine (19 mL, 135 mmol) 
was dissolved in THF (50 mL) and cooled 
to -78 °C. n-Butyllithium (54 mL, 135 mmol, 
2.5 M in hexane) was added drop wise. The 
reaction mixture was warmed up to 0 °C and 
stirred for 30 min. 51 (19.7 g, 90 mmol) was 
predried in vacuo, and dissolved in a second 
flask with THF (100 mL). Triisopropyl borate 
(32 mL, 139 mmol) was added drop wise 
while cooling the reaction mixture to 0 °C. 
The lithium diisopropylamide solution was 
added over a period of 1.5 h. After 16 h of 
stirring hydrochloric acid (150 mL, 2 M) was 
added to quench the reaction over 15 min at 
ambient temperature. The organic layer was 
separated and the aqueous layer was ex-
tracted with ethylacetate (4 x 50 mL). The 
combined organic layer was washed with 
BRINE (3 x 50 mL), dried over sodium sul-
fate and concentrated in vacuo to dryness. 
The dark orange oil (23.5 g, 90 mmol, 
quant.) was processed directly to the cou-
pling reaction without further characterisa-
tion due to the instability of the boronic acid 
intermediate. 
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5.2.1.15 1-(tert-butoxycarbonyl)-5-(tert-butyl-
dimethylsilyloxy)-1H-indol-2-ylboro-
nic acid (56) 
 
 
Diisopropylamine (1.21 mL, 
8.64 mmol) was dissolved in THF 
(0.865 mL) and cooled to -78 °C. n-
Butyllithium (3.46 mL, 8.64 mmol, 2 M in 
hexane) was added drop wise. The reaction 
mixture was warmed up to 0 °C and stirred 
for 30 min. 52 (1.95 g, 5.61 mmol) was 
predried in vacuo, and dissolved in a second 
flask with THF (15 mL). Triisopropyl borate 
(2.0 mL, 8.64 mmol) was added drop wise 
while cooling the reaction mixture to 0 °C. 
The lithium diisopropylamide solution was 
added over a period of 1.5 h. The colour of 
the reaction mixture turned from pallid to 
yellow. After 2 h of stirring hydrochloric acid 
(15 mL, 2 M) was added to quench the reac-
tion over 15 min at ambient temperature. 
The organic layer was separated and the 
aqueous layer was extracted with ethyl-
acetate (4 x 25 mL). the combined organic 
layer was washed with BRINE (3 x 50 mL), 
dried over sodium sulfate and concentrated 
in vacuo to dryness. The dark brown oil 
(2.1 g, 5.5 mmol, 98%) was processed di-
rectly to the coupling reaction without further 
characterisation due to the instability of the 
boronic acid intermediate. 
5.2.1.16 5-(benzyloxy)-1-(tert-butoxycarbo-
nyl)-1H-indol-2-ylboronic acid (57) 
 
 
53 (2.98 g, 9.2 mmol) was predried 
in vacuo, and dissolved in a second flask 
with THF (15 mL). Triisopropyl borate 
(3.2 mL, 14.2 mmol) was added drop wise 
while cooling the reaction mixture to 0 °C. 
Lithium diisopropylamide solution (6.96 mL, 
13.8 mmol, 2 M in hexane) was added over 
a period of 1 h. The colour of the reaction 
mixture turned from pallid to yellow. After 
2 h of stirring hydrochloric acid (22 mL, 2 M) 
was added to quench the reaction over 
15 min at ambient temperature. The organic 
layer was separated and the aqueous layer 
was extracted with ethylacetate (5 x 25 mL). 
The combined organic layer was washed 
with BRINE (3 x 50 mL), dried over sodium 
sulfate and concentrated in vacuo to dry-
ness. The dark brown oil (3.3 g, 9 mmol, 
98%) was processed directly to the coupling 
reaction without further characterisation due 
to the instability of the boronic acid interme-
diate. 
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5.2.1.17 1-(tert-butoxycarbonyl)-5-methoxy-
1H-indol-2-ylboronic acid (58) 
 
 
54 (4 g, 16.2 mmol) was predried in 
vacuo, and dissolved in THF (18.8 mL). 
Triisopropyl borate (5.7 mL, 24.9 mmol) was 
added drop wise while cooling the reaction 
mixture to 0 °C. Lithium diisopropylamide 
solution (13.5 mL, 24.3 mmol, 1.8 M in hex-
ane) was added over a period of 1 h. After 
2 h of stirring hydrochloric acid (40 mL, 2 M) 
was added to quench the reaction over 
15 min at 0 °C. The organic layer was sepa-
rated and the aqueous layer was extracted 
with ethylacetate (5 x 25 mL). The combined 
organic layer was washed with BRINE 
(3 x 50 mL), dried over sodium sulfate and 
concentrated in vacuo to dryness. The dark 
orange oil (4.6 g, 15.8 mmol, 98%) was pro-
cessed directly to the coupling reaction 
without further characterisation due to the 
instability of the boronic acid intermediate. 
5.2.1.18 tert-butyl 2-(5-(trifluoromethyl) pyri-
din-2-yl)-1H-indole-1-carboxylate 
(65) 
 
 
Sodium carbonate (4.7 g, 
45.0 mmol), and tetrakis(triphenylphos-
phine)palladium (1.04 g, 0.90 mmol) were 
reacted with the boronic acid 55 (4.7 g, 
18 mmol) dissolved in dimethoxy-
ethane : water (95 mL, 4:1). 2-bromo-5-(tri-
fluoromethyl)pyridine (3.7 g, 16.4 mmol) was 
added and the entire reaction mixture re-
fluxed for 16 h. The dark red suspension 
was cooled to ambient temperature and di-
luted with water (65 mL). The organic layer 
was separated. The aqueous layer was ex-
tracted with ethylacetate (3 x 50 mL), the 
combined organic layer was washed with 
BRINE (3 x 50 mL), dried over sodium sul-
fate. The crude material was concentrated in 
vacuo and subjected to column chromatog-
raphy using hexane : ethylacetate (20:1  
5:1). The product 65 was obtained as a 
white solid (3.71 g, 10.2 mmol, 61.6%). 
Rf = 0.54 (hexane : ethylacetate 8:1). 
1H-NMR (300 MHz, CDCl3): δ(ppm) 8.80 
(dd, J = 1.4, 0.9 Hz, 1H, CHar-6´), 8.05 (dd, J 
= 8.4, 0.8 Hz, 1H, CHar-7), 7.83 (ddd, J = 
8.2, 2.3, 0.6 Hz, 1H, CHar), 7.52 – 7.43 (m, 
2H, CHar-4, CHar), 7.26 (ddd, J = 8.6, 7.2, 
1.3 Hz, 1H, CHar-6), 7.18 – 7.10 (m, 1H, 
CHar-5), 6.73 (d, J = 0.6 Hz, 1H, CHar-3), 
1.25 (s, 9H, OCq(CH3)3). 
13C-NMR (75 MHz, 
CDCl3): δ(ppm) 156.62 (Car-2´), 149.93 (Ccar-
bonyl), 145.98 (q, J = 4.0 Hz), 138.18, 138.08, 
133.25 (q, J = 3.4 Hz), 128.80, 125.76, 
125.22, 124.78, 123.31, 122.85, 121.45, 
115.25, 112.67, 84.08 (OCq(CH3)3), 27.74 
(OCq(CH3)3). IR (film): v (cm
-1) 2983, 1726, 
1601, 1557, 1479, 1449, 1398, 1367, 1316, 
1227, 1153, 1114, 1076, 1036, 1008, 938, 
852, 822, 770, 743. 
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5.2.1.19 tert-butyl 2-(5-hydroxypyridin-2-yl)-
1H-indole-1-carboxylate (66) 
 
 
Sodium carbonate (4.7 g, 45 mmol), 
and tetrakis(triphenylphosphine)palladium 
(1.04 g, 0.9 mmol) were reacted with the 
boronic acid 55 (4.7 g, 18 mmol) dissolved 
in dimethoxyethane : water (95 mL, 4:1). 
6-bromopyridin-3-ol (2.85 g, 16.4 mmol) was 
added and the entire reaction mixture re-
fluxed for 16 h. The dark brown suspension 
was cooled to ambient temperature and di-
luted with water (65 mL). The organic layer 
was separated. The aqueous layer was ex-
tracted with ethylacetate (3 x 50 mL), the 
combined organic layer was washed with 
BRINE (3 x 50 mL), dried over sodium sul-
fate. The crude material was concentrated in 
vacuo and subjected to column chromatog-
raphy using methylene chloride : methanol 
(35:1  10:1). The product 66 was obtained 
as brown oil (2.40 g, 7.7 mmol, 47%). 
Rf = 0.51 (hexane : ethylacetate 8:1). The 
product could only be obtained as mixture of 
tert-butyloxycarbonyl protected and unpro-
tected form and was therefore processed 
without further characterisation. 
5.2.1.20 tert-butyl 2-(5-nitropyridin-2-yl)-1H-
indole-1-carboxylate (67) 
 
 
Sodium carbonate (4.7 g, 
45.0 mmol), and tetrakis(triphenylphos-
phine)palladium (1.04 g, 0.90 mmol) were 
reacted with the boronic acid 55 (4.7 g, 
18 mmol) dissolved in dimethoxy-
ethane : water (95 mL, 4:1). 2-bromo-5-
nitropyridine (3.3 g, 16.4 mmol) was added 
and the entire reaction mixture refluxed for 
16 h. The dark red suspension was cooled 
to ambient temperature and diluted with wa-
ter (65 mL). The organic layer was separat-
ed. The aqueous layer was extracted with 
ethylacetate (3 x 50 mL), the combined or-
ganic layer was washed with BRINE 
(3 x 50 mL), dried over sodium sulfate. The 
crude material was concentrated in vacuo 
and subjected to column chromatography 
using hexane : ethylacetate (20:1  5:1). 
The product 67 was obtained as a yellow 
solid (3.58 g, 10.5 mmol, 64%). Rf = 0.27 
(hexane : ethylacetate 8:1). 1H-NMR 
(300 MHz, CDCl3): δ(ppm) 9.48 (dd, J = 2.6, 
0.5 Hz, 1H, CHar-6´), 8.55 (dd, J = 8.7, 2.6 
Hz, 1H, CHar-4´), 8.14 (d, J = 9.2 Hz, 1H, 
CHar-7), 7.72 (dd, J = 8.7, 0.6 Hz, 1H, 
CHar-3´), 7.64 (d, J = 7.8 Hz, 1H, CHar-4), 
7.43 (ddd, J = 8.5, 7.2, 1.3 Hz, 1H, CHar-6), 
7.35–7.28 (m, 1H, CHar-5), 7.02 (d, J = 0.6 
Hz, 1H, CHar-3), 1.46 (s, 9H, OCq(CH3)3). IR 
(film): v (cm-1) 3048, 2974, 2929, 1731, 
1595, 1566, 1513, 1474, 1445, 1399, 1342, 
1314, 1266, 1223, 1189, 1142, 1110, 944, 
848, 830, 768. 
  
131 Experimental 
5.2.1.21 tert-butyl 2-(5-aminopyridin-2-yl)-
1H-indole-1-carboxylate (68) 
 
 
Sodium carbonate (4.7 g, 45 mmol), 
and tetrakis(triphenylphosphine)palladium 
(1.04 g, 0.9 mmol) were reacted with the 
boronic acid 55 (4.7 g, 18 mmol) dissolved 
in dimethoxyethane : water (95 mL, 4:1). 
6-bromopyridin-3-amine (2.8 g, 16.4 mmol) 
was added and the entire reaction mixture 
refluxed for 16 h. The dark brown suspen-
sion was cooled to ambient temperature and 
diluted with water (65 mL). The organic layer 
was separated. The aqueous layer was ex-
tracted with ethylacetate (3 x 50 mL), the 
combined organic layer was washed with 
BRINE (3 x 50 mL), dried over sodium sul-
fate. The crude material was concentrated in 
vacuo and subjected to column chro-
matography using methylene chlo-
ride : methanol (35:1  10:1). The product 
68 was obtained as a brown oil (2.40 g, 
14 mmol, 77%). Rf = 0.56 (hexane : ethyl-
acetate 8:1). The product could only be ob-
tained as mixture of tert-butyloxycarbonyl 
protected and unprotected form and was 
therefore processed without further charac-
terisation. 
5.2.1.22 tert-butyl 2-(5-cyanopyridin-2-yl)-
1H-indole-1-carboxylate (69) 
 
 
Sodium carbonate (4.7 g, 
45.0 mmol), and tetrakis(triphenylphos-
phine)palladium (1.04 g, 0.90 mmol) were 
reacted with the boronic acid 55 (4.7 g, 
18 mmol) dissolved in dimethoxye-
thane : water (95 mL, 4:1). 6-bromo-
nicotinonitrile (2.9 g, 16.4 mmol) was added 
and the entire reaction mixture refluxed for 
16 h. The dark red suspension was cooled 
to ambient temperature and diluted with wa-
ter (65 mL). The organic layer was separat-
ed. The aqueous layer was extracted with 
ethylacetate (3 x 50 mL), the combined or-
ganic layer was washed with BRINE 
(3 x 50 mL), dried over sodium sulfate. The 
crude material was concentrated in vacuo 
and subjected to column chromatography 
using hexane : ethylacetate (15:1  3:1). 
The product 69 was obtained as a brown oil 
(3.9 g, 12.2 mmol, 68%). Rf = 0.62 (methyl-
ene chloride : methanol 35:1). 1H-NMR 
(300 MHz, CDCl3): δ(ppm) 8.76 (dd, J = 2.1, 
0.8 Hz, 1H, CHar-6´), 8.00 (dd, J = 8.4, 0.8 
Hz, 1H, CHar-7), 7.82 (dd, J = 8.2, 2.2 Hz, 
1H, CHar-4´), 7.49–7.42 (m, 2H, CHar-4, 
CHar-3´), 7.26 (ddd, J = 8.3, 7.3, 1.3 Hz, 1H, 
CHar-6), 7.18–7.09 (m, 1H, CHar-5), 6.77 (d, 
J = 0.4 Hz, 1H, CHar-3), 1.28 (s, 9H, 
OCq(CH3)3). 
13C-NMR (75 MHz, CDCl3): 
δ(ppm) 156.26 (Car-2´), 151.74 (Ccarbonyl), 
139.09, 128.65, 126.10, 124.78, 123.40, 
122.79, 121.87, 121.62, 120.87, 119.28, 
116.89, 115.18, 113.52, 84.35 (OCq(CH3)3), 
27.81 (OCq(CH3)3). IR (film): v (cm
-1) 2227, 
1731, 1587, 1552, 1470, 1445, 1391, 1363, 
1316, 1227, 1139, 1023, 945, 849, 824, 794, 
772, 743, 686, 660. HRMS calculated for 
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C19H18N3O2 (M + H
+) 320.1394 found 
(M + H+) 320.1395. 
5.2.1.23 tert-butyl 5-(tert-butyldimethyl-
silyloxy)-2-(5-fluoropyridin-2-yl)-1H-
indole-1-carboxylate (70) 
 
 
Sodium carbonate (1.53 g, 
14.44 mmol), and tetrakis(triphenylphos-
phine)palladium (350 mg, 0.303 mmol) were 
reacted with the boronic acid 56 (2.25 g, 
5.76 mmol) dissolved in dimethoxy-
ethane : water (30 mL, 4:1). 5-Fluoro-2-
bromopyridine (0.95 g, 5.40 mmol) was 
added and the entire reaction mixture re-
fluxed for 16 h. The dark red suspension 
was cooled to ambient temperature and di-
luted with water (25 mL). The organic layer 
was separated. The aqueous layer was ex-
tracted with ethylacetate (4 x 25 mL), the 
combined organic layer was washed with 
BRINE (3 x 50 mL), dried over sodium sul-
fate. The crude material was concentrated in 
vacuo and subjected to column chromatog-
raphy with hexane : ethylacetate (15:1). The 
product 70 was obtained as a colourless oil 
(1.52 g, 3.43 mmol, 60%). Rf = 0.53 (hex-
ane : ethylacetate 15:1). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 8.52 (dd, J = 2.0, 1.0, 1H, 
CHar-6´), 8.01 (d, J = 8.9 Hz, 1H, CHar-7), 
7.53 - 7.42 (m, 2H, CHar-3´,CHar-4´), 7.00 (d, 
J = 2.3 Hz, 1H, CHar-4), 6.89 (dd, J = 8.9, 
2.4, 1H, CHar-6), 6.64 (s, 1H, CHar-3), 1.37 
(s, 9H, OCq(CH3)3), 1.00 (s, 9H, SiCq(CH3)3), 
0.20 (s, 6H, Si(CH3)2). 
13C-NMR (75 MHz, 
CDCl3): δ(ppm) 158.72 (d, J = 256. Hz, 
Car-5´), 151.78 (Ccarbonyl), 150.06 (Car-5), 
149.71 (d, J = 3.9 Hz, Car-2´) , 138.78 
(Car-2), 137.23 (d, J = 23.7 Hz, Car-6´), 
132.98 (Car-7a), 129.79 (Car-3a), 124.47 (d, 
J = 4.4 Hz, Car-3´), 122.99 (d, J = 18.79 Hz, 
Car-4´), 118.77 (Car-6), 115.91 (Car-7), 
111.28 (Car-4), 110.99 (Car-3), 83.59 
(OCq(CH3)3), 27.86 (OCq(CH3)3), 25.91 
(SiCq(CH3)3), 18.40 (SiCq(CH3)3), -4.28 
(Si(CH3)2). HRMS calculated for 
C24H31FN2O3SiNa (M + Na
+) 465.1980 found 
(M + Na+) 465.1981. 
5.2.1.24 2-(5-fluoropyridin-2-yl)-5-methoxy-
1H-indole (71) 
 
 
Sodium carbonate (4.5 g, 
42.5 mmol), and tetrakis(triphenylphos-
phine)palladium (1.9 g, 1.7 mmol) were re-
acted with the boronic acid 58 (4.95 g, 
17 mmol) dissolved in dimethoxye-
thane : water (72 mL, 4:1). 2-Bromo-5-
fluoropyridine (2.69 g, 15.4 mmol) was add-
ed and the entire reaction mixture refluxed 
for 16 h. The dark yellow suspension was 
cooled to ambient temperature and diluted 
with water (50 mL). The organic layer was 
separated. The aqueous layer was extracted 
with ethylacetate (5 x 30 mL), the combined 
organic layer was washed with BRINE 
(3 x 50 mL), dried over sodium sulfate. The 
crude material was concentrated in vacuo 
and subjected to column chromatography 
using hexane : ethylacetate (10:1). The tert-
butyloxycarbonyl protected intermediate was 
obtained as a brown oil (4.43 g, 12.9 mmol). 
The intermediate was dissolved in methyl-
ene chloride and subjected to silica gel 
(40 g). After complete removal of the solvent 
under reduced pressure, the soaked com-
pound was heated to 80 °C in vacuo for 
16 h. The silica gel was suspended in ethyl-
acetate and filtrated over CELITE. The prod-
uct was dried in vacuo to obtained 71 as a 
beige solid (3.24 g, 13.4 mmol, 79% over 2 
steps). Rf = 0.26 (hexane : ethylacetate 8:1). 
1H-NMR (300 MHz, CDCl3): δ(ppm) 9.38 
(bs, 1H, NH), 8.41 (d, J = 2.9 Hz, 1H, CHar-
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6´), 7.75 (dd, J = 8.8, 4.3 Hz, 1H, CHar-3´), 
7.47–7.40 (m, 1H, CHar-4´), 7.30 (d, J = 8.8 
Hz, 1H, CHar-7), 7.09 (d, J = 2.4 Hz, 1H, 
CHar-4), 6.90 (dd, J = 8.9, 2.5 Hz, 1H, 
CHar-6), 6.88–6.86 (m, 1H, CHar-3), 3.87 (s, 
3H, OCH3). 
13C-NMR (75 MHz, CDCl3): 
δ(ppm) 158.63 (d, J = 255.7 Hz, Car-5´), 
154.72 (Car-5), 147.01 (d, J = 3.9 Hz, Car-2´), 
137.17 (d, J = 24.4 Hz, Car-6´), 136.48 (Car-
2), 132.11 (Car-7a), 129.68 (Car-3a), 124.01 
(d, J = 19.1 Hz, Car-4´), 120.73 (d, J = 4.3 
Hz, Car-3´), 114.13 (Car-6), 112.26 (Car-7), 
102.66 (Car-4), 100.34 (Car-3), 55.98 (OCH3). 
IR (film): v (cm-1) 3446, 1545, 1455, 1354, 
1297, 1216, 1148, 1111, 1027, 942, 888, 
825, 787, 738, 652, 616, 577, 516. 
5.2.1.25 5-(tert-butyldimethylsilyloxy)-2-(5-
fluoropyridin-2-yl)-1H-indole (72) 
 
 
Pyridylindole 70 (1.44 g, 3.26 mmol) 
was dissolved in methylene chloride and 
subjected to silica gel (15 g). After complete 
removal of the solvent under reduced pres-
sure, the soaked compound was heated to 
80 °C in vacuo for 16 h. The silica gel was 
suspended in ethylacetate and filtrated over 
CELITE. The crude material was concen-
trated in vacuo and subjected to column 
chromatography with hexane : ethylacetate 
(6:1). The product 72 was dried in vacuo 
and obtained as a white solid (1.04 g, 
3.04 mmol, 93%). Rf = 0.40 (hexane : ethyl-
acetate 6:1). 1H-NMR (300 MHz, CDCl3): 
δ(ppm) 9.35 (s, 1H, NH), 8.41 (d, J = 2.8 Hz, 
1H, CHar-6´), 7.76 (dd, J = 8.5, 4.3 Hz, 1H, 
CHar-3´), 7.45 (ddd, J = 8.7, 8.2, 2.9 Hz, 1H, 
CHar-4´), 7.25 (d, J = 8.7 Hz, 1H, CHar-7), 
7.06 (d, J = 2.3 Hz, 1H, CHar-4), 6.84 (d, J = 
1.4 Hz, 1H, CHar-3), 6.80 (dd, J = 8.7, 2.3 
Hz, CHar-6), 1.01 (s, 9H, SiCq(CH3)3), 0.21 
(s, 6H, Si(CH3)2). 
13C-NMR (75 MHz, 
CDCl3): δ(ppm) 158.59 (d, J = 255.7 Hz, 
Car-5´), 155.18 (Car-2´), 149.86 (Car-5), 
136.99 (d, J = 24.55 Hz, Car-6´), 132.54 
(Car-2), 132.53 (Car-7a), 129.85 (Car-3a), 
124.18 (d, J = 18.98 Hz, Car-4´), 120.81 (d, J 
= 4.46, Car-3´), 118.12 (Car-4), 111.86 
(Car-6), 110.40 (Car-7), 100.30 (Car-3), 25.96 
(SiCq(CH3)3), 18.40 (SiCq(CH3)3), -4.25 
(Si(CH3)2). IR (film): v (cm
-1) 3457, 2957, 
2858, 2251, 1625, 1549, 1459, 1385, 1288, 
1229, 1152, 1118, 1010, 965, 903, 835, 784, 
724, 650, 585, 527, 488, 440, 395. HRMS 
calculated for C19H23FN2OSiH (M + H
+) 
343.1642 found (M + H+) 343.1636. 
5.2.1.26 3-bromo-4-(5-(tert-butyldimethyl-
silyloxy)-2-(5-fluoropyridin-2-yl)-1H-
indol-3-yl)-1-methyl-1H-pyrrole-2,5-
dione (73) 
 
 
72 (921 mg, 2.69 mmol) was dis-
solved in THF (8 mL) and cooled to -15 °C. 
Lithium bis(trimethylsilyl)amide (8.1 mL, 
8.07 mmol, 1 M in hexane) was added drop 
wise over a period of 90  min and the solu-
tion turned from colourless to yellow. 38 
(796 mg, 2.96 mmol) was dissolved in THF 
(5 mL) and added drop wise to the reaction 
mixture over a period of 20 min. An immedi-
ate colour change from yellow to dark purple 
was observed. The reaction mixture was 
protected from light and stirred for 1 h 
at -15 °C followed by 16 h at ambient tem-
perature. The reaction was finished by pour-
ing the entire reaction mixture into ice 
cooled hydrochloric acid (63 mL). The or-
ganic layer was separated and the aqueous 
layer was extracted with ethylacetate 
(4 x 50 mL). The combined organic layer 
was washed with BRINE (3 x 50 mL), and 
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dried over sodium sulfate. The crude mate-
rial was concentrated in vacuo and subject-
ed to column chromatography hex-
ane : ethylacetate (6:1  1:1). The product 
73 was dried in vacuo and obtained as a red 
solid (923 mg, 1.74 mmol, 65%). Rf = 0.26 
(hexane : ethylacetate 3:1). Due to its light 
sensitivity the mono bromide intermediate 
was directly processed to the cyclisation 
reaction without further characterisation. 
5.2.1.27 3-bromo-1-(tert-butyldimethylsilyl)-
4-(2-(5-fluoropyridin-2-yl)-5-meth-
oxy-1H-indol-3-yl)-1H-pyrrole-2,5-
dione (74) 
 
 
71 (3.25 g, 13.4 mmol) was dis-
solved in THF (40 mL) and cooled to -15 °C. 
Lithium bis(trimethylsilyl)amide (40 mL, 
40 mmol, 1 M in hexane) was added drop 
wise over a period of 90  min and the solu-
tion turned from colourless to yellow. 42 
(5.43 g, 14.74 mmol) was dissolved in THF 
(30 mL) and added drop wise to the reaction 
mixture over a period of 30 min. An immedi-
ate colour change from yellow to dark purple 
was observed. The reaction mixture was 
protected from light and stirred for 1 h 
at -15 °C followed by 16 h at ambient tem-
perature. The reaction was finished by pour-
ing the entire reaction mixture into ice 
cooled hydrochloric acid (400 mL). The or-
ganic layer was separated and the aqueous 
layer was extracted with ethylacetate 
(5 x 75 mL). The combined organic layer 
was washed with BRINE (3 x 50 mL), and 
dried over sodium sulfate. The crude mate-
rial was concentrated in vacuo and subject-
ed to column chromatography using hex-
ane : ethylacetate (8:1  1:1). The product 
74 was dried in vacuo and obtained as a red 
solid (5.03 g, 9.46 mmol, 71%). Rf = 0.78 
(hexane : ethylacetate 1:1). Due to its light 
sensitivity the mono bromide intermediate 
was directly proceeded to the cyclisation 
reaction without further characterisation. 
5.2.1.28 3-bromo-1-(tert-butyldimethylsilyl)-
4-(2-(pyridin-2-yl)-1H-indol-3-yl)-
1H-pyrrole-2,5-dione (75) 
 
 
46 (875 g, 4.5 mmol) was dissolved 
in THF (15 mL) and cooled to -15 °C. Lithi-
um bis(trimethylsilyl)amide (13.5 mL, 1 M in 
hexane) was added drop wise over a period 
of 45  min and the solution turned from col-
ourless to yellow. 42 (1.85 g, 5.0 mmol) was 
dissolved in THF (20 mL) and added drop 
wise to the reaction mixture over a period of 
20 min. An immediate colour change from 
yellow to dark purple was observed. The 
reaction mixture was protected from light 
and stirred for 1 h at -15 °C followed by 16 h 
at ambient temperature. The reaction mix-
ture turned into a dark purple colour. The 
reaction was finished by pouring the entire 
reaction mixture into ice cooled hydrochloric 
acid (135 mL). The organic layer was sepa-
rated and the aqueous layer was extracted 
with ethylacetate (5 x 50 mL). The combined 
organic layer was washed with BRINE 
(3 x 50 mL), and dried over sodium sulfate. 
The crude material was concentrated in 
vacuo and subjected to column chroma-
tography using hexane : ethylacetate (6:1  
1:1). The product was dried in vacuo and 
obtained as a red solid (1.47 g, 3.1 mmol, 
68%). Due to its light sensitivity the mono 
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bromide intermediate was directly pro-
ceeded to the cyclisation reaction without 
further characterisation. 
5.2.1.29 1-benzyl-3-bromo-4-(2-(pyridin-2-
yl)-1H-indol-3-yl)-1H-pyrrole-2,5-
dione (76) 
 
 
46 (1.1 g, 5.68 mmol) was dissolved 
in THF (14.5 mL) and cooled to -15 °C. Lith-
ium bis(trimethylsilyl)amide (25 mL, 1 M in 
hexane) was added drop wise over a period 
of 90  min and the solution turned from col-
ourless to yellow. 37 (2.05 g, 5.95 mmol) 
was dissolved in THF (18 mL) and added 
drop wise to the reaction mixture over a pe-
riod of 20 min. An immediate colour change 
from yellow to dark red was observed. The 
reaction mixture was protected from light 
and stirred for 1 h at -15 °C followed by 16 h 
at ambient temperature. The reaction mix-
ture turned into a dark purple colour. The 
reaction was finished by pouring the entire 
reaction mixture into ice cooled hydrochloric 
acid (125 mL). The organic layer was sepa-
rated and the aqueous layer was extracted 
with ethylacetate (4 x 50 mL). The combined 
organic layer was washed with BRINE 
(3 x 50 mL), and dried over sodium sulfate. 
The crude material was concentrated in 
vacuo and subjected to column chroma-
tography using hexane : ethylacetate (3:1  
1:1). The product 76 was dried in vacuo and 
obtained as a orange solid (1.4 mg, 
3.7 mmol, 54%). Rf = 0.51 (hexane : ethyl-
acetate 3:1). Due to its light sensitivity the 
mono bromide intermediate was directly pro-
ceeded to the cyclisation reaction without 
further characterisation. 
5.2.1.30 9-(tert-butyldimethylsilyloxy)-3-
fluoro-6-methylpyrido[2,3-a]pyr-
rolo[3,4-c]carbazole-5,7(6H,12H)-
dione (77) 
 
 
Mono bromide 73 (860 mg, 
1.62 mmol) was suspended in toluene 
(900 mL), continuously purged with nitrogen 
and subjected 2 h to an iron iodide endowed 
mercury UV lamp (700 W, max = 350 nm) 
under intensive stirring and water cooling in 
a UV reactor. The crude material was con-
centrated under reduced pressure and sub-
jected to column chromatography using 
methylene chloride : methanol (100:0  
20:1). The product 77 was dried in vacuo 
and obtained as an orange solid (388 mg, 
0.86 mmol, 53%). Rf = 0.39 (methylene chlo-
ride 100%). 1H-NMR (300 MHz, 
CDCl3/(CD3)2SO (4:1)): δ(ppm) 8.65 (dd, J = 
6.3, 2.7 Hz, 2H, CHar-2, CHar-4), 8.24 (d, J = 
2.3 Hz, 1H, CHar-8), 7.48 (d, J = 8.6 Hz, 1H, 
CHar-11), 6.99 (dd, J = 8.7, 2.4 Hz, 1H, 
CHar-10), 3.10 (s, 3H, NCH3), 0.97 (s, 9H, 
SiCq(CH3)3), 0.23 (s, 6H, Si(CH3)2). 
13C-NMR 
(75 MHz, CDCl3/(CD3)2SO (4:1)): δ(ppm) 
168.90 (Car-7), 168.04 (Car-5), 156.80 (d, J = 
257.7 Hz, Car-3), 149.83 (Car-9), 140.20 
(Car), 139.79 (d, J = 27.6 Hz, Car-2), 135.05 
(Car), 134.11 (Car), 128.67 (Car), 121.46 (Car), 
121.29 (Car), 121.20 (Car), 120.51 (Car), 
116.02 (d, J = 19.0 Hz, Car-4), 113.22 (Car), 
112.20 (Car), 25.29 (SiCq(CH3)3), 23.13 
(NCH3), 17.70 (SiCq(CH3)3), -4.88 (Si(CH3)2). 
IR (film): v (cm-1) 3322, 2931, 2892, 2857, 
1753, 1689, 1620, 1566, 1527, 1468, 1442, 
1415, 1373, 1331, 1279, 1250, 1219, 1167, 
1125, 959, 891. HRMS calculated for 
C24H25FN3O3Si (M + H
+) 450.1644 found 
(M + H+) 450.1664. 
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5.2.1.31 6-(tert-butyldimethylsilyl)-3-fluoro-9-
methoxypyrido[2,3-a]pyrrolo[3,4-
c]carbazole-5,7(6H,12H)-dione (78) 
 
 
74 (2.2 g, 4.15 mmol) were dissolved 
in toluene (900 mL), continuously purged 
with nitrogen and subjected 5 h to an iron 
iodide endowed mercury UV lamp (700 W, 
max = 350 nm) under intensive stirring and 
water cooling in a UV reactor. The orange 
coloured crude material was concentrated 
under reduced pressure and subjected to 
column chromatography using methylene 
chloride : methanol (100:1  10:1). The 
product 78 was dried in vacuo and obtained 
as an orange solid (1.25 g, 2.7 mmol, 67%). 
Rf = 0.42 (hexane : ethylacetate 3:1). 
1H-NMR (300 MHz, CDCl3): δ(ppm) 10.12 
(bs, NH), 9.27 (dd, J = 9.1, 2.6 Hz, 1H, 
CHar-4), 8.89 (d, J = 2.7 Hz, 1H, CHar-2), 
8.61 (d, J = 2.2 Hz, 1H, CHar-8), 7.63 (d, J = 
8.9 Hz, 1H, CHar-11), 7.29 (m, 1H, CHar-10), 
4.04 (s, 3H, OCH3), 1.06 (s, 9H, SiCq(CH3)3), 
0.63 (s, 6H, Si(CH3)2). IR (film): v (cm
-1) 
3443, 2929, 2855, 1744, 1687, 1627, 1557, 
1528, 1473, 1412, 1363, 1337, 1305, 1252, 
1213, 1179, 1153, 1035, 938, 904, 823, 804. 
HRMS calculated for C24H25FN3O3Si 
(M + H+) 450.1644 found (M + H+) 450.1644. 
5.2.1.32 6-(tert-butyldimethylsilyl)pyrido[2,3-
a]pyrrolo[3,4-c]carbazole-
5,7(6H,12H)-dione (79) 
 
 
Mono bromide 75 (1.00 g, 
2.08 mmol) was suspended in toluene 
(900 mL), continuously purged with nitrogen 
and subjected 3 h to an iron iodide endowed 
mercury UV lamp (700 W, max = 350 nm) 
under intensive stirring and water cooling in 
a UV reactor. The crude material was con-
centrated under reduced pressure and sub-
jected to column chromatography using 
methylene chloride : methanol (100:0  
20:1). The product 79 was dried in vacuo 
and obtained as an orange solid (526 mg, 
1.31 mmol, 63%). Rf = 0.71 (methylene chlo-
ride : methanol 15:1). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 10.27 (bs, 1H, NH), 9.41 
(dd, J = 8.6 Hz, J = 1.6 Hz, 1H, CHar), 9.09 
(d, J = 7.9 Hz, 1H, CHar), 9.02 (dd, J = 4.2 
Hz, J = 1.7 Hz, 1H, CHar), 7.65 (dd, J = 8.4 
Hz, J = 4.3 Hz, 1H, CHar), 7.65-7.54 (m, 2H, 
CHar), 7.45–7.40 (m, 1H, CHar), 1.07 (s, 9H, 
SiCq(CH3)3), 0.64 (s, 6H, Si(CH3)2). 
13C-NMR 
(75 MHz, CDCl3): δ(ppm) 175.5 (Car-7), 
173.9 (Car-5), 150.4, 140.1, 139.7, 138.5, 
134.5, 130.8, 127.3, 125.7, 122.8, 122.3, 
121.7, 121.9, 120.9, 115.3, 111.6, 26.6 
(SiCq(CH3)3), 19.1 (SiCq(CH3)3), −4.0 
(Si(CH3)2). HRMS calculated for 
C23H24N3O2Si (M + H
+) 402.1632 found 
(M + H+) 402.1632. 
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5.2.1.33 6-benzylpyrido[2,3-a]pyrrolo[3,4-
c]carbazole-5,7(6H,12H)-dione (80) 
 
 
76 (334 mg, 729 µmol) were dis-
solved in toluene (900 mL), continuously 
purged with nitrogen and subjected 2.5 h to 
an iron iodide endowed mercury UV lamp 
(700 W, max = 350 nm) under intensive stir-
ring and water cooling in a UV reactor. The 
orange coloured crude material was concen-
trated under reduced pressure and subject-
ed to column chromatography using meth-
ylene chloride : methanol (100:1  10:1). 
The product 80 was dried in vacuo and ob-
tained as an orange solid (220 mg, 
583 µmol, 80%). Rf = 0.28 (hexane : ethyl-
acetate 1:1). 1H-NMR (300 MHz, CDCl3): 
δ(ppm) 10.40 (s, 1H, NH), 9.28 (dd, J = 8.5, 
1.6, Hz, 1H, CHar), 8.93 (d, J = 8.0 Hz, 1H, 
CHar), 8.89 (dd, J = 1.6, 4.3 Hz, 1H, CHar), 
7.58-7.50 (m, 5H, CHar), 7.41-7.28 (m, 4H, 
CHar), 4.94 (s, 2H, CHbenzyl). IR (film): v 
(cm-1) 3334, 2924, 2853, 2078, 1754, 1695, 
1640, 1529, 1499, 1461, 1430, 1385, 1334, 
1295, 1234, 1145, 1104, 1070, 976, 934, 
796, 737, 694, 624, 498. HRMS calculated 
for C24H15N3O2Na (M + Na
+) 400.1062 found 
(M + Na+) 400.1056. 
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5.2.2 Synthesis of ligands and related 
intermediates 
5.2.2.1 1,4,7-trithiacyclodecan-9-one (90) 
 
 
Caesium Carbonate (860 mg, 
2.64 mmol) were suspended in 150 mL 
freshly distilled DMF and heated to 60 °C 
under a nitrogen atmosphere. The reaction 
mixture was stirred continuously while 
2,2’-thiodiethanthiol (311 µL, 2.39 mmol) 
and 1,3-dichloracetone (304.5 mg, 
2.39 mmol) were added dropwise via a 
dropping funnel diluted in a total amount of 
150 mL DMF. The drop wise addition of the 
reactants was performed over a time period 
of 8 h followed by an additional 8 h of stir-
ring at 60 °C. The white suspension turned 
into a pale red solution. The reaction mixture 
was concentrated to dryness in vacuo. The 
crude product was absorbed onto silica gel 
and purified by column chromatography us-
ing hexane : ethylacetate (3:1). The com-
bined product eluents were dried in vacuo to 
provide 90 as a white solid (229 mg, 
1.09 mmol, 46%). Rf = 0.47 (hexane : ethyl-
acetate 3:1). 1H-NMR (300 MHz, CDCl3): 
δ(ppm) 3.53 (s, 4H, 2xSCH2CO), 2.72 (s, 
8H, 4xCH2). 
13C-NMR (75.5 MHz, CDCl3): 
δ(ppm) 199.84 (Ccarbonyl), 37.68, 32.03, 
31.35. IR (film): ν (cm-1) 2961, 1695, 1417, 
1394, 1365, 1252, 1193, 1144, 1070, 680, 
565, 485. HRMS calculated for C8H12OS3Na 
(M + Na)+ 230.9948, found (M + Na)+ 
230.9975. 
5.2.2.2 N-methyl-1,4,7-trithiacyclodecan-9-
amine (91) 
 
 
Potassium carbonate (548 mg, 
3.97 mmol) was added to a solution of 
MeNH2∙HCl (268 mg, 3.97 mmol) stirring in 
methanol (5 mL) at 0 °C under a nitrogen 
atmosphere. The resulting mixture was 
stirred at 0 °C for an additional 1 hour, fol-
lowed by the addition of 90 (694.8 mg, 
3.33 mmol) in methanol (45 mL). The sus-
pension was then stirred at 34 °C for 1 hour. 
After the addition of NaBH3CN (419 mg, 
6.66 mmol) the reaction mixture was stirred 
over night at 34 °C. After the addition of sat-
urated NaHCO3 (25 mL) the crude product 
was extracted using methylene chloride 
(3 x 50 mL). The combined organic layers 
were dried using Na2SO4, filtered and con-
centrated to dryness in vacuo. The crude 
material was adsorbed onto silica gel and 
subjected to silica gel chromatography with 
methylene chloride : methanol (35:1  
20:1). The combined product eluents were 
dried in vacuo to provide 91 (271 mg, 
1.21 mmol, 36%) as a pale oil. Rf = 0.21 
(methylene chloride : methanol 15:1). 
1H-NMR (300 MHz, CDCl3): δ(ppm) 3.34-
2.86 (m, 13H), 2.82 (br, 1H, NHCH3), 2.51 
(s, 3H, NHCH3). 
13C-NMR (75.5 MHz, 
CDCl3): δ(ppm) 59.85 (CNHCH3), 34.33, 
34.22, 34.09, 34.05. IR (film): ν (cm-1) 3381, 
3321, 2919, 1697, 1415, 1264, 1188, 1129, 
1066, 1025, 951, 812, 685, 507, 429. HRMS 
calculated for C8H18NS3 (M + H)
+ 224.0596, 
found (M + H)+ 224.0596. 
  
139 Experimental 
5.2.2.3 Allyl-N-methyl-(1,4,7-trithiacyclo-
decan-9-y)carbamate (93) 
 
 
To a solution of 91 (271 mg, 
1.21 mmol) in methylene chloride (9 mL) at 
0 °C were added allyl chloroformiate (92) 
(194 µL, 1.82 mmol), pyridine (98 µL, 
1.21 mmol), and 4-dimethylaminopyridine 
(7 mg, 57 µmol) under a nitrogen atmo-
sphere. The resulting mixture solution was 
then allowed to warm up to ambient tempe-
rature slowly and stirred overnight. The solu-
tion was diluted with methylene chloride and 
washed with water (3 x 20 mL) and brine 
(3 x 20 mL). The organic layer was separat-
ed and dried using Na2SO4, filtered and 
concentrated to dryness in vacuo. The crude 
material was subjected to silica gel chroma-
tography using hexane : ethyl acetate 
(10:1  8:1). The product 93 (259 mg, 
844 µmol, 70%) was obtained as a pale oil. 
Rf = 0.47 (hexane : ethylacetate 3:1). 
1H-NMR (300 MHz, CDCl3): δ(ppm) 6.01-
5.88 (m, 1H, CCH2), 5.34-5.19 (m, 2H, 
CCH2), 4.60 (d, J = 5.5 Hz, 2H, CH2allyl), 
3.29-3.00 (m, 13H), 2.88 (s, 3H, NCH3). 
13C-NMR (75.5 MHz, CDCl3): δ(ppm) 71.0, 
70.5, 70.4, 38.4, 36.7, 34.1, 33.8, 33.1, 32.4 
IR (film): ν(cm-1) 2910, 1692, 1448, 1399, 
1321, 1266, 1231, 1198, 1145, 992, 928, 
768. HRMS calculated for C12H21NO2S3Na 
(M + Na)+ 330.0627, found (M + Na)+ 
330.0626. 
5.2.2.4 (R)-methyl pyrrolidine-2-carboxy-
late hydrochloride ((R)-102) 
 
 
(R)-pyrrolidine-2-carboxylic acid 
(2.00 g, 17.4 mmol) was suspended in 
methanol (25.0 mL) and thionylchloride 
(1.52 mL, 20.8 mmol) was added drop wise 
at 0 °C. The reaction mixture was refluxed 
for 18 h. The solvent was removed under 
reduced pressure and the residue resolved 
in methanol (10.0 mL) then concentrated 
again under reduced pressure. This proce-
dure was repeated three times. The product 
(R)-102 was obtained as white solid (2.91 g, 
17.6 mmol, quant.). Rf = 0.41 (methylene 
chloride : methanol 5:1). 1H-NMR (300 MHz, 
CD3OD): δ(ppm) 4.29 (s, 3H, OCH3), 3.89 
(m, 1H, CH), 2.90–2.78 (m, 2H), 1.98–1.80 
(m, 1H), 1.68–1.46 (m, 3H). 13C-NMR 
(75 MHz, CD3OD): δ(ppm) 170.47 (Ccarbonyl), 
60.67 (C), 53.94 (OCH3), 47.16 (C), 29.26 
(C), 24.49 (C). IR (film): v (cm
-1) 3396, 
2917, 2732, 2555, 1738, 1632, 1568, 1441, 
1389, 1356, 1287, 1234, 1091, 1042, 1002, 
918, 859, 658, 551, 459. HRMS calculated 
for C6H12NO2 (M + H
+) 180.0863 found 
(M + H+) 180.0863. 
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5.2.2.5 (S)-methyl pyrrolidine-2-carboxylate 
hydrochloride ((S)-102) 
 
 
(S)-pyrrolidine-2-carboxylic acid 
(5.00 g, 43.5 mmol) was suspended in 
methanol (50.0 mL) and thionylchloride 
(3.17 mL, 43.5 mmol) was added drop wise 
at 0 °C. The reaction mixture was refluxed 
for 16 h. The solvent was removed under 
reduced pressure and the residue resolved 
in methanol (10.0 mL) then concentrated 
again under reduced pressure. This proce-
dure was repeated three times. The product 
(S)-102 was obtained as white solid (6.95 g, 
42.0 mmol, 96%). Rf = 0.41 (methylene chlo-
ride : methanol 5:1). 1H-NMR (300 MHz, 
CD3OD): δ(ppm) 10.84 (s, 1H, NHH), 8.68 
(s, 1H, NHH), 4.39–4.23 (m, 1H, CH), 3.68 
(s, 3H, OCH3), 3.48–3.33 (m, 2H), 2.34–2.20 
(m, 1H), 2.07–1.81 (m, 3H). 13C-NMR 
(75 MHz, CD3OD): δ(ppm) 170.45 (Ccarbonyl), 
60.69 (C), 53.95 (OCH3), 47.19 (C), 29.27 
(C), 24.51 (C). IR (film): v (cm
-1) 3403, 
2952, 2731, 2551, 1739, 1632, 1569, 1443, 
1389, 1355, 1234, 1091, 1046, 1003, 918, 
862, 730. HRMS calculated for C6H12NO2 
(M + H+) 130.0863 found (M + H+) 130.0867. 
5.2.2.6 (R)-methyl 1-(pyridin-2-ylmethyl) 
pyrrolidine-2-carboxylate ((R)-104) 
 
 
Palladium on carbon (460 mg, 
0.4 mmol, 10 wt. %) was suspended in 
methanol (30.0 mL) and picolinaldehyde 
(103) (1.37 mL, 14.3 mmol) was added at 
0 °C. Sodium acetate (2.34 g, 28.6 mmol) 
was added to the reaction mixture. Then, 
(R)-102 (2.00 g, 14.3 mmol) was added. The 
reaction mixture was stirred for 1 h and the 
nitrogen atmosphere was completely sub-
stituted by hydrogen in three turns. The re-
action was continued for 16 h allowing the 
mixture to warm up to ambient temperature. 
The reaction mixture was filtrated over 
CELITE and the crude material was sub-
jected to column chromatography using 
methylene chloride :  methanol (35:1  
10:1). The product (R)-104 was obtained as 
a brown oil (1.92 g, 8.73 mmol, 61%). 
Rf = 0.45 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, CDCl3): δ(ppm) 
8.53 (dd, J = 4.8, 0.7 Hz, 1H, CHar-6), 7.65 
(td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.46 (d, J = 
7.8 Hz, 1H, CHar-3), 7.20 – 7.12 (m, 1H, 
CHar-5), 4.05 (d, J = 13.5 Hz, 1H, NCHH), 
3.79 (d, J = 13.5 Hz, 1H, NCHH), 3.66 (s, 
3H, OCH3), 3.49 – 3.33 (m, 1H, CH), 3.18 – 
3.03 (m, 1H), 2.54 (dd, J = 16.7, 7.9 Hz, 
1H), 2.26 – 2.09 (m, 1H), 2.05 – 1.72 (m, 
3H). 13C-NMR (75 MHz, CDCl3): δ(ppm) 
174.21 (Ccarbonyl), 158.24 (Car-2), 148.65 
(Car-6), 136.96 (Car-4), 123.83 (Car-3), 
122.41 (Car-5), 65.33 (NCH2), 59.76 (C), 
53.56 (OCH3), 51.87 (C), 29.33 (C), 23.24 
(C). IR (film): v (cm
-1) 3380, 3056, 2953, 
1665, 1628, 1590, 1570, 1529, 1474, 1435, 
1384, 1306, 1205, 1151, 1090, 1047, 995, 
927, 888, 824, 752. HRMS calculated for 
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C12H17N2O2 (M + H
+) 221,1285 found 
(M + H+) 221.1286. 
5.2.2.7 (S)-methyl 1-(pyridin-2-ylmethyl) 
pyrrolidine-2-carboxylate ((S)-104) 
 
 
Palladium on carbon (293 mg, 
0.25 mmol, 10 wt. %) was suspended in 
methanol (20.0 mL) and picolinaldehyde 
(103) (870 µL, 9.1 mmol) was added at 0 °C. 
Sodium acetate (1.5 g, 18.3 mmol) was 
added to the reaction mixture. Then, (S)-102 
(1.3 g, 9.1 mmol) was added. The reaction 
mixture was stirred for 1 h and the nitrogen 
atmosphere was completely substituted by 
hydrogen in three turns. The reaction was 
continued for 16 h allowing the mixture to 
warm up to ambient temperature. The reac-
tion mixture was filtrated over CELITE and 
the crude material was subjected to column 
chromatography using methylene chlo-
ride :  methanol (35:1  10:1). The product 
(S)-104 was obtained as a brown oil (1.83 g, 
8.31 mmol, 58%). Rf = 0.45 (methylene chlo-
ride : methanol 15:1). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 8.52 – 8.43 (m, 1H, CHar-6), 
7.59 (td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.39 
(d, J = 7.8 Hz, 1H, CHar-3), 7.09 (dd, J = 6.8, 
5.5 Hz, 1H, CHar-5), 3.99 (d, J = 13.5 Hz, 
1H, NCHH), 3.72 (d, J = 13.5 Hz, 1H, 
NCHH), 3.60 (s, 3H, OCH3), 3.36 – 3.27 (m, 
1H, CH), 3.11 – 2.99 (m, 1H), 2.47 (dd, J = 
16.7, 7.9 Hz, 1H), 2.20 – 2.03 (m, 1H), 1.99 
– 1.85 (m, 2H), 1.84 – 1.68 (m, 1H). 
13C-NMR (75 MHz, CDCl3): δ(ppm) 174.49 
(Ccarbonyl), 158.96 (Car-2), 149.01 (Car-6), 
136.39 (Car-4), 123.35 (Car-3), 122.01 
(Car-5), 65.38 (NCH2), 60.29 (C), 53.50 
(OCH3), 51.66 (C), 29.38 (C), 23.31 (C). 
IR (film): v (cm-1) 2952, 2877, 2814, 1735, 
1591, 1470, 1434, 1362, 1276, 1197, 1169, 
1089, 1041, 996, 929, 893, 836, 757, 698, 
622, 469, 403. 
5.2.2.8 (R)-1-(pyridin-2-ylmethyl)pyrrol-
idine-2-carboxylic acid ((R)-105) 
 
 
(R)-104 (2.40 g, 11.0 mmol) was 
suspended in sodium hydroxide (15.0 mL, 1 
M) at 0 °C and reacted for 18 h. The reaction 
mixture was washed with methylene chlo-
ride (5 x 20 ml). The combined aqueous 
layer was neutralised to pH 7 with hydro-
chloric acid (1 M). The aqueous layer was 
concentrated and the solvent removed un-
der reduced pressure. The residue was 
suspended in ethanol (10.00 mL) and filtrat-
ed via a syringe filter. The residue was dried 
in vacuo to obtain the product (R)-105 as a 
brown oil (2.06 g, 10.0 mmol, 91%). 
Rf = 0.05 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CD3OD): δ(ppm) 
8.21 (d, J = 4.8 Hz, 1H, CHar-6), 7.45 (td, J = 
7.7, 1.7 Hz, 1H, CHar-4), 7.13 (d, J = 7.8 Hz, 
1H, CHar-3), 7.01 (dd, J = 7.6, 4.9 Hz, 1H, 
CHar-5), 4.22 (d, J = 13.9 Hz, 1H, NCHH), 
4.09 (d, J = 13.9 Hz, 1H, NCHH), 3.37 – 
3.26 (m, 1H, CH), 2.93–2.77 (m, 1H), 2.15–
1.97 (m, 1H), 1.86–1.66 (m, 2H), 1.65–1.45 
(m, 1H). 13C-NMR (75 MHz, CD3OD): 
δ(ppm) 173.29 (Ccarbonyl), 152.36 (Car-2), 
150.84 (Car-6), 138.88 (Car-4), 125.38 
(Car-3), 125.32 (Car-5), 70.61 (NCH2), 59.78 
(C), 55.99 (C), 29.98 (C), 24.40 (C). IR 
(film): v (cm-1) 3374, 2982, 1620, 1440, 
1390, 1316, 1209, 1157, 1098, 1052, 996, 
928, 831, 76. HRMS calculated for 
C11H14N2O2Na (M + Na
+) 229.0947 found 
(M + Na+) 229.0946. 
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5.2.2.9 (S)-1-(pyridin-2-ylmethyl)pyrrol-
idine-2-carboxylic acid ((S)-105) 
 
 
(S)-104 (1.20 g, 5.5 mmol) were 
suspended in sodium hydroxide (7.08 mL, 
1 M) at 0 °C and reacted for 16 h. The reac-
tion mixture was washed with methylene 
chloride (3 x 20 ml). The combined aqueous 
layer was neutralised to pH 7 with hydro-
chloric acid (1 M). The aqueous layer was 
concentrated and the solvent removed un-
der reduced pressure. The residue was 
suspended in ethanol (10.00 mL) and filtrat-
ed via a syringe filter. The residue was dried 
in vacuo to obtain the product (S)-105 as 
brown oil (1.09 mg, 5.4 mmol, quant.). 
Rf = 0.05 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CD3OD): δ(ppm) 
8.63 (ddd, J = 4.9, 1.5, 0.9 Hz, 1H, CHar-6), 
7.87 (td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.52 
(d, J = 7.8 Hz, 1H, CHar-3), 7.42 (ddd, J = 
7.6, 4.9, 0.9 Hz, 1H, CHar-5), 4.59 (d, J = 
13.9 Hz, 1H, NCHH), 4.38 (d, J = 13.9 Hz, 
1H, NCHH), 4.01 (dd, J = 8.9, 6.2 Hz, 1H), 
3.72–3.62 (m, 1H), 3.22–3.11 (m, 1H), 2.53–
2.36 (m, 1H), 2.24–1.91 (m, 3H). 13C-NMR 
(75 MHz, CD3OD): δ(ppm) 173.35 (Ccarbonyl), 
151.96 (Car-2), 151.04 (Car-6), 138.85 (Car-
4), 125.38 (Car-3), 125.17 (Car-5), 70.57 
(NCH2), 59.78 (C), 55.99 (C), 29.98 (C), 
24.40 (C). IR (film): v (cm
-1) 3368, 2973, 
1675, 1479, 1435, 1395, 1301, 1215, 1151, 
997, 621, 571, 485, 401. HRMS calculated 
for C11H14N2O2Na (M + Na
+) 229.0947 found 
(M + Na+) 229.0946. 
5.2.2.10 (S)-methyl 2-methylpyrrolidine-2-
carboxylate hydrochloride ((S)-112) 
 
 
(S)-2-methylpyrrolidine-2-carboxylic 
acid ((S)-111) (550 mg, 4.26 mmol) was 
suspended in methanol (5.0 mL) and thio-
nylchloride (311 µL, 4.26 mmol) was added 
drop wise at 0 °C. The reaction mixture was 
refluxed for 16 h. The solvent was removed 
under reduced pressure and the residue 
resolved in methanol (15.0 mL) then con-
centrated again under reduced pressure. 
This procedure was repeated three times. 
The product (S)-112 was obtained as white 
solid (757 mg, 4.21 mmol, quant.). Rf = 0.27 
(meth¬ylene chloride : methanol 10:1). 
1H-NMR (300 MHz, CDCl3): δ(ppm) 10.56 
(s, 1H, NHH), 9.35 (s, 1H, NHH), 3.86 (s, 
3H, OCH3), 3.66–3.53 (m, 2H), 2.46–2.33 
(m, 1H), 2.22–1.95 (m, 3H), 1.86 (s, 3H, 
CH3). IR (film): v (cm
-1) 2882, 2682, 2624, 
2511, 2447, 1742, 1586, 1454, 1431, 1374, 
1319, 1293, 1239, 1210, 1173, 1121, 1049, 
978, 893, 863. 
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5.2.2.11 (S)-methyl 2-methyl-1-(pyridin-2-yl-
methyl)pyrrolidine-2-carboxylate 
((S)-113) 
 
 
Palladium on carbon (142 mg, 
0.13 mmol, 10 wt. %) was suspended in 
methanol (10.0 mL) and picolinaldehyde 
(103) (512 µL, 5.37 mmol) was added at 
0 °C. Sodium acetate (0.73 g, 8.96 mmol) 
was added to the reaction mixture. Then, 
(S)-112 (802 mg, 4.48 mmol) was added. 
The reaction mixture was stirred for 1 h and 
the nitrogen atmosphere was completely 
substituted by hydrogen in three turns. The 
reaction was continued for 16 h allowing the 
mixture to warm up to ambient temperature. 
The reaction mixture was filtrated over 
CELITE and the crude material was sub-
jected to column chromatography using 
methylene chloride :  methanol (35:1  
15:1). The product (S)-113 was obtained as 
a dark green oil (400 mg, 1.71 mmol, 38%). 
Rf = 0.65 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CDCl3): δ(ppm) 
8.48 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H, CHar-6), 
7.62 (td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.45 
(d, J = 7.8 Hz, 1H, CHar-3), 7.11 (ddd, J = 
7.3, 4.9, 1.0 Hz, 1H, CHar-5), 3.94 (d, J = 
14.4 Hz, 1H, NCHH), 3.71 (d, J = 13.4 Hz, 
1H, NCHH), 3.68 (s, 3H, OCH3), 2.95–2.84 
(m, 1H), 2.83–2.71 (m, 1H), 2.30–2.16 (m, 
1H), 1.90–1.74 (m, 3H), 1.38 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): δ(ppm) 175.77 
(Ccarbonyl), 160.40 (Car-2), 148.92 (Car-6), 
136.62 (Car-4), 122.65 (Car-3), 121.89 
(Car-5), 67.98 (NCH2), 55.76 (C), 51.81 
(OCH), 51.49 (C), 37.66 (CH3), 21.77 (C), 
21.59 (C). IR (film): v (cm
-1) 2973, 2950, 
2878, 2835, 1722, 1588, 1569, 1459, 1431, 
1372, 1361, 1307, 1256, 1189, 1169, 1120, 
1045, 993, 976, 896, 839, 756. HRMS cal-
culated for C13H19N2O2 (M + H
+) 235.1441 
found (M + H+) 235.1442. 
5.2.2.12 (S)-2-methyl-1-(pyridin-2-ylmethyl) 
pyrrolidine-2-carboxylic acid ((S)-
114) 
 
 
(S)-113 (360 mg, 1.5 mmol) were 
suspended in sodium hydroxide (2 mL, 1 M) 
at 0 °C and reacted for 18 h. The reaction 
mixture was washed with methylene chlo-
ride (3 x 20 ml). The combined aqueous 
layer was neutralised to pH 7 with hydro-
chloric acid (1 M). The aqueous layer was 
concentrated and the solvent removed un-
der reduced pressure. The residue was 
suspended in ethanol (5.00 mL) and filtrated 
via a syringe filter. The residue was dried in 
vacuo to obtain the product (S)-114 as a 
brown oil (308 mg, 1.4 mmol, 93%). 
Rf = 0.05 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CD3OD): δ(ppm) 
8.66 (ddd, J = 4.9, 1.5, 0.9 Hz, 1H, CHar-6), 
7.89 (td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.51 
(d, J = 7.8 Hz, 1H, CHar-3), 7.43 (dd, J = 7.4, 
5.0 Hz, 1H, CHar-5), 4.63 (d, J = 14.0 Hz, 
1H, NCHH), 4.29 (d, J = 14.0 Hz, 1H, 
NCHH), 3.70–3.64 (m, 1H), 3.23–3.05 (m, 
1H), 2.52–2.37 (m, 1H), 2.19–2.06 (m, 2H), 
2.03–1.86 (m, 1H), 1.65 (s, 3H, CH3). 
13C-NMR (75 MHz, CD3OD): δ(ppm) 175.70 
(Ccarbonyl), 152.74 (Car-2), 150.77 (Car-6), 
138.94 (Car-4), 125.21 (Car-3), 124.81 
(Car-5), 76.82 (NCH2), 55.58 (C), 54.80 
(C), 37.83 (CH3), 22.69 (C), 18.91 (C). IR 
(film): v (cm-1) 2959, 2926, 2756, 2128, 
1735, 1443, 1365, 1285, 1243, 1216, 1172, 
1074, 1031, 941, 829, 750. HRMS calculat-
ed for C12H17N2O2 (M + H
+) 221.1285 found 
(M + H+) 221.1285. 
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5.2.2.13 (2S,4R)-methyl 4-hydroxypyrrol-
idine-2-carboxylate hydrochloride 
((S,R)-116) 
 
 
(2S,4R)-4-hydroxypyrrolidine-2-carb-
oxylic acid ((S,R)-115) (10.00 g, 76.3 mmol) 
was suspended in methanol (88.0 mL) and 
thionylchloride (5.56 mL, 76.3 mmol) was 
added drop wise at 0 °C. The reaction mix-
ture was refluxed for 16 h. The solvent was 
removed under reduced pressure and the 
residue resolved in methanol (15.0 mL) then 
concentrated again under reduced pressure. 
This procedure was repeated three times. 
The product (S,R)-116 was obtained as 
white solid (13.85 g, 76.4 mmol, quant.). 
1H-NMR (300 MHz, (CD3)2SO): δ(ppm) 5.55 
(d, J = 3.0 Hz, 1H CH), 4.49 (dd, J = 10.8, 
7.6 Hz, 1H, CH), 4.42 (bs, 1H, OH), 3.76 (s, 
3H, OCH3), 3.08 (dt, J = 12.1, 1.4 Hz, 1H), 
2.24–2.02 (m, 3H). 13C-NMR (75 MHz, 
CD3OD): δ(ppm) 161.06 (Ccarbonyl), 61.09 
(C), 49.98 (C), 45.53 (C), 44.49 (OCH3), 
29.05 (C). IR (film): v (cm
-1) 3320, 2953, 
2857, 2696, 2599, 2566, 2449, 2418, 1737, 
1589, 1436, 1396, 1335, 1276, 1238, 1178, 
1073, 1025, 955, 927, 900, 865, 781, 743. 
HRMS calculated for C6H12NO3 (M + H
+) 
146.0812 found (M + H+) 146.0812. 
5.2.2.14 (2S,4R)-methyl 4-hydroxy-1-(pyri-
din-2-ylmethyl)pyrrolidine-2-carb-
oxylate ((S,R)-117) 
 
 
Palladium on carbon (2.43 g, 
2.29 mmol, 10 wt. %) was suspended in 
methanol (150.0 mL) and picolinaldehyde 
(103) (9.45 mL, 99.14 mmol) was added at 
0 °C. Sodium acetate (12.15 g, 152.5 mmol) 
was added to the reaction mixture. Then, 
(S,R)-116 (13.85 g, 76.26 mmol) was dis-
solved in methanol (60 mL) and then added 
to the reaction mixture. The reaction mixture 
was stirred for 1 h and the nitrogen atmos-
phere was completely substituted by hydro-
gen in three turns. The reaction was contin-
ued for 72 h allowing the mixture to warm up 
to ambient temperature. The reaction mix-
ture was filtrated over CELITE and the crude 
material was subjected to column chroma-
tography using methylene chloride :  meth-
anol (35:1  25:1). The product (S,R)-117 
was obtained as a brown oil (7.17 g, 
30.4 mmol, 40%). Rf = 0.41 (methylene chlo-
ride : methanol 10:1). 1H-NMR (300 MHz, 
CD3OD): δ(ppm) 8.11 (ddd, J = 5.0, 1.7, 0.8 
Hz, 1H, CHar-6), 7.31 (td, J = 7.7, 1.8 Hz, 
1H, CHar-4), 6.95 (d, J = 7.8 Hz, 1H, CHar-3), 
6.83 (ddd, J = 7.4, 5.0, 1.0 Hz, 1H, CHar-5), 
4.70 (bs, 1H, OH), 4.03 (dq, J = 7.2, 2.4 Hz, 
1H, CH) 3.81 (d, J = 15.7 Hz, 1H, NCHH), 
3.69 (d, J = 15.7 Hz, 1H, NCHH), 3.60–3.50 
(m, 1H, CH), 3.31 (s, 3H, OCH3) 3.17–3.08 
(m, 1H), 2.50 (ddd, J = 10.6, 2.2, 1.2 Hz, 
1H), 1.86–1.75 (m, 2H). 13C-NMR (75 MHz, 
CDCl3): δ(ppm) 174.57 (Ccarbonyl), 158.43 
(Car-2), 148.19 (Car-6), 137.17 (Car-4), 
123.45 (Car-3), 122.29 (Car-5), 70.87 (NCH2), 
62.83 (C), 61.28 (C), 56.88 (OCH3), 51.82 
(C), 40.17 (C). IR (film): v (cm
-1) 3359, 
  
145 Experimental 
2948, 2837, 1733, 1642, 1593, 1472, 1434, 
1355, 1270, 1199, 1086, 1047, 1002, 902, 
838, 757, 624. 
5.2.2.15 (2S,4R)-methyl 4-(tert-butyldimeth-
ylsilyloxy)-1-(pyridin-2-ylmethyl)pyr-
rolidine-2-carboxylate ((S,R)-118) 
 
 
(S,R)-117 (1.9 g, 8.04 mmol) was 
dissolved in dimethylformamide (30 mL) and 
diisopropylethylamine (7 mL, 40.20 mmol) 
was added over a period of 5 min. The reac-
tion mixture was stirred for 10 min at 0 °C 
prior to the addition of tert-butyldimethylsilyl 
triflate (7.7 mL, 8.85 mmol) and stirred for 
16 h. The reaction mixture was allowed to 
warm up to ambient temperature. The reac-
tion mixture was then reacted with ammoni-
um acetate solution (1 M, 40 mL) and the 
organic layer was separated. The aqueous 
layer was then extracted using methylene 
chloride (3 x 50 mL). The solvent was evap-
orated under reduced pressure and the 
crude material was subjected to column 
chromatography using methylene chlo-
ride : methanol (10:1). Rf = 0.70 (methylene 
chloride : methanol 10:1). The product 
(S,R)-118 was obtained as brown oil 
(1.28 g, 3.7 mmol, 46%). 1H-NMR 
(300 MHz, CDCl3): δ(ppm) 8.51 (ddd, J = 
4.9, 1.8, 0.9 Hz, 1H, CHar-6), 7.63 (td, J = 
7.6, 1.8 Hz, 1H, CHar-4), 7.43 (d, J = 7.8 Hz, 
1H, CHar-3), 7.13 (ddd, J = 7.4, 4.9, 1.1 Hz, 
1H, CHar-5), 4.49 – 4.31 (m, 1H, CH), 4.04 
(d, J = 13.7 Hz, 1H, NCHH), 3.80 (d, J = 
13.7 Hz, 1H, NCHH), 3.67 (dd, J = 6.5, 4.7 
Hz, 1H, CH), 3.63 (s, 3H, OCH3), 3.31 (dd, 
J = 9.8, 5.7 Hz, 1H, CHH), 2.47 (dd, J = 
9.8, 4.9 Hz, 1H, CHH), 2.23 – 2.11 (m, 1H, 
CHH), 2.03 (ddd, J = 12.7, 8.3, 4.1 Hz, 1H, 
CHH), 0.84 (s, 9H, SiCq(CH3)3), -0.00 (d, J 
= 5.1 Hz, 6H, Si(CH3)2). 
13C-NMR (75 MHz, 
CD3OD): δ(ppm) 174.25 (Ccarbonyl), 158.77 
(Car-2), 149.08 (Car-6), 136.56 (Car-4), 
123.45 (Car-3), 122.16 (Car-5), 70.76 (NCH2), 
64.55 (C), 62.11 (C), 60.93 (OCH3), 51.91 
(C), 39.67 (C), 25.61 (SiCq(CH3)3), 18.10 
(SiCq(CH3)3), -4.74 (Si(CH3)2). IR (film): v 
(cm-1) 2950, 2892, 2855, 1741, 1591, 1468, 
1435, 1366, 1252, 1198, 1170, 1096, 1036, 
905, 832, 771, 671. 
5.2.2.16 (2S,4R)-4-(tert-butyldimethylsilyl-
oxy)-1-(pyridin-2-ylmethyl)pyrrol-
idine-2-carboxylic acid ((S,R)-119) 
 
 
(S,R)-118 (1.27 g, 3.6 mmol) were 
suspended in sodium hydroxide (4.8 mL, 
1 M) at 0 °C and reacted for 18 h. The reac-
tion mixture was washed with methylene 
chloride (3 x 30 ml). The combined aqueous 
layer was neutralised to pH 7 with hydro-
chloric acid (1 M). The aqueous layer was 
concentrated and the solvent removed un-
der reduced pressure. The residue was 
suspended in ethanol (5.00 mL) and filtrated 
via a syringe filter. The residue was dried in 
vacuo to obtain the product (S,R)-119 as 
orange highly viscous oil (985 mg, 
2.92 mmol, 81%). Rf = 0.16 (methylene chlo-
ride : methanol 10:1). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 8.66 – 8.56 (m, 1H, CHar-6), 
8.50 (bs, 1H, COOH), 7.72 (td, J = 7.7, 1.7 
Hz, 1H, CHar-4), 7.37 (d, J = 7.7 Hz, 1H, 
CHar-3), 7.31 – 7.27 (m, 1H, CHar-5), 4.44 – 
4.42 (m, 1H, CH 4.43 (d, J = 14.4 Hz, 1H, 
NCHH), 4.27 (d, J = 14.5 Hz, 1H, NCHH), 
4.16 – 4.01 (m, 1H, CH), 3.60 (dd, J = 11.4, 
4.4 Hz, 1H, CHH), 2.93 (dd, J = 11.3, 2.0 
Hz, 1H, CHH), 2.32 (dt, J = 8.1, 4.1 Hz, 
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2H, CHH), 0.88 (s, 9H, (SiCq(CH3)3), 0.06 
(d, J = 4.5 Hz, 6H, (Si(CH3)2). 
13C-NMR 
(75 MHz, CDCl3): δ(ppm) 173.72 (Ccarbonyl), 
155.22 (CHar-2), 149.24 (CHar-6), 137.68 
(Car-4), 123.55 (Car-3), 123.49 (Car-5), 71.85 
(NCH2), 67.22 (C), 62.46 (C), 61.43 (C), 
39.39 (C), 25.88 (SiCq(CH3)3), 18.06 
(SiCq(CH3)3), -4.67 (Si(CH3)2). IR (film): v 
(cm-1) 2931, 2890, 2855, 1709, 1627, 1468, 
1437, 1385, 1252, 1214, 1101, 1029, 1000, 
886, 831, 769, 693, 668. 
5.2.2.17 (R)-methyl piperidine-2-carboxylate 
hydrochloride ((R)-121) 
 
 
(R)-piperidine-2-carboxylic acid 
((R)-120) (3.00 g, 23.2 mmol) was sus-
pended in methanol (30.0 mL) and thionyl-
chloride (1.69 mL, 23.2 mmol) was added 
drop wise at 0 °C. The reaction mixture was 
stirred for 16 h and warmed up to ambient 
temperature. The solvent was removed un-
der reduced pressure and the residue re-
solved in methanol (10.0 mL) then con-
centrated again under reduced pressure. 
This procedure was repeated three times. 
The product (R)-121 was obtained as white 
solid (4.16 g, 23.15 mmol, quant.). 1H-NMR 
(300 MHz, CD3OD): δ(ppm) 4.31 (s, 3H, 
OCH3), 3.53 (dd, J = 11.3, 3.5 Hz, 1H, CH), 
2.95–2.83 (m, 1H, CHH), 2.53 (td, J = 12.3, 
3.3 Hz, 1H, CHH), 1.74 (ddd, J = 9.3, 6.1, 
3.8 Hz, 1H, CHH), 1.40–1.31 (m, 1H, 
CHH), 1.26–1.11 (m, 4H, CHH CHH). 
13C-NMR (75 MHz, CD3OD): δ(ppm) 170.30 
(Ccarbonyl), 57.85 (C), 53.71 (OCH3), 45.20 
(C), 27.10 (C), 22.82 (C), 22.71 (C). IR 
(film): v (cm-1) 2919, 2802, 2680, 2564, 
2499, 2411, 1742, 1581, 1448, 1422, 1366, 
1340, 1275, 1211, 1131, 1052, 1038, 984, 
948, 917, 889, 754, 687, 534. HRMS calcu-
lated for C7H14NO2 (M + H
+) 144.1019 found 
(M + H+) 144.1020. 
5.2.2.18 (S)-methyl piperidine-2-carboxylate 
hydrochloride ((S)-121) 
 
 
(S)-piperidine-2-carboxylic acid 
((S)-120) (2.00 g, 15.48 mmol) was sus-
pended in methanol (20.0 mL) and thio-
nylchloride (1.13 mL, 15.48 mmol) was add-
ed drop wise at 0 °C. The reaction mixture 
was stirred for 16 h and warmed up to am-
bient temperature. The solvent was re-
moved under reduced pressure and the res-
idue resolved in methanol (10.0 mL) then 
concentrated again under reduced pressure. 
This procedure was repeated three times. 
The product (S)-121 was obtained as white 
solid (2.70 g, 15.07 mmol, 97%). 1H-NMR 
(300 MHz, CD3OD): δ(ppm) 4.09 – 3.98 (m, 
1H, CH), 3.85 (s, 3H, OCH3), 3.42 (d, J = 
11.9 Hz, 1H, CHH), 3.04 (t, J = 11.2 Hz, 
1H, CHH), 2.28 (d, J = 10.8 Hz, 1H), 1.98–
1.81 (m, 2H), 1.80–1.56 (m, 3H). 13C-NMR 
(75 MHz, CD3OD): δ(ppm) 170.24 (Ccarbonyl), 
57.83 (C), 53.72 (OCH3), 45.23 (C), 27.03 
(C), 22.75 (C), 22.68 (C). IR (film): v (cm
-1) 
2919, 2802, 2681, 2564, 2499, 2412, 1743, 
1581, 1449, 1422, 1366, 1340, 1275, 1211, 
1132, 1052, 1038, 984, 949, 918. HRMS 
calculated for C7H14NO2 (M + H
+) 144.1019 
found (M + H+) 144.1024. 
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5.2.2.19 2-(chloromethyl)pyridine (122) 
 
 
Pyridine-2-ylmethanol (11.3 g; 
103.5 mmol) were dissolved in Et2O (50 mL) 
and cooled to 0 °C under continuous stirring. 
Then, thionylchloride (8.26 mL, 13.5 g; 
113.5 mmol) was added drop wise under 
formation of a pink precipitation. The reac-
tion was continued for 16 h and the reaction 
mixture was allowed to warm up to ambient 
temperature. The solvent was evaporated 
unde reduced pressure and the residue was 
dried in vacuo to obtain the product as pink 
solid (14.79 g, 90 mmol, 87%). Rf = 0.67 
(methylene chloride : methanol 10:1). 
1H-NMR (300 MHz, CDClD3): δ(ppm) 8.74 
(d, J = 5.2 Hz, 1H, CHar-6), 8.40 (t, J = 7.7 
Hz, 1H, CHar-4), 8.05 (d, J = 8.0 Hz, 1H, 
CHar-3), 7.91 – 7.80 (m, 1H, CHar-5), 5.18 (s, 
2H, CH2Cl). 
13C-NMR (75 MHz, CDCl3): 
δ(ppm) 152.47 (Car-2), 145.83 (Car-6), 
141.33 (Car-4), 127.01 (Car-3), 126.14 
(Car-5), 39.85 (CH2Cl). IR (film): v (cm
-1) 
3094, 3039, 2304, 2056, 1983, 1863, 1609, 
1531, 1462, 1422, 1395, 1314, 1275, 1228, 
1160, 1063, 1035, 995, 957, 904, 820, 772, 
745, 685, 619. HRMS calculated for 
C6H7ClN (M + H
+) 128.0262 found (M + H+) 
128.0262. 
. 
5.2.2.20 (R)-methyl 1-(pyridin-2-ylmethyl)pi-
peridine-2-carboxylate ((R)-123) 
 
 
122 (1.31 g, 8.02 mmol) was dis-
solved in DMF (30 mL) and stirred with so-
dium carbonate (0.935 g, 8.8 mmol) and 
sodium iodide (57 mg, 0.38 mmol) at 50 °C 
for 2 h. (R)-121 (2.16 g, 12.02 mmol) was 
dissolved in DMF (15 mL) and added drop 
wise to the reaction mixture. The reaction 
was continued for 36 h. Water (50 mL) was 
added to the reaction mixture and the prod-
uct was extracted with methylene chloride 
(3 x 50 mL). The combined organic layer 
was concentrated under reduced pressure 
and dried in vacuo. The crude material was 
subjected to column chromatography using 
methylene chloride : methanol (100:0  
15:1). After evaporation of eluent solvent 
under reduced pressure, the residue was 
dried in vacuo to obtain the product as yel-
low oil (1.52 g, 6.49 mmol, 81%). Rf = 0.49 
(methylene chloride : methanol 15:1). 
1H-NMR (300 MHz, CDClD3): δ(ppm) 8.53 – 
8.45 (m, 1H, CHar-6), 7.61 (td, J = 7.6, 1.8 
Hz, 1H, CHar-4), 7.47 (d, J = 7.8 Hz, 1H, 
CHar-3), 7.11 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H, 
CHar-5), 3.87 (d, J = 14.1 Hz, 1H, NCHH), 
3.69 (s, 3H, OCH3), 3.57 (d, J = 14.1 Hz, 1H, 
NCHH), 3.24 (dd, J = 7.6, 4.4 Hz, 1H, CH), 
3.00 – 2.88 (m, 1H, CHH), 2.31 – 2.18 (m, 
1H, CHH), 1.93 – 1.74 (m, 2H, CHH), 
1.65 – 1.50 (m, 3H), 1.46 – 1.31 (m, 1H). 
13C-NMR (75 MHz, CDCl3): δ(ppm) 174.25 
(Ccarbonyl), 159.15 (Car-2), 149.07 (Car-6), 
136.45 (Car-4), 123.24 (Car-3), 122.01 
(Car-5), 64.44 (NCH2), 62.41 (C), 51.56 
(OCH3), 50.60 (C), 29.60 (C), 25.35 (C), 
22.37 (C). IR (film): v (cm
-1) 3008, 2936, 
2855, 1733, 1646, 1589, 1569, 1471, 1432, 
1368, 1340, 1281, 1265, 1191, 1164, 1146, 
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1127, 1106, 1060, 1048, 1009, 993, 969, 
921, 888, 866, 830, 803, 755, 729, 634, 612, 
590. HRMS calculated for C13H19N2O2 
(M + H+) 235.1441 found (M + H+) 235.1448. 
5.2.2.21 (S)-methyl 1-(pyridin-2-ylmethyl)pi-
peridine-2-carboxylate ((S)-123) 
 
 
122 (1.9 g, 12.06 mmol) was dis-
solved in DMF (25 mL) and stirred with so-
dium carbonate (2.6 g, 24.12 mmol) and 
sodium iodide (144 mg, 0.96 mmol) at 50 °C 
for 2 h. (S)-121 (2.6 g, 14.47 mmol) was 
dissolved in DMF (25 mL) and added drop 
wise to the reaction mixture. The reaction 
was continued for 36 h. Water (50 mL) was 
added to the reaction mixture and the prod-
uct was extracted with methylene chloride 
(3 x 50 mL). The combined organic layer 
was concentrated under reduced pressure 
and dried in vacuo. The crude material was 
subjected to column chromatography using 
methylene chloride : methanol (100:0  
15:1). After evaporation of eluent solvent 
under reduced pressure, the residue was 
dried in vacuo to obtain the product as yel-
low oil (2.16 g, 9.25 mmol, 77%). Rf = 0.49 
(methylene chloride : methanol 15:1). 
1H-NMR (300 MHz, CDClD3): δ(ppm) 8.45 
(ddd, J = 4.9, 1.7, 0.9 Hz, 1H, CHar-6), 7.58 
(td, J = 7.6, 1.8 Hz, 1H, CHar-4), 7.43 (d, J = 
7.8 Hz, 1H, CHar-3), 7.08 (ddd, J = 7.4, 4.9, 
1.1 Hz, 1H, CHar-5), 3.83 (d, J = 14.1 Hz, 
1H, NCHH), 3.65 (s, 3H, OCH3), 3.54 (d, J = 
14.1 Hz, 1H, NCHH), 3.20 (dd, J = 7.5, 4.4 
Hz, 1H, CH), 2.97 – 2.83 (m, 1H, CHH), 
2.27 – 2.14 (m, 1H, CHH), 1.85 – 1.72 (m, 
2H), 1.60 – 1.45 (m, 3H), 1.41 – 1.25 (m, 
1H). 13C-NMR (75 MHz, CDCl3): δ(ppm) 
174.17 (Ccarbonyl), 159.02 (Car-2), 148.92 
(Car-6), 136.41 (Car-4), 123.17 (Car-3), 
121.94 (Car-5), 64.36 (NCH2), 62.27 (C), 
51.49 (OCH3), 50.50 (C), 29.51 (C), 25.25 
(C), 22.29 (C). IR (film): v (cm
-1) 3006, 
2938, 2854, 1734, 1657, 1590, 1436, 1368, 
1271, 1164, 1054, 1008, 925, 891, 830, 798, 
756, 614. HRMS calculated for C13H19N2O2 
(M + H+) 235.1441 found (M + H+) 235.1442. 
5.2.2.22 (R)-1-(pyridin-2-ylmethyl)piperidine-
2-carboxylic acid ((R)-124) 
 
 
(R)-123 (300 g, 1.3 mmol) were sus-
pended in sodium hydroxide (1.7 mL, 1 M) at 
0 °C and reacted for 16 h. The reaction mix-
ture was washed with methylene chloride 
(3 x 10 ml). The combined aqueous layer 
was neutralised to pH 7 with hydrochloric 
acid (1 M). The aqueous layer was concen-
trated and the solvent removed under re-
duced pressure. The residue was suspend-
ed in ethanol (5.00 mL) and filtrated via a 
syringe filter. The residue was dried in vac-
uo to obtain the product (R)-124 as a yellow 
solid (283 mg, 1.28 mmol, quant.). Rf = 0.05 
(methylene chloride : methanol 10:1). 
1H-NMR (300 MHz, CD3OD): δ(ppm) 8.62 
(ddd, J = 4.9, 1.6, 0.8 Hz, 1H, CHar-6), 7.86 
(td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.57 (d, J = 
7.8 Hz, 1H, CHar-3), 7.41 (ddd, J = 7.6, 4.9, 
0.9 Hz, 1H, CHar-5), 4.63 (d, J = 13.8 Hz, 
1H, NCHH), 4.35 (d, J = 13.8 Hz, 1H, 
NCHH), 3.61 (dd, J = 10.1, 3.8 Hz, 1H, 
CH), 3.52 (dd, J = 12.4, 4.3 Hz, 1H, CHH), 
3.13–2.98 (m, 1H, CHH), 2.31–2.15 (m, 
1H, CHH), 2.07–1.90 (m, 1H, CHH), 
1.88–1.71 (m, 3H), 1.65–1.48 (m, 1H). 
13C-NMR (75 MHz, CD3OD): δ(ppm) 173.73 
(Ccarbonyl), 152.51 (Car-2), 150.65 (Car-6), 
138.82 (Car-4), 126.14 (Car-3), 125.20 
(Car-5), 68.24 (NCH2), 60.11 (C), 52.74 (C), 
28.43 (C), 23.37 (C), 22.62 (C). HRMS 
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calculated for C12H17N2O2 (M + H
+) 221.1285 
found (M + H+) 221.1284. 
5.2.2.23 (S)-1-(pyridin-2-ylmethyl)piperidine-
2-carboxylic acid ((S)-124) 
 
 
(S)-123 (300 g, 1.3 mmol) were sus-
pended in sodium hydroxide (1.7 mL, 1 M) at 
0 °C and reacted for 16 h. The reaction mix-
ture was washed with methylene chloride 
(3 x 10 ml). The combined aqueous layer 
was neutralised to pH 7 with hydrochloric 
acid (1 M). The aqueous layer was concen-
trated and the solvent removed under re-
duced pressure. The residue was suspend-
ed in ethanol (5.00 mL) and filtrated via a 
syringe filter. The residue was dried in vac-
uo to obtain the product (S)-124 as a yellow 
solid (283 mg, 1.28 mmol, quant.). Rf = 0.05 
(methylene chloride : methanol 10:1). 
1H-NMR (300 MHz, CD3OD): δ(ppm) 8.62 
(ddd, J = 4.9, 1.6, 0.8 Hz, 1H, CHar-6), 7.86 
(td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.57 (d, J = 
7.8 Hz, 1H, CHar-3), 7.41 (ddd, J = 7.6, 4.9, 
0.9 Hz, 1H, CHar-5), 4.63 (d, J = 13.8 Hz, 
1H, NCHH), 4.35 (d, J = 13.8 Hz, 1H, 
NCHH), 3.61 (dd, J = 10.1, 3.8 Hz, 1H, 
CH), 3.52 (dd, J = 12.4, 4.3 Hz, 1H, CHH), 
3.13–2.98 (m, 1H, CHH), 2.31–2.15 (m, 
1H, CHH), 2.07–1.90 (m, 1H, CHH), 
1.88–1.71 (m, 3H), 1.65–1.48 (m, 1H). 
13C-NMR (75 MHz, CD3OD): δ(ppm) 173.73 
(Ccarbonyl), 152.51 (Car-2), 150.65 (Car-6), 
138.82 (Car-4), 126.14 (Car-3), 125.20 
(Car-5), 68.24 (NCH2), 60.11 (C), 52.74 (C), 
28.43 (C), 23.37 (C), 22.62 (C). HRMS 
calculated for C12H17N2O2 (M + H
+) 221.1285 
found (M + H+) 221.1284. 
5.2.2.24 2,6-bis(bromomethyl)pyridine (142) 
 
 
Phosphoryl bromide (3.6 g, 
12.5 mmol) was melted at 60 °C turning the 
brown crystalline solid into a brown clear 
liquid. 2,6-Pyridinedimethanol (141) 
(100 mg, 0.72 mmol) was added drop wise 
at 70 °C and the reaction mixture turned into 
dark brown. The reaction was continued for 
1.5 h at 70° C. Distilled water (6 mL) was 
added carefully drop wise at 0 °C. The reac-
tion mixture was poured into ice and neutral-
ised using sodium hydroxide (2 M). The 
aqueous layer was extracted with methylene 
chloride (4 x 30 mL), dried over sodium sul-
fate, filtrated and concentrated in vacuo. 
The product 142 was obtained as white 
needles (188 mg, 0.71 mmol, 98%). 
Rf = 0.75 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CDCl3): δ(ppm) 
7.71 (t, J = 7.8 Hz, 1H, CHar-4), 7.38 (d, J = 
7.7 Hz, 2H, CHar-3 & CHar-5), 4.54 (s, 4H, 
2xCH2Br). 
13C-NMR (75.5 MHz, CDCl3): 
δ(ppm) 156.85 (2C, Car-2 & Car-6), 138.34 
(Car-4), 122.96 (2C, (Car-3 & Car-5), 33.42 
(2C, 2xCH2Br). IR (film): ν(cm
-1) 2962, 1568, 
1448, 1260, 1204, 1158, 1081, 1020, 954, 
865, 809, 744, 585, 548. HRMS calculated 
for C7H8Br2N (M + H)
+ 265.9003, found 
(M + H)+ 265.9008. 
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5.2.2.25 2,5,8-Trithia-{9}(2,6)pyridinophane 
(144) 
 
 
Caesium carbonate (430 mg, 
1.32 mmol) was suspended in dimethyl-
formamide (75 mL) at 60 °C. A homogene-
ous solution of 142 (316 mg, 1.20 mmol) 
and 2,2-Bis(2-mercaptoethyl) sulfide (143) 
(156 µL, 1.20 mmol) dissolved in dimethyl-
formamide (75 mL) were added drop wise 
via a syringe pump over a period of 18 h. 
The reaction was continued for 2 h. The 
solvent was evaporated under reduced 
pressure and the residual yellow oil was 
suspended in water (25 mL) and methylene 
chloride (40 mL). After sonification the crude 
product was extracted with methylene chlo-
ride (4 x 50 mL). The combined organic lay-
er was washed with BRINE (2 x 30 mL), dried 
over sodium sulfate and concentrated under 
reduced pressure. The crude material was 
subjected to column chromatography using 
hexane : ethylacetate (10:1). The product 
144 was obtained a white solid (88 mg, 
0.34 mmol, 28 %). Rf = 0.50 (hexane : ethyl-
acetate 10:1). 1H-NMR (300 MHz, CDCl3): 
δ(ppm) 7.77 (t, J = 7.5 Hz, 1H, CHar-4), 7.39 
(d, J = 7.7 Hz, 2H, CHar-3 & CHar-5), 3.98 (s, 
4H, Car-2CH2 & Car-6CH2), 2.56 (s, 8H, 
4xCH2). 
13C-NMR (75 MHz, CDCl3): δ(ppm) 
157.65 (2C, Car-2 & Car-6), 138.59 (Car-4), 
122.17 (2C, Car-3 & Car-5) 36.35 (2C, Car-
2CH2 & Car-6CH2) 31.14 (2C, Car-2CH2SCH2 & 
Car-6CH2 SCH2), 30.16 (2C, CH2SCH2). IR 
(film): v (cm-1) 2924, 2097, 2039, 1966, 
1580, 1565, 1446, 1424, 1275, 1202, 1153, 
1131, 1078, 1023, 991, 967, 911, 859, 813, 
749. HRMS calculated for C11H15NS3Na 
(M + Na+) 280.0264 found (M + Na+) 
280.0262. 
5.2.2.26 2,11-dithia[3.3](2,6)pyridinophane 
(146) 
 
 
142 (495 mg, 1.86 mmol) and thio-
acetamide (140 mg, 1.86 mmol) were dis-
solved in dimethylformamide (9.5 mL) in 
separated syringes. Lithium carbonate 
(275 mg, 3.72 mmol) was suspended in di-
methylformamide (30 mL) and stirred at 
55 °C. Over a period of 30 min 142 as well 
as thioacetamide were added drop wise 
simultaneously. The reaction was continued 
for 2 h at 55 °C. The solvent was evapo-
rated under reduced pressure and the resi-
due was dissolved in water (50 mL). The 
turbid suspension was neutralised with hy-
drochloric acid (10% aq.). The aqueous lay-
er was extracted using chloroform 
(4 x 50 mL). The combined organic layer 
was dried over sodium sulfate, filtrated and 
concentrated under reduced pressure. The 
crude material was subjected to column 
chromatography using methylene chlo-
ride : methanol (30:1  8:1). The product 
146 was obtained as yellow highly viscous 
oil (102 mg, 0.37 mmol, 20 %). Rf = 0.13 
(hexane : ethylacetate 3:1). 1H-NMR (300 
MHz, (CD3)2SO): δ(ppm) 7.87–7.13 (m, 6H, 
6xCHar), 4.05–3.77 (m, 8H, 4xCH2). HRMS 
calculated for C14H15N2S2 (M + H)
+ 
275.0677, found (M + H)+ 275.0670. 
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5.2.2.27 2,2'-(ethane-1,2-diylbis(sulfane-
diyl))diethanethiol (149) 
 
 
2,2'-(ethane-1,2-diylbis(sulfanediyl)) 
diethanol (147) (3.98 g, 21.8 mmol), thio-
urea (148) (3.35 g, 4.40 mmol) were added 
in hydroboric acid (7.50 mL, 132 mmol, 47% 
aq.) and refluxed for 8.5 h. The yellow solu-
tion was cooled to ambient temperature and 
sodium hydroxide (5.28 g, 132 mmol) in wa-
ter (30 mL) was added slowly. A white pre-
cipitate was observed and the reaction mix-
ture was refluxed for 16 h. After cooling to 
ambient temperature, the reaction mixture 
was neutralised using hydrochloric acid. The 
aqueous layer was extracted with methylene 
chloride (3 x 100 mL). The combined organ-
ic layer was dried over sodium sulfate, fil-
trated and dried in vacuo. The product 149 
was obtained as highly viscous pale oil 
(1.96 g, 9.17 mmol, 42 %). 1H-NMR (300 
MHz, CDCl3): δ(ppm) 2.89-2.68 (m, 12H, 
6xCH2), 1.76-1.70 (m, 2H, SH). 
5.2.2.28 1,4,7,10-tetrathiacyclododecane 
(151) 
 
 
Caesium carbonate (1.14 g, 
3.50 mmol) suspended in DMF (100 mL) 
was heated to 50 °C. A homogeneous solu-
tion of 149 (519 mg, 2.42 mmol) and 1,2-di-
bromoethane (150) (208 µL, 2.24 mmol) 
dissolved in DMF (50 mL) was added drop 
wise over a period of 12 h at 50 °C via a 
syringe pump. The reaction was continued 
for an additional 2 h and then cooled to am-
bient temperature over a period of 16 h. The 
solvent was evaporated under reduced 
pressure, water (50 mL) and methylene 
chloride (75 mL) was added to the residue 
and the mixture was stirred for 30 min at 
ambient temperature. Both layers were sep-
arated and the aqueous layer was extracted 
using methylene chloride (2 x 50 mL). The 
combined organic layer was washed with 
BRINE (3 x 50 mL), dried over sodium sul-
fate, filtrated and concentrated under re-
duced pressure. The crude material was 
recrystallised using chloroform. The product 
151 was obtained as white crystals (58 mg, 
0.24 mmol, 10%). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 2.72 (s, 16H, 8xCH2). 
13C-NMR (75 MHz, CDCl3): δ(ppm) 28.82 
(8C). HRMS calculated for C8H16S4Na 
(M + Na+) 263.0033 found (M + Na+) 
263.0027. 
5.2.2.29 (S)-methyl 2-aminopropanoate hy-
drochloride ((S)-162) 
 
 
(S)-2-aminopropanoic acid ((S)-155) 
(5.00 g, 56.1 mmol) was suspended in 
methanol (50.0 mL) and thionylchloride 
(4.09 mL, 56.1 mmol) was added drop wise 
at 0 °C. The reaction mixture was refluxed 
for 16 h. The solvent was removed under 
reduced pressure and the residue resolved 
in methanol (25.0 mL) then concentrated 
again under reduced pressure. This proce-
dure was repeated three times. The product 
(S)-162 was obtained as white solid (7.90 g, 
56.6 mmol, quant.). 1H-NMR (300 MHz, 
MeOD3): δ(ppm) 4.32 (s, 3H, OCH3), 3.59 
(q, J = 7.2 Hz, 1H, CH), 1.02 (d, J = 7.2 Hz, 
3H, CH3). 
13C-NMR (75 MHz, CD3OD): 
δ(ppm) 171.41 (Ccarbonyl), 53.69 (OCH3), 
49.85 (C), 16.18 (C). IR (film): v (cm
-1) 
2957, 2895, 2736, 2698, 2605, 1739, 1599, 
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1474, 1383, 1336, 1232, 1212, 1113, 1009, 
976, 902, 840. 
5.2.2.30 (R)-methyl 2-aminopropanoate hy-
drochloride ((R)-162) 
 
 
(R)-2-aminopropanoic acid ((R)-155) 
(1.79 g, 20.1 mmol) was suspended in 
methanol (20.0 mL) and thionylchloride 
(1.47 mL, 20.1 mmol) was added drop wise 
at 0 °C. The reaction mixture was refluxed 
for 16 h. The solvent was removed under 
reduced pressure and the residue resolved 
in methanol (15.0 mL) then concentrated 
again under reduced pressure. This proce-
dure was repeated three times. The product 
(R)-162 was obtained as white solid (2.83 g 
20.2 mmol, quant.). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 4.37–4.15 (m, 1H, CH), 
3.81 (s, 3H, OCH3), 1.73 (d, J = 7.3 Hz, 3H, 
CH). 
13C-NMR (75 MHz, CD3OD): δ(ppm) 
171.40 (Ccarbonyl), 53.70 (OCH3), 49.87 (C), 
16.18 (C). IR (film): v (cm
-1) 2956, 2897, 
2816, 2783, 2736, 2695, 2607, 2491, 2003, 
1741, 1601, 1570, 1477, 1435, 1392, 1374, 
1339, 1234, 1214, 1184, 1137, 1114, 1013, 
976, 902. 
5.2.2.31 (S)-methyl 2-amino-3-phenylpro-
panoate hydrochloride ((S)-163) 
 
 
(S)-2-amino-3-phenylpropanoic acid 
((S)-156) (10.00 g, 60.5 mmol) was sus-
pended in methanol (70 mL). SOCl2 (4.8 mL, 
66.6 mmol) was added drop wise at 0 °C 
over a period of 30 min. The reaction mix-
ture was stirred for an additional hour at 
0 °C then refluxed for 28 h. The solvent was 
evaporated under reduced pressure and the 
residue was resolved in methanol (15.0 mL) 
then concentrated again under reduced 
pressure. This procedure was repeated 
three times. The product (S)-163 was ob-
tained as white solid (12.9 g, 59.8 mmol, 
quant.). Rf = 0.67 (methylene chloride : me-
thanol 15:1). 1H-NMR (300 MHz, CD3OD): 
δ(ppm) 7.41-7.25 (m, 5H, 5xCHar), 4.33 (dd, 
1H, J = 6.3, 7.3 Hz, CH), 3.80 (s, 3H, 
OCH3), 3.27 (dd, 1H, J = 6.2, 14.4 Hz, 
CHH), 3.18 (dd, 1H, J = 7.3, 14.4 Hz, 
CHH). 
13C-NMR (75 MHz, CD3OD): δ(ppm) 
170.39 (Ccarbonyl), 135.36 (Car-1), 130.49 (2C, 
Car-3 & Car-5), 130.13 (2C, Car-2 & Car-6), 
128.96 (Car-4), 55.25 (C), 53.58 (OCH3), 
37.34 (C). IR (film): v (cm
-1) 3386, 2956, 
2519, 2030, 1743, 1627, 1525, 1502, 1446, 
1387, 1289, 1243, 1151, 1081, 1053, 994, 
944, 910, 852, 811, 750, 699, 590, 475. 
HRMS calculated for C10H14NO2 (M + H
+) 
180.1025 found (M + H+) 180.1019. 
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5.2.2.32 (S)-methyl 2-amino-3-(1H-imidazol-
4-yl)propanoate dihydrochloride 
((S)-164) 
 
 
(S)-2-amino-3-(1H-imidazol-4-yl)pro-
panoic acid ((S)-157) (10 g, 64.5 mmol) was 
dissolved in methanol (60.0 mL) and thionyl-
chloride (5.14 mL, 70.9 mmol) was added 
dropwise at 0 °C. The reaction mixture was 
refluxed for 18 h. The solvent was removed 
under reduced pressure and the residue 
resolved in methanol (20.0 mL) then con-
centrated again under reduced pressure. 
This procedure was repeated three times. 
The product (S)-164 was obtained as a 
beige solid (15.4 g, 63.7 mmol, 98.8 %). 
Rf = 0.40 (methylene chloride : methanol 
7:3). 1H-NMR (300 MHz, (CD3)2SO): δ(ppm) 
9.08 (d, J = 1.3 Hz, 1H, CHar-2), 7.52 (d, J = 
1.1 Hz, 1H, CHar-5), 4.48 (t, J = 6.9 Hz, 1H, 
CH), 3.73 (s, 3H, OCH3) 3.31 (m, 2H, 
CH2). 
13C-NMR (75 MHz, (CD3)2SO): 
δ(ppm) 168.5 (Ccarbonyl), 134.0 (Car-2), 126.6 
(Car-4), 118.0 (Car-5), 53.0 (C), 51.0 
(OCH3), 25.0 (C). IR (film): v (cm
-1) 3112, 
2971, 2920, 2879, 2772, 2679, 2552, 1757, 
1624, 1599, 1514, 1458, 1433, 1290, 1256, 
1146, 1079, 1065, 987, 832, 817, 718, 621, 
537, 408. 
5.2.2.33 (S)-methyl 2-amino-4-methylpent-
anoate hydrochloride ((S)-165) 
 
 
(S)-2-amino-4-methylpentanoic acid 
((S)-158) (5.00 g, 38.11 mmol) was sus-
pended in methanol (45.0 mL) and thionyl-
chloride (2.78 mL, 38.11 mmol) was added 
drop wise at 0 °C. The reaction mixture was 
refluxed for 18 h. The solvent was removed 
under reduced pressure and the residue 
resolved in methanol (15.0 mL) then con-
centrated again under reduced pressure. 
This procedure was repeated three times. 
The product (S)-165 was obtained as a 
white solid (6.78 g, 37.3 mmol, 98%.). 
Rf = 0.27 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CD3OD): δ(ppm) 
4.07–4.00 (m, 1H, CH), 3.84 (s, 3H, OCH3), 
1.84–1.72 (m, 2H, CH2), 1.69–1.62 (m, 1H, 
CH), 1.00 (dd, J = 6.2, 3.4 Hz, 6H, 
CH(CH3)2). 
13C-NMR (75 MHz, CD3OD): 
δ(ppm) 171.33 (Ccarbonyl), 53.65 (C, 52.55 
(OCH3), 40.62 (C, 25.56 (C, 22.51 (C, 
22.43 (C’. 
5.2.2.34 (S)-methyl 2-amino-3-methylbutan-
oate hydrochloride ((S)-167) 
 
 
(S)-2-amino-3-methylbutanoic acid 
(S)-160 (1.17 g, 10.0 mmol) was dissolved 
in methanol (15.0 mL) at 0 °C and thionyl-
chloride (726 µL, 10.0 mmol) was added 
drop wise over a period of 15 min. The reac-
tion mixture was stirred for 2 h at ambient 
temperature and then refluxed for 8 h. The 
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solvent was removed under reduced pres-
sure and the residue resolved in methanol 
(50.0 mL) then concentrated again under 
reduced pressure. This procedure was re-
peated three times and then dried in vacu-
uo. The product (S)-167 was obtained as a 
white solid (1.68 g, 10.0 mmol, quant.). 
Rf = 0.44 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, CD3OD): δ(ppm) 
4.91 (m, 3H, NH3Cl), 3.94 (d, J = 4.4 Hz, 1H, 
CH), 3.85 (s, 3H, OCH3), 2.35-2.25 (m, 1H, 
CH), 1.07 (dd, J = 6.8, 2.8 Hz, 6H, 
CH(CH3)2). 
13C-NMR (75 MHz, CD3OD): 
δ(ppm) 170.4 (Ccarbonyl), 59.4 (C, 53.4 
(OCH3), 31.0 (C, 18.4 (C, 18.2 (C’. 
5.2.2.35 (S)-methyl 2-amino-3-(4-hydroxy-
phenyl)propanoate hydrochloride 
((S)-168) 
 
 
(S)-2-amino-3-(4-hydroxyphenyl) 
propanoate ((S)-161) (10.00 g, 55.2 mmol) 
was suspended in methanol (60 mL). SOCl2 
(4.4 mL, 60.7 mmol) was added drop wise at 
0 °C over a period of 30 min. The reaction 
mixture was stirred for an additional hour at 
0 °C then refluxed for 16 h. The solvent was 
evaporated under reduced pressure and the 
residue was resolved in methanol (15.0 mL) 
then concentrated again under reduced 
pressure. This procedure was repeated 
three times. The product (S)-168 was ob-
tained as white solid (12.6 g, 54.7 mmol, 
quant.). Rf = 0.42 (methylene chloride : me-
thanol 15:1). 1H-NMR (300 MHz, CD3OD): 
δ(ppm) 7.08 (d, 2H, J = 8.6 Hz, CHar-2 & 
CHar-6), 6.79 (d, 2H, J = 8.5 Hz, CHar-3 & 
CHar-5), 4.25 (dd, 1H, J = 6.1, 7.1 Hz, CH), 
3.81 (s, 3H, OCH3), 3.17 (dd, 1H, J = 6.0, 
14.5 Hz, CHH), 3.09 (dd, 1H, J = 7.2, 14.5 
Hz, CHH). 
13C-NMR (75 MHz, CD3OD): 
δ(ppm) 170.51 (Ccarbonyl), 158.36 (Car-4), 
131.53 (Car-1), 125.60 (2C, Car-2 & Car-6), 
116.89 (2C, Car-3 & Car-5), 55.42 (C, 53.54 
(OCH3), 36.59 (C. IR (film): v (cm
-1) 3209, 
3015, 2954, 1742, 1610, 1513, 1445, 1379, 
1239, 1142, 1113, 1054, 988, 942, 897, 833, 
729, 635, 553, 513. HRMS calculated for 
C10H14NO3 (M + H
+) 196.0974 found 
(M + H+) 196.0968. 
5.2.2.36 (S)-methyl 2-(pyridin-2-ylmethyl-
amino)propanoate ((S)-169) 
 
 
Palladium on carbon (1.70 g, 
1.67 mmol, 10 wt. %) was suspended in 
methanol (120.0 mL) and picolinaldehyde 
(103) (6.39 mL, 67.0 mmol) was added at 
0 °C. Sodium acetate (9.15 g, 111.6 mmol) 
was added to the reaction mixture. Then, 
(S)-162 (7.80 g, 55.8 mmol) was dissolved 
in methanol (45 mL) and then added to the 
reaction mixture. The reaction mixture was 
stirred for 1 h and the nitrogen atmosphere 
was completely substituted by hydrogen in 
three turns. The reaction was continued for 
72 h allowing the mixture to warm up to am-
bient temperature. The reaction mixture was 
filtrated over CELITE and the crude material 
was subjected to column chromatography 
using methylene chloride :  methanol (35:1 
 20:1). The product (S)-169 was obtained 
as a brown oil (7.08 g, 36.4 mmol, 65%). 
Rf = 0.51 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CDCl3): δ(ppm) 
8.56 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H, CHar-6), 
7.67 (td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.35 
(d, J = 7.8 Hz, 1H, CHar-3), 7.19 (dd, J = 7.1, 
5.3 Hz, 1H, CHar-5), 4.03 (d, J = 14.2 Hz, 
1H, NCHH), 3.96 (d, J = 14.3 Hz, 1H, 
NCHH), 3.74 (s, 3H, OCH3), 3.63–3.54 (m, 
1H, CH), 1.45 (d, J = 7.0 Hz, 3H, CH3). 
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13C-NMR (75 MHz, CDCl3): δ(ppm) 175.01 
(Ccarbonyl), 158.09 (Car-2), 149.30 (Car-6), 
136.84 (Car-4), 122.54 (Car-3), 122.42 (Car-
5), 56.19 (NCH2), 52.62 (C, 52.14 (OCH3), 
18.49 (C. IR (film): v (cm
-1) 2985, 2948, 
1733, 1677, 1591, 1435, 1374, 1202, 1151, 
1038, 992, 915, 729, 616, 530, 471, 404. 
HRMS calculated for C10H15N2O2 (M + H
+) 
195.1128 found (M + H+) 195.1128. 
5.2.2.37 (R)-methyl 2-(pyridin-2-ylmethyl-
amino)propanoate ((R)-169) 
 
 
Palladium on carbon (637 mg, 
0.6 mmol, 10 wt. %) was suspended in 
methanol (45.0 mL) and picolinaldehyde 
(103) (2.29 mL, 24.07 mmol) was added at 
0 °C. Sodium acetate (3.29 g, 40.12 mmol) 
was added to the reaction mixture. Then, 
(R)-162 (2.80 g, 20.06 mmol) was added. 
The reaction mixture was stirred for 1 h and 
the nitrogen atmosphere was completely 
substituted by hydrogen in three turns. The 
reaction was continued for 72 h allowing the 
mixture to warm up to ambient temperature. 
The reaction mixture was filtrated over 
CELITE and the crude material was subject-
ed to column chromatography using meth-
ylene chloride :  methanol (35:1  20:1). 
The product (R)-169 was obtained as a 
brown oil (2.21 g, 11.3 mmol, 57%). 
Rf = 0.51 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CDCl3): δ(ppm) 
8.56 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H, CHar-6), 
7.66 (td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.35 
(d, J = 7.8 Hz, 1H, CHar-3), 7.22–7.16 (m, 
1H, CHar-5), 4.02 (d, J = 14.1 Hz, 1H, 
NCHH), 3.95 (d, J = 14.1 Hz, 1H, NCHH), 
3.74 (s, 3H, OCH3), 3.57 (q, J = 7.0 Hz, 1H, 
CH), 1.45 (d, J = 7.0 Hz, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): δ(ppm) 175.79 
(Ccarbonyl), 159.28 (Car-2), 149.41 (Car-6), 
136.55 (Car-4), 122.26 (Car-3), 122.10 
(Car-5), 56.37 (NCH2), 53.27 (C, 51.92 
(OCH3), 19.03 (C. IR (film): v (cm
-1) 2978, 
2951, 1731, 1591, 1570, 1472, 1433, 1373, 
1331, 1197, 1150, 1093, 1068, 1046, 994, 
976, 851, 753, 656, 626, 529, 469, 403. 
5.2.2.38 (S)-methyl 3-phenyl-2-(pyridin-2-yl-
methylamino)propanoate ((S)-170) 
 
 
Palladium on carbon (2.39 g, 
2.26 mmol, 10 wt. %) was suspended in 
methanol (160.0 mL) and picolinaldehyde 
(7.2 mL, 75.28 mmol) was added at 0 °C. 
Sodium acetate (10.2 g, 125.46 mmol) was 
added to the reaction mixture. Then, (S)-163 
(13.53 g, 62.73 mmol) was added. The reac-
tion mixture was stirred for 1 h and the ni-
trogen atmosphere was completely sub-
stituted by hydrogen in three turns. The 
reaction was continued for 22 h allowing the 
mixture to warm up to ambient temperature. 
The reaction mixture was filtrated over 
CELITE and the crude material was sub-
jected to column chromatography using 
methylene chloride :  methanol (35:1). The 
product (S)-170 was obtained as a brown oil 
(14.58 g, 53.95 mmol, 86%). Rf = 0.39 
(methylene chloride : methanol 15:1). 
1H-NMR (300 MHz, CD3OD): δ(ppm) 8.42 
(d, J = 4.8 Hz, 1H, CHar-6), 7.72 (ddd, J = 
9.4, 7.8, 1.7 Hz, 1H, CHar-4), 7.33 (d, J = 8.0 
Hz, 1H, CHar-3), 7.30-7.16 (m, 6H, CHar-5, 
CHar-2’-5’), 3.91 (d, J = 14.5 Hz, 1H, 
NCHH), 3.84 (d, 1H, J = 14.5 Hz, NCHH), 
3.60 (s, 3H, OCH3), 3.54 (t, 1H, J = 7.2 Hz, 
CH), 2.97 (d, 2H, J = 7.3 Hz, CH2), 1.97 (s, 
1H, NH). 13C-NMR (75 MHz, CD3OD): 
δ(ppm) 175.66 (Ccarbonyl), 160.18 (Car-2), 
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149.58 (Car-6), 138.61 (Car-4), 138.51 
(Car-1’), 130.31 (2C, Car-3’ & Car-5’), 129.41 
(2C, Car-2’ & Car-6’), 127.73 (Car-4’), 123.82 
(Car-3), 123.62 (Car-5), 63.59 (NCH2), 53.56 
(C, 52.16 (OCH3), 40.29 (C. IR (film): v 
(cm-1) 3322, 3060, 3026, 2948, 2848, 1732, 
1593, 1435, 1362, 1264, 1200, 1170, 1076, 
996, 753, 700, 621, 528, 490, 405. HRMS 
calculated for C16H19N2O2 (M + H
+) 271.1441 
found (M + H+) 271.1441. 
5.2.2.39 (S)-methyl 4-methyl-2-(pyridin-2-yl-
methylamino)pentanoate ((S)-171) 
 
 
Palladium on carbon (1.55 g, 
1.46 mmol, 10 wt. %) was suspended in 
methanol (50.0 mL) and picolinaldehyde 
(103) (5.59 mL, 58.7 mmol) was added at 
0 °C. Sodium acetate (8.02 g, 82.1 mmol) 
was added to the reaction mixture. Then, 
(S)-165 (6.78 g, 37.8 mmol) was added. The 
reaction mixture was stirred for 1 h and the 
nitrogen atmosphere was completely substi-
tuted by hydrogen in three turns. The reac-
tion was continued for 72 h allowing the mix-
ture to warm up to ambient temperature. 
The reaction mixture was filtrated over 
CELITE and the crude material was subject-
ed to column chromatography using meth-
ylene chloride :  methanol (50:1  25:1). 
The product (S)-171 was obtained as a 
brown oil (4.88 g, 20.65 mmol, 55%). 
Rf = 0.62 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CDCl3): δ(ppm) 
8.54 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H, CHar-6), 
7.65 (td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.35 
(d, J = 7.8 Hz, 1H, CHar-3), 7.17 (dd, J = 7.0, 
5.4 Hz, 1H, CHar-5), 3.98 (d, J = 14.2 Hz, 
1H, NCHH), 3.85 (d, J = 14.2 Hz, 1H, 
NCHH), 3.72 (s, 3H, OCH3), 3.42 (t, J = 7.2 
Hz, 1H, CH), 1.83–1.71 (m, 1H, CH), 1.58 
(td, J = 7.1, 3.0 Hz, 2H, CH2), 0.95–0.84 
(m, 6H, CH(CH3)2). 
13C-NMR (75 MHz, 
CDCl3): δ(ppm) 176.10 (Ccarbonyl), 159.56 
(Car-2), 149.31 (Car-6), 136.48 (Car-4), 
122.24 (Car-3), 122.05 (Car-5), 59.76 (NCH2), 
53.60 (C, 51.74 (OCH3), 42.82 (C, 25.00 
(C, 22.83 (C, 22.37 (C'. IR (film): v 
(cm-1) 2953, 2869, 1732, 1590, 1570, 1468, 
1433, 1385, 1367, 1330, 1308, 1269, 1230, 
1194, 1149, 1046, 992, 826, 754. 
5.2.2.40 (S)-methyl 3-hydroxy-2-(pyridin-2-
ylmethylamino)propanoate 
((S)-172) 
 
 
Palladium on carbon (258 mg, 
0.23 mmol, 10 wt. %) was suspended in 
methanol (17.0 mL) and picolinaldehyde 
(103) (767 µL, 8.17 mmol) was added at 
0 °C. Sodium acetate (1.32 g, 16.02 mmol) 
was added to the reaction mixture. Then, 
(S)-methyl 2-amino-3-hydroxypropanoate 
hydrochloride ((S)-166) (1.25 g, 8.17 mmol) 
dissolved in methanol (8.5 mL) was added. 
The reaction mixture was stirred for 1 h and 
the nitrogen atmosphere was completely 
substituted by hydrogen in three turns. The 
reaction was continued for 16 h allowing the 
mixture to warm up to ambient temperature. 
The reaction mixture was filtrated over 
CELITE and the crude material was sub-
jected to column chromatography using 
methylene chloride :  methanol (50:1  
10:1). The product (S)-172 was obtained as 
a yellow oil (1.03 g, 4.8 mmol, 58%). 
Rf = 0.41 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CDCl3): δ(ppm) 
8.57 (ddd, J = 4.9, 1.6, 0.9 Hz, 1H, CHar-6), 
7.68 (td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.31 
(d, J = 7.8 Hz, 1H, CHar-3), 7.22 (dd, J = 7.0, 
5.4 Hz, 1H, CHar-5), 4.13 (d, J = 14.7 Hz, 
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1H, NCHH), 4.01 (d, J = 14.7 Hz, 1H, 
NCHH), 3.89 (d, J = 4.1 Hz, 1H, CH), 3.80 
(d, J = 6.0 Hz, 1H, CHH), 3.76 (s, 3H, 
OCH3), 3.60 (dd, J = 6.0, 4.0 Hz, 1H, 
CHH). IR (film): v (cm
-1) 3315, 2951, 2874, 
1732, 1659, 1593, 1571, 1472, 1434, 1367, 
1335, 1199, 1175, 1149, 1061, 1048, 995, 
836, 756. HRMS calculated for C10H15N2O3 
(M + H+) 211.1083 found (M + H+) 211.1078. 
5.2.2.41 (S)-methyl 3-methyl-2-(pyridin-2-
ylmethylamino)butanoate ((S)-173) 
 
 
Palladium on carbon (200 mg, 
0.19 mmol, 10 wt. %) was suspended in 
methanol (15.0 mL) and picolinaldehyde 
(103) (908 µL, 9.5 mmol) was added at 0 °C. 
Sodium acetate (1.56 g, 19.0 mmol) was 
dissolved in methanol (15.0 mL) and added 
to the reaction mixture. Then, (S)-167 
(1.60 g, 9.5 mmol) presolved in methanol 
(10 mL) was added. The reaction mixture 
was stirred for 30 min and the nitrogen at-
mosphere was completely substituted by 
hydrogen in three turns. The reaction was 
continued for 5 h allowing the mixture to 
warm up to ambient temperature. The reac-
tion mixture was filtrated over CELITE, dried 
over sodium sulfate, filtrated and concen-
trated under reduced pressure. The crude 
material was subjected to column chroma-
tography using methylene chloride :  metha-
nol (35:1). The product (S)-173 was ob-
tained as a yellow oil (510 mg, 2.3 mmol, 
24%). Rf = 0.46 (methylene chloride : me-
thanol 35:1). 1H-NMR (300 MHz, CDCl3): 
δ(ppm) 8.53 (d, J = 4.9 Hz, 1H, CHar-6), 7.64 
(td, J = 7.7 Hz, 1.8 Hz, 1H, CHar-4), 7.38 (d, 
J = 7.8 Hz, 1H, CHar-3), 7.15 (dd, J = 7.4 Hz, 
5.4 Hz, 1H, CHar-5), 3.97 (d, J = 14.2 Hz, 
1H, NCHH), 3.78 (d, J = 14.2 Hz, 1H, 
NCHH), 3.71 (s, 3H, OCH3), 3.10 (dd, J = 
6.1 Hz, 1.3 Hz, 1H, CH), 2.01-1.94 (m, 1H, 
CH), 0.97 (dd, J = 10.4, 6.9 Hz, 6H, 
CH(CH3)2). 
13C-NMR (75 MHz, CDCl3): 
δ(ppm) 175.2 (Ccarbonyl), 159.5 (Car-2), 149.2 
(Car-6), 137.4 (Car-4), 126.6 (Car-3), 122.1 
(Car-5), 67.1 (NCH2), 54.0 (C, 51.6 (OCH3), 
31.7 (C, 19.3 (C, 18.9 (C'. IR (film): v 
(cm-1) 2960, 2876, 1730, 1685, 1591, 1516, 
1465, 1434, 1367, 1238, 1192, 1147, 1044, 
994, 896, 757, 699, 619, 469, 409. HRMS 
calculated for C12H18N2O2Na (M + Na
+) 
245.1266 found (M + Na+) 245.1270. 
5.2.2.42 (S)-methyl 3-(4-hydroxyphenyl)-2-
(pyridin-2-ylmethylamino)propa-
noate ((S)-174) 
 
 
Palladium on carbon (2.15 g, 
2.03 mmol, 10 wt. %) was suspended in 
methanol (100.0 mL) and picolinaldehyde 
(103) (6.4 mL, 67.6 mmol) was added at 
0 °C. Sodium acetate (9.23 g, 112.52 mmol) 
was added to the reaction mixture. Then, 
(S)-168 (13.05 g, 56.33 mmol) dissolved in 
methanol (70 mL) was added drop wise. 
The reaction mixture was stirred for 1 h and 
the nitrogen atmosphere was completely 
substituted by hydrogen in three turns. The 
reaction was continued for 16 h allowing the 
mixture to warm up to ambient temperature. 
The reaction mixture was filtrated over 
CELITE and the crude material was subject-
ed to column chromatography using meth-
ylene chloride :  methanol (35:1). The prod-
uct (S)-174 was obtained as a beige solid 
(10.66 g, 37.23 mmol, 66%). Rf = 0.35 
(methylene chloride : methanol 15:1). 
1H-NMR (300 MHz, CD3OD): δ(ppm) 8.43 
(d, J = 4.2 Hz, 1H, CHar-6), 7.74 (ddd, J = 
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9.2, 7.7, 1.5 Hz, 1H, CHar-4), 7.34 (d, J = 7.9 
Hz, 1H, CHar-3), 7.27 (dd, J = 5.4, 6.7 Hz, 
1H, CHar-5), 6.98 (d, J = 8.5 Hz, 2H, CHar-2’ 
& CHar-6’), 6.69 (d, J = 8.5 Hz, 2H, CHar-3’ & 
CHar-5’), 3.90 (d, J = 14.3 Hz, 1H, NCHH), 
3.75 (d, J = 14.5 Hz, 1H, NCHH), 3.61 (s, 
3H, (OCH3), 3.48 (t, J = 6.9 Hz, 1H, CH), 
2.88 (d, J = 7.9 Hz, 2H, CH2). 
13C-NMR 
(75 MHz, CD3OD): δ(ppm) 175.94 (Ccarbonyl), 
160.27 (Car-2), 157.34 (Car-4’), 149.63 
(Car-6), 138.58 (Car-4), 131.28 (Car-1’), 
129.09 (2C, Car-2’ & Car-6’), 123.94 (Car-3), 
123.67 (Car-5), 116.22 (2C, Car-3’ & Car-5’), 
63.85 (NCH2), 53.64 (C, 52.13 (OCH3), 
39.54 (C. IR (film): v (cm
-1) 3319, 3014, 
2947, 2852, 2680, 2597, 1731, 1595, 1513, 
1438, 1368, 1236, 1203, 1170, 1049, 1001, 
826, 759, 632, 551, 526, 491, 405. HRMS 
calculated for C16H19N2O3 (M + H
+) 287.1396 
found (M + H+) 287.1390. 
5.2.2.43 (S)-2-(pyridin-2-ylmethylamino) 
propanoic acid ((S)-175) 
 
 
(S)-169 (1.63 g, 8.4 mmol) was sus-
pended in sodium hydroxide solution (1 M, 
16.8 mL) and stirred for 16 h at 0 °C. The 
reaction mixture was neutralised with hydro-
chlorid acid (2 M) and extracted with meth-
ylene chloride (3 x 50 mL). The aqueous 
layer was concentrated and the solvent 
evaporated under reduced pressure. The 
residue was suspended in ethanol (25 mL) 
and filtrated over CELITE. The orange col-
oured filtrate was concentrated and and 
dried in vacuuo to provide the product 
(S)-175 as brown oil (605 mg, 3.36 mmol, 
40%). Rf = 0.85 (methylene chloride : me-
thanol 15:1). 1H-NMR (300 MHz, CD3OD): 
δ(ppm) 8.63-8.59 (m, 1H, CHar-6), 7.89-7.81 
(m, 1H, CHar-4), 7.46 (d, J = 7.9 Hz, 1H, 
CHar-3), 7.39-7.28 (m, 1H, CHar-5) 4.29 (d, J 
= 14.5 Hz, 1H, NCHH), 4.20 (d, J = 14.6 Hz, 
1H, NCHH), 4.01 (d, J = 7.7 Hz, 1H, CH), 
1.49 (d, J = 7.2 Hz, 3H, CH3). HRMS calcu-
lated for C9H13N2O2 (M + H
+) 181.0972 
found (M + H+) 181.0973. 
5.2.2.44 (R)-2-(pyridin-2-ylmethylamino) 
propanoic acid ((R)-175) 
 
 
(R)-169 (530 g, 2.73 mmol) were 
suspended in sodium hydroxide (3.40 mL, 
1 M) at 0 °C and reacted for 18 h. The reac-
tion mixture was washed with methylene 
chloride (3 x 10 ml). The combined aqueous 
layer was neutralised to pH 7 with hydro-
chloric acid (1 M). The aqueous layer was 
concentrated and the solvent removed un-
der reduced pressure. The residue was 
suspended in ethanol (5.00 mL) and filtrated 
via a syringe filter. The residue was dried in 
vacuo to obtain the product (R)-175 as a 
yellow oil (262 mg, 1.09 mmol, 40%). 
Rf = 0.85 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, CD3OD): δ(ppm) 
8.52 (ddd, J = 4.9, 1.6, 0.8 Hz, 1H, CHar-6), 
7.79 (td, J = 7.7, 1.8 Hz, 1H, CHar-4), 7.45 
(d, J = 7.8 Hz, 1H, CHar-3), 7.30 (ddd, J = 
7.5, 5.0, 1.0 Hz, 1H, CHar-5), 3.96 (d, J = 
13.8 Hz, 1H, NCHH), 3.85 (d, J = 13.9 Hz, 
1H, NCHH), 3.24 (q, J = 6.9 Hz, 1H, CH), 
1.34 (d, J = 7.0 Hz, 3H, CH3). 
13C-NMR 
(75 MHz, CD3OD): δ(ppm) 181.78 (Ccarbonyl), 
159.80 (Car-2), 150.03 (Car-6), 138.51 
(Car-4), 124.04 (Car-3), 123.69 (Car-5), 59.81 
(C), 53.60 (OCH3), 19.31 (C). IR (film): v 
(cm-1) 3307, 3056, 2975, 2931, 2844, 1572, 
1470, 1430, 1397, 1358, 1281, 1147, 1093, 
1053, 995, 826, 754, 675, 623, 540. HRMS 
calculated for C9H13N2O2+ (M + H
+) 
181.0972 found (M + H+) 181.0972. 
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5.2.2.45 (S)-3-phenyl-2-(pyridin-2-ylmethyl-
amino)propanoic acid ((S)-176) 
 
 
(S)-170 (3.05 g, 11.28 mmol) was 
suspended in sodium hydroxide (15 mL, 
1 M aq.) and cooled to 0 °C. After 18 h the 
aqueous layer was extracted with methylene 
chloride (3 x 5 mL). The aqueous layer was 
then neutralised using hydrochloric acid 
(1 M aq.). The solvent was evaporated under 
reduced pressure. The residue was sus-
pended in ethanol (10.00 mL) by sonifica-
tion. The suspension was filtrated using a 
syringe filter and the filtrate was concentrat-
ed in vacuo. The product (S)-176 was ob-
tained as brown solid (2.29 g, 8.93 mmol, 
80%). Rf = 0.10 (methylene chloride : me-
thanol 35:1). IR (film): v (cm-1) 3372, 3059, 
2928, 2855, 1587, 1434, 1391, 1267, 1148, 
1104, 1053, 1000, 896, 732, 698, 622, 547, 
499, 404. HRMS calculated for C15H17N2O2 
(M + H+) 257.1285 found (M + H+) 257.1285. 
5.2.2.46 (S)-4-methyl-2-(pyridin-2-ylmethyl-
amino)pentanoic acid ((S)-177) 
 
 
(S)-171 (2.22 g, 9.40 mmol) were 
suspended in sodium hydroxide (12 mL, 
1 M) at 0 °C and reacted for 18 h. The reac-
tion mixture was washed with methylene 
chloride (3 x 20 ml). The combined aqueous 
layer was neutralised to pH 7 with hydro-
chloric acid (1 M). The aqueous layer was 
concentrated and the solvent removed un-
der reduced pressure. The residue was 
suspended in ethanol (10.00 mL) and filtrat-
ed via a syringe filter. The residue was dried 
in vacuo to obtain the product (S)-177 as a 
yellow oil (1.94 g, 8.74 mmol, 93%). 
Rf = 0.08 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CD3OD): δ(ppm) 
8.57 – 8.53 (m, 1H, CHar-6), 7.82 (td, J = 
7.7, 1.8 Hz, 1H, CHar-4), 7.47 (d, J = 7.8 Hz, 
1H, CHar-3), 7.34 (dd, J = 7.1, 5.3 Hz, 1H, 
CHar-5), 4.20 (d, J = 14.5 Hz, 1H, NCHH), 
4.07 (d, J = 14.5 Hz, 1H, NCHH), 3.39 (t, J = 
7.1 Hz, 1H, CH), 1.94–1.79 (m, 1H, CH), 
1.75–1.51 (m, 2H, CH2), 0.97 (d, J = 6.5 
Hz, 3H, CH3), 0.93 (d, J = 6.6 Hz, 3H, 
CH3'). 
13C-NMR (75 MHz, CD3OD): δ(ppm) 
177.80 (Ccarbonyl), 156.50 (Car-2), 150.11 
(Car-6), 138.60 (Car-4), 124.26 (Car-3), 
124.08 (Car-5), 63.13 (NCH2), 52.48 (C), 
42.60 (C), 26.15 (C), 23.03 (C), 22.99 
(C'). IR (film): v (cm
-1) 2952, 2867, 1733, 
1581, 1467, 1434, 1396, 1207, 1149, 1121, 
1040, 997, 928, 815, 755, 679, 628, 546, 
487. 
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5.2.2.47 (S)-3-methyl-2-(pyridin-2-ylmethyl-
amino)butanoic acid ((S)-178) 
 
 
(S)-173 (460 mg, 2.07 mmol) were 
suspended in sodium hydroxide solution 
(1 M, 4.14 mL, aq.) at 0 °C and stirred at 
ambient temperature for 16 h. The reaction 
mixture was neutralised with hydrochloric 
acid (2 M) and the solvent was evaporated 
under reduced pressure. The pale solid was 
suspended in ethanol (25 mL) and filtrated 
over CELITE. The filtrate was dried in vacuuo 
to provide the product (S)-178 as a yellow 
solid (420 mg, 2.02 mmol, 98%). Rf = 0.85 
(methylene chloride : methanol 15:1). 
1H-NMR (300 MHz, CD3OD): δ(ppm) 8.63 
(d, J = 4.6 Hz, 1H, CHar-6), 7.85 (td, J = 7.7, 
1.8 Hz, 1H, CHar-4), 7.47-7.38 (m, 2H, 
CHar-3 & CHar-5), 4.40 (d, J = 15.0 Hz, 1H, 
NCHH), 4.30 (d, J = 15.0 Hz, 1H, NCHH), 
3.43 (d, J = 3.9 Hz, 1H, CH), 2.29 (m, 1H, 
CH), 1.10 (t, 6H, J = 6.9 Hz, CH(CH3)2). IR 
(film): v (cm-1) 3089, 2800, 2257, 1986, 
1921, 1574, 1474, 1434, 1396, 1357, 1283, 
1137, 1093, 1064, 1000, 880, 850, 817, 756, 
679, 625, 545, 478, 437, 414. HRMS calcu-
lated for C11H17N2O2 (M + H
+) 209.1285 
found (M + H+) 209.1287. 
5.2.2.48 (R)-methyl 2-amino-2-phenyl-
acetate hydrochloride ((R)-180) 
 
 
(R)-2-amino-2-phenylacetic acid 
((R)-179) (5.00 g, 33.1 mmol) was suspend-
ed in methanol (30.0 mL) and thionylchloride 
(2.40 mL, 33.1 mmol) was added drop wise 
at 0 °C. The reaction mixture was refluxed 
for 18 h. The solvent was removed under 
reduced pressure and the residue resolved 
in methanol (10.0 mL) then concentrated 
again under reduced pressure. This proce-
dure was repeated three times. The product 
(R)-180 was obtained as white solid (6.05 g, 
30 mmol, quant.). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 7.49 (m, 5H, CHar-2-5), 5.19 
(s, 1H, CH), 3.81 (s, 3H, OCH3). 
13C-NMR 
(75 MHz, CDCl3): δ(ppm) 170.1 (Ccarbonyl), 
133.3 (Car-1), 131.2 (2C, Car-2 & Car-6), 
130.6 (2C, Car-3 & Car-5), 129.1 (Car-4), 57.5 
(C), 53.9 (OCH3). IR (film): v (cm
-1) 2959, 
2839, 2697, 2625, 1736, 1568, 1501, 1456, 
1432, 1361, 1384, 1239, 1179, 1142, 1054, 
1027, 960, 920, 885, 726, 690, 588, 497. 
HRMS calculated for C9H12N1O2 (M + H
+) 
166.0863 found (M + H+) 166.0865. 
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5.2.2.49 (R)-methyl 2-phenyl-2-(pyridin-2-
ylmethylamino)acetate ((R)-181) 
 
 
Palladium on carbon (1.06 g, 
1.00 mmol, 10 wt. %) was suspended in 
methanol (70.0 mL) and picolinaldehyde 
(103) (2.62 mL, 40.2 mmol) was added at 
0 °C. Sodium acetate (2.85 g, 67.0 mmol) 
was dissolved in methanol (30.0 mL ) and 
added to the reaction mixture. Then, (R)-180 
(6.75 g, 33.5 mmol) was added. The reac-
tion mixture was stirred for 30 min and the 
nitrogen atmosphere was completely substi-
tuted by hydrogen in three turns. The reac-
tion was continued for 16 h allowing the mix-
ture to warm up to ambient temperature. 
The reaction mixture was filtrated over 
CELITE and the crude material was subject-
ed to column chromatography using meth-
ylene chloride :  methanol (35:1). The prod-
uct (R)-181 was obtained as a brown oil 
(3.63 g, 14.2 mmol, 42.3%). Rf = 0.10 
(methylene chloride : methanol 35:1). 
1H-NMR (300 MHz, CDCl3): δ(ppm) 8.56 (d, 
J = 5.0 Hz, 1H, CHar-6), 7.68 (m, 1H, 
CHar-4), 7.44-7.34 (m, 7H, CHar-3, CHar-5, 
CHar-2’-6’), 4.63 (s, 1H, CHa), 3.81-3.98 (m, 
2H, NHCH2), 3.72 (s, 3H, OCH3), 2.08 (s, 
1H, NH). 
5.2.2.50 (R)-2-phenyl-2-(pyridin-2-ylmethyl-
amino)acetic acid ((R)-182) 
 
 
(R)-181 (1.00 g, 3.90 mmol) were 
suspended in sodium hydroxide (4.90 mL, 1 
M) at 0 °C and reacted for 18 h. The reaction 
mixture was washed with methylene chlo-
ride (3 x 20 ml). The combined aqueous 
layer was neutralised to pH 7 with hydro-
chloric acid (1 M). The aqueous layer was 
concentrated and the solvent removed un-
der reduced pressure. The residue was 
suspended in ethanol (8.00 mL) and filtrated 
via a syringe filter. The residue was dried in 
vacuo to obtain the product (R)-182 as a 
yellow solid (940 mg, 3.87 mmol, quant.). 
1H-NMR (300 MHz, CD3OD): δ(ppm) 8.55 
(d, J = 4.8 Hz, 1H, CHar-6), 7.83-7.77 (dt, J = 
7.7, 1.8 Hz, 1H, CHar-4), 7.51-7.48 (m, 2H, 
CHar-3 & CHar-5), 7.42-7.32 (m, 5H, 5xCHar), 
4.49 (s, 1H, CH), 4.35-4.01 (m, 2H, NCH2). 
13C-NMR (75 MHz, CD3OD): δ(ppm) 174.7 
(Ccarbonyl), 155.7 (Car-2), 150.2 (Car-6), 138.6 
(Car-3), 137.6 (Car-1’), 129.8 (2C, Car-2’ & 
Car-6’), 129.6 (2C, Car-3’ & Car-5’), 124.3 
(Car-4’), 124.1 (Car-5), 67.7 (NCH2), 51.5 
(C). IR (film): v (cm
-1) 3377, 3058, 2836, 
1589, 1569, 1473, 1454, 1434, 1382, 1361, 
1262, 1191, 1150, 997, 746, 696, 611, 508. 
HRMS calculated for C14H15N2O2 (M + H
+) 
243.1128 found (M + H+) 243.1131. 
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5.2.2.51 (S)-tert-butyl 4-(2-(tert-butoxycarbo-
nylamino)-3-methoxy-3-oxopropyl)-
1H-imidazole-1-carboxylate hydro-
chloride ((S)-183) 
 
 
(S)-164 (15.4 g, 63.7 mmol) was dis-
solved in methanol (70.0 mL) and di-tert-
butyl dicarbonate (27.8 g, 127 mmol) pre-
solved in methanol (10.0 mL) was added 
drop wise. Then, triethylamine was added 
drop wise under extensive stirring at 0 °C. 
The reaction was proceeded for 16 h and 
warmed up to ambient temperature. The 
entire reaction mixture was poured into wa-
ter (100 mL) and then extracted with meth-
ylene chloride (3 x 100 mL). The combined 
organic layer was dried over sodium sulfate, 
filtrated and concentrated under reduced 
pressure. The crude material was subjected 
to column chromatography using dieth-
yl ether : ethylacetate (3:1  ethylacetate). 
The product (S)-183 was obtained as white 
solid (16.6 g, 45.1 mmol, 70.7%). Due to 
protonation and deprotonation a second 
fraction of the product was obtained as col-
ourless oil (3.45 g, 8.50 mmol, 13.4%). 
Rf = 0.29 (diethylether : hexane 3:1). 
1H-NMR (300 MHz, (CD3)2SO): δ(ppm) 8.12 
(d, J = 1.1 Hz, 1H, NH), 7.31-7.20 (m, 2H, 
CHar-2 & CHar-5), 4.24 (m, 1H, CH), 3.62 (s, 
3H, OCH3), 2.83 (m, 2H, CH2), 1.55 (s, 9H, 
OCq(CH3)3), 1.34 (s, 9H, OCq(CH3)3). 
13C-NMR (75 MHz, (CD3)2SO): δ(ppm) 172.3 
(COOMe), 155.2 (CNHCOOtBu), 146.6 
(NarCOOtBu), 138.9 (Car-2), 136.7 (Car-5), 
114.4 (Car-4), 85.1 (NarCOOCq(CH3)3), 78.3 
(NHCOOCq(CH3)3), 53.0 (C), 51.8 (OCH3), 
29.4 (C), 28.0 (NHCOOCq(CH3)3), 27.3 
(NarCOOCq(CH3)3). IR (film): v (cm
-1) 3248, 
3128, 2982, 1739, 1702, 1578, 1527, 1504, 
1484, 1388, 1366, 1334, 1300, 1274, 1255, 
1227, 1155, 1130, 973, 839, 772, 755, 706, 
603, 554. HRMS calculated for 
C17H27N3O6Na (M + Na
+) 399.1792 found 
(M + H+) 399.1800. 
5.2.2.52 (S)-methyl 2-(tert-butoxycarbonyl-
amino)-3-(1H-imidazol-4-yl)propa-
noate ((S)-184) 
 
 
(S)-183 (16.6 g, 44.7 mmol) was dis-
solved in methanol (65.0 mL) and potassium 
carbonate (617 mg, 4.47 mmol) was added. 
The reaction mixture was refluxed and the 
end of the reaction was monitored via TLC. 
The entire mixture was cooled to ambient 
temperature and poured into water (80 mL) 
and extracted with ethyl acetate (3 x 80 mL). 
The combined organic layer was dried over 
sodium sulfate, filtrated and concentrated 
under reduced pressure. The product 
(S)-184 was obtained as a white solid 
(10.1 g, 37.5 mmol, 84.1%). Rf = 0.81 
(methylene chloride : methanol 7:3). 
1H-NMR (300 MHz, (CD3)2SO): δ(ppm) 11.8 
(s, 1H, NarH), 7.54 (s, 1H, CHar-2), 7.17 (d, J 
= 7.3 Hz, 1H, CHar-5), 6.80 (s, 1H, 
NHCOOtBu), 4.25-4.18 (m, 1H, CH), 3.58 
(s, 3H, OCH3), 2.84 (m, 2H, CH2), 1.35 (s, 
9H, OCq(CH3)3). IR (film): v (cm
-1) 3384, 
3153, 3131, 2985, 2956, 2935, 1736, 1696, 
1561, 1517, 1451, 1420, 1367, 1308, 1255, 
1218, 1155, 1113, 1071, 1057, 1041, 984, 
850, 761, 619, 541, 463, 422. HRMS calcu-
lated for C12H20N3O4 (M + H
+) 270.1448 
found (M + H+) 270.1452. 
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5.2.2.53 (S)-methyl 3-(pyridin-2-ylmethyl)ox-
azolidine-4-carboxylate ((S)-185) 
 
 
(S)-172 (1.00 g, 4.75 mmol) was dis-
solved in methylene chloride (45 mL) at 
0 °C. Trifluoroacetic acid (366 µL, 
4.75 mmol, 0.1 N) was added drop wise fol-
lowed by water (45 mL). Under extensive 
stirring formaldehyde (705 µL, 7.12 mmol, 
37% aq.) was added drop wise to the reac-
tion mixture. The reaction was continued for 
16 h at ambient temperature. The solvent 
was evaporated under reduced pressure 
and the crude material subjected to column 
chromatography using methylene chlo-
ride : methanol (35:1). After drying in vacuo 
(S)-185 was obtained as yellow oil (760 mg, 
3.72 mmol, 72%). Rf = 0.65 (methylene chlo-
ride : methanol 10:1). 1H-NMR (300 MHz, 
CDCl3): δ(ppm) 8.54 (ddd, J = 4.9, 1.7, 0.9 
Hz, 1H, CHar-6), 7.71 (td, J = 7.7, 1.8 Hz, 
1H, CHar-4), 7.58 (d, J = 7.8 Hz, 1H, CHar-3), 
7.21 (ddd, J = 7.4, 4.9, 1.2 Hz, 1H, CHar-5), 
4.51 (s, 2H, NCH2), 4.22–4.15 (m, 1H, CH), 
4.05 (s, 2H, NCH2O), 3.93–3.79 (m, 2H, 
CH2), 3.70 (s, 3H, OCH3). 
13C-NMR 
(75 MHz, CDCl3): δ(ppm) 172.44 (Ccarbonyl), 
149.06 (Car-2), 137.02 (Car-6), 123.25 
(Car-3), 122.59 (Car-5), 87.50 (NCH2O), 
67.45 (NCH2), 64.72 (C), 60.54 (C), 52.33 
(OCH3). IR (film): v (cm
-1) 2951, 2883, 1734, 
1670, 1593, 1470, 1435, 1360, 1277, 1201, 
1166, 1119, 1047, 1007, 947, 869, 758, 701. 
5.2.2.54 (S)-3-(pyridin-2-ylmethyl)oxazol-
idine-4-carboxylic acid ((S)-186) 
 
 
(S)-185 (760 mg, 3.42 mmol) were 
suspended in sodium hydroxide (4.50 mL, 
1 M) at 0 °C and reacted for 16 h. The reac-
tion mixture was washed with methylene 
chloride (3 x 20 ml). The combined aqueous 
layer was neutralised to pH 7 with hydro-
chloric acid (1 M). The aqueous layer was 
concentrated and the solvent removed un-
der reduced pressure. The residue was 
suspended in ethanol (5.00 mL) and filtrated 
via a syringe filter. The residue was dried in 
vacuo to obtain the product (S)-186 as a 
white solid (705 mg, 3.39 mmol, quant.). 
Rf = 0.05 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, CD3OD): δ(ppm) 
8.44 (d, J = 5.0, 1H, CHar-6), 7.86 – 7.77 (m, 
2H, CHar-4, CHar-3), 7.29 (dd, J = 8.8, 5.0 
Hz, 1H, CHar-5), 4.40 (dd, J = 13.3, 5.2 Hz, 
2H, NCH2O), 4.17 (t, J = 8.0 Hz, 1H, CH), 
4.03 (d, J = 14.7 Hz, 1H; NCHH), 3.91 (d, J 
= 14.5 Hz, 1H, NCHH), 3.78 (dd, J = 7.9, 5.7 
Hz, 1H, CHH), 3.56–3.48 (m, 1H, CHH). 
IR (film): v (cm-1) 3380, 2481, 2077, 1639, 
1590, 1441, 1212, 1116, 1087, 969, 528, 
462. HRMS calculated for C10H13N2O3 
(M + H+) 209,0921 found (M + H+) 209,0922. 
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5.2.2.55 (S)-methyl 3-(4-(tert-butyldimethyl-
silyloxy)phenyl)-2-(pyridin-2-ylme-
thylamino)propanoate ((S)-187) 
 
 
(S)-174 (2.00 g, 6.98 mmol) was dis-
solved in dimethylformamide (60 mL) and 
cool to 0 °C. Diisopropylethylamine (6.0 mL, 
34.90 mmol) was added drop wise over a 
period of 2 h. Then, tert-butyldimethylsilyl tri-
fluoromethanesulfonate (2.1 mL, 7.81 mmol) 
was added drop wise over a period of 1 h. 
The reaction was continued for 24 h and the 
was allowed to warm up to ambient temper-
ature. Ammonium acetate (60 mL, 1 M aq.) 
was added and the reaction mixture was 
extracted with ethylacetate (3 x 60 mL). The 
combined organic layer was washed with 
BRINE, dried over sodium sulfate, filtrated 
and concentrated under reduced pressure. 
The crude material was subjected to column 
chromatography using methylene chlo-
ride : methanol (35:1). Rf = 0.53 (methylene 
chloride : methanol 15:1). The product 
(S)-187 was obtained as yellow oil (2.77 g, 
6.92 mmol, 99%). 1H-NMR (300 MHz, 
CD3OD): δ(ppm) 7.08 (d, J = 4.9 Hz, 1H, 
CHar-6), 6.40-6.29 (m, 1H, CHar-4), 5.80 (d, 
J = 7.9 Hz, 1H, CHar-3), 5.93-5.89 (m, 1H, 
CHar-5), 5.69 (d, J = 8.4 Hz, 2H, CHar-2’ & 
CHar-6’), 5.40 (d, J = 8.4 Hz, 2H, CHar-3’ & 
CHar-5’), 2.56 (d, J = 14.5 Hz, 1H, NCHH), 
2.40 (d, J = 14.5 Hz, 1H, NCHH), 2.25 (s, 
3H, OCH3), 2.15 (dd, J = 10.4, 7.1 Hz, 1H, 
CH), 1.96 (s, 1H, OH), 1.60 (d, J = 18.8 Hz, 
1H, CHH), 1.52 (d, J = 12.6 Hz, 1H, 
CHH), -0.37 (s, 9H, (SiCq(CH3)3), -1.17 (s, 
6H, (Si(CH3)2). 
13C-NMR (75 MHz, CD3OD): 
δ(ppm) 172.18 (Ccarbonyl), 159.01 (Car-2), 
154.39 (Car-4’), 148.45 (Car-6), 137.362 
(Car-4), 130.79 (Car-1’), 130.28 (2C, Car-2’ & 
Car-6’), 123.31 (Car-3), 122.42 (Car-5), 
120.08 (2C, Car-3’ & Car-5’), 68.40 (NCH2), 
60.12 (C), 51.38 (OCH3), 38.48 (C), 25.84 
(SiCq(CH3)3), 18.36 (SiCq(CH3)3), -4.27 
(Si(CH3)2). IR (film): v (cm
-1) 3339, 2953, 
2934, 2892, 2858, 1740, 1680, 1600, 1510, 
1469, 1436, 1359, 1258, 1201, 1170, 1106, 
1003, 915, 839, 781, 691, 634, 543, 475, 
401. HRMS calculated for C22H33N2O3Si 
(M + H+) 401.2260 found (M + H+) 437.2255. 
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5.2.3 Synthesis of complexes and relat-
ed intermediates 
5.2.3.1 Synthesis of organoruthenium (II) 
precursor 95 
 
 
A solution of 93 (259 mg, 0.84 mmol) 
and RuCl2(dmso)4 (468 mg, 0.84 mmol) in 
chloroform (24 mL) was refluxed under ni-
trogen for 5 h, then the resulting solution 
was concentrated and precipitated by the 
addition into diethyl ether. The solid was 
collected and washed with diethyl ether 
(3 x 12 mL) and dried in vacuo. The crude 
material was directly carried forward for lig-
and exchange. Therefore, the crude material 
(434.9 mg, 0.78 mmol) was dissolved in 
MeCN (40 mL) with silver triflate (187 mg, 
0.78 mmol) under a nitrogen atmosphere 
and refluxed for 6 h. The resulting suspen-
sion was cooled to ambient temperature and 
filtered through CELITE. The yellow filtrate 
was reduced to a volume of 1 mL and pre-
cipitated by the addition into cold diethyl 
ether. The solid was then again washed with 
diethyl ether (3 x 12 mL). Finally the residual 
brown solid was concentrated to dryness in 
vacuo to provide 95 as amber coloured 
foam (605 mg, 0.73 mmol, 87% over two 
steps). Due to the high moisture sensibility 
of this compound, a direct continuance into 
the complex synthesis is necessary. 
Rf = 0.05 (hexane : ethylacetate 3:1). 
1H-NMR (300 MHz, CD3CN): δ(ppm) 6.01 
(m, 1H, CHCH2), 5.33-5.24 (m, 2H, CHCH2), 
4.58-4.56 (m, 2H, CH2allyl), 3.31-2.72 (m, 
13H, CHN & 6xCH2), 2.51 (s, 3H, NCH3), 
2.50 (s, 3H, CspCH3), 2.40 (s, 6H, 2x 
CspCH3). 
13C-NMR (75.5 MHz, CD3CN): 
(ppm) 134.0, 125.7, 124.2, 120.0, 80.0, 
67.1, 46.9, 46.3, 45.5, 44.3, 41.4, 37.6, 36.6, 
35.2, 34.6, 34.4, 34.0, 33.5, 32.5, 32.3 IR 
(film): ν(cm-1) 3513, 3000, 2936, 2322, 2294, 
1689, 1453, 1409, 1328, 1248, 1150, 1023, 
954, 834, 763, 632, 571, 514, 423. HRMS 
calculated for C19H30F3N4O5S4Ru (M + H)
+ 
681.0089, found (M + H)+ 681.0085. 
5.2.3.2 Synthesis of organoruthenium(II) 
complex 96 
 
 
A suspension of the ligand 78 
(25 mg, 56 µmol), potassium carbonate 
(8.5 mg, 61 µmol), and ruthenium precursor 
95 (50.8 mg, 61 µmol) in DMF (3 mL) was 
stirred at 85 °C under microwave irradiation 
for 40 min, followed by adding sodium thio-
cyanate (9 mg, 111 µmol), then the mixture 
was stirred at 85 °C for an additional 40 min. 
The resulting suspension was dried in vacuo 
and the crude material was adsorbed onto 
silica gel and subjected to silica gel chroma-
tography with methylene chloride : methanol 
(35:1) to obtain the metal complex 96 as a 
dark green solid (26 mg, 33 µmol, 59%). 
The quick regio-isomerisation of the mono-
dentate isothiocyanate ligand from the 
N-bound to the S-bound form and vice versa 
leads to a second signal set in the NMR 
spectra. Rf = 0.45 (methylene chlo-
ride : methanol 15:1). 1H-NMR (300 MHz, 
(CD3)2CO): δ(ppm) 9.87 (s, 1H, NH), 9.18-
9.06 (m, 1H, CHar-4), 8.90-8.81 (m, 1H, 
CHar-2), 8.44-8.43 (m, 1H, CHar-8), 8.13 (d, 
J = 9.0 Hz, 1H, CHar-11), 7.17-7.10 (m, 1H, 
CHar-10), 6.07-5.92 (m, 1H, CHCH2), 5.38-
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5.21 (m, 2H, CHCH2), 4.56-4.55 (m, 2H, 
CH2allyl) 3.93 (s, 3H, OCH3), 3.69-2.92 (m, 
13H, CHN & 6xCH2), 2.78 (s, 3H, NCH3). IR 
(film): ν(cm-1) 2923, 2098, 1699, 1558, 1468, 
1403, 1327, 1285, 1206, 1141, 1024, 950, 
810, 759, 694, 635, 516. HRMS calculated 
for C31H30FN5O5RuS4Na
+ (M + Na)+ 
824.0050, found (M + Na)+ 824.0044. 
Measureable crystals of compound 96 were 
obtained after one week in (CD3)2CO at 
4 °C. 
5.2.3.3 Synthesis of organoruthenium(II) 
complex 87 
 
 
To a solution of the solid product 96 
(21 mg, 26 µmol) in methylene chloride 
(11 mL) was added 1,3-dimethylbarbituric 
acid (61 mg, 39 µmol) and Pd(PPh3)4 
(4.5 mg, 4 µmol) under nitrogen. The result-
ing mixture was stirred at ambient tem-
perature for 14 h, followed by the addition of 
saturated NaHCO3 (1 x 0.5 mL) solution to 
quench the reaction. The resulting sus-
pension was dried in vacuo and the crude 
material was adsorbed onto silica gel and 
subjected to silica gel chromatography with 
methylene chloride : methanol : 2% triethyl-
amine (10:1  5:1) as the eluting solvent to 
obtain the metal complex 87. The purified 
complex 87 was then extracted with satur-
ated NH4Cl (2 x 20 mL), saturated NaHCO3 
(4 x 15 mL) and Brine (2 x 20 mL) to remove 
residual NEt3. The metal complex 87 was 
obtained as a dark green solid (8.7 mg, 
12 µmol, 47%). Rf = 0.38 (methylene chlo-
ride : methanol 2% triethylamine 15:1). 
1H-NMR (300 MHz, (CH3)2SO): δ(ppm) 
11.02 (s, 1H, NH), 8.98 (m, 1H, CHar-4), 
8.80 (dd, J = 9.3, 2.4 Hz, 1H, CHar-2), 8.30 
(d, J = 2.7 Hz, 1H, CHar-8), 8.04 (d, J = 9.0 
Hz, 1H, CHar-11), 7.15 (dd, J = 9.0, 2.7 Hz, 
1H, CHar-10), 3.89 (s, 3H, OCH3), 3.58-3.39 
(m, 13H, CHN & 6xCH2), 2.40 (s, 3H, 
NHCH3). 
13C-NMR (125.8 MHz, (CH3)2SO): 
δ(ppm) 170.7 (2C, Car-5 & Car-7), 170.52 
(Car-3) 156.76 (Car-9), 153.7 (Car-12b), 147.7 
(Car), 146.7 (Car), 141.1 (Car), 134.27 (NCS), 
131.4 (Car), 131.1 (Car), 128.7 (Car), 124.1 
(Car), 120.8 (Car), 115.7 (Car), 114.5 (Car), 
110.5 (Car), 106.1 (Car-8), 69.7 (CHNHCH3), 
55.5 (OCH3), 53.7 (SCH2CHNHCH3), 51.7 
(SCH2CHNHCH3), 48.5 (CHNHCH3), 35.9 
(Caliph), 34.2 (Caliph), 33.3 (Caliph), 31.8 (Caliph). 
IR (film): ν(cm-1) 3452, 3058, 2924, 1747, 
1677, 1615, 1561, 1492, 1439, 1408, 1369, 
1328, 1287, 1225, 1022, 948, 883, 759, 610, 
447. HRMS calculated for 
C27H26FN5O3RuS4Na (M + Na)
+ 739.8447, 
found (M + Na)+739.8443. 
5.2.3.4 Synthesis of organorhodium(III) 
complexes -(R)-106 and 
-(R)-107 
 
 
A suspension of 79 (17.6 mg, 
44 µmol) and RhCl3∙3H2O (11.5 mg, 
44 µmol) in an ethanol : water mixture (1:1, 
20 mL) under nitrogen atmosphere in a 
sealed vessel was heated to 90 °C for 3 h. 
During this time the suspension turned from 
pale brown into dark red. The reaction mix-
ture was then cooled down slightly to add 
(R)-105 (9.9 mg, 48 µmol). After addition of 
(R)-105, the reaction was further proceeded 
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at 90 °C for 16 h. The reaction mixture was 
then cooled down to ambient temperature 
and the solvent was removed in vacuo. The 
crude material was purified via column 
chromatography using methylene chlo-
ride : methanol (20:1  10:1). The separat-
ed diastereomers were further purified and 
concentrated via preparative TLC using 
methylene chloride : methanol (10:1). The 
products were obtained as red solids, 
-(R)-107 (4.2 mg, 6.6 µmol, 15%) and 
-(R)-106 (6.1 mg, 9.7 µmol, 22%). 
-(R)-107: Rf = 0.25 (methylene chlo-
ride : methanol 15:1). 1H-NMR (500 MHz, 
(CD3)2SO): δ(ppm) 11.24 (s, 1H, NH), 9.68 
(d, J = 5.7 Hz, 1H, CHar-6’), 9.30 (dd, J = 
8.4, 1.1 Hz, 1H, CHar-4), 8.87 (d, J = 5.1 Hz, 
1H, CHar-2), 8.68 (dd, J = 7.8, 0.5 Hz, 1H, 
CHar-8), 8.48 (td, J = 7.8, 1.5 Hz, 1H, 
CHar-4’), 8.08 (dd, J = 8.4, 5.2 Hz, 1H, 
CHar-3), 8.06 – 8.01 (m, 1H, CHar-5’), 7.99 
(d, J = 7.8 Hz, 1H, CHar-3’), 7.28 – 7.24 (m, 
1H, CHar-10), 7.21 (ddd, J = 8.4, 7.2, 1.4 Hz, 
1H, CHar-9), 5.70 (d, J = 8.2 Hz, 1H, 
CHar-11), 4.60 (d, J = 15.6 Hz, 1H, NCHH), 
4.34 (d, J = 15.7 Hz, 1H, NCHH), 3.81 (dd, J 
= 9.6, 4.3 Hz, 1H, CH), 2.50 (m, 1H, 
CHH), 2.28 – 2.15 (m, 2H, CHH& 
CHH), 2.00 (dt, J = 11.3, 4.8 Hz, 1H, 
CHH), 1.58 (m, J = 11.7, 5.9 Hz, 1H, 
CHH), 1.11 – 1.01 (m, 1H, CHH). 
13C-NMR (126 MHz, (CD3)2SO): δ(ppm) 
182.02 (Ccarbonyl), 170.59 (Car-7), 170.23 
(Car-5), 161.13 (Car-2’), 152.62 (Car-6’), 
152.54 (Car-12b), 148.90 (Car-12a), 148.89 
(Car-11a), 148.74 (Car-2), 142.09 (Car-4’), 
141.17 (Car-7b), 135.24 (Car-4), 131.23 
(Car-7a), 126.61 (Car-9), 126.27 (Car-5’), 
124.75 (Car-8), 123.90 (Car-3), 123.47 
(Car-3’), 121.34 (Car-10), 119.59 (Car-4a), 
115.08 (Car-7c), 114.59 (Car-4b), 111.79 
(Car-11), 72.91 (C), 70.02 (NCH2), 61.27 
(C), 30.43 (C), 24.31 (C). IR (film): ν (cm
-1) 
3037, 2075, 1994, 1751, 1703, 1646, 1519, 
1482, 1413, 1337, 1296, 1262, 1225, 1132, 
1017, 930, 884, 856, 743, 704, 636, 493, 
436. HRMS calculated for C28H21ClN5O4Rh 
(M + Na)+ 652.0229, found (M + Na)+ 
652.0220. -(R)-106: Rf = 0.08 (methylene 
chloride : methanol 15:1). 1H-NMR 
(300 MHz, (CD3)2SO): δ(ppm) 11.24 (s, 1H, 
NH), 9.54 (d, J = 5.5 Hz, 1H, CHar-6‘), 9.17 
(d, J = 7.7 Hz, 1H, CHar-4), 8.71 (d, J = 7.8 
Hz, 1H, CHar-8), 8.38 (m, 1H, CHar-4‘), 7.99 
– 7.89 (m, 3H, CHar-2, CHar-5‘ & CHar-11), 
7.82 (d, J = 8.3 Hz, 1H, CHar-3‘), 7.74 (dd, J 
= 8.4, 5.3 Hz, 1H, CHar-3), 7.58 – 7.51 (m, 
1H, CHar-9), 7.41 – 7.33 (m, 1H, CHar-10), 
4.59 (s, 2H, NCH2), 3.79 (dd, J = 9.4, 4.7 
Hz, 1H, CH), 2.50 (m, 1H, CHH), 2.29 – 
2.09 (m, 2H, CHH& CHH), 1.86 (dt, J = 
11.3, 5.9 Hz, 1H, CHH), 1.44 (dt, J = 11.7, 
5.8 Hz, 1H, CHH), 1.10 (dt, J = 12.7, 7.0 
Hz, 1H, CHH). 
13C-NMR (101 MHz, 
(CD3)2SO): δ(ppm) 181.89 (Ccarbonyl), 159.96 
(Car-2’), 151.72 (Car-6’), 151.25 (Car-12b), 
150.17 (Car-2), 149.43 (Car-12a), 149.13 
(Car-11a), 141.85 (Car-7b), 140.53 (Car-4‘), 
134.41 (Car-4), 130.75 (Car-7a), 125.67 
(Car-9), 125.79 (Car-5‘), 123.84 (Car-3), 
123.57 (Car-8), 122.67 (Car-11), 120.87 
(Car-10), 119.14 (Car-4a), 114.73 (Car-3‘), 
114.44 (Car-7c), 113.63 (Car-4b), 73.51 (C), 
69.35 (NCH2), 60.75 (C), 30.74 (C), 24.01 
(C). The 
13C-signals of Car-5 and Car-7 are 
missing. IR (film): ν(cm-1) 3045, 2724, 1819, 
1750, 1704, 1644, 1519, 1481, 1413, 1336, 
1297, 1225, 1134, 1014, 932, 824, 786, 743, 
703, 635, 492, 436, 392. HRMS calculated 
for C28H21ClN5O4RhNa (M + Na)
+ 652.0229, 
found (M + Na)+ 652.0238. 
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5.2.3.5 Synthesis of organorhodium(III) 
complexes -(S)-106 and -(S)-107 
 
 
A suspension of 79 (17.6 mg, 
44 µmol) and RhCl3∙3H2O (11.5 mg, 
44 µmol) in an ethanol : water mixture (1:1, 
20 mL) under nitrogen atmosphere in a 
sealed vessel was heated to 90 °C for 3 h. 
During this time the suspension turned from 
pale brown into dark red. The reaction mix-
ture was then cooled down slightly to add 
(S)-105 (9.9 mg, 48 µmol). After addition of 
(S)-105, the reaction was further proceeded 
at 90 °C for 16 h. The reaction mixture was 
then cooled down to ambient temperature 
and the solvent was removed in vacuo. The 
crude material was purified via column 
chromatography using methylene chlo-
ride : methanol (20:1  10:1). The separat-
ed diastereomers were further purified and 
concentrated via preparative TLC using 
methylene chloride : methanol (10:1). The 
products were obtained as red solids, 
-(S)-107 (3.9 mg, 6.6 µmol, 14%) and 
-(S)-106 (6.7 mg, 10.6 µmol, 24%). 
-(S)-107: Rf = 0.25 (methylene chlo-
ride : methanol 15:1). 1H-NMR (500 MHz, 
(CD3)2SO): δ(ppm) 11.25 (s, 1H, NH), 9.68 
(d, J = 5.4 Hz, 1H, CHar-6’), 9.30 (d, J = 8.3 
Hz, 1H, CHar-4), 8.87 (d, J = 4.8 Hz, 1H, 
CHar-2), 8.68 (d, J = 7.7 Hz, 1H, CHar-8), 
8.51 – 8.43 (m, 1H, CHar-4’), 8.08 (dd, J = 
8.3, 5.2 Hz, 1H, CHar-3), 8.06 – 8.01 (m, 1H, 
CHar-5’), 7.99 (d, J = 7.7 Hz, 1H, CHar-3’), 
7.26 (t, J = 7.4 Hz, 1H, CHar-10), 7.21 (t, J = 
7.4 Hz, 1H, CHar-9), 5.70 (d, J = 8.2 Hz, 1H, 
CHar-11), 4.60 (d, J = 15.8 Hz, 1H, NCHH), 
4.34 (d, J = 15.8 Hz, 1H, NCHH), 3.81 (dd, J 
= 9.3, 4.0 Hz, 1H, CH), 2.50 (m, 1H, 
CHH), 2.21 (dd, J = 17.3, 10.9 Hz, 2H, 
CHH& CHH), 2.04 – 1.97 (m, 1H, 
CHH), 1.61 – 1.54 (m, 1H, CHH), 1.11 – 
1.01 (m, 1H, CHH). 
13C-NMR (126 MHz, 
(CD3)2SO): δ(ppm) 181.79 (Ccarbonyl), 169.97 
(Car-7), 169.89 (Car-5), 160.83 (Car-2’), 
152.46 (Car-6’), 152.14 (Car-12b), 148.53 
(Car-12a), 148.38 (Car-11a) 148.27 (Car-2), 
141.77 (Car-4’), 140.87 (Car-7a), 134.93 
(Car-4), 130.85 (Car-7a), 126.11 (Car-9), 
125.92 (Car-5’), 124.34 (Car-8), 123.23 
(Car-3), 123.01 (Car-3’), 121.07 (Car-10), 
119.14 (Car-4a), 114.27 (Car-7c), 114.13 
(Car-4b), 111.43 (Car-11), 72.27 (C), 69.75 
(NCH2), 61.02 (C), 30.13 (C), 24.16 (C). 
IR (film): ν (cm-1) 3034, 2159, 2096, 1751, 
1704, 1646, 1519, 1483, 1413, 1337, 1295, 
1262, 1225, 1131, 1015, 930, 828, 784, 744, 
705, 636, 527, 491. HRMS calculated for 
C28H21ClN5O4Rh (M + Na)
+ 652.0229, found 
(M + Na)+ 652.0208. -(S)-106: Rf = 0.08 
(methylene chloride : methanol 15:1). 1H-
NMR (300 MHz, (CD3)2SO): δ(ppm) 11.22 
(s, 1H, NH), 9.54 (d, J = 5.1 Hz, 1H, 
CHar-6‘), 9.18 (dd, J = 8.4, 1.0 Hz, 1H, CHar-
4), 8.71 (d, J = 7.9 Hz, 1H CHar-8), 8.38 (td, 
J = 7.7, 1.5 Hz, 1H, CHar-4‘), 8.00 – 7.89 (m, 
3H, CHar-2, CHar-5‘ & CHar-11), 7.82 (d, J = 
8.3 Hz, 1H, CHar-3‘), 7.74 (dd, J = 8.4, 5.3 
Hz, 1H, CHar-3), 7.59 – 7.50 (m, 1H, CHar-9), 
7.41 – 7.33 (m, 1H, CHar-10), 4.58 (s, 2H, 
NCH2), 3.79 (dd, J = 9.4, 4.8 Hz, 1H, CH), 
2.51 – 2.48 (m, 1H, CHH), 2.25 – 2.12 (m, 
2H, CHH& CHH), 1.94 – 1.77 (m, 1H, 
CHH), 1.50 – 1.37 (m, 1H, CHH), 1.17 – 
0.98 (m, 1H, CHH). 
13C-NMR (101 MHz, 
(CD3)2SO): δ(ppm) 182.29 (Ccarbonyl), 160.16 
(Car-2’), 152.22 (Car-6’), 151.65 (Car-12b), 
150.37 (Car-2), 149.86 (Car-12a), 149.83 
(Car-11a) 142.35 (Car-7a), 140.73 (Car-4‘), 
134.81 (Car-4), 131.25 (Car-4b), 126.57 
(Car-9), 126.09 (Car-5‘), 124.26 (Car-3), 
123.90 (Car-8), 123.07 (Car-11), 121.10 
(Car-10), 119.66 (Car-4a), 114.96 (Car-3‘), 
114.89 (Car-7c), 114.01 (Car-7b), 73.52 (C), 
69.25 (NCH2), 61.45 (C), 30.38 (C), 23.83 
(C). The 
13C-signals of Car-5 and Car-7 are 
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missing. IR (film): ν (cm-1) 3046, 2723, 1818, 
1752, 1703, 1647, 1518, 1482, 1414, 1337, 
1295, 1224, 1133, 1012, 932, 824, 786, 742, 
701, 637, 492, 436. HRMS calculated for 
C28H21ClN5O4RhNa (M + Na)
+ 652.0229, 
found (M + Na)+ 652.0228.
5.2.3.6 Synthesis of organorhodium(III) 
complexes -(S,R)-125 and 
-(S,R)-126 
 
 
A suspension of 79 (30 mg, 75 µmol) 
and RhCl3∙3H2O (19.6 mg, 75 µmol) in an 
ethanol : water mixture (1:1, 10 mL) under 
nitrogen atmosphere in a sealed vessel was 
heated to 90 °C for 3 h. During this time the 
suspension turned from pale brown into dark 
red. The reaction mixture was then cooled 
down slightly to add (S, R)-119 (27.9 mg, 
83 µmol). After addition of (S, R)-119, the 
reaction was further proceeded at 90 °C for 
16 h. The reaction mixture was then cooled 
down to ambient temperature and the sol-
vent was removed in vacuo. The crude ma-
terial was purified via column chroma-
tography using methylene chloride : meth-
anol (20:1  10:1). The separated diastere-
omers were further purified and concen-
trated via preparative TLC using methylene 
chloride : methanol (15:1). The products 
were obtained as red solids, -(S,R)-125 
(11 mg, 17.3 µmol, 23%) and -(S,R)-126 
(8.2 mg, 12.8 µmol, 17%). -(S,R)-125: 
Rf = 0.14 (methylene chloride : methanol 
15:1). 1H-NMR (500 MHz, (CD3)2SO): 
δ(ppm) 9.55 (d, J = 5.8 Hz, 1H, CHar-6’), 
9.18 (dd, J = 8.4, 1.0 Hz, 1H, CHar-4), 8.71 
(d, J = 8.0 Hz, 1H, CHar-8), 8.36 (td, J = 7.8, 
1.5 Hz, 1H, CHar-4’), 8.10 – 7.87 (m, 3H, 
CHar-11, CHar-5’ & CHar-2), 7.77 (d, J = 8.3 
Hz, 1H, CHar-3’), 7.76 – 7.73 (m, 1H, 
CHar-3), 7.54 (ddd, J = 8.3, 7.1, 1.3 Hz, 1H, 
CHar-9), 7.41 – 7.35 (m, 1H, CHar-10), 4.82 – 
4.74 (m, 2H, NCH2), 4.74 – 4.70 (m, 1H 
CH) 4.01 (t, J = 8.8 Hz, 1H, CH), 3.72 – 
3.62 (m, 1H, CHH), 3.51 (s, 1H, OH) 2.52 
(d, J = 1.9 Hz, 1H, CHH), 2.26 – 2.11 (m, 
1H, CHH), 1.91 – 1.78 (m, 1H, CHH). 
13C-NMR (126 MHz, (CD3)2SO): δ(ppm) 
181.83 (Ccarbonyl), 160.49 (Car-2’), 151.89 
(Car-6’), 151.32 (Car-2), 151.31 (Car-12b), 
150.81 (Car-12a), 146.75 (Car-11a), 142.44 
(Car-7b) 140.95 (Car-4’), 135.27 (Car-4), 
131.17 (Car-7a), 127.10 (Car-9), 126.21 
(Car-5’), 124.81 (Car-3), 124.60 (Car-8), 
124.09 (Car-11), 120.14 (Car-10), 119.70 
(Car-4a), 115.09 (Car-3’), 114.66 (Car-7c), 
114.22 (Car-4b), 73.71 (C), 72.66 (NCH2), 
72.64 (C), 67.41 (C), 39.82 (C). The 
13C-signals of Car-5 and Car-7 are missing. 
IR (film): ν (cm-1) 2925, 2855, 2724, 2252, 
2126, 1750, 1705, 1649, 1498, 1446, 1412, 
1342, 1294, 1231, 1148, 1001, 878, 820, 
755, 707, 635, 530, 490, 432. HRMS calcu-
lated for C28H21ClN5NaO5Rh (M + Na)
+ 
668.0178, found (M + Na)+ 668.0178. 
-(S,R)-126: Rf = 0.08 (methylene chlo-
ride : methanol 15:1). 1H-NMR (300 MHz, 
(CD3)2SO): δ(ppm) 9.67 (d, J = 5.7 Hz, 1H, 
CHar-6’), 9.29 (dd, J = 8.4, 1.0 Hz, 1H, 
CHar-4), 8.84 (d, J = 5.1 Hz, 1H, CHar-2), 
8.71 – 8.65 (m, 1H, CHar-8), 8.47 (td, J = 
7.8, 1.4 Hz, 1H, CHar-4’), 8.09 (d, J = 8.4 Hz, 
1H, CHar-3), 8.07 (d, J = 8.4 Hz, 1H, 
CHar-5’), 8.01 (dd, J = 10.3, 4.2 Hz, 1H, 
CHar-3’), 7.32 – 7.11 (m, 2H, CHar-10 & 
CHar-9), 5.74 (d, J = 7.8 Hz, 1H, CHar-11), 
5.23 (s, 1H, CH), 4.84 (d, J = 15.8 Hz, 1H, 
NCHH), 4.44 (d, J = 15.8 Hz, 1H, NCHH), 
4.01 (t, J = 8.5 Hz, 1H, CH), 3.77 (s, 1H, 
OH), 2.51 – 2.48 (m, 1H, CHH), 2.30 – 
2.11 (m, 2H, CHH & CHH), 2.08 – 1.87 
(m, 1H, CHH). IR (film): ν (cm
-1) 2973, 
2937, 2250, 1746, 1709, 1666, 1579, 1497, 
1448, 1415, 1337, 1296, 1261, 1227, 1152, 
 
170 Experimental 
1127, 1049, 1005, 878, 821, 763, 733, 707, 
631, 532, 488. HRMS calculated for 
C28H21ClN5NaO5Rh (M + Na)
+ 668.0178, 
found (M + Na)+ 668.0178. 
5.2.3.7 Synthesis of organorhodium(III) 
complexes -(R)-127 and 
-(R)-128 
 
 
A suspension of 79 (30 mg, 75 µmol) 
and RhCl3∙3H2O (19.6 mg, 75 µmol) in an 
ethanol : water mixture (1:1, 10 mL) under 
nitrogen atmosphere in a sealed vessel was 
heated to 90 °C for 3 h. During this time the 
suspension turned from pale brown into dark 
red. The reaction mixture was then cooled 
down slightly to add (R)-124 (18.3 mg, 
83 µmol). After addition of (R)-124, the reac-
tion was further proceeded at 90 °C for 16 h. 
The reaction mixture was then cooled down 
to ambient temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol (20:1  5:1). 
The separated diastereomers were further 
purified and concentrated via preparative 
TLC using methylene chloride : methanol 
(15:1). The products were obtained as red 
solids, -(R)-127 (11.5 mg, 18 µmol, 24%) 
and -(R)-128 (7.7 mg, 12 µmol, 16%). 
-(R)-127: Rf = 0.11 (methylene chlo-
ride : methanol 15:1). 1H-NMR (300 MHz, 
(CD3)2SO): δ(ppm) 11.19 (s, 1H, NH), 9.55 
(d, J = 5.6 Hz, 1H, CHar-6‘), 9.16 (dd, J = 
8.2, 1.2 Hz, 1H, CHar-4), 8.72 (d, J = 7.9 Hz, 
1H, CHar-8), 8.39 (td, J = 7.8, 1.4 Hz, 1H, 
CHar-4‘), 8.06 – 7.91 (m, 3H, CHar-2, CHar-5‘ 
& CHar-11), 7.76 – 7.64 (m, 2H, CHar-3‘ & 
CHar-3), 7.60 – 7.51 (m, 1H, CHar-9), 7.42 – 
7.35 (m, 1H, CHar-10), 4.86 (d, J = 16.4 Hz, 
1H, NCHH), 4.48 (d, J = 16.1 Hz, 1H, 
NCHH), 3.45 – 3.35 (m, 1H, CH), 2.45 – 
2.35 (m, 1H, CHaliph), 2.33 – 2.28 (m, 1H, 
CHaliph), 1.99 – 1.82 (m, 1H, CHaliph), 1.79 – 
1.59 (m, 1H, CHaliph), 1.56 – 1.39 (m, 1H, 
CHaliph), 1.32 – 1.21 (m, 2H, CHaliph), 1.07 – 
0.92 (m, 1H, CHaliph). A second set of signals 
for each proton was observed. IR (film): ν 
(cm-1) 2956, 2920, 2853, 2268, 2209, 2169, 
2133, 2058, 2008, 1754, 1708, 1648, 1444, 
1339, 1229, 1012, 915, 748, 677, 637, 534, 
488, 434. HRMS calculated for 
C29H23ClN5NaO4Rh (M + Na)
+ 666.0386, 
found (M + Na)+ 666.0387. -(R)-128: 
Rf = 0.24 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 11.25 (s, 1H, NH), 9.71 (d, J = 4.7 
Hz, 1H, CHar-6’), 9.32 – 9.19 (m, 1H, 
CHar-4), 8.88 (d, J = 5.2 Hz, 1H, CHar-2), 
8.67 (t, J = 7.2 Hz, 1H, CHar-8), 8.54 – 8.33 
(m, 1H, CHar-4’), 8.20 – 8.07 (m, 1H, 
CHar-3), 8.05 (dd, J = 11.4, 6.2 Hz, 1H, 
CHar-5’), 7.96 – 7.84 (m, 1H, CHar-3’), 7.33 – 
7.07 (m, 2H, CHar-9 & CHar-10), 5.41 (d, J = 
8.2 Hz, 1H, CHar-11), 4.92 (d, J = 15.5 Hz, 
1H, NCHH), 4.20 (d, J = 15.7 Hz, 1H, 
NCHH), 3.43 (t, J = 5.5 Hz, 1H, CH), 2.38 – 
2.19 (m, 2H, CHaliph), 2.00 – 1.63 (m, 4H, 
CHaliph), 1.58 – 1.40 (m, 2H, CHaliph). A sec-
ond set of signals for each proton was ob-
served. IR (film): ν(cm-1) 1751, 1705, 1653, 
1521, 1491, 1415, 1339, 1296, 1261, 1225, 
1080, 1016, 821, 792, 745, 707, 636, 527. 
HRMS calculated for C29H23ClN5NaO4Rh 
(M + Na)+ 666.0386, found (M + Na)+ 
666.0386. 
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5.2.3.8 Synthesis of organorhodium(III) 
complexes -(S)-127 and -(S)-128 
 
 
A suspension of 79 (30 mg, 75 µmol) 
and RhCl3∙3H2O (19.6 mg, 75 µmol) in an 
ethanol : water mixture (1:1, 10 mL) under 
nitrogen atmosphere in a sealed vessel was 
heated to 90 °C for 3 h. During this time the 
suspension turned from pale brown into dark 
red. The reaction mixture was then cooled 
down slightly to add (S)-124 (18.3 mg, 
83 µmol). After addition of (S)-124, the reac-
tion was further proceeded at 90 °C for 16 h. 
The reaction mixture was then cooled down 
to ambient temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol (35:1  
10:1). The separated diastereomers were 
further purified and concentrated via prepar-
ative TLC using methylene chlo-
ride : methanol (15:1). The products were 
obtained as red solids, -(S)-127 (10.5 mg, 
15.8 µmol, 21%) and -(S)-128 (7.5 mg, 
11.3 µmol, 15%). -(S)-127: Rf = 0.11 
(methylene chloride : methanol 15:1). 1H-
NMR (300 MHz, (CD3)2SO): δ(ppm) 9.54 (d, 
J = 5.7 Hz, 1H, CHar-6‘), 9.16 (dd, J = 8.2, 
1.2 Hz, 1H, CHar-4), 8.72 (d, J = 7.9 Hz, 1H, 
CHar-8), 8.39 (td, J = 7.7, 1.4 Hz, 1H, 
CHar-4’), 7.97 (d, J = 8.2 Hz, 3H, CHar-2, 
CHar-5‘ & CHar-11), 7.70 (dt, J = 12.4, 4.8 
Hz, 2H, CHar-3‘ & CHar-3), 7.59 – 7.52 (m, 
1H, CHar-9), 7.42 – 7.35 (m, 1H, CHar-10), 
4.86 (d, J = 16.6 Hz, 1H, NCHH), 4.48 (d, J 
= 16.4 Hz, 1H, NCHH), 3.45 – 3.35 (m, 1H, 
CH), 2.44 – 2.32 (m, 1H, CHaliph), 2.33 – 
2.28 (m, 1H, CHaliph), 1.94– 1.80 (m, 1H, 
CHaliph), 1.79 – 1.59 (m, 1H, CHaliph), 1.56 – 
1.39 (m, 1H, CHaliph), 1.33 – 1.20 (m, 2H, 
CHaliph), 1.06 – 0.90 (m, 1H, CHaliph). A sec-
ond set of signals for each proton was ob-
served. IR (film): ν (cm-1) 1750, 1705, 1650, 
1524, 1497, 1413, 1339, 1268, 1228, 1017, 
999, 822, 794, 753, 706, 635, 585, 527, 489, 
438. HRMS calculated for 
C29H23ClN5NaO4Rh (M + Na)
+ 666.0386, 
found (M + Na)+ 666.0387. -(S)-128: 
Rf = 0.24 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 11.22 (s, 1H, NH), 9.71 (d, J = 4.8 
Hz, 1H, CHar-6’), 9.29 (ddd, J = 8.4, 4.5, 1.0 
Hz, 1H, CHar-4), 8.88 (d, J = 5.1 Hz, 1H, 
CHar-2), 8.72 – 8.62 (m, 1H, CHar-8), 8.48 
(td, J = 7.8, 1.4 Hz, 1H, CHar-4’), 8.13 (dd, J 
= 8.4, 5.2 Hz, 1H, CHar-3), 8.02 (d, J = 7.7 
Hz, 1H, CHar-3’), 7.91 (dd, J = 13.5, 7.0 Hz, 
1H, CHar-5’), 7.29 – 7.21 (m, 1H, CHar-9), 
7.19 – 7.10 (m, 1H, CHar-10), 5.41 (d, J = 
8.2 Hz, 1H, CHar-11), 4.91 (d, J = 15.7 Hz, 
1H, NCHH), 4.20 (d, J = 15.5 Hz, 1H, 
NCHH), 3.42 (t, J = 5.6 Hz, 1H, CH), 2.38 – 
2.19 (m, 1H, CHaliph) 2.02 – 1.86 (m, 2H, 
CHaliph), 1.86 – 1.63 (m, 1H, CHaliph), 1.58 – 
1.39 (m, 2H, CHaliph), 1.38 – 1.25 (m, 1H, 
CHaliph), 1.07 – 0.89 (m, 1H, CHaliph). A sec-
ond set of signals for each proton was ob-
served. IR (film): ν (cm-1) 1749, 1702, 1657, 
1517, 1489, 1419, 1341, 1293, 1264, 1222, 
1080, 1011, 818, 796, 745, 707, 636, 527. 
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5.2.3.9 Synthesis of organorhodium(III) 
complexes -(R)-129 and 
-(R)-130 
 
 
A suspension of 79 (30 mg, 75 µmol) 
and RhBr3∙xH2O (26 mg, 75 µmol) in an eth-
anol : water mixture (1:1, 20 mL) under ni-
trogen atmosphere in a sealed vessel was 
heated to 90 °C for 3 h. During this time the 
suspension turned from pale brown into dark 
red. The reaction mixture was then cooled 
down slightly to add (R)-105 (17 mg, 
83 µmol). After addition of (R)-105, the reac-
tion was further proceeded at 90 °C for 16 h. 
The reaction mixture was then cooled down 
to ambient temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol (100:0  
10:1). The separated diastereomers were 
further purified and concentrated via prepar-
ative TLC using methylene chlo-
ride : methanol (15:1). The products were 
obtained as red solids, -(R)-129 (8.1 mg, 
12 µmol, 16%) and -(R)-130 (5.0 mg, 7.5 
µmol, 10%). -(R)-129: Rf = 0.16 (methy-
lene chloride : methanol 15:1). 1H-NMR 
(300 MHz, (CD3)2SO): δ(ppm) 9.75 (d, J = 
5.5 Hz, 1H, CHar-6‘), 9.18 (dd, J = 8.4, 2.5 
Hz, 1H, CHar-4), 8.71 (d, J = 7.9 Hz, 1H, 
CHar-8), 8.44 – 8.32 (m, 1H, CHar-4’), 7.98 – 
7.91 (m, 3H, CHar-2, CHar-5‘ & CHar-11), 
7.82 (dd, J = 8.6, 4.2 Hz, 1H, CHar-3‘), 7.74 
(dd, J = 8.3, 5.3 Hz, 1H, CHar-3), 7.59 – 7.48 
(m, 1H, CHar-9), 7.38 (t, J = 7.5 Hz, 1H, 
CHar-10), 4.59 (s, 2H, NCH2), 3.83 – 3.68 
(m, 1H, CH), 2.50 – 2.48 (m, 1H, CHH), 
2.24 – 2.06 (m, 2H, CHH& CHH), 1.90 – 
1.78 (m, 1H, CHH), , 1.51 – 1.35 (m, 1H, 
CHH), 1.12 – 0.98 (m, 1H, CHH). IR (film): 
ν (cm-1) 2923, 2855, 2250, 2127, 1749, 
1705, 1647, 1523, 1496, 1470, 1447, 1416, 
1340, 1294, 1228, 1147, 1020, 1001, 820, 
755, 707, 635, 573. HRMS calculated for 
C28H21BrN5NaO4Rh (M + Na)
+ 695.9724, 
found (M + Na)+ 695.9726. -(R)-130: 
Rf = 0.37 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 9.68 (d, J = 5.6 Hz, 1H, CHar-6’), 
9.29 (dd, J = 8.4, 1.1 Hz, 1H, CHar-4), 8.86 
(d, J = 5.1 Hz, 1H, CHar-2), 8.68 (dd, J = 7.0, 
1.0 Hz, 1H, CHar-8), 8.48 (td, J = 7.8, 1.5 Hz, 
1H, CHar-4’), 8.08 (dd, J = 8.4, 5.2 Hz, 1H, 
CHar-3), 8.03 – 7.95 (m, 2H, CHar-5’ & 
CHar-3’), 7.30 – 7.16 (m, 2H, CHar-9 & 
CHar-10), 5.69 (d, J = 7.9 Hz, 1H, CHar-11), 
4.60 (d, J = 16.0 Hz, 1H, NCHH), 4.33 (d, J 
= 15.4 Hz, 1H, NCHH), 3.81 (dd, J = 9.5, 4.3 
Hz, 1H, CH), 2.50 – 2.48 (m, 1H, CHH) 
2.25 -2.14 (m, 2H, CHH& CHH), 2.07 – 
1.90 (m, 1H, CHH), 1.67 – 1.40 (m, 1H, 
CHH), 1.11 – 1.00 (m, 1H, CHH). IR (film): 
ν(cm-1) 2921, 2852, 2246, 2182, 2129, 1750, 
1703, 1645, 1569, 1520, 1482, 1446, 1409, 
1336, 1288, 1222, 1157, 1129, 1020, 998, 
931, 824, 742, 704, 635. 
5.2.3.10 Synthesis of organorhodium(III) 
complexes -(S)-131 and -(S)-132 
 
 
A suspension of 78 (34 mg, 75 µmol) 
and RhCl3∙3H2O (18.3 mg, 69 µmol) in an 
ethanol : water mixture (1:1, 15 mL) under 
nitrogen atmosphere in a sealed vessel was 
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heated to 90 °C for 3 h. During this time the 
suspension turned from pale brown into dark 
red. The reaction mixture was then cooled 
down slightly to add (S)-105 (15.5 mg, 
75 µmol). After addition of (S)-105, the reac-
tion was further proceeded at 90 °C for 16 h. 
The reaction mixture was then cooled down 
to ambient temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol 
(20:1  10:1). The separated diastereomers 
were further purified and concentrated via 
preparative TLC using methylene chlo-
ride : methanol (10:1). The products were 
obtained as dark purple solids, -(S)-131 
(10.7 mg, 15.9 µmol, 23%) and -(S)-132 
(5.6 mg, 8.3 µmol, 12%). -(S)-131: 
Rf = 0.14 (methylene chlo-
ride : methanol 15:1). 1H-NMR (300 MHz, 
(CD3)2SO): δ(ppm) 11.26 (s, 1H, NH), 9.51 
(d, J = 5.7 Hz, 1H, CHar-6‘), 8.85 (dd, J = 
9.2, 2.3 Hz, 1H, CHar-4), 8.36 (td, J = 7.8, 
1.5 Hz, 1H, CHar-4‘), 8.23 (d, J = 2.6 Hz, 1H, 
CHar-8), 8.10 (td, J = 2.5, 0.8 Hz, 1H, 
CHar-2), 7.95 – 7.87 (m, 2H, CHar-3’ & 
CHar-5’), 7.71 (d, J = 9.0 Hz, 1H, CHar-11), 
7.24 (dd, J = 9.0, 2.7 Hz, 1H, CHar-10), 4.75 
(d, J = 16.0 Hz, 1H, NCHH), 4.55 (d, J = 
16.1 Hz, 1H, NCHH), 3.92 (s, 3H, OCH3), 
3.77 (dd, J = 9.4, 5.1 Hz, 1H, CH), 2.50 – 
2.48 (m, 1H, CHH), 2.28 – 2.10 (m, 2H, 
CHH& CHH), 1.89 – 1.74 (m, 1H, 
CHH), 1.47 (tt, J = 12.1, 6.1 Hz, 1H, 
CHH), 1.17 – 0.95 (m, 1H, CHH). IR (film): 
ν (cm-1) 2919, 1716, 1653, 1563, 1502, 
1465, 1408, 1335, 1258, 1226, 1163, 1096, 
1021, 924, 860, 814, 763, 725, 633, 582, 
519, 478, 443. HRMS calculated for 
C29H22ClFN5NaO5Rh (M + Na)
+ 700.0241, 
found (M + Na)+ 700.0264. -(S)-132: 
Rf = 0.27 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 11.31 (s, 1H, NH), 9.66 (d, J = 5.8 
Hz, 1H, CHar-6’), 8.98 (dd, J = 9.1, 2.4 Hz, 
1H, CHar-4), 8.70 (dt, J = 2.3, 1.1 Hz, 1H, 
CHar-8), 8.48 (td, J = 7.8, 1.4 Hz, 1H, 
CHar-4’), 8.21 (d, J = 2.6 Hz, 1H, CHar-2), 
8.05 – 7.95 (m, 2H, CHar-3’ & CHar-5’), 6.92 
(dd, J = 9.0, 2.7 Hz, 1H, CHar-10), 5.59 (d, J 
= 9.0 Hz, 1H, CHar-11), 4.61 (d, J = 15.9 Hz, 
1H, NCHH), 4.32 (d, J = 15.7 Hz, 1H, 
NCHH), 3.83 (s, 3H, OCH3), 3.82 – 3.74 (m, 
1H, CH), 2.50 – 2.48 (m, 1H, CHH), 2.30 
– 2.14 (m, 2H, CHH& CHH), 2.10 – 1.94 
(m, 1H, CHH), 1.69 – 1.58 (m, 1H, CHH), 
1.46 (dd, J = 15.5, 9.0 Hz, 1H, CHH). IR 
(film): ν(cm-1) 2919, 1718, 1650, 1563, 1500, 
1468, 1408, 1337, 1277, 1259, 1228, 1167, 
1098, 1023, 993, 923, 893, 857, 825, 793, 
727, 701, 636, 523, 475, 442. HRMS calcu-
lated for C29H22ClFN5NaO5Rh (M + Na)
+ 
700.0241, found (M + Na)+ 700.0263. 
5.2.3.11 Synthesis of organorhodium(III) 
complexes -(R)-131 and 
-(R)-132 
 
 
A suspension of 78 (34 mg, 75 µmol) 
and RhCl3∙3H2O (18.3 mg, 69 µmol) in an 
ethanol : water mixture (1:1, 15 mL) under 
nitrogen atmosphere in a sealed vessel was 
heated to 90 °C for 3 h. During this time the 
suspension turned from pale brown into dark 
red. The reaction mixture was then cooled 
down slightly to add (R)-105 (15.5 mg, 
75 µmol). After addition of (R)-105, the reac-
tion was further proceeded at 90 °C for 16 h. 
The reaction mixture was then cooled down 
to ambient temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol (15:1  
10:1). The separated diastereomers were 
further purified and concentrated via prepar-
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ative TLC using methylene chlo-
ride : methanol (15:1). The products were 
obtained as dark purple solids, -(R)-131 
(10.3 mg, 15.2 µmol, 22%) and -(R)-132 
(6.0 mg, 8.9 µmol, 13%). -(R)-131: 
Rf = 0.14 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 11.17 (s, 1H, NH), 9.50 (d, J = 5.7 
Hz, 1H, CHar-6’), 8.85 (dd, J = 9.2, 2.2 Hz, 
1H, CHar-4), 8.35 (td, J = 7.7, 1.4 Hz, 1H, 
CHar-4’), 8.22 (d, J = 2.6 Hz, 1H, CHar-8), 
8.09 (td, J = 2.5, 0.8 Hz, 1H, CHar-2), 7.99 – 
7.84 (m, 2H, CHar-3’ & CHar-5’), 7.70 (d, J = 
8.9 Hz, 1H, CHar-11), 7.23 (dd, J = 9.0, 2.7 
Hz, 1H, CHar-10), 4.74 (d, J = 15.9 Hz, 1H, 
NCHH), 4.54 (d, J = 16.5 Hz, 1H, NCHH), 
3.91 (s, 3H, OCH3), 3.77 (dd, J = 9.2, 4.9 
Hz, 1H, CH), 2.50 – 2.48 (m, 1H, CHH) 
2.28 – 2.10 (m, 2H, CHH& CHH), 1.89 – 
1.74 (m, 1H, CHH), 1.47 (tt, J = 12.1, 6.1 
Hz, 1H, CHH), 1.17 – 0.95 (m, 1H, CHH). 
13C-NMR (75 MHz, (CD3)2SO): δ(ppm) 
182.54 (Ccarbonyl), 170.54 (Car-7), 170.17 
(Car-5), 160.25 (Car-2’), 156.93 (d, J = 249.7 
Hz, Car-3), 154.05 (Car-9), 152.33 (Car-6’), 
151.77 (Car-12b), 144.60 (Car), 141.20 (d, J 
= 33.9 Hz, Car-2), 140.85 (Car), 140.10 (Car), 
132.23 (Car), 126.21 (Car), 124.05 (Car), 
123.43 (Car), 120.77 (d, J = 8.8 Hz, Car-4a), 
119.15 (d, J = 20.0 Hz, Car-4), 116.68 (Car), 
115.65 (Car), 114.70 (Car), 112.77 (Car), 
106.28 (Car), 73.53 (C), 69.48 (NCH2), 
61.53 (C), 55.60 (OCH3), 30.45 (C), 23.87 
(C). IR (film): ν (cm
-1) 1751, 1711, 1652, 
1562, 1502, 1467, 1409, 1332, 1284, 1204, 
1162, 1023, 997, 919, 856, 816, 760, 695, 
632, 581, 520, 476, 445, 404. HRMS calcu-
lated for C29H23ClFN5O5Rh (M + H)
+ 
678.0421, found (M + H)+ 678.0427. 
-(R)-132: Rf = 0.27 (methylene chlo-
ride : methanol 15:1). 1H-NMR (500 MHz, 
(CD3)2SO): δ(ppm) 9.65 (d, J = 5.7 Hz, 1H, 
CHar-6’), 8.98 (dd, J = 9.1, 2.4 Hz, 1H, 
CHar-4), 8.70 (dd, J = 2.2, 1.8 Hz, 1H, 
CHar-8), 8.47 (td, J = 7.8, 1.5 Hz, 1H, 
CHar-4’), 8.19 (d, J = 2.6 Hz, 1H, CHar-2), 
8.02 (t, J = 6.8 Hz, 1H, CHar-5’), 7.98 (d, J = 
7.9 Hz, 1H, CHar-3’), 6.91 (dd, J = 9.0, 2.7 
Hz, 1H, CHar-10), 5.59 (d, J = 9.0 Hz, 1H, 
CHar-11), 4.62 (d, J = 15.7 Hz, 1H, NCHH), 
4.32 (d, J = 15.6 Hz, 1H, NCHH), 3.82 (s, 
3H, OCH3), 3.82 – 3.77 (m, 1H, CHa), 2.54 
(dt, J = 11.2, 5.7 Hz, 1H, CHH), 2.29 – 
2.18 (m, 2H, CHH& CHH), 2.09 – 2.00 
(m, 1H, CHH), 1.64 (dp, J = 12.5, 6.3 Hz, 
1H, CHH), 1.27 – 1.15 (m, 1H, CHH). 
13C-NMR (126 MHz, (CD3)2SO): δ(ppm) 
182.05 (Ccarbonyl), 170.43 (Car-7), 170.07 
(Car-5), 161.22 (Car-2’), 156.68 (d, J = 250.7 
Hz, Car-3), 153.98 (Car-6’), 152.79 (Car-12b), 
143.60 (Car), 141.41 (Car), 139.84 (Car), 
138.31 (d, J = 35.1 Hz, CHar-2), 132.40 (Car), 
126.45 (Car), 123.84 (Car), 123.71 (Car), 
121.24 (d, J = 8.4 Hz, Car-4a), 119.80 (d, J = 
20.2 Hz, Car-4), 116.43 (Car), 114.87 (Car), 
113.36 (Car), 112.57 (Car), 107.09 (Car), 
72.87 (C), 69.89 (NCH2), 61.14 (OCH3), 
55.65 (C), 30.25 (C), 24.33 (C). IR (film): 
ν(cm-1) 1752, 1714, 1652, 1562, 1499, 1470, 
1408, 1336, 1285, 1207, 1167, 1055, 1025, 
995, 920, 893, 856, 824, 793, 774, 699, 632, 
614, 523. HRMS calculated for 
C29H22ClFN5NaO5Rh (M + Na)
+ 700.0241, 
found (M + Na)+ 700.0262. 
5.2.3.12 Synthesis of organorhodium(III) 
complexes -(S)-133 and -(S)-134 
 
 
A suspension of 81 (45 mg, 75 µmol) 
and RhCl3∙3H2O (18.3 mg, 69 µmol) in an 
ethanol : water mixture (1:1, 15 mL) under 
nitrogen atmosphere in a sealed vessel was 
heated to 90 °C for 3 h. During this time the 
suspension turned from pale brown into dark 
red. The reaction mixture was then cooled 
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down slightly to add (S)-105 (15.5 mg, 
75 µmol). After addition of (S)-105, the reac-
tion was further proceeded at 90 °C for 16 h. 
The reaction mixture was then cooled down 
to ambient temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol (35:1  
10:1). The separated diastereomers were 
further purified and concentrated via prepar-
ative TLC using methylene chlo-
ride : methanol (15:1). The products were 
obtained as dark purple solids, -(S)-133 
(7.8 mg, 11.1 µmol, 16%) and -(S)-134 
(4.4 mg, 6.2 µmol, 9%). -(S)-133: Rf = 0.11 
(methylene chloride : methanol 15:1). 
1H-NMR (300 MHz, (CD3)2SO): δ(ppm) 
11.34 (s, 1H, NH), 9.53 (d, J = 5.3 Hz, 1H, 
CHar-6’), 9.43 (s, 1H, CHar-4), 9.33 (d, J = 
0.8 Hz, 1H, CHar-2), 8.39 (td, J = 7.8, 1.4 Hz, 
1H, CHar-4’), 8.17 (d, J = 2.4 Hz, 1H, 
CHar-8), 7.97 – 7.89 (m, 3H, OH, CHar-3’& 
CHar-5‘), 7.69 (d, J = 8.9 Hz, 1H, CHar-11), 
7.14 (dd, J = 8.9, 2.5 Hz, 1H, CHar-10), 4.76 
(d, J = 16.2 Hz, 1H, NCHH), 4.57 (d, J = 
16.2 Hz, 1H, NCHH), 3.79 (dd, J = 9.4, 4.9 
Hz, 1H, CHa), 2.51 – 2.48 (m, 1H, CHH), 
2.25 – 2.11 (m, 2H, CHH& CHH), 1.84 
(dt, J = 17.9, 5.9 Hz, 1H, CHH), 1.48 (ddd, 
J = 17.8, 11.7, 5.9 Hz, 1H, CHH), 1.16 – 
1.00 (m, 1H, CHH). IR (film): ν (cm
-1) 3226, 
2923, 1757, 1712, 1613, 1558, 1526, 1496, 
1420, 1332, 1295, 1244, 1178, 1135, 1089, 
1054, 1026, 924, 864, 767, 729, 699, 640, 
531, 505, 446. HRMS calculated for 
C29H20ClF3N5NaO5Rh (M + Na)
+ 736.0052, 
found (M + Na)+ 736.0074. -(S)-134: 
Rf = 0.21 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 11.38 (s, 1H, NH), 9.65 (d, J = 5.8 
Hz, 1H, CHar-6’), 9.46 (d, J = 0.9 Hz, 1H, 
CHar-4), 8.81 (d, J = 0.9 Hz, 1H, CHar-4), 
8.48 (td, J = 7.8, 1.4 Hz, 1H, CHar-4’), 8.15 
(d, J = 2.4 Hz, 1H, CHar-8), 8.06 – 7.87 (m, 
3H, OH, CHar-3’ & CHar-5‘), 6.80 (dd, J = 8.9, 
2.5 Hz, 1H, CHar-10), 5.57 (d, J = 8.9 Hz, 
1H, CHar-11), 4.63 (d, J = 15.7 Hz, 1H, 
NCHH), 4.33 (d, J = 15.7 Hz, 1H, NCHH), 
3.83 (dd, J = 9.3, 4.5 Hz, 1H, CH), 2.51 – 
2.48 (m, 1H, CHH), 2.31 – 2.14 (m, 2H, 
CHH& CHH), 2.00 (td, J = 11.0, 5.5 Hz, 
1H, CHH), 1.63 (ddd, J = 18.0, 11.9, 5.9 
Hz, 1H, CHH), 1.14 – 0.97 (m, 1H, CHH). 
IR (film): ν(cm-1) 3267, 2919, 1711, 1660, 
1568, 1501, 1463, 1420, 1391, 1332, 1295, 
1252, 1218, 1127, 1085, 1048, 1020, 933, 
901, 860, 821, 781, 729, 697, 633, 530, 503, 
481, 447, 409. HRMS calculated for 
C29H20ClF3N5NaO5Rh (M + Na)
+ 736.0052, 
found (M + Na)+ 736.0076. 
5.2.3.13 Synthesis of organorhodium(III) 
complexes -(R)-133 and 
-(R)-134 
 
 
A suspension of 81 (45 mg, 75 µmol) 
and RhCl3∙3H2O (18.3 mg, 69 µmol) in an 
ethanol : water mixture (1:1, 15 mL) under 
nitrogen atmosphere in a sealed vessel was 
heated to 90 °C for 3 h. During this time the 
suspension turned from pale brown into dark 
red. The reaction mixture was then cooled 
down slightly to add (R)-105 (15.5 mg, 
75 µmol). After addition of (R)-105, the reac-
tion was further proceeded at 90 °C for 16 h. 
The reaction mixture was then cooled down 
to ambient temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol (20:1  
10:1). The separated diastereomers were 
further purified and concentrated via prepar-
ative TLC using methylene chlo-
ride : methanol (15:1). The products were 
obtained as dark purple solids, -(R)-133 
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(8.6 mg, 12.4 µmol, 18%) and -(R)-134 
(4.9 mg, 6.9 µmol, 10%). -(R)-133: 
Rf = 0.11 (methylene chloride : methanol 
15:1). 1H-NMR (600 MHz, (CD3)2SO): 
δ(ppm) 11.33 (s, 1H, NH), 9.53 (d, J = 5.5 
Hz, 1H, CHar-6’), 9.44 (s, 1H, CHar-4), 9.33 
(d, J = 1.0 Hz, 1H, CHar-2), 8.38 (td, J = 7.8, 
1.5 Hz, 1H, CHar-4’), 8.17 (d, J = 2.2 Hz, 1H, 
CHar-8), 7.99 – 7.92 (m, 3H, OH, CHar-3’ & 
CHar-5‘), 7.91 (s, 1H, OH), 7.68 (d, J = 8.7 
Hz, 1H, CHar-11), 7.14 (dd, J = 8.8, 2.5 Hz, 
1H, CHar-10), 4.76 (d, J = 16.2 Hz, 1H, 
NCHH), 4.57 (d, J = 16.2 Hz, 1H, NCHH), 
3.79 (dd, J = 9.5, 5.0 Hz, 1H, CH), 2.51 – 
2.48 (m, 1H, CHH), 2.20 (td, J = 11.7, 5.9 
Hz, 2H, CHH& CHH), 1.84 (td, J = 11.8, 
5.6 Hz, 1H, CHH), 1.55 – 1.40 (m, 1H, 
CHH), 1.16 – 1.00 (m, 1H, CHH). 
13C-NMR (151 MHz, (CD3)2SO): δ(ppm) 
182.42 (Ccarbonyl), 170.42 (Car-7), 170.00 
(Car-5), 160.32 (Car-2’), 152.18 (Car-9), 
151.86 (Car-6’), 151.07 (Car-12b), 144.20 
(Car), 143.78 (Car), 140.93 (Car), 133.50 (Car), 
132.55 (Car), 132.11 (Car), 126.25 (Car), 
123.85 (Car), 121.75 (Car), 119.25 (Car), 
118.11 (Car), 116.10 (Car), 115.77 (Car), 
112.92 (Car), 111.33 (Car), 108.52 (Car), 
73.41 (C), 69.36 (NCH2), 61.52 (C), 30.31 
(C), 23.78 (C). Due to the signal to noise 
ratio a unambiguous assignment of the CF3 
carbon signals was not possible. IR (film): ν 
(cm-1) 1750, 1709, 1657, 1606, 1502, 1461, 
1421, 1391, 1330, 1295, 1252, 1212, 1171, 
1129, 1084, 1021, 934, 901, 858, 822, 777, 
696, 631, 530, 500, 481. HRMS calculated 
for C29H20ClF3N5NaO5Rh (M + Na)
+ 
736.0052, found (M + Na)+ 736.0074. 
-(R)-134: Rf = 0.21 (methylene chlo-
ride : methanol 15:1). 1H-NMR (300 MHz, 
(CD3)2SO): δ(ppm) 9.65 (d, J = 5.4 Hz, 1H, 
CHar-6‘), 9.47 – 9.45 (m, 1H, CHar-4), 8.81 
(d, J = 0.8 Hz, 1H, CHar-2), 8.48 (td, J = 7.8, 
1.3 Hz, 1H, CHar-4‘), 8.15 (d, J = 2.4 Hz, 1H, 
CHar-8), 8.06 – 7.96 (m, 3H, OH CHar-3’ & 
CHar-5‘), 6.81 (dd, J = 8.9, 2.5 Hz, 1H, 
CHar-10), 5.57 (d, J = 8.9 Hz, 1H, CHar-9), 
4.63 (d, J = 15.4 Hz, 1H, NCHH), 4.33 (d, J 
= 15.4 Hz, 1H, NCHH), 3.83 (dd, J = 9.2, 4.5 
Hz, 1H, CH), 2.58 – 2.52 (m, 1H, CHH), 
2.32 – 2.14 (m, 2H, CHH& CHH), 2.00 
(td, J = 11.6, 5.5 Hz, 1H, CHH), 1.64 (tt, J 
= 11.6, 5.8 Hz, 1H, CHH), 1.14 – 0.97 (m, 
1H, CHH). 
13C-NMR (75 MHz, (CD3)2SO): 
δ(ppm) 182.05 (Ccarbonyl), 170.38 (Car-7), 
169.97 (Car-5), 161.19 (Car-2‘), 152.65 
(Car-9), 152.19 (Car-6‘), 151.59 (Car-12b), 
143.51 (Car), 143.31 (Car), 141.43 (Car), 
139.65 (Car), 137.21 (Car), 132.71 (Car), 
126.48 (Car), 124.12 (Car), 123.72 (Car), 
121.18 (Car), 119.65 (Car), 118.06 (Car), 
116.40 (Car), 113.61 (Car), 112.76 (Car), 
109.09 (Car), 72.84 (C), 69.96 (NCH2), 
61.29 (C), 30.25 (C), 24.50 (C). Due to the 
signal to noise ratio a unambiguous assign-
ment of the CF3 carbon signals was not 
possible. IR (film): ν(cm-1) 1757, 1715, 1663, 
1611, 1565, 1497, 1419, 1337, 1293, 1246, 
1134, 1083, 1049, 1022, 994, 914, 858, 822, 
790, 762, 697, 629, 528, 499, 443. HRMS 
calculated for C29H20ClF3N5NaO5Rh 
(M + Na)+ 736.0052, found (M + Na)+ 
736.0072. 
5.2.3.14 Synthesis of organorhodium(III) 
complexes -(S)-135 and -(S)-136 
 
 
A suspension of 82 (42.1 mg, 
75 µmol) and RhCl3∙3H2O (18.3 mg, 
69 µmol) in an ethanol : water mixture (1:1, 
15 mL) under nitrogen atmosphere in a 
sealed vessel was heated to 90 °C for 3 h. 
During this time the suspension turned from 
pale brown into dark red. The reaction mix-
ture was then cooled down slightly to add 
(S)-105 (15.5 mg, 75 µmol). After addition of 
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(S)-105, the reaction was further proceeded 
at 90 °C for 16 h. The reaction mixture was 
then cooled down to ambient temperature 
and the solvent was removed in vacuo. The 
crude material was purified via column 
chromatography using methylene chlo-
ride : methanol (25:1  10:1). The separat-
ed diastereomers were further purified and 
concentrated via preparative TLC using 
methylene chloride : methanol (15:1). The 
products were obtained as dark purple sol-
ids, -(S)-135 (7.9 mg, 11.7 µmol, 17%) and 
-(S)-136 (5.1 mg, 7.6 µmol, 11%). 
-(S)-135: Rf = 0.11 (methylene chlo-
ride : methanol 15:1). 1H-NMR (300 MHz, 
(CD3)2SO): δ(ppm) 11.12 (s, 1H, NH), 9.51 
(dd, J = 5.8, 0.7 Hz, 1H, CHar-6’), 8.49 (d, J 
= 2.3 Hz, 1H, CHar-4), 8.36 (td, J = 7.8, 1.5 
Hz, 1H, CHar-4’), 8.09 (d, J = 2.3 Hz, 1H, 
CHar-8), 7.96 – 7.85 (m, 2H, CHar-3’ & 
CHar-5’), 7.56 (d, J = 8.8 Hz, 1H, CHar-11), 
7.45 (dd, J = 2.3, 0.9 Hz, 1H, CHar-2), 7.01 
(dd, J = 8.8, 2.5 Hz, 1H, CHar-10), 4.70 (d, J 
= 16.3 Hz, 1H, NCHH), 4.55 (d, J = 16.3 Hz, 
1H, NCHH), 3.97 (s, 3H, OCH3), 3.77 (dd, J 
= 9.5, 4.8 Hz, 1H, CH), 2.58 – 2.52 (m, 1H, 
CHH), 2.30 – 2.21 (m, 2H, CHH& 
CHH), 2.01 – 1.92 (m, 1H, CHH), 1.85 
(dd, J = 12.5, 6.4 Hz, 1H, CHH), 1.67 – 
1.59 (m, 1H, CHH). 
13C-NMR (126 MHz, 
(CD3)2SO): δ(ppm) 182.35 (Ccarbonyl), 170.83 
(Car-7), 170.33 (Car-5), 160.30 (Car-2’), 
154.88 (Car-3), 152.96  (Car-9), 151.56 
(Car-6’), 151.47 (Car-12b), 143.67 (Car), 
142.17 (Car), 140.70 (Car), 137.46 (Car), 
131.67 (Car), 129.59 (Car), 126.06 (Car), 
123.81 (Car), 121.68 (Car), 73.50 (C), 69.78 
(NCH2), 61.45 (C), 56.21 (OCH3), 31.28 
(C), 22.09 (C). IR (film): ν (cm
-1) 2917, 
2850, 1716, 1608, 1566, 1445, 1406, 1373, 
1341, 1229, 1094, 1019, 931, 871, 800, 723. 
HRMS calculated for C29H23ClN5NaO6Rh 
(M + Na)+ 698.0284, found (M + Na)+ 
698.0286. -(S)-136: Rf = 0.24 (methylene 
chloride : methanol 15:1). 1H-NMR 
(300 MHz, (CD3)2SO): δ(ppm) 11.15 (s, 1H, 
NH), 9.65 (d, J = 5.2 Hz, 1H, CHar-6‘), 9.18 
(s, 1H, OH), 8.60 (d, J = 2.4 Hz, 1H, CHar-4), 
8.46 (td, J = 7.8, 1.5 Hz, 1H, CHar-4‘), 8.34 
(dd, J = 2.4, 0.8 Hz, 1H, CHar-2), 8.08 (d, J = 
2.4 Hz, 1H, CHar-8), 8.04 – 7.92 (m, 2H, 
CHar-3’ & CHar-5’), 6.67 (dd, J = 8.8, 2.5 Hz, 
1H, CHar-10), 5.46 (d, J = 8.8 Hz, 1H, 
CHar-11), 4.70 – 4.52 (m, 2H, NCH2), 4.12 
(s, 3H, OCH3), 3.80 (dd, J = 5.2, 4.1 Hz, 1H, 
CH), 2.51 – 2.48 (m, 1H, CHH), 2.07 – 
1.88 (m, 2H, CHH& CHH), 1.62 (dt, J = 
11.5, 5.8 Hz, 1H, CHH), 1.56 – 1.38 (m, 
1H, CHH), 1.17 – 0.98 (m, 1H, CHH). IR 
(film): ν(cm-1) 2957, 2918, 2850, 1716, 1577, 
1459, 1407, 1372, 1341, 1230, 1093, 1019, 
931, 871, 800, 723, 468. HRMS calculated 
for C29H23ClN5NaO6Rh (M + Na)
+ 698.0284, 
found (M + Na)+ 698.0286. 
5.2.3.15 Synthesis of organorhodium(III) 
complexes -(R)-135 and 
-(R)-136 
 
 
A suspension of 82 (42 mg, 75 µmol) 
and RhCl3∙3H2O (18.3 mg, 69 µmol) in an 
ethanol : water mixture (1:1, 15 mL) under 
nitrogen atmosphere in a sealed vessel was 
heated to 90 °C for 3 h. During this time the 
suspension turned from pale brown into dark 
red. The reaction mixture was then cooled 
down slightly to add (R)-105 (15.5 mg, 
75 µmol). After addition of (R)-105, the reac-
tion was further proceeded at 90 °C for 16 h. 
The reaction mixture was then cooled down 
to ambient temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol (20:1  
10:1). The separated diastereomers were 
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further purified and concentrated via prepar-
ative TLC using methylene chlo-
ride : methanol (15:1). The products were 
obtained as dark purple solids-(R)-135 
(8.8 mg, 13.1 µmol, 19%) and -(R)-136 
(4.2 mg, 6.2 µmol, 9%). -(R)-135: Rf = 0.11 
(methylene chloride : methanol 15:1). 
1H-NMR (600 MHz, (CD3)2SO): δ(ppm) 
11.10 (s, 1H, NH), 9.51 (d, J = 5.5 Hz, 1H, 
CHar-6’), 9.22 (s, 1H, OH), 8.48 (d, J = 2.3 
Hz, 1H, CHar-4), 8.35 (td, J = 7.8, 1.4 Hz, 
1H, CHar-4’), 8.09 (d, J = 2.5 Hz, 1H, CHar-
8), 7.96 – 7.84 (m, 2H, CHar-3’ & CHar-5’), 
7.55 (d, J = 8.8 Hz, 1H, CHar-11), 7.44 (d, J 
= 2.2 Hz, 1H, CHar-2), 7.01 (dd, J = 8.8, 2.5 
Hz, 1H, CHar-10), 4.69 (d, J = 16.1 Hz, 1H, 
NCHH), 4.54 (d, J = 16.2 Hz, 1H, NCHH), 
3.97 (s, 3H, OCH3), 3.77 (dd, J = 9.6, 4.9 
Hz, 1H, CHa), 2.48 – 2.44 (m, 1H, CHH), 
2.25 (dt, J = 11.7, 5.7 Hz, 1H, CHH), 2.21 
– 2.13 (m, 1H, CHH), 1.85 (td, J = 11.6, 
5.4 Hz, 1H, CHH), 1.51 – 1.41 (m, 1H, 
CHH), 1.16 – 1.08 (m, 1H, CHH). IR (film): 
ν (cm-1) 1749, 1707, 1630, 1567, 1496, 
1449, 1419, 1339, 1297, 1260, 1215, 1054, 
1015, 927, 867, 819, 764, 732, 698, 635, 
568, 510, 482, 448, 401. HRMS calculated 
for C29H23ClN5NaO6Rh (M + Na)
+ 698.0284, 
found (M + Na)+ 698.0286. -(R)-136: 
Rf = 0.24 (methylene chloride : methanol 
15:1). 1H-NMR (500 MHz, (CD3)2SO): 
δ(ppm) 9.64 (d, J = 5.7 Hz, 1H, CHar-6’), 
9.21 (bs, 1H, OH), 8.59 (d, J = 2.4 Hz, 1H, 
CHar-4), 8.45 (td, J = 7.8, 1.5 Hz, 1H, 
CHar-4’), 8.34 (d, J = 2.4 Hz, 1H, CHar-2), 
8.07 (d, J = 2.5 Hz, 1H, CHar-8), 8.04 – 7.98 
(m, 1H, CHar-5’), 7.96 (d, J = 8.0 Hz, 1H, 
CHar-3’), 6.67 (dd, J = 8.8, 2.5 Hz, 1H, 
CHar-10), 5.45 (d, J = 8.8 Hz, 1H, CHar-11), 
4.59 (d, J = 15.5 Hz, 1H, NCHH), 4.30 (d, J 
= 15.6 Hz, 1H, NCHH), 4.12 (s, 3H, OCH3), 
3.79 (dd, J = 9.4, 4.5 Hz, 1H, CH), 2.54 – 
2.51 (m, 1H, CHH), 2.27 – 2.16 (m, 2H, 
CHH& CHH), 2.05 – 1.95 (m, 1H, 
CHH), 1.67 – 1.58 (m, 1H, CHH), 1.13 (tt, 
J = 13.5, 6.6 Hz, 1H, CHH). IR (film): 
ν(cm-1) 1748, 1705, 1646, 1566, 1492, 1456, 
1414, 1337, 1297, 1263, 1215, 1018, 925, 
864, 818, 763, 701, 666, 634, 518, 484. 
HRMS calculated for C29H23ClN5NaO6Rh 
(M + Na)+ 698.0284, found (M + Na)+ 
698.0285. 
5.2.3.16 Synthesis of organorhodium(III) 
complexes -(S)-137 and -(S)-138 
 
 
A suspension of 83 (34.6 mg, 
75 µmol) and RhCl3∙3H2O (18.3 mg, 
69 µmol) in an ethanol : water mixture (1:1, 
15 mL) under nitrogen atmosphere in a 
sealed vessel was heated to 90 °C for 3 h. 
During this time the suspension turned from 
pale brown into dark red. The reaction mix-
ture was then cooled down slightly to add 
(S)-105 (15.5 mg, 75 µmol). After addition of 
(S)-105, the reaction was further proceeded 
at 90 °C for 16 h. The reaction mixture was 
then cooled down to ambient temperature 
and the solvent was removed in vacuo. The 
crude material was purified via column 
chromatography using methylene chlo-
ride : methanol (25:1  10:1). The separat-
ed diastereomers were further purified and 
concentrated via preparative TLC using 
methylene chloride : methanol (15:1). The 
products were obtained as dark purple sol-
ids, -(S)-137 (11.9 mg, 17.3 µmol, 25%) 
and -(S)-138 (6.6 mg, 9.7 µmol, 14%). 
-(S)-137: Rf = 0.16 (methylene chlo-
ride : methanol 15:1). 1H-NMR (300 MHz, 
(CD3)2SO): δ(ppm) 11.17 (s, 1H, NH), 9.51 
(d, J = 5.7 Hz, 1H, CHar-6’), 8.50 (d, J = 2.3 
Hz, 1H, CHar-4), 8.36 (td, J = 7.8, 1.5 Hz, 
1H, CHar-4’), 8.20 (d, J = 2.6 Hz, 1H, 
CHar-8), 7.97 – 7.84 (m, 2H, CHar-3’ & 
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CHar-5’), 7.66 (d, J = 8.9 Hz, 1H, CHar-11), 
7.48 (dd, J = 2.3, 0.8 Hz, 1H, CHar-2), 7.19 
(dd, J = 8.9, 2.7 Hz, 1H, CHar-10), 4.72 (d, J 
= 16.2 Hz, 1H, NCHH), 4.64 (d, J = 15.7 Hz, 
1H, NCHH), 3.98 (s, 3H, OCH3), 3.91 (s, 3H, 
OCH3), 3.78 (dd, J = 9.5, 4.8 Hz, 1H, CH), 
2.58 – 2.52 (m, 1H, CHH), 2.29 – 2.11 (m, 
2H, CHH& CHH), 1.70 – 1.57 (m, 1H, 
CHH), 1.46 (ddd, J = 20.1, 13.3, 6.6 Hz, 
2H, CHH& CHH). IR (film): ν (cm
-1) 3511, 
3432, 3230, 2920, 2852, 1714, 1655, 1567, 
1496, 1462, 1428, 1343, 1264, 1215, 1174, 
1101, 1061, 1020, 925, 859, 820, 776, 728, 
698, 658, 630, 575, 518, 476, 443, 400. 
HRMS calculated for C30H25ClN5NaO6Rh 
(M + Na)+ 712.0441, found (M + Na)+ 
712.0468. -(S)-138: Rf = 0.27 (methylene 
chloride : methanol 15:1). 1H-NMR 
(300 MHz, (CD3)2SO): δ(ppm) 11.21 (s, 1H, 
NH), 9.66 (d, J = 5.7 Hz, 1H, CHar-6’), 8.61 
(d, J = 2.4 Hz, 1H, CHar-4), 8.46 (td, J = 7.8, 
1.5 Hz, 1H, CHar-4’), 8.36 (dd, J = 2.4, 0.8 
Hz, 1H, CHar-2), 8.18 (d, J = 2.6 Hz, 1H, 
CHar-8), 8.04 – 7.93 (m, 2H, CHar-3’ & 
CHar-5’), 6.86 (dd, J = 9.0, 2.7 Hz, 1H, 
CHar-10), 5.55 (d, J = 8.9 Hz, 1H, CHar-11), 
4.60 (d, J = 15.9 Hz, 1H, NCHH), 4.31 (d, J 
= 15.7 Hz, 1H, NCHH), 4.13 (s, 3H, OCH3), 
3.82 (s, 3H, OCH3), 3.79 (d, J = 4.8 Hz, 1H, 
CH), 2.58 – 2.52 (m, 1H, CHH), 2.25 – 
2.14 (m, 2H, CHH& CHH), 2.01 (dt, J = 
18.9, 5.6 Hz, 1H, CHH), 1.71 – 1.57 (m, 
1H, CHH), 1.54 – 1.39 (m, 1H, CHH). IR 
(film): ν(cm-1) 3350, 2971, 1599, 1451, 1388, 
1297, 1270, 1235, 1179, 1155, 1099, 1011, 
971, 911, 861, 831, 780, 739, 701, 655, 595. 
HRMS calculated for C30H25ClN5NaO6Rh 
(M + Na)+ 712.0441, found (M + Na)+ 
712.0466. 
5.2.3.17 Synthesis of organorhodium(III) 
complexes -(R)-137 and 
-(R)-138 
 
 
A suspension of 83 (34.6 mg, 
75 µmol) and RhCl3∙3H2O (18.3 mg, 
69 µmol) in an ethanol : water mixture (1:1, 
15 mL) under nitrogen atmosphere in a 
sealed vessel was heated to 90 °C for 3 h. 
During this time the suspension turned from 
pale brown into dark red. The reaction mix-
ture was then cooled down slightly to add 
(R)-105 (15.5 mg, 75 µmol). After addition of 
(R)-105, the reaction was further proceeded 
at 90 °C for 16 h. The reaction mixture was 
then cooled down to ambient temperature 
and the solvent was removed in vacuo. The 
crude material was purified via column 
chromatography using methylene chlo-
ride : methanol (25:1  10:1). The separat-
ed diastereomers were further purified and 
concentrated via preparative TLC using 
methylene chloride : methanol (15:1). The 
products were obtained as dark purple sol-
ids, -(R)-137 (11.4 mg, 16.6 µmol, 24%) 
and -(R)-138 (6.6 mg, 9.7 µmol, 14%). 
-(R)-137: Rf = 0.16 (methylene chlo-
ride : methanol 15:1). 1H-NMR (300 MHz, 
(CD3)2SO): δ(ppm) 9.51 (d, J = 5.7 Hz, 1H, 
CHar-6’), 8.50 (d, J = 2.3 Hz, 1H, CHar-4), 
8.36 (td, J = 7.8, 1.5 Hz, 1H, CHar-4’), 8.20 
(d, J = 2.6 Hz, 1H, CHar-8), 7.98 – 7.87 (m, 
2H, CHar-3’ & CHar-5’), 7.65 (d, J = 8.9 Hz, 
1H, CHar-11), 7.48 (dd, J = 2.3, 0.8 Hz, 1H, 
CHar-2), 7.19 (dd, J = 9.0, 2.7 Hz, 1H, 
CHar-10), 4.72 (d, J = 16.1 Hz, 1H, NCHH), 
4.55 (d, J = 16.4 Hz, 1H, NCHH), 3.97 (s, 
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3H, OCH3), 3.90 (s, 3H, OCH3), 3.78 (dd, J 
= 9.4, 4.8 Hz, 1H, CH), 2.47 – 2.41 (m, 1H, 
CHH), 2.31 – 2.08 (m, 2H, CHH& 
CHH), 1.92 – 1.78 (m, 1H, CHH), 1.53 – 
1.38 (m, 1H, CHH), 1.18 – 1.02 (m, 1H, 
CHH). 
13C-NMR (75 MHz, (CD3)2SO): 
δ(ppm) 182.43 (Ccarbonyl), 170.88 (Car-7), 
170.34 (Car-5), 160.32 (Car-2’), 155.01 
(Car-3/Car-9), 153.72 (Car-9/Car-3), 153.08 
(Car-6’), 151.63 (Car-12b), 144.57 (Car), 
142.58 (Car), 140.76 (Car), 137.52 (Car), 
132.97 (Car), 131.68 (Car), 126.12 (Car), 
123.96 (Car), 123.50 (Car), 121.74 (Car), 
115.95 (Car), 115.28 (Car), 113.84 (Car), 
112.77 (Car), 112.10 (Car), 106.36 (Car), 
73.53 (C), 65.07 (NCH2) 61.53 (C), 56.27 
(OCH3), 55.58 (OCH3), 30.40 (C), 23.90 
(C). IR (film): ν (cm
-1) 1748, 1707, 1652, 
1567, 1499, 1465, 1425, 1340, 1269, 1211, 
1145, 1018, 929, 859, 815, 759, 696, 664, 
631, 515, 474, 446, 400. HRMS calculated 
for C30H25ClN5NaO6Rh (M + Na)
+ 712.0441, 
found (M + Na)+ 712.0461. -(R)-138: 
Rf = 0.27 (methylene chloride : methanol 
15:1). 1H-NMR (500 MHz, (CD3)2SO): 
δ(ppm) 9.65 (d, J = 5.8 Hz, 1H, CHar-6’), 
8.61 (d, J = 2.4 Hz, 1H, CHar-4), 8.46 (td, J = 
7.8, 1.5 Hz, 1H, CHar-4‘), 8.37 (dd, J = 2.4, 
0.6 Hz, 1H, CHar-2), 8.18 (d, J = 2.6 Hz, 1H, 
CHar-8), 8.04 – 7.99 (m, 1H, CHar-5‘), 7.97 
(d, J = 7.7 Hz, 1H, CHar-3‘), 6.86 (dd, J = 
8.9, 2.7 Hz, 1H, CHar-10), 5.55 (d, J = 9.0 
Hz, 1H, CHar-11), 4.60 (d, J = 15.7 Hz, 1H, 
NCHH), 4.31 (d, J = 15.7 Hz, 1H, NCHH), 
4.13 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.79 
(d, J = 4.7 Hz, 1H, CH), 2.55 – 2.51 (m, 1H, 
CHH), 2.28 – 2.17 (m, 2H, CHH& 
CHH), 2.00 (td, J = 12.1, 5.6 Hz, 1H, 
CHH), 1.68 – 1.58 (m, 1H, CHH), 1.13 (tt, 
J = 14.7, 7.2 Hz, 1H, CHH). 
13C-NMR (126 
MHz, (CD3)2SO): δ(ppm) 182.01 (Ccarbonyl), 
170.86 (Car-7), 170.31 (Car-5), 161.15 
(Car-2‘), 154.85 (Car-3/Car-9), 153.67 
(Car-9/Car-3), 153.60 (Car-6‘), 152.58 
(Car-12b), 143.56 (Car), 141.25 (Car), 140.28 
(Car), 137.24 (Car), 131.84 (Car), 126.32 (Car), 
123.95 (Car), 123.58 (Car), 122.12 (Car), 
115.71 (Car), 113.90 (Car), 113.36 (Car), 
112.68 (Car), 112.17 (Car), 107.18 (Car), 
72.75 (C), 69.89 (NCH2) 61.09 (C), 56.68 
(OCH3), 55.64 (OCH3), 30.18 (C), 24.38 
(C). IR (film): ν(cm
-1) 1818, 1751, 1708, 
1648, 1563, 1492, 1466, 1413, 1332, 1287, 
1263, 1209, 1169, 1059, 1003, 880, 854, 
821, 779, 760, 698, 670, 625, 521, 478. 
HRMS calculated for C30H25ClN5NaO6Rh 
(M + Na)+ 712.0441, found (M + Na)+ 
712.0466. 
5.2.3.18 Synthesis of organorhodium(III) 
complex-(S)-191 
 
 
80 (50.0 mg, 0.13 mmol) was sus-
pended in a mixture of ethanol/water (1:1, 
15 mL) and rhodium(III)-chloride trihydrate 
(34.7 mg, 0.13 mmol) was added. The mix-
ture was reacted at 90 °C for 3 h. Then, lig-
and (S)-178 (30.2 mg, 0.13 mmol) was add-
ed and the reaction was continued at 90 °C 
for 16 h. The solvent was evaporated under 
reduced pressure and the crude material 
was subjected to column chromatography 
using methylene chloride : methanol (20:1) 
followed by preparative TLC using meth-
ylene chloride : methanol (15:1). The prod-
uct -(S)-191 was obtained as red solid 
(6.5 mg, 9.1 µmol, 7%). Rf = 0.45 (methy-
lene chloride : methanol 15:1). 1H-NMR (300 
MHz, (CD3)2SO): δ(ppm) 9.69 (d, J = 5.6 Hz, 
1H, CHar-6’), 9.25 (dd, J = 8.4 Hz, 0.9 Hz, 
1H, CHar-4), 8.78 (d, J = 5.2 Hz, 1H, CHar-2), 
8.68 (d, J = 7.4 Hz, 1H, CHar-8), 8.45 (dd, J 
= 7.8 Hz, 1.3 Hz, 1H, CHar-4’), 8.06 – 7.96 
(m, 3H, 3xCHar), 7.41 – 7.15 (m, 6H, 
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6xCHar), 7.10 – 6.99 (m, 1H, CHar-10), 5.54 
(d, J = 8.1 Hz, 1H, CHar-11), 4.93 (s, 2H, 
CH2benzyl), 4.23-4.07 (m, 3H, NCH2 & CH), 
2.21-2.12 (m, 1H, CH), 0.86 (d, J = 7.0 Hz, 
6H, (CH32). IR (film): ν (cm
-1) 3384, 1691, 
1638, 1424, 1388, 1353, 1022, 995, 763, 
698, 631, 552, 429. HRMS calculated for 
C35H29ClN5O4RhNa (M + Na)
+ 744.0855, 
found (M + Na)+ 744.0857. 
5.2.3.19 Synthesis of organorhodium(III) 
complex -(S)-194 
 
 
77 (58.4 mg, 0.13 mmol) was sus-
pended in a mixture of ethanol/water (1:1, 
15 mL) and rhodium(III)-chloride trihydrate 
(34.7 mg, 0.13 mmol) was added. The mix-
ture was reacted at 90 °C for 3 h. Then, lig-
and (S)-178 (30.2 mg, 0.13 mmol) was add-
ed and the reaction was continued at 90 °C 
for 16 h. The solvent was evaporated under 
reduced pressure and the crude material 
was subjected to column chromatography 
using methylene chloride : methanol (20:1 
10:1) followed by preparative TLC using 
methylene chloride : methanol (15:1). The 
product -(S)-194 was obtained as purple 
solid (15.9 mg, 23.4 µmol, 18%,). Rf = 0.41 
(methylene chloride : methanol 15:1). 1H-
NMR (300 MHz, (CD3)2SO): δ(ppm) 9.65 (d, 
J = 5.5 Hz, 1H, CHar-6’), 9.30 (s, 1H, OH), 
8.95 (dd, J = 9.1 Hz, 2.3 Hz, 1H, CHar-4), 
8.56 (s, 1H, CHar), 8.45 (ddd, J = 8.8 Hz, 7.7 
Hz, 1.0 Hz, 1H, CHar-4’), 8.13 (d, J = 2.3 Hz, 
CHar-2), 8.03-7.96 (m, 2H, CHar-3‘ & 
CHar-5’), 7.12 (s, 1H, CHar), 6.69 (dd, J = 6.4 
Hz, J = 2.3 Hz, 1H, CHar-10), 5.35 (d, J = 8.8 
Hz, 1H, CHar-11), 4.25-4.09 (m, 3H, NCH2 & 
CH), 3.18 (s, 3H, NCH3), 2.24-2.11 (m, 1H, 
CH), 0.88 (d, J = 7.2 Hz, 3H, CH3), 0.58 (d, 
J = 6.9 Hz, 3H, CH3). IR (film): ν (cm
-1) 
3393, 2960, 2874, 1746, 1695, 1653, 1566, 
1464, 1416, 1374, 1331, 1300, 1158, 1029, 
884, 803, 740, 610, 510, 456. HRMS calcu-
lated for C29H24ClFN5O5RhNa (M + Na)
+ 
702.0397, found (M + Na)+ 702.0392. 
5.2.3.20 Synthesis of organorhodium(III) 
complexes -(R)-195 and 
-(S)-195 
 
 
77 (60.0 mg, 139 µmol) was sus-
pended in a mixture of ethanol/water (1:1, 
15 mL) and rhodium(III)-chloride trihydrate 
(36.3 mg, 139 µmol) was added. The mix-
ture was reacted at 90 °C for 3 h. Then, lig-
and (R)-182 (37.1 mg, 153 µmol) was added 
and the reaction was continued at 90 °C for 
16 h. The solvent was evaporated under 
reduced pressure and the crude material 
was subjected to column chromatography 
using methylene chloride : methanol (50:1 
 5:1) followed by preparative TLC using 
methylene chloride : methanol (20:1). The 
racemic products -(R)-195 and -(S)-195 
were obtained as purple solid (8.9 mg, 
12.5 µmol, 9%). Rf = 0.85 (methylene chlo-
ride : methanol 10:1). 1H-NMR (300 MHz, 
(CD3)2SO): δ(ppm) 9.72 (d, J = 5.9 Hz, 1H, 
CHar-6’), 9.27 (s, 1H, OH), 8.98-8.49 (dd, J = 
9.0, 2.4 Hz, 1H, CHar), 8.81 (s, 1H, CHar), 
8.47 (m, 1H, CHar), 8.03 (m, 3H, 3xCHar), 
7.78 (m, 1H, CHar), 7.13 (m, 5H, 5xCHar), 
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6.66 (m, 1H, CHar-10), 5.31 (m, 1H, 
CHar-11), 4.45 (m, 2H, NCH2), 4.02-3.96 (m, 
1H, CH), 3.16 (s, 3H, NCH3). 
5.2.3.21 Synthesis of organorhodium(III) 
complexes -196 
 
 
77 (20.0 mg, 44 µmol) was suspend-
ed in a mixture of ethanol/water (1:1, 15 mL) 
and rhodium(III)-chloride trihydrate 
(11.5 mg, 44 µmol) was added. The mixture 
was reacted at 90 °C for 3 h. Then, ligand 
189 (8.6 mg, 48 µmol) was added and the 
reaction was continued at 90 °C for 16 h. 
The solvent was evaporated under reduced 
pressure and the crude material was sub-
jected to column chromatography using 
methylene chloride : methanol (30:1  5:1) 
followed by preparative TLC using meth-
ylene chloride : methanol (20:1). The race-
mic products -(R)-195 and -(S)-195 was 
obtained as dark green solid (4.9 mg, 
7.5 µmol, 17%). Rf = 0.45 (methylene chlo-
ride : methanol 10:1). 1H-NMR (300 MHz, 
(CD3)2SO): δ(ppm) 9.63 (d, J = 5.7 Hz, 1H, 
CHar-6’), 9.31 (s, 1H, OH), 8.94 (dd, J = 9.2, 
2.3 Hz, 1H, CHar-4’), 8.73 (dd, J = 2.2, 1.6 
Hz, 1H, CHar-2), 8.46 (td, J = 7.8, 1.4 Hz, 
1H, CHar-4’), 8.11 (d, J = 2.4 Hz, 1H, 
CHar-8), 8.05 – 7.96 (m, 2H, CHar-3’ & 
CHar-5’), 6.74 (dd, J = 8.8, 2.5 Hz, 1H, 
CHar-10), 5.58 (d, J = 8.8 Hz, 1H, CHar-11), 
4.55 (d, J = 16.0 Hz, 1H, NCHH), 4.25 (d, J 
= 15.9 Hz, 1H, NCHH), 3.97 (d, J = 17.5 Hz, 
1H, CHH), 3.64 (d, J = 17.5 Hz, 1H, 
CHH), 3.16 (s, 3H, NimidCH3), 1.92 (s, 3H, 
NCH3). HRMS calculated for 
C27H20ClFN5NaO5Rh (M + Na)
+ 674.0084, 
found (M + Na)+ 674.0077. 
5.2.3.22 Synthesis of organorhodium(III) 
complexes -(R)-197 and 
-(R)-198 
 
 
A suspension of KBr (94.5 mg, 
792 µmol) and RhCl3∙3H2O (23 mg, 
88 µmol) in water (1:1, 8 mL) under nitrogen 
atmosphere in a sealed vessel was heated 
to 90 °C for 45 min. Then, 77 (40 mg, 
88 µmol) dissolved in ethanol (8 mL) was 
added and the reaction mixture was stirred 
for another 3 h at 90 °C. During this time the 
suspension turned from pale brown into dark 
green. The reaction mixture was then cooled 
down slightly to add 189 (17.2 mg, 96 µmol). 
After addition of 189, the reaction was fur-
ther proceeded at 90 °C for 16 h. The reac-
tion mixture was then cooled down to ambi-
ent temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol (20:1  
10:1). The separated diastereomers were 
further purified and concentrated via prepar-
ative TLC using methylene chlo-
ride : methanol (10:1). The products were 
obtained as dark green solids, -197 
(11.6 mg, 16.7 µmol, 19%) and -198 
(6.1 mg, 8.8 µmol, 10%). , -197: 
Rf = 0.30 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 9.70 (dd, J = 5.0, 1.6 Hz, 1H, 
CHar-6’), 9.36 (s, 1H, OH), 8.82 (dt, J = 9.2, 
2.4 Hz, 1H, CHar-4’), 8.39 – 8.29 (m, 1H, 
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CHar-4), 8.23 – 8.16 (m, 2H, CHar-2 & 
CHar-8), 7.95 – 7.87 (m, 2H, CHar-3’ & 
CHar-5’), 7.56 (d, J = 8.9 Hz, 1H, CHar-11), 
7.09 (dd, J = 8.9, 2.6 Hz, 1H, CHar-10), 4.75 
(d, J = 16.2 Hz, 1H, NCHH), 4.52 (d, J = 
16.4 Hz, 1H, NCHH), 3.68 (d, J = 4.1 Hz, 
2H, CH2), 3.16 (s, 3H, NimidCH3), 1.73 (s, 
3H, NCH3). IR (film): ν (cm
-1) 2922, 2852, 
2243, 2181, 2126, 2001, 1749, 1696, 1650, 
1564, 1502, 1443, 1411, 1368, 1330, 1296, 
1221, 1153, 1021, 992, 882, 815, 758, 690, 
608, 515, 451. HRMS calculated for 
C27H20BrFN5NaO5Rh (M + Na)
+ 719.2753, 
found (M + Na)+ 719.9553. -198: 
Rf = 0.48 (methylene chloride : methanol 
10:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 9.84 (d, J = 5.8 Hz, 1H, CHar-6’), 
9.31 (s, 1H, CHar), 8.94 (dd, J = 9.2, 2.4 Hz, 
1H, CHar), 8.75 – 8.70 (m, 1H, CHar), 8.45 
(td, J = 7.8, 1.4 Hz, 1H, CHar-4’), 8.11 (d, J = 
2.4 Hz, 1H, CHar), 8.04 – 7.95 (m, 2H, 
CHar-3’ & CHar-5’), 6.74 (dd, J = 8.8, 2.5 Hz, 
1H, CHar-10), 5.57 (d, J = 8.8 Hz, 1H, 
CHar-10), 4.54 (d, J = 16.1 Hz, 1H, NCHH), 
4.23 (d, J = 15.9 Hz, 1H, NCHH), 3.91 (d, J 
= 17.4 Hz, 1H, CHH), 3.59 (d, J = 17.5 Hz, 
1H, CHH), 3.16 (s, 3H, NimidCH3), 1.86 (s, 
3H, NCH3). IR (film): ν(cm
-1) 1748, 1655, 
1559, 1526, 1492, 1438, 1406, 1371, 1322, 
1288, 1198, 1145, 1020, 984, 953, 924, 884, 
842, 793, 753, 688, 610, 524, 447. HRMS 
calculated for C27H21BrFN5O5Rh (M + H)
+ 
697.2935, found (M + H)+ 697.9729. 
5.2.3.23 Synthesis of organorhodium(III) 
complexes -(R)-199 and 
-(R)-200 
 
 
A suspension of 77 (20 mg, 44 µmol) 
and RhCl3∙3H2O (11.5 mg, 44 µmol) in an 
ethanol : water mixture (1:1, 20 mL) under 
nitrogen atmosphere in a sealed vessel was 
heated to 90 °C for 3 h. During this time the 
suspension turned from pale brown into dark 
green. The reaction mixture was then cooled 
down slightly to add (R)-105 (9.9 mg, 
48 µmol). After addition of (R)-105, the reac-
tion was further proceeded at 90 °C for 16 h. 
The reaction mixture was then cooled down 
to ambient temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol (25:1  
10:1). The separated diastereomers were 
further purified and concentrated via prepar-
ative TLC using methylene chlo-
ride : methanol (15:1). The products were 
obtained as dark green solids, -(R)-199 
(6.3 mg, 9.3 µmol, 21%) and -(R)-200 
(3.8 mg, 5.7 µmol, 13%). -(R)-199: 
Rf = 0.13 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 9.50 (d, J = 5.6 Hz, 1H, CHar-6’), 
9.36 (s, 1H, OH), 8.81 (dd, J = 9.2, 2.2 Hz, 
1H, CHar-4), 8.35 (td, J = 7.8, 1.5 Hz, 1H, 
CHar-4’), 8.14 (d, J = 2.4 Hz, 1H, CHar-8), 
8.09 – 8.03 (m, 1H, CHar-2), 7.97 – 7.87 (m, 
2H, CHar-3’ & CHar-5’), 7.62 (d, J = 8.8 Hz, 
1H, CHar-11), 7.09 (dd, J = 8.8, 2.5 Hz, 1H, 
CHar-10), 4.75 (d, J = 16.1 Hz, 1H, NCHH), 
4.57 (d, J = 16.1 Hz, 1H, NCHH), 3.77 (dd, J 
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= 9.4, 5.1 Hz, 1H, CH), 3.15 (s, 3H, NCH3), 
2.52 – 2.48 (m, 1H, CHH) 2.18 (dt, J = 
13.4, 6.1 Hz, 2H, CHH& CHH), 1.82 (td, 
J = 11.7, 5.6 Hz, 1H, CHH), 1.55 – 1.40 
(m, 1H, CHH), 1.17 – 1.01 (m, 1H, CHH). 
13C-NMR (75 MHz, (CD3)2SO): δ(ppm) 
182.28 (Ccarbonyl), 169.02 (Car-7), 168.73 
(Car-5), 160.17 (Car-2’), 156.77 (d, J = 252.4 
Hz, Car-3), 152.15 (Car-12b), 151.87 (Car-6’), 
151.62 (Car-9), 143.68 (Car), 140.87 (Car), 
140.66 (Car), 140.41 (Car), 139.68 (Car), 
131.37 (Car), 126.02 (Car), 123.90 (Car), 
123.67 (Car), 120.57 (d, J = 8.1 Hz, Car-4a), 
118.63 (d, J = 21.0 Hz, Car-4), 117.03 (Car), 
115.32 (Car), 114.68 (Car), 111.04 (Car), 
108.64 (Car), 73.42 (C), 69.36 NCH2), 61.33 
(C), 30.34 (C), 23.67 (C), 23.63 (NCH3). 
IR (film): ν (cm-1) 2921, 2852, 1747, 1697, 
1619, 1566, 1502, 1444, 1411, 1373, 1331, 
1272, 1220, 1151, 1065, 987, 958, 882, 805, 
766, 731, 690, 610, 579. HRMS calculated 
for C29H22ClFN5NaO5Rh (M + Na)
+ 
700.0241, found (M + Na)+ 700.0257. 
-(R)-200: 1H-NMR (300 MHz, Rf = 0.22 
(methylene chloride : methanol 15:1). 
(CD3)2SO): δ(ppm) 9.65 (d, J = 5.6 Hz, 1H, 
CHar-6’), 9.32 (s, 1H, OH), 8.93 (dd, J = 9.1, 
2.3 Hz, 1H, CHar-4), 8.72 – 8.60 (m, 1H, 
CHar-2), 8.47 (td, J = 7.7, 1.2 Hz, 1H, 
CHar-4’), 8.12 (d, J = 2.4 Hz, 1H, CHar-8), 
8.06 – 7.93 (m, 2H, CHar-3’ & CHar-5’), 6.74 
(dd, J = 8.8, 2.5 Hz, 1H, CHar-10), 5.51 (d, J 
= 8.8 Hz, 1H, CHar-11), 4.63 (d, J = 15.7 Hz, 
1H, NCHH), 4.32 (d, J = 15.6 Hz, 1H, 
NCHH), 3.80 (dd, J = 9.3, 5.0 Hz, 1H, CH), 
3.14 (s, 3H, NCH3), 2.62 – 2.52 (m, 1H, 
CHH), 2.34 – 2.16 (m, 2H, CHH& 
CHH), 2.12 – 1.98 (m, 1H, CHH), 1.65 
(dt, J = 18.6, 6.0 Hz, 1H, CHH), 1.24 – 1.02 
(m, 1H, CHH). 
13C-NMR (75 MHz, 
(CD3)2SO): δ(ppm) 181.83 (Ccarbonyl), 168.94 
(Car-7), 168.65 (Car-5), 161.12 (Car-2’), 
156.54 (d, J = 252.9 Hz, Car-3), 152.72 
(Car-12b), 152.58 (Car-6’), 151.87 (Car-9), 
142.69 (Car), 142.67 (Car), 141.25 (Car), 
139.46 (Car), 137.81 (d, J = 34.5 Hz, Car-2), 
131.56 (Car), 126.29 (Car), 124.06 (Car), 
123.56 (Car), 121.03 (d, J = 8.3 Hz, Car-4a), 
119.31 (d, J = 20.2 Hz, Car-4), 116.92 (Car), 
114.87 (Car), 112.28 (Car), 111.64 (Car-10), 
109.19 (Car-11), 72.76 (C), 69.84 (NCH2), 
61.00 (C), 30.17 (C), 24.20 (C), 23.65 
(NCH3). IR (film): ν(cm
-1) 2921, 2850, 1744, 
1694, 1615, 1563, 1502, 1441, 1411, 1370, 
1329, 1270, 1217, 1151, 1062, 985, 958, 
880, 801, 762, 731, 688, 607, 575. HRMS 
calculated for C29H22ClFN5NaO5Rh 
(M + Na)+ 700.0241, found (M + Na)+ 
700.0254. 
5.2.3.24 Synthesis of organorhodium(III) 
complexes -(S)-199 and -(S)-200 
 
 
A suspension of 77 (20 mg, 44 µmol) 
and RhCl3∙3H2O (11.5 mg, 44 µmol) in an 
ethanol : water mixture (1:1, 20 mL) under 
nitrogen atmosphere in a sealed vessel was 
heated to 90 °C for 3 h. During this time the 
suspension turned from pale brown into dark 
green. The reaction mixture was then cooled 
down slightly to add (S)-105 (9.9 mg, 
48 µmol). After addition of (S)-105, the reac-
tion was further proceeded at 90 °C for 16 h. 
The reaction mixture was then cooled down 
to ambient temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol (25:1  
10:1). The separated diastereomers were 
further purified and concentrated via prepar-
ative TLC using methylene chlo-
ride : methanol (15:1). The products were 
obtained as dark green solids, -(S)-199 
(6.8 mg, 10.1 µmol, 23%) and -(S)-200 
(4.7 mg, 7.0 µmol, 16%). -(S)-199: 
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Rf = 0.13 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 9.50 (d, J = 5.6 Hz, 1H, CHar-6’), 
9.41 (s, 1H, OH), 8.82 (dd, J = 9.2, 2.1 Hz, 
1H, CHar-4), 8.36 (td, J = 7.8, 1.4 Hz, 1H, 
CHar-4’), 8.14 (d, J = 2.4 Hz, 1H, CHar-8), 
8.10 – 8.05 (m, 1H, CHar-2), 7.98 – 7.88 (m, 
2H, CHar-3’ & CHar-5’), 7.61 (d, J = 8.8 Hz, 
1H, CHar-11), 7.08 (dd, J = 8.8, 2.5 Hz, 1H, 
CHar-10), 4.74 (d, J = 16.0 Hz, 1H, NCHH), 
4.54 (d, J = 16.1 Hz, 1H, NCHH), 3.77 (dd, J 
= 9.5, 5.2 Hz, 1H, CH), 3.16 (s, 3H, NCH3), 
2.45 – 2.38 (m, 1H, CHH), 2.24 – 2.10 (m, 
2H, CHH& CHH), 1.90 – 1.72 (m, 1H, 
CHH), 1.53 – 1.38 (m, 1H, CHH), 1.17 – 
1.01 (m, 1H, CHH). 
13C-NMR (75 MHz, 
(CD3)2SO): δ(ppm) 182.29 (Ccarbony), 169.02 
(Car-7), 168.73 (Car-5), 160.17 (Car-2’), 
156.47 (d, J = 245.5 Hz, Car-3), 152.16 
(Car-12b), 151.87 (Car-6’), 151.62 (Car-9), 
147.32 (Car), 144.37 (Car), 143.68 (Car), 
140.67 (Car), 139.81 (d, J = 19.1 Hz, Car-2), 
132.52 (Car), 131.37 (Car), 126.02, 123.79 
(d, J = 18.0 Hz, Car-4), 119.33 (Car), 118.49 
(Car), 117.04 (Car), 115.32 (Car), 114.67 (Car), 
110.98 (Car), 108.63 (Car), 73.42 (C), 69.35 
(NCH2), 61.33 (C), 30.35 (C), 23.67 (C), 
23.64 (NCH3). IR (film): ν (cm
-1) 2920, 2852, 
1747, 1698, 1619, 1567, 1502, 1444, 1412, 
1374, 1332, 1272, 1221, 1152, 1089, 987, 
960, 937, 882, 806, 770, 732, 691, 611, 581. 
HRMS calculated for C29H22ClFN5NaO5Rh 
(M + Na)+ 700.0241, found (M + Na)+ 
700.0225. -(S)-200: Rf = 0.22 (methylene 
chloride : methanol 15:1). 1H-NMR 
(300 MHz, CD3CN): δ(ppm) 9.82 – 9.73 (m, 
1H, CHar-6‘), 8.98 (dd, J = 9.2, 2.4 Hz, 1H, 
CHar-4), 8.69 (td, J = 2.4, 0.9 Hz, 1H, 
CHar-4‘), 8.33 (td, J = 7.8, 1.5 Hz, 1H, 
CHar-2), 8.21 (d, J = 2.6 Hz, 1H, CHar-8), 
7.94 – 7.79 (m, 2H, CHar-3‘ & CHar-5‘), 6.76 
(dd, J = 8.9, 2.6 Hz, 1H, CHar-10), 5.66 – 
5.57 (m, 1H, CHar-11), 4.44 (d, J = 15.5 Hz, 
1H, NCHH), 4.36 (d, J = 15.2 Hz, 1H, 
NCHH), 3.67 (dd, J = 9.4, 5.2 Hz, 1H, CH), 
3.19 (s, 3H, NCH3), 2.52 – 2.41 (m, 1H, 
CHH), 2.40 – 2.31 (m, 2H, CHH& 
CHH), 1.70 – 1.59 (m, 1H, CHH), 1.37 – 
1.29 (m, 2H, CHH& CHH). 
13C-NMR (75 
MHz, (CD3)2SO): δ(ppm) 181.84 (Ccarbonyl), 
168.94 (Car-7), 168.65 (Car-5), 161.12 
(Car-2‘), 156.56 (d, J = 251.0 Hz, Car-3), 
152.72 (Car-12b), 152.58 (Car-6’), 151.88 
(Car-9), 142.70 (Car), 141.26 (Car), 139.46 
(Car), 137.82 (d, J = 34.7 Hz, Car-2), 131.57 
(Car), 126.30 (Car), 124.06 (Car), 123.57 (Car), 
121.03 (d, J = 8.0 Hz, Car-4a), 119.32 (d, J = 
20.3 Hz, Car-4), 116.92 (Car), 114.87 (Car), 
112.29 (Car-10), 111.58 (Car), 109.19 
(Car-11), 72.76 (C), 69.85 (NCH2), 61.00 
(C), 30.17 (C), 24.21 (C), 23.66 (NCH3). 
IR (film): ν(cm-1) 2923, 2851, 1747, 1678, 
1622, 1562, 1492, 1439, 1408, 1369, 1328, 
1291, 1225, 1201, 1154, 1058, 985, 957, 
932, 883, 839, 794, 763, 688, 646, 611, 581, 
520, 448, 397. HRMS calculated for 
C29H22ClFN5NaO5Rh (M + Na)+ 700.0241, 
found (M + Na)+ 700.0254. 
5.2.3.25 Synthesis of organorhodium(III) 
complexes -(S)-201 and -(S)-202 
 
 
A suspension of KBr (94.5 mg, 
792 µmol) and RhCl3∙3H2O (23 mg, 
88 µmol) in water (1:1, 8 mL) under nitrogen 
atmosphere in a sealed vessel was heated 
to 90 °C for 45 min. Then, 77 (40 mg, 
88 µmol) dissolved in ethanol (8 mL) was 
added and the reaction mixture was stirred 
for another 3 h at 90 °C. During this time the 
suspension turned from pale brown into dark 
green. The reaction mixture was then cooled 
down slightly to add (S)-105 (19.8 mg, 
96 µmol). After addition of (S)-105, the reac-
tion was further proceeded at 90 °C for 16 h. 
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The reaction mixture was then cooled down 
to ambient temperature and the solvent was 
removed in vacuo. The crude material was 
purified via column chromatography using 
methylene chloride : methanol (20:1  
10:1). The separated diastereomers were 
further purified and concentrated via prepar-
ative TLC using methylene chlo-
ride : methanol (10:1). The products were 
obtained as dark green solids, -(S)-201 
(12.1 mg, 16.7 µmol, 19%) and -(S)-202 
(7.6 mg, 10.6 µmol, 12%). -(S)-201: 
Rf = 0.11 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 9.70 (d, J = 6.3 Hz, 1H, CHar-6’), 
9.35 (s, 1H, OH), 8.82 (dd, J = 9.2, 2.2 Hz, 
1H, CHar-4), 8.35 (td, J = 7.8, 1.4 Hz, 1H, 
CHar-4’), 8.14 (d, J = 2.3 Hz, 1H, CHar-8), 
8.11 – 8.04 (m, 1H, CHar-2), 7.98 – 7.86 (m, 
2H, CHar-3’ & CHar-5’), 7.60 (d, J = 8.8 Hz, 
1H, CHar-11), 7.07 (dd, J = 8.8, 2.5 Hz, 1H, 
CHar-10), 4.73 (d, J = 15.8 Hz, 1H, NCHH), 
4.55 (d, J = 16.3 Hz, 1H, NCHH), 3.72 (dd, J 
= 9.4, 5.1 Hz, 1H, CH), 3.16 (s, 3H, NCH3), 
2.45 – 2.39 (m, 1H, CHH), 2.15 (ddd, J = 
17.5, 12.3, 6.3 Hz, 2H, CHH& CHH), 
1.87 – 1.74 (m, 1H, CHH), 1.49 – 1.39 (m, 
1H, CHH), 1.15 – 1.00 (m, 1H, CHH). IR 
(film): ν (cm-1) 2928, 2872, 1748, 1695, 
1651, 1564, 1502, 1442, 1411, 1371, 1330, 
1290, 1203, 1150, 1102, 1053, 1026, 995, 
962, 934, 882, 811, 766, 688, 649, 610, 522, 
484, 453, 404. HRMS calculated for 
C29H22BrFN5NaO5Rh (M + Na)
+ 743.9736, 
found (M + Na)+ 743.9722. -(S)-202: 
Rf = 0.30 (methylene chloride : methanol 
15:1). 1H-NMR (300 MHz, (CD3)2SO): 
δ(ppm) 9.86 (d, J = 6.5 Hz, 1H, CHar-6’), 
9.33 (s, 1H, OH), 8.95 (dd, J = 9.2, 2.3 Hz, 
1H, CHar-4), 8.66 (d, J = 2.5 Hz, 1H, CHar-2), 
8.46 (td, J = 7.6, 1.4 Hz, 1H, CHar-4’), 8.13 
(d, J = 2.5 Hz, 1H, CHar-8), 8.06 – 7.93 (m, 
2H, CHar-3’ & CHar-5’), 6.73 (dd, J = 8.9, 2.5 
Hz, 1H, CHar-10), 5.50 (d, J = 8.8 Hz, 1H, 
CHar-11), 4.61 (d, J = 15.4 Hz, 1H, NCHH), 
4.29 (d, J = 14.8 Hz, 1H, NCHH), 3.75 (dd, J 
= 9.1, 4.4 Hz, 1H, CH), 3.17 (s, 3H, NCH3), 
2.60 – 2.56 (m, 1H, CHH), 2.24 – 2.12 (m, 
2H, CHH& CHH), 2.05 – 1.92 (m, 1H, 
CHH), 1.59 (ddd, J = 14.9, 11.0, 4.2 Hz, 
1H, CHH), 1.37 – 1.27 (m, 1H, CHH). 
HRMS calculated for C29H22BrFN5NaO5Rh 
(M + Na)+ 743.9736, found (M + Na)+ 
743.9732.  
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5.3 Biological Experiments 
5.3.1 PI3K Kinase-Glo Assay 
 
The PI3K Kinase-Glo Assays for the 
IC50 determinations were performed in the 
MARMORSTEIN group by JIE QIN AND JULIE S. 
BARBER-ROTENBERG, the Wistar Institute, 
3601 Spruce Street, Philadelphia, Pennsyl-
vania 19104, United States. Recombinantly 
expressed human PI3K catalytic domain or 
PI3K respectively, was preincubated with 
various concentrations of inhibitors with a 
final DMSO concentration of 2% in reaction 
buffer (20 mM Tris pH 7.5, 100 mM NaCl, 
10 mM MgCl2) for 1 h at RT. Then, this mix-
ture was added to a solution of 0.1 mg/mL 
D-myo-phosphatidylinositol-4,5-bisphophate 
(PtdIns(4,5)P2, Echelon Bio-sciences) and 
10 µM ATP. 1.4 pmoles PI3K were used for 
each compound. The kinase reaction was 
carried out in a final volume of 50 µL in a 96-
well microtiter plate at 37 °C for 3 h. Then, 
50 µL of Kinase-Glo (Promega) developing 
solution was added into the mixture to gen-
erate a luminescence signal. The signal was 
recorded using the PerkinElmer Wallac 
1420 luminometer using a luminescence 
filter. Data were processed and IC50 values 
were normalised to control samples using 
2% DMSO and no kinase. The sigmoidal 
dose response curve fitting was processed 
using Origin8. 
5.3.2 Cloning, Expression, and Purifica-
tion of S6K1 Constructs 
 
The cloning, expression and purifica-
tion of S6K1 constructs were performed in 
the MARMORSTEIN group by JIE QIN, the 
Wistar Institute, 3601 Spruce Street, Phila-
delphia, Pennsylvania 19104, United States. 
Full length human S6K1 cDNA (1−525) was 
purchased from Epitope (catalogue number 
IHS1380-97652397). S6K1 constructs 
(84−384, 1−421, 1−421 T412E) were sub-
cloned into the pFASTbac HTB vector for 
protein expression. Sf9 cells were transfect-
ed with the recombinant bacmid DNA using 
Cellfectin (Invitrogen). Cells were harvested 
after being incubated for 48 h at 28 °C and 
stored at −80 °C. The 1−421 T412E con-
struct was coexpressed with PDK1 to phos-
phorylate the T412E residue (cloned from 
cDNA purchased from OpenBioSystems). 
Frozen pellets of the S6K1 kinase domain, 
S6K1(84−384) used for crystallography 
were resuspended in sonication buffer 
(50 mM KPi, pH 7.0, 250 mM NaCl, 5% 
glycerol, 1:1000 PMSF) and sonicated at a 
power output of 5.5 for 120 s with 20 s inter-
vals (Misonix Sonicator 3000). Lysates were 
cleared by highspeed centrifugation at 18 
000 rpm for 35 min at 4 °C. Equilibrated 
Talon metal affinity resin (Clontech) was 
added to cleared lysates and incubated at 
4 °C for 1 h with gentle shaking. The res-
in/lysate mixture was loaded into a gravi-
tyflow column, and the resin was extensively 
washed with wash buffer (50 mM KPi, 
pH 7.0, 250 mM NaCl, 5% glycerol). Protein 
was then eluted with elution buffer (50 mM 
KPi, pH 7.0, 250 mM NaCl, 500 mM imidaz-
ole, and 5% glycerol) in a single step. 
Pooled Talon eluent was diluted 3.5-fold in 
dilution buffer (50 mM KPi, pH 7.0, 5% glyc-
erol) and loaded onto an SP anion ex-
change column pre-equilibrated with buffer 
A (50 mM KPi, pH 7.0, 50 mM NaCl, 5% 
glycerol). Protein was eluted with buffer B 
(50 mM KPi, pH 7.0, 500 mM NaCl, 5% glyc-
erol) in a single step. Elution after the Q col-
umn was concentrated and loaded to a Su-
perdex s200 column equilibrated with 50 mM 
Na citrate, pH 6.5, 300 mM NaCl, 1 mM DTT, 
5% glycerol. The eluent was collected and 
concentrated to 3 mg/mL before protein 
wasflash frozen in dry ice and stored at 
−80 °C. Purification of the 1−421 T412E 
construct was completed as above, with 
gelfiltration on the Superdex s200 column 
using a buffer containing 25 mM Tris, 
pH 7.5, 200 mM NaCl, 1 mM EDTA, and 5% 
glycerol. 
 
188 Experimental 
5.3.3 Cloning, Expression, and Purifica-
tion of S6K2 Construct 
 
The cloning, expression and purifica-
tion of S6K2 constructs were performed in 
the MARMORSTEIN group by JULIE S. BAR-
BER-ROTENBERG, the Wistar Institute, 3601 
Spruce Street, Philadelphia, Pennsylvania 
19104, United States. Full-length human 
S6K2 cDNA was purchased from GE 
Healthcare Dharmacon (RPS6KB2, clone 
identification number 2959036). The S6K2 
1−423 construct, equivalent to S6K1 1−421, 
was subcloned into the pFASTbac HTB vec-
tor for protein expression. Sf9 cells were 
transfected and grown as described above. 
The construct was coexpressed with PDK1, 
similar to the S6K1 construct. Frozen pellets 
were purified identically to the S6K1 1−423 
T412E pellets. 
5.3.4 Radioactive Kinase Assay target-
ing S6K1 and S6K2 constructs 
 
The radioactive kinase assay target-
ing S6K1 and S6K2 constructs were per-
formed in the MARMORSTEIN group by JULIE 
S. BARBER-ROTENBERG, the Wistar Institute, 
3601 Spruce Street, Philadelphia, Pennsyl-
vania 19104, United States. Each reaction 
mixture contained 5 μL of 5×reaction buffer 
(100 mM MOPS, pH 7.0, 150 mM MgCl2), 
2 μL of inhibitor in 50% DMSO, 3.6 μL of 
S6K1 substrate peptide (RRRLSSLRA), 
1 μL of BSA (20 mg/mL), 3.2 μL of S6K1 
(concentration as described in results), and 
5 μL of ATP/ATP* mix (concentration as 
described in results) in a total reaction vol-
ume of 25 μL. Reaction mixtures were incu-
bated for 1 h at ambient temperature before 
being transferred to Whatman paper and 
washed with 0.75% phosphoric acid. Data 
were collected using a scintillation counter. 
All experiments were performed in triplicate. 
IC50 values were determined using sigmoidal 
dose response with a variable curve in 
Origin 8. 
5.3.5 Cell Culture and Western Blotting 
 
Cell culture and Western blotting 
were performed in the MARMORSTEIN group 
by PATRICIA REYES-URIBE, the Wistar Insti-
tute, 3601 Spruce Street, Philadelphia, 
Pennsylvania 19104, United States. Human 
cell lines were cultured in RPMI (10-040-
CM; Cellgro) supplemented with 5% fetal 
bovine serum and harvested at 70% conflu-
ence. For immunoblotting, cells were treated 
for the specified times with the indicated 
drugs, washed with cold phosphate buffered 
saline (PBS) containing 100 mM Na3VO4, 
and lysed using TNE buffer (150 mM NaCl, 
1% (v/v) NP-40, 2 mM EDTA, 50 mM Tris-
HCl, pH 8.0) supplemented with protease 
inhibitors (11697498001; Roche). Proteins 
were separated by SDS−PAGE and trans-
ferred to nitrocellulose membranes 
(9004700; BioRad). After blocking for 1 h in 
5% (wt/vol) dry milk/Tris-buffered saline 
(TBS)/0.1% (v/v) Tween-20, membranes 
were incubated overnight at 4 °C with prima-
ry antibodies followed by incubation with 
Alexa Fluor-labeled secondary antibodies 
(IRDye 680LT goat-antimouse or IRDye 
800CW goat-anti-rabbit antibodies (LI-COR 
Biosciences) for 1 h. -Actin (A5441) and 
vinculin (V9131) antibodies were obtained 
from Sigma. p-AKT (4056, 4060), S6 (2317), 
p-S6 (4858, 5364), S6K1 (2708), p-S6K1 
(9234), p-eEF2k (3691), peIF4B (3591), and 
cleaved PARP (5625) were obtained from 
Cell Signaling Technologies. Fluorescent 
images were acquired and by LI-COR Od-
yssey Imaging System. 
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5.3.6 Yeast Cell Culture and Lysis 
 
Yeast cell culture and lysis were per-
formed in the DANG group by HAIYING LIU, 
Huffington Center on Aging, Baylor College 
of Medicine, Houston, Texas 77030, United 
States. Overnight cultures of wild-type yeast 
cells (BY4742) were diluted in synthetic 
complete (SC) medium and regrown at 
30 °C to early log phase (OD600 of 0.2). 87 
was added to an aliquot of culture to the 
final concentration of 1, 10, 100, and 
1000 nM. The treated cultures were further 
grown at 30 °C for 4 h before harvesting. A 
culture of sch9 cells (KS68) was grown 
and harvested in parallel as a control. Yeast 
cell pellets were lysed by spinning down 
cultures at ∼3000 rpm for 3 min at 4 °C, 
washing with ice-cold water, and broken in 
lysis buffer as previously described.[432] 
Whole cell extracts were separated on a 
4−12% Bolt gel with MOPS running buffer 
(Life Technologies), followed by transfer to a 
PVDF membrane in a Mini Trans-Blot cell 
(Bio-Rad) at 20 V overnight. The blot was 
blocked with 3% BSA at room temperature 
for 2 h and then at 4 °C for 4 h, followed by 
incubation with primary antibodies, Phos-
pho-S6 (Cell Signaling, catalog no. 2211, 
1:1000 dilution), and GAPDH (Thermo, cata-
log no. MA5-15738, 1:1000 dilution) at 4 °C 
overnight. Incubation with secondary anti-
bodies (anti-rabbit-DyLight-680 and anti-
mouse-DyLight-800, Pierce, 1:10000 dilu-
tion) was carried out at room temperature 
for 1 h before imaging with Li-Cor Odyssey. 
5.3.7 Radioactive Kinase Assay target-
ing PIM-1, Aurora A, and FLT 3 
 
Various concentrations of the rhodi-
um(III) complexes were incubated at ambi-
ent temperature in 20 mM 3-(N-morpho-
lino)propanesulfonic acid/ sodium hydroxide, 
1 mM ethylenediaminetetraacetic acid 
(EDTA), 0.01% Brij 35, 5% 2-mercapto-
ethanol, 1 mg/mL bovine serum albumin 
(BSA), and 10% DMSO (resulting from the 
inhibitor stock solution) at pH 7.0 in the 
presence of a kinase substrate for an incu-
bation time of T1. The reaction was then 
initiated by adding ATP in a final concentra-
tion of 10 μM and approximately 0.1 μCi/μL 
of [-33P]-ATP. Reactions were performed in 
a total volume of 25 μL. After an incubation 
time of T2, the reaction was terminated by 
spotting 17.5 μL of the reaction mixture on a 
circular P81 phosphocellulose paper (2.1 cm 
diameter, Whatman), followed by washing 
three times with 0.75% phosphoric acid and 
once with acetone. The dried P81 papers 
were transferred to scintillation vials and 
added with 5 mL of scintillation cocktail 
(purchased from Roth). The counts per mi-
nute (CPM) were measured using a Beck-
mann Coulter LS6500 multipurpose scintilla-
tion counter and corrected by the 
background CPM. The IC50 values were 
determined in dublicat for each single con-
centration and compound. The experiments 
were repeated independently under the 
same conditions to verify the results. Non-
linear regression and data evaluation were 
performed using OriginPro 8G (OriginLab). 
Modifications for the corresponding kinase 
targets: The amount of PIM-1 used was 
0.1 ng/μL, the concentration of the kinase 
substrate S6 was 50 μM (purchased from 
MoBiTec), and the incubation times 
wereT1 = 30 min and T2 = 30 min. The 
amount of Aurora A used was 0.13 ng/μL, 
the concentration of the kinase substrate 
Kemptide was 250 μM (purchased from 
Promega), and the incubation times were 
T1 = 45 min and T2 = 45 min. The amount of 
FLT-3 used was 1 ng/mL, the concentration 
of Abltide was 100 μM (purchased from 
Merck Millipore), and incubation times were 
T1 = 90 min and T2 = 90 min. All kinases 
were purchased from Merck Millipore.  
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5.4 Kinase Profiling 
5.4.1 Kinase Profiling of Complexes 85, 
and 86 
 
The compounds 85 and 86 were pro-
filed by the Millipore (KinaseProfilerTM) 
against a panel of 263 kinases. Shown are 
the remaining kinase activities at a concen-
tration of 100 nM of 85 or 86. The presence 
of ATP is 10 µM. 
Table 4: Kinome Profiling 85 and 86. 
  
85 (0.1 µM) 86 (0.1 µM) 
Abl(h) 96 101 
Abl(m) 96 103 
Abl (H396P) (h) 96 99 
Abl (M351T)(h) 95 106 
Abl (Q252H) (h) 90 95 
Abl(T315I)(h) 103 107 
Abl(Y253F)(h) 118 120 
ACK1(h) 53 96 
ALK(h) 30 60 
ALK4(h) 122 123 
Arg(h) 93 93 
AMPK(r) 49 93 
Arg(m) 90 113 
ARK5(h) 31 88 
ASK1(h) 114 104 
Aurora-A(h) 44 117 
Axl(h) 63 100 
Blk(m) 8 113 
Bmx(h) 107 124 
BRK(h) 110 114 
BrSK1(h) 51 92 
BrSK2(h) 32 80 
BTK(h) 78 99 
BTK(R28H)(h) 111 112 
CaMKI(h) 79 108 
CaMKIIβ(h) 28 63 
CaMKIIγ(h) 5 29 
CaMKIδ(h) 21 49 
CaMKIIδ(h) 5 23 
CaMKIV(h) 11 59 
CDK1/cyclinB(h) 97 120 
CDK2/cyclinA(h) 82 115 
CDK2/cyclinE(h) 83 103 
CDK3/cyclinE(h) 116 119 
CDK5/p25(h) 69 106 
CDK5/p35(h) 58 98 
CDK7/cyclinH/MAT1(h) 25 114 
CDK9/cyclin T1(h) 75 108 
CHK1(h) 65 97 
CHK2(h) 34 89 
CHK2(I157T)(h) 37 87 
CHK2(R145W)(h) 33 88 
CK1γ1(h) 3 66 
CK1γ2(h) -3 44 
CK1γ3(h) -2 28 
CK1δ(h) 2 24 
CK1(y) 3 14 
CK2(h) 112 113 
CK2α2(h) 113 107 
CLK2(h) 1 2 
CLK3(h) 90 105 
cKit(h) 113 121 
cKit(D816V)(h) 91 103 
cKit(D816H)(h) 5 54 
cKit(V560G)(h) 13 64 
cKit(V654A)(h) 20 73 
CSK(h) 108 102 
c-RAF(h) 100 111 
cSRC(h) 40 80 
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DAPK1(h) 2 21 
DAPK2(h) 2 8 
DCAMKL2(h) 72 97 
DDR2(h) 92 92 
DMPK(h) 112 110 
DRAK1(h) 59 94 
DYRK2(h) 110 114 
eEF-2K(h) 105 107 
EGFR(h) 114 121 
EGFR(L858R)(h) 61 88 
EGFR(L861Q)(h) 108 111 
EGFR(T790M)(h) 83 111 
EGFR(T790M,L858R)(
h) 
31 85 
EphA1(h) 107 107 
EphA2(h) 99 97 
EphA3(h) 110 115 
EphA4(h) 113 107 
EphA5(h) 126 124 
EphA7(h) 109 113 
EphA8(h) 136 134 
EphB2(h) 117 116 
EphB1(h) 117 146 
EphB3(h) 117 109 
EphB4(h) 111 113 
ErbB4(h) 109 111 
FAK(h) 100 98 
Fer(h) 56 101 
Fes(h) 69 97 
FGFR1(h) 74 132 
FGFR1(V561M)(h) 16 83 
FGFR2(h) 81 118 
FGFR2(N549H)(h) 55 102 
FGFR3(h) 95 100 
FGFR4(h) 86 98 
Fgr(h) 49 81 
FLT1(h) 17 64 
FLT3(D835Y)(h) -3 5 
FLT3(h) 5 32 
FLT4(h) 42 55 
Fms(h) 27 68 
Fyn(h) 35 77 
GCK(h) 108 109 
GRK5(h) 55 65 
GRK6(h) 42 53 
GRK7(h) 39 46 
GSK3α(h) 20 58 
GSK3β(h) 56 90 
Haspin(h) 71 79 
Hck(h) 15 50 
HIPK1(h) 35 85 
HIPK2(h) 39 70 
HIPK3(h) 63 91 
IGF-1R(h) 82 92 
IGF-1R(h), activated 43 54 
IKKα(h) 111 119 
IKKβ(h) 83 97 
IR(h) 96 104 
IR(h), activated 27 60 
IRR(h) 29 54 
IRAK1(h) 40 97 
IRAK4(h) 94 108 
Itk(h) 66 96 
JAK2(h) 71 108 
JAK3(h) 61 103 
JNK1α1(h) 103 106 
JNK2α2(h) 93 98 
JNK3(h) 95 86 
KDR(h) 27 78 
Lck(h) 35 105 
LIMK1(h) 86 103 
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LKB1(h) 106 106 
LOK(h) 86 93 
Lyn(h) 7 86 
Lyn(m) 7 72 
MAPK1(h) 2 47 
MAPK2(h) 7 89 
MAPK2(m) 5 95 
MAPKAP-K2(h) 112 115 
MAPKAP-K3(h) 117 105 
MEK1(h) 108 103 
MARK1(h) 16 78 
MELK(h) 1 4 
Mer(h) 4 19 
Met(h) 91 132 
MINK(h) 51 77 
MKK4(m) 55 103 
MKK6(h) 100 115 
MKK7β(h) 38 63 
MLCK(h) 0 2 
MLK1(h) 74 86 
Mnk2(h) 83 95 
MRCKα(h) 110 108 
MRCKβ(h) 96 105 
MSK1(h) 17 15 
MSK2(h) 4 22 
MSSK1(h) 68 57 
MST1(h) 12 78 
MST2(h) 6 50 
MST3(h) 16 43 
mTOR(h) 105 99 
mTOR/FKBP12(h) 121 108 
MuSK(h) 113 108 
NEK2(h) 80 105 
NEK3(h) 95 97 
NEK6(h) 57 94 
NEK7(h) 64 83 
NEK11(h) 94 101 
NLK(h) 85 104 
p70S6K(h) 7 54 
PAK2(h) 42 91 
PAK3(h) 29 98 
PAK4(h) 71 104 
PAK5(h) 31 96 
PAK6(h) 62 96 
PAR-1Bα(h) 7 54 
PASK(h) 68 102 
PDGFRα(h) 113 127 
PDGFRα(D842V)(h) 7 63 
PDGFRα(V561D)(h) 8 65 
PDGFRβ(h) 111 107 
PDK1(h) 8 24 
PhKγ2(h) 93 95 
PIM-1(h) 1 31 
PIM-2(h) 3 24 
PIM-3(h) 14 30 
PKA(h) 13 72 
PKBα(h) 10 76 
PKBβ(h) 57 90 
PKBγ(h) 6 49 
PKCα(h) 94 113 
PKCβI(h) 56 99 
PKCβII(h) 76 82 
PKCγ(h) 90 99 
PKCδ(h) 73 88 
PKCε(h) 62 90 
PKCη(h) 84 106 
PKCι(h) 87 88 
PKCμ(h) 76 100 
PKCθ(h) 16 42 
PKCζ(h) 88 96 
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PKD2(h) 81 103 
PKG1α(h) 10 25 
PKG1β(h) 8 24 
Plk1(h) 97 103 
Plk3(h) 102 113 
PRAK(h) 66 86 
PRK2(h) 33 76 
PrKX(h) 36 66 
PTK5(h) 29 73 
Pyk2(h) 40 62 
Ret(h) 9 45 
Ret (V804L)(h) 11 38 
Ret(V804M)(h) 5 28 
RIPK2(h) 87 87 
ROCK-I(h) 98 113 
ROCK-II(h) 91 99 
ROCK-II(r) 80 107 
Ron(h) 92 108 
Ros(h) 112 102 
Rse(h) 15 61 
Rsk1(h) 5 26 
Rsk1(r) 5 25 
Rsk2(h) 6 21 
Rsk3(h) 5 31 
Rsk4(h) 3 22 
SAPK2a(h) 111 111 
SAPK2a(T106M)(h) 101 106 
SAPK2b(h) 98 106 
SAPK3(h) 102 109 
SAPK4(h) 78 91 
SGK(h) 51 82 
SGK2(h) 27 53 
SGK3(h) 74 92 
SIK(h) 19 69 
Snk(h) 93 96 
Src(1-530)(h) 31 79 
Src(T341M)(h) 35 94 
SRPK1(h) 38 35 
SRPK2(h) 39 30 
STK33(h) 67 100 
Syk(h) 120 114 
TAK1(h) 104 107 
TAO1(h) 96 105 
TAO2(h) 93 103 
TAO3(h) 89 100 
TBK1(h) 40 90 
Tec(h) activated 66 102 
Tie2(h) 78 86 
Tie2(R849W)(h) 93 98 
Tie2(Y897S)(h) 100 108 
TLK2(h) 110 108 
TrkA(h) 17 104 
TrkB(h) 68 75 
TSSK1(h) 11 50 
TSSK2(h) 61 100 
Txk(h) 106 99 
ULK2(h) 102 106 
ULK3(h) 83 109 
WNK2(h) 76 90 
WNK3(h) 95 99 
VRK2(h) 63 77 
Yes(h) 26 81 
ZAP-70(h) 134 123 
ZIPK(h) 1 18 
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5.4.2 Kinase Profiling of Complexes 87, 
-(R)-106, -(S)-106, -(R)-107, 
and -(S)-107 
 
The compounds 87, -(R)-106, 
-(S)-106, -(R)-107, and -(S)-107 were 
profiled by the KINOMEscan, DiscoveRx 
profiling of Lead Hunter Discovery against a 
panel of 456. Shown are the remaining ki-
nase activities at a concentration of 100 nM 
in case of 87 and 1 µM in the cases of 
-(R)-106, -(S)-106, -(R)-107, and 
-(S)-107 in the absence of ATP. 
 
Table 5: Kinase Profiling of Complexes 87, -(R)-106, -(S)-106, -(R)-107, and -(S)-107. 
 
87 
(100 nM) 
-(S)-106 
(1 µM) 
-(S)-107 
(1 µM) 
-(R)-106 
(1 µM) 
-(R)-107 
(1 µM) 
AAK1 100 71 89 100 82 
ABL1(E255K)-
phosphorylated 
77 97 100 90 91 
ABL1(F317I)-
nonphosphorylated 
92 89 91 87 66 
ABL1(F317I)-
phosphorylated 
73 97 100 100 100 
ABL1(F317L)-
nonphosphorylated 
100 92 97 87 78 
ABL1(F317L)-
phosphorylated 
100 100 97 100 100 
ABL1(H396P)-
nonphosphorylated 
88 92 100 94 70 
ABL1(H396P)-
phosphorylated 
98 96 100 97 100 
ABL1(M351T)-
phosphorylated 
100 98 100 94 99 
ABL1(Q252H)-
nonphosphorylated 
90 100 99 82 70 
ABL1(Q252H)-
phosphorylated 
94 96 99 100 93 
ABL1(T315I)-
nonphosphorylated 
97 100 100 100 89 
ABL1(T315I)-
phosphorylated 
100 100 81 100 95 
ABL1(Y253F)-
phosphorylated 
93 100 100 100 100 
ABL1-nonphosphorylated 97 85 88 91 71 
ABL1-phosphorylated 100 89 97 94 91 
ABL2 97 100 97 100 97 
ACVR1 100 88 92 98 100 
ACVR1B 92 85 86 97 99 
ACVR2A 100 99 100 100 98 
ACVR2B 100 100 100 96 94 
ACVRL1 99 100 100 97 100 
ADCK3 88 78 87 91 92 
ADCK4 96 100 86 68 100 
AKT1 99 98 82 99 96 
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AKT2 100 100 100 90 94 
AKT3 100 87 73 96 98 
ALK 95 100 90 100 85 
ALK(C1156Y) 83 100 100 100 100 
ALK(L1196M) 86 94 89 94 88 
AMPK-alpha1 100 68 85 85 87 
AMPK-alpha2 88 83 90 98 86 
ANKK1 92 96 92 100 100 
ARK5 85 69 72 76 92 
ASK1 100 81 83 93 93 
ASK2 88 86 95 93 90 
AURKA 84 2.4 92 94 91 
AURKB 87 29 82 91 80 
AURKC 93 22 89 96 89 
AXL 95 79 68 86 84 
BIKE 100 86 85 90 91 
BLK 90 73 69 94 95 
BMPR1A 90 96 97 88 89 
BMPR1B 100 75 82 90 85 
BMPR2 100 100 100 100 98 
BMX 84 95 97 100 96 
BRAF 100 96 96 100 98 
BRAF(V600E) 95 93 98 94 97 
BRK 100 88 88 96 76 
BRSK1 100 94 94 100 100 
BRSK2 62 90 92 100 97 
BTK 98 91 97 96 93 
BUB1 88 87 96 100 93 
CAMK1 93 93 71 89 89 
CAMK1D 31 58 40 100 95 
CAMK1G 96 68 92 100 98 
CAMK2A 44 1.9 52 89 52 
CAMK2B 71 3.2 72 77 68 
CAMK2D 87 4.4 72 100 90 
CAMK2G 84 5 72 100 79 
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CAMK4 15 100 81 100 89 
CAMKK1 100 76 93 98 89 
CAMKK2 99 79 94 100 85 
CASK 94 88 97 100 84 
CDC2L1 95 100 97 100 94 
CDC2L2 96 98 91 97 94 
CDC2L5 95 80 96 84 78 
CDK11 74 100 100 100 88 
CDK2 97 86 90 99 94 
CDK3 95 83 100 100 91 
CDK4-cyclinD1 95 86 96 100 98 
CDK4-cyclinD3 100 100 100 100 100 
CDK5 88 96 98 100 95 
CDK7 96 51 80 100 95 
CDK8 73 98 100 98 100 
CDK9 90 90 87 100 98 
CDKL1 100 78 98 98 81 
CDKL2 92 82 100 100 100 
CDKL3 82 100 100 98 90 
CDKL5 98 100 100 100 100 
CHEK1 71 85 100 100 99 
CHEK2 91 71 100 100 95 
CIT 92 100 90 100 91 
CLK1 94 100 100 100 88 
CLK2 1.8 23 54 76 18 
CLK3 100 87 100 95 84 
CLK4 50 74 82 95 68 
CSF1R 55 90 78 100 94 
CSF1R-autoinhibited 99 50 51 60 52 
CSK 100 100 96 100 95 
CSNK1A1 90 93 100 92 81 
CSNK1A1L 89 100 85 96 100 
CSNK1D 72 87 90 100 90 
CSNK1E 100 97 100 95 93 
CSNK1G1 100 82 82 99 94 
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CSNK1G2 95 98 77 100 100 
CSNK1G3 100 100 100 97 80 
CSNK2A1 97 87 83 79 47 
CSNK2A2 78 82 48 69 27 
CTK 91 87 73 95 98 
DAPK1 3.1 76 16 93 68 
DAPK2 5.8 65 33 76 54 
DAPK3 5.7 73 25 74 61 
DCAMKL1 52 74 76 60 60 
DCAMKL2 100 100 93 99 97 
DCAMKL3 48 60 80 100 88 
DDR1 99 91 94 81 90 
DDR2 100 97 100 68 58 
DLK 92 71 75 86 93 
DMPK 99 61 72 96 89 
DMPK2 93 88 98 97 92 
DRAK1 49 99 100 100 99 
DRAK2 69 99 100 100 98 
DYRK1A 85 73 94 100 33 
DYRK1B 41 78 91 88 21 
DYRK2 100 78 89 89 74 
EGFR 100 100 100 95 100 
EGFR(E746-A750del) 61 93 94 86 81 
EGFR(G719C) 100 76 97 100 97 
EGFR(G719S) 100 93 99 94 93 
EGFR(L747-E749del, 
A750P) 
92 86 91 100 87 
EGFR(L747-S752del, 
P753S) 
82 100 91 95 80 
EGFR(L747-T751del,Sins) 97 97 75 89 88 
EGFR(L858R) 98 89 90 98 92 
EGFR(L858R,T790M) 100 77 86 97 96 
EGFR(L861Q) 84 100 100 100 100 
EGFR(S752-I759del) 98 77 100 86 93 
EGFR(T790M) 100 66 85 96 88 
EIF2AK1 82 66 80 100 90 
EPHA1 100 83 100 96 80 
 
198 Experimental 
EPHA2 92 86 93 100 89 
EPHA3 58 81 86 87 89 
EPHA4 96 87 100 100 94 
EPHA5 86 97 97 100 91 
EPHA6 94 83 86 96 90 
EPHA7 99 89 96 98 88 
EPHA8 100 100 99 100 92 
EPHB1 100 84 100 100 89 
EPHB2 100 95 100 100 100 
EPHB3 90 82 94 100 89 
EPHB4 90 88 99 97 96 
EPHB6 93 92 94 99 93 
ERBB2 100 98 100 86 89 
ERBB3 100 100 100 97 100 
ERBB4 100 96 98 100 98 
ERK1 100 99 90 100 100 
ERK2 91 98 100 100 92 
ERK3 91 89 98 91 98 
ERK4 86 85 96 82 93 
ERK5 45 25 93 100 90 
ERK8 100 26 69 88 27 
ERN1 100 79 98 89 84 
FAK 90 100 93 100 97 
FER 100 90 86 88 89 
FES 95 86 97 95 88 
FGFR1 71 88 88 94 92 
FGFR2 82 89 80 96 94 
FGFR3 92 80 89 98 95 
FGFR3(G697C) 100 81 81 95 67 
FGFR4 100 82 94 100 88 
FGR 90 85 91 100 83 
FLT1 100 88 100 100 95 
FLT3 31 71 4.9 67 50 
FLT3(D835H) 30 44 41 95 49 
FLT3(D835Y) 12 17 4.4 69 22 
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FLT3(ITD) 35 53 12 80 57 
FLT3(K663Q) 34 81 7.8 71 53 
FLT3(N841I) 23 20 2.8 43 28 
FLT3(R834Q) 44 77 26 70 75 
FLT3-autoinhibited 100 83 78 96 72 
FLT4 100 91 58 97 82 
FRK 100 91 94 100 87 
FYN 100 78 79 90 86 
GAK 14 97 95 93 100 
GCN2(Kin.Dom.2,S808G) 91 100 88 90 100 
GRK1 4.4 15 41 71 22 
GRK4 100 84 100 100 98 
GRK7 8.4 15 56 53 14 
GSK3A 88 4.1 41 45 11 
GSK3B 99 83 99 99 94 
HASPIN 81 51 46 55 42 
HCK 85 100 97 87 90 
HIPK1 89 56 78 86 15 
HIPK2 78 22 45 87 3.3 
HIPK3 95 36 57 56 2.4 
HIPK4 73 84 100 100 78 
HPK1 94 83 81 100 85 
HUNK 85 63 93 99 86 
ICK 71 65 100 100 90 
IGF1R 100 96 79 97 100 
IKK-alpha 99 91 96 94 82 
IKK-beta 80 100 100 100 96 
IKK-epsilon 100 100 100 100 88 
INSR 99 57 75 78 70 
INSRR 100 88 95 100 90 
IRAK1 87 83 100 100 91 
IRAK3 71 17 73 93 81 
IRAK4 85 62 69 69 73 
ITK 100 100 100 100 100 
JAK1(JH1domain-catalytic) 94 80 83 77 98 
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JAK1(JH2domain-
pseudokinase) 
98 91 80 91 82 
JAK2(JH1domain-catalytic) 88 100 86 100 100 
JAK3(JH1domain-catalytic) 70 45 37 53 63 
JNK1 100 94 100 90 98 
JNK2 96 79 78 95 97 
JNK3 100 86 94 87 96 
KIT 62 77 55 100 88 
KIT(A829P) 30 81 35 78 93 
KIT(D816H) 40 79 60 90 91 
KIT(D816V) 14 68 22 100 78 
KIT(L576P) 56 89 52 78 80 
KIT(V559D) 53 77 41 89 81 
KIT(V559D,T670I) 86 88 74 100 93 
KIT(V559D,V654A) 75 100 96 100 94 
KIT-autoinhibited 95 83 92 82 73 
LATS1 89 82 72 90 88 
LATS2 90 85 61 100 93 
LCK 98 92 86 100 90 
LIMK1 100 98 92 100 100 
LIMK2 92 83 91 98 96 
LKB1 100 92 82 88 72 
LOK 100 94 100 90 90 
LRRK2 85 91 96 94 99 
LRRK2(G2019S) 80 70 60 94 78 
LTK 100 100 100 98 95 
LYN 96 97 93 100 100 
LZK 98 80 81 87 81 
MAK 51 93 79 72 96 
MAP3K1 99 96 92 96 96 
MAP3K15 98 60 81 100 91 
MAP3K2 100 94 99 100 92 
MAP3K3 96 100 100 100 94 
MAP3K4 100 75 84 94 72 
MAP4K2 89 93 86 95 80 
MAP4K3 100 92 93 92 94 
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MAP4K4 97 100 100 100 93 
MAP4K5 100 99 100 100 92 
MAPKAPK2 90 92 100 100 98 
MAPKAPK5 100 90 95 85 90 
MARK1 62 56 68 86 77 
MARK2 38 39 51 94 82 
MARK3 61 12 62 92 99 
MARK4 71 61 79 82 89 
MAST1 77 20 100 96 96 
MEK1 100 93 100 96 96 
MEK2 100 80 82 85 84 
MEK3 87 83 29 92 80 
MEK4 100 100 64 95 100 
MEK5 78 82 93 99 75 
MEK6 100 83 53 100 98 
MELK 29 59 53 95 77 
MERTK 100 100 100 91 100 
MET 100 89 88 100 82 
MET(M1250T) 82 100 95 96 75 
MET(Y1235D) 100 100 100 100 75 
MINK 79 87 91 100 100 
MKK7 100 98 98 90 99 
MKNK1 77 82 80 94 96 
MKNK2 89 94 100 99 100 
MLCK 100 97 100 93 84 
MLK1 99 100 90 96 100 
MLK2 80 76 90 94 89 
MLK3 98 99 100 100 96 
MRCKA 99 100 100 94 98 
MRCKB 100 94 95 100 92 
MST1 100 96 80 70 85 
MST1R 96 80 83 78 100 
MST2 95 73 68 89 69 
MST3 74 75 98 96 94 
MST4 96 70 87 85 72 
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MTOR 98 72 90 77 100 
MUSK 88 92 100 99 94 
MYLK 0.8 34 33 52 30 
MYLK2 85 92 99 99 94 
MYLK4 97 94 89 100 81 
MYO3A 92 69 86 89 87 
MYO3B 70 84 93 86 90 
NDR1 100 90 78 100 100 
NDR2 100 74 93 100 76 
NEK1 100 79 86 93 94 
NEK10 100 71 71 64 73 
NEK11 98 93 100 98 96 
NEK2 100 97 95 89 97 
NEK3 79 80 77 90 64 
NEK4 100 93 100 100 93 
NEK5 81 100 100 100 100 
NEK6 88 87 100 100 92 
NEK7 86 85 87 92 100 
NEK9 87 86 87 96 97 
NIK 100 80 100 90 90 
NIM1 90 100 100 100 100 
NLK 82 78 72 91 87 
OSR1 56 94 88 99 100 
p38-alpha 98 87 89 97 71 
p38-beta 83 95 97 99 97 
p38-delta 49 68 78 70 100 
p38-gamma 94 84 94 96 55 
PAK1 100 81 83 86 86 
PAK2 100 61 58 71 48 
PAK3 100 91 93 96 79 
PAK4 100 90 87 98 86 
PAK6 94 90 90 90 92 
PAK7 80 81 98 88 86 
PCTK1 100 75 89 96 100 
PCTK2 100 85 80 98 97 
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PCTK3 93 76 90 98 94 
PDGFRA 57 77 72 75 87 
PDGFRB 15 85 5.4 100 76 
PDPK1 58 52 57 85 77 
PFCDPK1(P.falciparum) 100 96 100 95 100 
PFPK5(P.falciparum) 99 100 97 96 100 
PFTAIRE2 89 82 88 100 100 
PFTK1 95 45 76 81 84 
PHKG1 56 86 97 100 92 
PHKG2 56 61 87 87 70 
PIK3C2B 100 90 96 96 100 
PIK3C2G 79 100 100 100 100 
PIK3CA 100 100 92 100 97 
PIK3CA(C420R) 89 100 100 92 91 
PIK3CA(E542K) 97 87 100 100 79 
PIK3CA(E545A) 82 79 83 84 77 
PIK3CA(E545K) 100 96 100 98 84 
PIK3CA(H1047L) 95 100 100 97 95 
PIK3CA(H1047Y) 100 82 74 90 94 
PIK3CA(I800L) 100 86 90 88 84 
PIK3CA(M1043I) 77 100 100 94 100 
PIK3CA(Q546K) 97 89 100 89 93 
PIK3CB 77 92 95 94 82 
PIK3CD 88 94 100 91 100 
PIK3CG 100 94 93 100 98 
PIK4CB 79 89 100 100 100 
PIM-1 0.4 13 10 60 1.8 
PIM-2 19 78 84 98 50 
PIM-3 5.6 27 20 68 1.8 
PIP5K1A 43 71 71 100 77 
PIP5K1C 97 100 40 87 71 
PIP5K2B 95 86 100 90 98 
PIP5K2C 95 100 100 100 100 
PKAC-alpha 98 78 61 91 75 
PKAC-beta 86 64 80 84 68 
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PKMYT1 92 94 99 94 80 
PKN1 88 32 57 100 89 
PKN2 94 25 37 95 83 
PKNB(M.tuberculosis) 99 93 100 99 95 
PLK1 96 99 100 100 94 
PLK2 67 84 86 99 89 
PLK3 58 90 100 98 94 
PLK4 53 71 82 92 87 
PRKCD 53 2.2 11 84 39 
PRKCE 68 6.6 38 88 25 
PRKCH 82 25 58 100 73 
PRKCI 100 45 48 82 73 
PRKCQ 77 32 73 100 95 
PRKD1 100 100 100 100 97 
PRKD2 100 70 81 81 97 
PRKD3 81 85 100 97 98 
PRKG1 63 79 100 88 73 
PRKG2 26 7.3 54 76 2.4 
PRKR 68 100 99 100 100 
PRKX 87 94 100 79 100 
PRP4 100 94 72 95 65 
PYK2 98 87 93 100 97 
QSK 85 92 92 93 93 
RAF1 100 100 100 97 76 
RET 90 100 93 100 89 
RET(M918T) 100 85 93 100 90 
RET(V804L) 100 90 89 95 84 
RET(V804M) 82 99 97 98 95 
RIOK1 100 84 83 100 83 
RIOK2 100 92 100 94 75 
RIOK3 96 85 72 100 86 
RIPK1 96 84 91 84 93 
RIPK2 100 78 85 81 87 
RIPK4 82 93 95 89 79 
RIPK5 74 87 94 98 95 
  
205 Experimental 
ROCK1 100 81 93 89 92 
ROCK2 88 75 91 95 94 
ROS1 100 86 95 98 92 
RPS6KA4(Kin.Dom.1-N-
terminal) 
77 53 83 94 100 
RPS6KA4(Kin.Dom.2-C-
terminal) 
7.2 89 88 89 94 
RPS6KA5(Kin.Dom.1-N-
terminal) 
46 80 78 97 88 
RPS6KA5(Kin.Dom.2-C-
terminal) 
35 92 100 88 93 
RSK1(Kin.Dom.1-N-
terminal) 
80 49 88 94 84 
RSK1(Kin.Dom.2-C-
terminal) 
77 76 85 90 83 
RSK2(Kin.Dom.1-N-
terminal) 
33 4 76 84 75 
RSK2(Kin.Dom.2-C-
terminal) 
100 72 94 87 85 
RSK3(Kin.Dom.1-N-
terminal) 
84 41 93 100 100 
RSK3(Kin.Dom.2-C-
terminal) 
69 93 100 100 94 
RSK4(Kin.Dom.1-N-
terminal) 
20 47 96 100 89 
RSK4(Kin.Dom.2-C-
terminal) 
58 65 91 80 90 
S6K1 71 15 51 100 84 
SBK1 92 67 88 70 71 
SGK 77 66 100 100 94 
SgK110 94 87 97 96 90 
SGK2 86 88 100 99 95 
SGK3 80 95 100 100 100 
SIK 83 91 98 100 93 
SIK2 100 94 89 97 94 
SLK 97 100 90 100 86 
SNARK 80 33 43 100 98 
SNRK 96 77 93 86 95 
SRC 98 98 82 92 100 
SRMS 94 100 100 100 85 
SRPK1 100 90 86 100 97 
SRPK2 82 100 95 93 100 
SRPK3 93 71 77 100 90 
STK16 84 86 49 87 61 
STK33 74 66 90 97 76 
STK35 100 98 100 97 94 
STK36 100 95 100 98 94 
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STK39 98 87 97 100 98 
SYK 94 98 91 100 100 
TAK1 99 98 99 100 89 
TAOK1 84 99 100 92 73 
TAOK2 100 81 76 91 61 
TAOK3 88 100 100 100 99 
TBK1 96 91 100 100 96 
TEC 93 100 100 100 90 
TESK1 100 83 87 95 78 
TGFBR1 100 100 97 87 80 
TGFBR2 99 96 100 100 89 
TIE1 100 79 100 98 93 
TIE2 88 85 100 98 92 
TLK1 88 88 98 93 95 
TLK2 95 84 94 90 93 
TNIK 47 82 77 100 96 
TNK1 100 86 77 100 100 
TNK2 100 92 89 99 98 
TNNI3K 100 88 98 92 81 
TRKA 100 73 77 82 52 
TRKB 100 80 87 97 65 
TRKC 99 77 81 89 62 
TRPM6 100 82 92 83 96 
TSSK1B 100 68 56 88 70 
TTK 49 90 43 97 82 
TXK 100 82 85 92 88 
TYK2(JH1domain-catalytic) 100 100 100 100 97 
TYK2(JH2domain-
pseudokinase) 
87 100 100 100 79 
TYRO3 94 88 79 100 98 
ULK1 71 87 82 96 93 
ULK2 96 98 100 100 100 
ULK3 88 83 98 100 95 
VEGFR2 96 92 62 100 84 
VRK2 97 72 100 98 92 
WEE1 100 99 100 96 91 
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WEE2 91 100 97 100 100 
WNK1 100 92 100 98 87 
WNK3 100 85 99 95 92 
YANK1 88 70 91 72 89 
YANK2 89 100 100 100 84 
YANK3 100 100 100 100 92 
YES 100 98 94 100 96 
YSK1 98 82 93 91 94 
YSK4 41 91 96 90 75 
ZAK 100 89 94 97 87 
ZAP70 100 80 80 86 90 
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5.5 Computational Procedures 
5.5.1 The Hot Spot Analysis 
 
The hot spot analysis to disclose fa-
vourable interactions of PI3K, using 
HOTSPOTSX developed in the KLEBE 
group by GERD NEUDERT, was applied 
analogously to published procedures, as 
in the case study of endothiapepsin.[407] 
Beside HOTSPOTSX, GERD NEUDERT kind-
ly provided the program FCONV for the 
calculation procedures to prepare protein 
and ligand molecule data.[402] 
5.5.1.1 FCONV 
 
As main application, FCONV can be 
used to handle molecule data and data 
parsing problems. The working principle is 
to define internal atom types to source 
data, i.e.: protein crystal structure data in 
.pdb format or molecule data in .mol2 for-
mat.[402] These internal annotation prin-
ciple consideres the chemical interactions, 
the hybridisation state, and the bonding 
type for each atom in a molecule. In total, 
157 atom types were defined and classi-
fied into five different generic physico-
chemical properties: H-bond donor, 
H-bond acceptor, doneptor (groups acting 
both as H-bond donor and H-bond accep-
tor), aromatic, and hydrophobic. Atoms 
which can not be assigned to any one of 
the five groups were assigned to the 
group X, see Figure 97. 12 atoms were 
assigned to the donor group, 29 atoms to 
the acceptor group, 15 atoms to the 
doneptor group, 9 atoms to the aromatic 
group, 18 atoms to the hydrophobic group, 
and 75 atoms to the X group. 
Every atom in the crystal structure of 
PI3K (pdb: 3CST) was assigned accor-
ding to the internal annotation; the coor-
dinates of the metal based kinase inhibitor 
were removed from the data set, and 
saved in a separate file, to provide the 
space in the binding site open for the hot 
spot calculation. 
 
 
Figure 97: Representative atoms (highlighted in 
red) assigned according to the internal annotation of 
FCONV. The annotation includes element symbol, 
chemical environment, hybridisation state, bonding 
state and interaction group. 
5.5.1.2 HOTSPOTSX 
 
HOTSPOTSX developed in the 
KLEBE group by GERD NEUDERT is based 
on different knowledge based potentials to 
predict interaction fields for different pre-
defined atom types in the binding pocket. 
The structural data, covering distances, 
angles, charge, hybridisation state, bond-
ing state and corresponding interaction 
partner were evaluated of entries in the 
Cambridge Structural Database (CSD), as 
first potential set, and of entries in the Pro-
tein Data Bank (PDB), as second potential 
set.[433,434] The atoms of these entries were 
assigned correspondding to the FCONV 
internal atom types. Then a inverse deter-
mination of coordinates for the structure of 
PI3K (pdb:3CST) of interaction partners 
were calculated by HOTSPOTSX resulting 
in specified contour maps. Areas with 
highly favorable interaction values were 
defined as hotspots (threshold ≥ 75% 
above the minimal contour map level). 
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5.6 Crystallographic Data 
5.6.1 Crystallographic Data of 96 
 
Single crystals of compound 96, 
C40D18FH30N5O8RuS4, were crystallised 
from acetone-d6 after 1 week at 4 °C. A 
suitable crystal was selected and mounted 
on a cryo-loop using inert oil on a 'STOE 
IPDS2 Image Plate' diffractometer. The 
crystal was kept at 100.15 K during data 
collection. Using Olex2,[435] the structure 
was solved with the SIR2011[436] structure 
solution program using Direct Methods 
and refined with the XLMP[437] refinement 
package using Least Squares minimi-
sation. The structure was solved by DR. 
KLAUS HARMS. 
 
Table 6: Crystal data and structure refinement for 96. 
 
Identification code    96 
Empirical formula     C40D18FH30N5O8RuS4 
Formula weight     993.25 
Temperature/K     100.15 
Crystal system     triclinic 
Space group     P-1 
a/Å      9.2703(4) 
b/Å      15.9175(6) 
c/Å      17.0090(7) 
/°      116.428(3) 
/°      90.389(3) 
/°      102.792(3) 
Volume/Å
3
     2175.77(16) 
Z      2 
ρcalcmg/mm
3
     1.516 
m/mm‑
1
      0.613 
F(000)      1008 
Crystal size/mm
3
     0.14 × 0.11 × 0.1 
2Θ range for data collection   2.946 to 50.996° 
Index ranges     -11 ≤ h ≤ 10, -16 ≤ k ≤ 19, -20 ≤ l ≤ 20 
Reflections collected    15490 
Independent reflections    8010[R(int) = 0.0306] 
Data/restraints/parameters    8010/6/565 
Goodness-of-fit on F
2
    0.938 
Final R indexes [I>=2σ (I)]    R1 = 0.0304, wR2 = 0.0698 
Final R indexes [all data]    R1 = 0.0430, wR2 = 0.0729 
Largest diff. peak/hole / e Å
-3
   0.65/-0.81 
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5.6.2 Crystallographic Data of (R)-106 
and -(S)-106 
 
The crystal structures were depicted us-
ing ORTEP drawing with 50% probability of 
thermal ellipsoid and determined of single 
crystals of -(R)-106 and -(S)-106.[438] The 
crystals were obtained after dissolution in 
methylene chloride/methanol mixture of 
(15:1) and slow evaporation of the solvent at 
4 °C for several days. Both compounds 
crystallised as orthorhombic red plates with 
an additional methylene chloride molecule. 
Crystals were measured on a 'Bruker D8 
QUEST area detector ' diffractometer. The 
temperature was kept at 100.15 K during 
data collection using a wavelength of 
0.71073 Å. In both cases the data collection 
software BRUKER APEX II was applied and 
the cell refinement and data reduction soft-
ware SAINT (Bruker AXS Inc.) was used.[439] 
Data were corrected for absorption using the 
program SADABS (Bruker AXS Inc.).[439] 
Non hydrogen atoms have been refined ani-
sotropically. Hydrogen atoms were placed 
on idealised positions and refined using the 
‘riding model’. The programs applied for 
solution and refinement were SHELXS-97 
(Sheldrick, 2008) and SHELXL-2013 (Shel-
drick, 2013).[439,440] The absolute structure of 
-(R)-106 and -(S)-106 were determined. 
The structures were solved by DR. KLAUS 
HARMS. 
 
 
 
Table 7: Crystal data and structure refinement for -(R)-106. 
Crystal data 
 
Identification code  -(R)-106 
Habitus, colour  plate, red 
Crystal size 0.51 x 0.22 x 0.01 mm3 
Crystal system  Orthorhombic 
Space group  P 21 21 21 Z = 4 
Unit cell dimensions a = 8.6511(6) Å = 90°. 
 b = 13.3092(9) Å = 90°. 
 c = 23.6366(14) Å  = 90°. 
Volume 2721.5(3) Å3 
Cell determination  3995 peaks with Theta 2.3 to 27.2°. 
Empirical formula  C29 H23 Cl3 N5 O4 Rh 
Formula weight  714.78 
Density (calculated) 1.745 Mg/m3 
Absorption coefficient 0.970 mm-1 
F(000) 1440 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.918 to 25.498°. 
Index ranges -10<=h<=10, -14<=k<=16, -28<=l<=28 
Data collection software  BRUKER APEX II 
Cell refinement software  SAINT V8.30C (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.30C (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 11484 
Independent reflections 5061 [R(int) = 0.0543] 
Completeness to theta = 25.242° 99.8 %  
Observed reflections  4306[II > 2(I)]  
Reflections used for refinement  5061 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.99 and 0.81 
Flack parameter (absolute struct.)   -0.07(2) 
Largest diff. peak and hole 0.514 and -0.488 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 5061 / 0 / 369 
Goodness-of-fit on F2 1.010 
R index (all data) wR2 = 0.0689 
R index conventional  [I>2sigma(I)] R1 = 0.0359 
 
 
Table 8 Crystal data and structure refinement for -(S)-106. 
Crystal data 
 
Identification code  -(S)-106 
Habitus, colour  plate, red 
Crystal size 0.26 x 0.12 x 0.02 mm3 
Crystal system  Orthorhombic 
Space group  P 21 21 21 Z = 4 
Unit cell dimensions a = 8.6398(10) Å = 90°. 
 b = 13.3545(14) Å = 90°. 
 c = 23.619(3) Å  = 90°. 
Volume 2725.2(5) Å3 
Cell determination  9855 peaks with Theta 2.5 to 27.5°. 
Empirical formula  C29 H23 Cl3 N5 O4 Rh 
Formula weight  714.78 
Density (calculated) 1.742 Mg/m3 
Absorption coefficient 0.969 mm-1 
F(000) 1440 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.302 to 27.574°. 
Index ranges -11<=h<=10, -17<=k<=16, -29<=l<=30 
Data collection software  BRUKER APEX II 
Cell refinement software  SAINT V8.27B (Bruker AXS Inc., 2012) 
Data reduction software  SAINT V8.27B (Bruker AXS Inc., 2012) 
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Solution and refinement: 
 
Reflections collected 26345 
Independent reflections 6038 [R(int) = 0.0419] 
Completeness to theta = 25.242° 98.6 %  
Observed reflections  5497[II > 2(I)]  
Reflections used for refinement  6038 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.98 and 0.89 
Flack parameter (absolute struct.)   -0.01(3) 
Largest diff. peak and hole 0.467 and -0.731 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. Ref. 
Programs used  XS (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND  
Data / restraints / parameters 6038 / 0 / 379 
Goodness-of-fit on F2 1.035 
R index (all data) wR2 = 0.0579 
R index conventional  [I>2sigma(I)] R1 = 0.0286 
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5.6.3 Crystallographic Data of 
(S,R)-125 
 
The crystal structure was depicted us-
ing ORTEP drawing with 50% probability of 
thermal ellipsoid and determined of single 
crystals of -(S,R)-125.[438] The crystals 
were obtained after dissolution in methylene 
chloride/methanol mixture of (15:1) and slow 
evaporation of the solvent at 4 °C for several 
days. The compound crystallised as ortho-
rhombic orange plates. Crystals were 
measured on a 'Bruker D8 QUEST area 
detector ' diffractometer. The temperature 
was kept at 100 K during data collection 
using a wavelength of 0.71073 Å. The data 
collection software BRUKER APEX II was 
applied and the cell refinement and data 
reduction software SAINT (Bruker AXS Inc.) 
was used.[439] Data were corrected for ab-
sorption using the program SADABS 
(Bruker AXS Inc.).[439] Non hydrogen atoms 
have been refined anisotropically. Hydrogen 
atoms were placed on idealised positions 
and refined using the ‘riding model’. The 
programs applied for solution and refine-
ment were SHELXS-97 (Sheldrick, 2008) 
and SHELXL-2014 (Sheldrick, 2014).[439,440] 
The absolute structure of -(S,R)-125 was 
determined. The structure was solved by 
DR. KLAUS HARMS. 
 
 
 
Table 9: Crystal data and structure refinement for -(S,R)-125. 
Crystal data 
 
Identification code  -(S,R)-125 
Habitus, colour  plate, orange 
Crystal size 0.30 x 0.23 x 0.05 mm3 
Crystal system  Orthorhombic 
Space group  P 21 21 21 Z = 4 
Unit cell dimensions a = 9.0050(4) Å = 90°. 
 b = 12.9421(5) Å = 90°. 
 c = 24.3372(11) Å = 90°. 
Volume 2836.3(2) Å3 
Cell determination  9982 peaks with Theta 2.3 to 27.4°. 
Empirical formula  C29H23Cl3N5O5Rh 
Formula weight  730.78 
Density (calculated) 1.711 Mg/m3 
Absorption coefficient 0.935 mm-1 
F(000) 1472 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
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Theta range for data collection 2.297 to 27.508°. 
Index ranges -9<=h<=11, -16<=k<=16, -31<=l<=31 
Data collection software  BRUKER APEX2 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 35650 
Independent reflections 6529 [R(int) = 0.0763] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  5781[II > 2(I)]  
Reflections used for refinement  6529 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.95 and 0.88 
Flack parameter (absolute struct.)   -0.030(15) 
Largest diff. peak and hole 0.560 and -0.443 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  CH calc, restr., NH, OH located, ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2014 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 6529 / 0 / 396 
Goodness-of-fit on F2 1.044 
R index (all data) wR2 = 0.0643 
R index conventional  [I>2sigma(I)] R1 = 0.0320 
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5.6.4 Crystallographic Data of 
(R)-127 
 
The crystal structure was depicted us-
ing ORTEP drawing with 50% probability 
of thermal ellipsoid and determined of 
single crystals of -(R)-127.[438] The crys-
tals were obtained after dissolution in 
methylene chloride/methanol mixture of 
(15:1) and slow evaporation of the solvent 
at 4 °C for several days. The compound 
crystallised as orthorhombic red plates. 
Crystals were measured on a 'Bruker D8 
QUEST area detector ' diffractometer. The 
temperature was kept at 100 K during 
data collection using a wavelength of 
0.71073 Å. The data collection software 
BRUKER APEX II was applied and the 
cell refinement and data reduction soft-
ware SAINT (Bruker AXS Inc.) was 
used.[439] Data were corrected for absorp-
tion using the program SADABS (Bruker 
AXS Inc.).[439] Non hydrogen atoms have 
been refined anisotropically. Hydrogen 
atoms were placed on idealised positions 
and refined using the ‘riding model’. The 
programs applied for solution and refine-
ment were SHELXS-97 (Sheldrick, 2008) 
and SHELXL-2013 (Sheldrick, 
2013).[439,440] The absolute structure of 
-(R)-127 was determined. The structure 
was solved by DR. KLAUS HARMS. 
 
 
Table 10: Crystal data and structure refinement for -(R)-127. 
Crystal data 
 
Identification code  -(R)-127 
Habitus, colour  plate, red 
Crystal size 0.610 x 0.220 x 0.080 mm3 
Crystal system  Orthorhombic 
Space group  P 21 21 21 Z = 4 
Unit cell dimensions a = 9.3547(5) Å = 90°. 
 b = 13.4551(7) Å = 90°. 
 c = 22.6839(12) Å  = 90°. 
Volume 2855.2(3) Å3 
Cell determination  9156 peaks with Theta 2.3 to 27.5°. 
Empirical formula  C30H25Cl3N5O4Rh 
Formula weight  728.81 
Density (calculated) 1.695 Mg/m3 
Absorption coefficient 0.926 mm-1 
F(000) 1472 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
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Theta range for data collection 2.349 to 27.550°. 
Index ranges -12<=h<=12, -16<=k<=17, -29<=l<=29 
Data collection software  BRUKER APEX2 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 38460 
Independent reflections 6573 [R(int) = 0.0481] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  6163[II > 2(I)]  
Reflections used for refinement  6573 
Absorption correction Numerical 
Max. and min. transmission 0.93 and 0.69 
Flack parameter (absolute struct.)   -0.039(10) 
Largest diff. peak and hole 0.429 and -0.343 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  CH calc., constr., NH located, isotr. Ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 6573 / 4 / 410 
Goodness-of-fit on F2 1.052 
R index (all data) wR2 = 0.0514 
R index conventional  [I>2sigma(I)] R1 = 0.0238 
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5.6.5 Crystallographic Data of (S)-191 
 
The crystal structure was depicted us-
ing ORTEP drawing with 50% probability of 
thermal ellipsoid and determined of a single 
crystal of -(S)-191.[438] The crystals were 
obtained after dissolution in methylene chlo-
ride and slow evaporation of the solvent at 
4 °C for several days. The compound crys-
tallised as trigonal red blocks. Crystals were 
measured on a 'Bruker D8 QUEST area 
detector ' diffractometer. The temperature 
was kept at 100 K during data collection 
using a wavelength of 0.71073 Å. The data 
collection software BRUKER APEX II was 
applied and the cell refinement and data 
reduction software SAINT (Bruker AXS Inc.) 
was used.[439] Data were corrected for ab-
sorption using the program SADABS 
(Bruker AXS Inc.).[439] Non hydrogen atoms 
have been refined anisotropically. Hydrogen 
atoms were placed on idealised positions 
and refined using the ‘riding model’. The 
programs applied for solution and refine-
ment were SHELXS-97 (Sheldrick, 2008) 
and SHELXL-2013 (Sheldrick, 2013).[439,440] 
The absolute structure of -(S)-191 was 
determined. The structure was solved by 
DR. KLAUS HARMS. 
 
 
 
Table 11: Crystal data and structure refinement for -(S)-191. 
Crystal data 
 
Identification code  -(S)-191 
Habitus, colour  block, red 
Crystal size 0.19 x 0.14 x 0.11 mm3 
Crystal system  Trigonal 
Space group  R 3 :H Z = 3 
Unit cell dimensions a = 24.8187(7) Å = 90°. 
 b = 24.8187(7) Å = 90°. 
 c = 16.1592(5) Å = 120°. 
Volume 8620.0(6) Å3 
Cell determination  9835 peaks with Theta 2.7 to 27.5°. 
Empirical formula  C112H100Cl18N15O12Rh3 
Formula weight  2794.89 
Density (calculated) 1.615 Mg/m3 
Absorption coefficient 0.912 mm-1 
F(000) 4242 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.693 to 25.500°. 
Index ranges -30<=h<=30, -30<=k<=30, -19<=l<=19 
Data collection software  BRUKER APEX II 
Cell refinement software  SAINT V8.32B (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.32B (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 54939 
Independent reflections 7150 [R(int) = 0.0409] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  6897[II > 2(I)]  
Reflections used for refinement  7150 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.91 and 0.74 
Flack parameter (absolute struct.)   -0.014(7) 
Largest diff. peak and hole 0.610 and -0.993 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  CH riding, NH located, isotr. ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 7150 / 1 / 495 
Goodness-of-fit on F2 1.084 
R index (all data) wR2 = 0.0817 
R index conventional  [I>2sigma(I)] R1 = 0.0303 
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5.6.6 Crystallographic Data of (S)-195 
 
The crystal structure was depicted us-
ing ORTEP drawing with 50% probability of 
thermal ellipsoid and determined of a single 
crystal of -(S)-195.[438] The crystals were 
obtained after dissolution in methylene chlo-
ride/methanol (15:1) and slow evaporation 
of the solvent at 4 °C for several days. The 
compound crystallised as triclinic dark red 
plates. Crystals were measured on a 'Bruker 
D8 QUEST area detector ' diffractometer. 
The temperature was kept at 100 K during 
data collection using a wavelength of 
0.71073 Å. The data collection software 
BRUKER APEX II was applied and the cell 
refinement and data reduction software 
SAINT (Bruker AXS Inc.) was used.[439] Data 
were corrected for absorption using the pro-
gram SADABS (Bruker AXS Inc.).[439] Non 
hydrogen atoms have been refined aniso-
tropically. Hydrogen atoms were placed on 
idealised positions and refined using the 
‘riding model’. The programs applied for 
solution and refinement were SHELXS-97 
(Sheldrick, 2008) and SHELXL-2013 (Shel-
drick, 2013).[439,440] The absolute structure of 
-(S)-195 was determined. The structure 
was solved by DR. KLAUS HARMS. 
 
 
 
Table 12: Crystal data and structure refinement for -(S)-195. 
Crystal data 
 
Identification code  -(S)-195 
Habitus, colour  plate, dark red 
Crystal size 0.14 x 0.08 x 0.05 mm3 
Crystal system  Triclinic 
Space group  P -1 Z = 2 
Unit cell dimensions a = 8.9766(4) Å = 82.9579(15)°. 
 b = 13.1877(5) Å = 72.1925(14)°. 
 c = 13.4671(5) Å = 81.2475(14)°. 
Volume 1495.28(10) Å3 
Cell determination  120 peaks with Theta 3.7 to 24.1°. 
Empirical formula  C32H29ClFN5O8.5Rh 
Formula weight  776.96 
Density (calculated) 1.726 Mg/m3 
Absorption coefficient 0.733 mm-1 
F(000) 790 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.462 to 27.165°. 
Index ranges -11<=h<=11, -16<=k<=16, -17<=l<=17 
Data collection software  Bruker Instrument Service v3.0.31 
Cell refinement software  APEX2 v2013.10-0 (Bruker AXS) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 41431 
Independent reflections 6635 [R(int) = 0.0515] 
Completeness to theta = 25.242° 99.8 %  
Observed reflections  5809[II > 2(I)]  
Reflections used for refinement  6635 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7455 and 0.7184 
Largest diff. peak and hole 0.424 and -0.560 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  CH calc., constr. Ref., NH, OH located, isotr. ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 6635 / 0 / 472 
Goodness-of-fit on F2 1.053 
R index (all data) wR2 = 0.0596 
R index conventional  [I>2sigma(I)] R1 = 0.0268 
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5.6.7 Crystallisation and Structure De-
termination of S6K1 
 
The crystallisation and structure de-
termination of S6K1 in complex with 
85/staurosporine and in complex with 87 
were performed in the MARMORSTEIN group 
by JOHN DOSMIC, the Wistar Institute, 3601 
Spruce Street, Philadelphia, Pennsylvania 
19104, United States. The S6K1 kinase do-
main crystals were obtained using room 
temperature hanging drop vapor diffusion by 
mixing equal volumes of protein (15 mg/mL) 
preincubated with 1 mM staurosporine with 
20−25% (w/v) PEG335, 0.1 M Bis-Tris 
(pH 5.5−5.7), and 0.2 M LiSO4. Following the 
growth of crystals, crystal soaking was car-
ried out by incubation with a final inhibitor 
concentration of 1 mM in cryoprotectant con-
taining the well solution and 15% (w/v) glyc-
erol for 4 h to overnight and flash frozen in 
liquid nitrogen. Diffraction images were col-
lected at APS beamline 23ID with a 5 μm 
microbeam. The structures were determined 
by molecular replacement using thereported 
S6K1/staurosporine complex (PDB acces-
sion code 3A60) as a search model with the 
staurosporine removed from the coordinate 
file and refined with CNS and Coot. The 
inhibitors were modeled last into the refined 
structures. Simulated annealing omit maps 
were employed to unambiguously confirm 
the modeled inhibitors. For the 85-soaked 
crystals, this revealed that one protein mol-
ecule in the asymmetric unit was bound to 
staurosporine while the other protein mole-
cule was bound to 85. For the 87-soaked 
crystals, the asymmetric unit contained a 
single, domain-swapped monomer and only 
the 87 inhibitor was modelled in the binding 
site. The structures were refined to conver-
gence with a final Rwork = 19.15% and Rfree = 
22.21% for the S6K1/85 structure and a final 
Rwork = 20.63% and Rfree = 23.01% for the 
S6K1/87 structure with excellent geometry, 
see Table 13. 
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Table 13: Data and refinement statistics of S6K1 in complex with  85/Staurosporine or 87 
  S6K1-85/Staurosporine S6K1-87 
Resolution range (Å) 49.03-2.527 (2.618-2.527) 29.91-2.794 (2.893-2.794) 
Space group P 1 21 1 C 2 2 21 
Unit cell (a, b, c, α, β, γ) 78.515, 62.882, 86.718, 90, 94.02, 90 62.13, 126.371, 110.571, 90, 90, 90 
Total reflections 110916 47648 
Unique reflections 28440 (2745) 10829 (1028) 
Multiplicity 3.9 (3.3) 4.4 (4.2) 
Completeness (%) 99.71 (97.10) 97.06 (90.33) 
Mean I/(I) 21.3 (4.1) 15.0 (2.0) 
Wilson B-factor 43.06 51.11 
Rmeas (%) 7.9 (40.7) 8.9 (67.8) 
Rwork (%) 19.15 (23.61) 20.63 (29.64) 
Rfree (%) 22.21 (26.70) 23.01 (32.07) 
No. of non-H atoms 4240 2114 
     Protein 4048 2040 
     Ligands 110 47 
     Solvent 82 27 
RMS (bonds/angles) 0.015/1.25 0.012/1.03 
Ramachandran (%fa-
voured/outliers) 95.0/0 95.0/0 
Average B-factor 40.7 55.0 
     Protein 40.6 55.0 
     Ligands 43.8 65.0 
     Solvent 37.3 38.8 
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6 Appendix 
6.1 Kinase Classification 
6.1.1 AGC Kinases 
 
This group of kinases is named after 
the protein Kinase A, G, and C families 
(PKA, PKG, PKC). The AGC group of ki-
nases covers 60 members containing many 
core intracellular signalling kinases which 
are modulated by cyclic nucleotides, phos-
pholipids and calcium.[1,23] Moreover, the 
group consists of 16 families, whereas eight 
are likely to have been in early eukaryotes, 
and another two (RSK, PKC) in the fun-
gal/metazoan lineage. Six of the families 
(PKG, PKN, DMPK, YANK, RSKR, RSKL) 
have only been found in metazoans. De-
tailed reviews on AGC structure and func-
tion are provided in literature.[23,441,442]. 
6.1.2 CMGC Kinases 
 
CMGC is an acronym based on the 
initials of key members like cyclin dependent 
kinase (CDK), mitogen activated protein 
kinase (MAPK), glycogen synthase kinase 
(GSK), and CDK-like kinases (CDKL). Most 
of the kinase families belonging to this group 
are related to growth and stress-response 
and cellular effects mediated by the corre-
sponding factors and hormones. Detailed 
reviews on CMGC members are provided in 
literature.[50,443–448] 
6.1.3 CK1 group 
 
The Casein Kinase 1 (CK1) is a 
small group of kinases with high sequence 
similarity between each other. Nevertheless, 
they are very distinct from other kinase 
groups. Several conserved motifs are modi-
fied in CK1s, i.e.: the APE motif is substitut-
ed by the SIN motif. Beside CK1 the other 
members of this group are Vaccinia Related 
Kinase (VRK), Tau-Tubulin Kinase (TTBK), 
and TTBK-like kinases (TTBKL), whereas 
the last ones were found only in nematodes. 
They play a role in membrane trafficking, 
circadian rhythm, cell cycle progression, 
chromosome segregation, spermatogenesis, 
apoptosis, cellular differentiation, and amy-
loidogenesis. Detailed reviews on CK1 
group members are provided in 
literature.[449–452] 
6.1.4 STE group 
 
Three families of this group are the 
main members activating each other and 
finally regulating the MAP kinase family. For 
instance, Ste20 members (MAPKKKK) act 
on Ste11 (MAPKKK), thus phosphorylating 
the Ste7 (MAPKK) which by themselves 
directly phosphorylate MAPKs. The abbrevi-
ations are deviated from the canonical pher-
omone-responsive MAPK cascade in yeast 
and were named subsequently according to 
the phosphorylated target. Distinct sets of 
Ste7 and Ste11 kinases are linked with spe-
cific classes of MAPK (Erk, Jnk, p38 and 
others) but some cross-talk is also ob-
served. Detailed reviews on STE kinases 
are provided in literature.[453–455] 
6.1.5 CAM Kinases 
 
CAM is an acronym for the 
Ca2+/calmodulin-dependent protein kinase 
class of enzymes. They are activated by 
increased concentrations of intracellular 
calcium ions and phosphorylate serine or 
threonine residues in substrate proteins. 
The CAMK´s are divided into four families 
(CAMK I-IV) and play a versatile role cover-
ing inflammatory effects, cell contraction, 
cell motility or cell plasticity. Detailed re-
views on CAMK members are provided in 
literature.[456–459] 
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6.1.6 TK group 
 
Despite the other groups introduced 
so far, this group phosphorylates almost 
exclusively tyrosine residues. Moreover, this 
group of kinases appears to be the youngest 
group from the evolutionary point of view, 
regarding their absence in plants and unicel-
lular organisms like dictyostelium and yeast. 
The most important function of tyrosine ki-
nases is particularly the transduction of ex-
tracellular signals into the cell: more than 
50% of the tyrosine kinases (TK) are cell 
surface receptor tyrosine kinases (RTKs). 
Moreover, many of the residual kinases act 
close to the cell membrane. Due to their 
importance, the TKs are the most studied 
group covering the largest number of distinct 
families of any group. Subsequently, each 
family is further divided into a receptor or 
cytoplasmic tyrosine kinase subfamily. Tyro-
sine Kinases are related to many physiolog-
ical effects covering proliferation, differentia-
tion, and cell survival. Detailed reviews on 
TKs are provided in literature.[53,460–462] 
6.1.7 TKL group 
 
The tyrosine kinase like (TKL) group 
consists of 7 subfamilies with relatively small 
similarity to each other. The group members 
generally phosphorylate serine/threonine 
residues. Moreover, all of them are similar to 
members of the TK group, although, in gen-
eral, they do not possess the tyrosine kinase 
specific motifs. The TKL group is present in 
almost all eukaryotes but is conspicuously 
absent from the yeast kinome. However, the 
high sequence similarity between TKLs and 
TKs suggests that the latter ones may have 
evolved from the more ancient TKL kinases. 
TKLs are among others involved in mediat-
ing necrosis signalling pathways, cell cycle 
progression, and metabolic stress signaling. 
Detailed reviews on members of TKLs are 
provided in literature.[463–466] 
6.1.8 RGC group 
 
Receptor Guanylate Cyclases (RGC) 
have an unusual structure among other re-
ceptor kinases possessing a single-pass 
transmembrane chain with an active 
guanylate cyclase domain and a catalytically 
inactive kinase domain on the intracellular 
side. The guanylate cyclase domain is re-
sponsible for the formation of the second 
messenger cyclic guanosine triphosphate 
(cGMP), whereas the kinase domain may 
have an allosterically mediated regulatory 
role via ATP binding. Moreover, also soluble 
cellular isoforms (CGC) are expressed and 
both together are present in nearly all cell 
types. GCs play physiological roles in differ-
ent processes like vascular smooth muscle 
motility, intestinal fluid and electrolyte ho-
meostasis, and retinal phototransduction. 
Detailed reviews on RGC and CGCs are 
provided in literature.[467–469] 
6.1.9 PKL group 
 
Several diverse kinase families be-
long to the protein kinases like (PKL) group 
having the PKL fold and catalytic mecha-
nism, but do not possess all structural re-
finements of the PKs. Many of these were 
previously classified as pseudokinases. The 
main subfamilies are ABC1 domain contain-
ing kinases (ADCK), alpha kinases, phos-
phatidyl inositol 3 kinase-related kinases 
(PIKK), phosphatidyl inositol kinases (PIK), 
golgi associated kinases (GASK), aminogly-
coside phosphotransferase domain contain-
ing 1 (AGPHD1), phosphatidyl inositol 
phosphate kinases (PIPK). The PKL mem-
bers play important roles in ribosome bio-
genesis, cell cycle progression, metabolism, 
phagocytosis, and other effects. Detailed 
reviews on members of the PKL group are 
provided in literature.[470–473] 
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6.1.10 Pseudokinases 
 
48 Pseudokinases were identified in 
the human phylogenetic kinome and they 
are defined by the lack of conservation of at 
least one of the catalytic site residues in the 
kinase core.[1,4] Their function has been ob-
scure but recent findings recognise them as 
participating proteins in signal transduction 
and cell-matrix adhesion.[5] The changed 
motifs in the pseudokinases include the gly-
cine-rich loop, the VAIK motif (3 lysine), 
HRD motif (catalytic aspartate), and DFG 
motif or combinations of them.[4,474] For ex-
ample, the giant protein titin contains a ki-
nase domain with an EFG motif instead of 
DFG.[475] Nevertheless, the altered structure 
and the increased space allow glutamate to 
perform the catalytic reaction. Detailed re-
views on Pseudokinases are provided in 
literature.[4,5,476] 
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6.2 Sructural Overview of Synthe-
sised Compounds 
6.2.1 Compounds of Chapter 3.1 
 
 
Figure 98: Synthesised compounds presented in Chapter 3.1. 
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6.2.2 Compounds of Chapter 3.2 
6.2.3 Compounds of Chapter 3.3 
 
 
 
 
 
 
Figure 99: Synthesised compounds presented in Chapter 3.2. 
 
Figure 100: Synthesised compounds presented in Chapter 3.3 (I). 
 
228 Appendix 
 
 
Figure 101: Synthesised compounds presented in Chapter 3.3 (II). 
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6.2.4 Compounds of Chapter 3.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 102: Synthesised compounds presented in Chapter 3.4 (I). 
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Figure 103: Synthesised compounds presented in Chapter 3.4 (II). 
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6.3 List of abbreviations 
 
Å   angström 
ABL   abelson murine leukemia viral oncogene 
AcOH   acetic acid 
ADME   absorption, distribution, metabolism and excretion 
ADP   adenosine diphosphate 
AGC kinases  named after protein kinase A, G, and C 
AKT   protein kinase B 
AML   acute myeloic leukemia 
APE-motif  conserved Ala Pro Glu motif 
ATP   adenosine triphosphate 
aq.   aqueous 
BAD   BCL-2-associated death promoter 
BCL-2   b-cell lymphoma 2 
BCR-ABL breakpoint cluster region - abelson murine leukemia viral oncogene homo-
logue 1 fusion protein 
BRAF = B-Raf  rapidyl accelerated fibrosarcoma protein isoform B 
BTK   Bruton´s tyrosine kinase 
CAMK kinases acronym for Ca2+/Calmodulin-dependent protein kinases 
cAMP   cyclic adenosine monophosphate 
CCDC   cambridge crystallographic data center 
CD   circular dichroism 
CDCl3   deuterised chloroform 
CDC25A  cell devision cycle 25 homolgue A 
CDC25C  cell devision cycle 25 homolgue C 
CDK2   cyclin-dependent protein kinase 2 
CDK5   cyclin dependent kinase 5 
CDKN1B  cyclin-dependent kinase inhibitor 1B 
CHARMM  chemistry at harvard molecular mechanics 
CIP   Cahn-Ingold-Prelog 
CK1   casein kinase 1 group 
CLL   chronic lymphocytic leukemia 
CMGC kinases acronym based on key members CDK, MAPK, GSK,CDK 
CML   chronic myleoid leukemia 
H,H-COSY  proton-proton correlation spectroscopy 
CPM   counts per minute 
d   dublett 
   chemical shift 
DAIM   decomposition and identification of molecules 
DFG-motif  conserved Asp-Phe-Gly motif 
DIPA   diisopropylamine 
DIPEA   diisopropylethylamine 
DMAP   4-dimethylaminopyridine 
DME   dimethoxyethane 
DMF   dimethylformamide 
DMPU   1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
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DMSO   dimethylsulfoxide 
DMSO-d6  deuterised dimethylsulfoxide 
EGFR   epidermal growth factor receptor 
eIF4B   eucaryotic translation initiation factor 4B 
eIF4EBP1  eucaryotic translation initiation factor 4E-binding protein 1 
ERK   extracellular-signaling-regulated kinase 
EtOH   ethanol 
eq.   equivalent 
FDA   Food and Drug Administration 
FLT-3   FMS-like tyrosine kinase 3 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GCK   glucokinase 
GHI-domain  G, H and, I helices 
GIST   gastrointestinal stomal tumor 
GSK-3  glycogen synthase kinase 3 beta 
HCl   hydrochloric acid 
HER   human epidermal growth factor receptor 
HMBC   heteronuclear multiple bond correlation 
HPLC   high performance liquid chromatography 
HRD-motif  conserved His-Arg-Asp motif 
HR-MS  high resolution mass spectrometry 
HSQC   heteronuclear single quantum coherence 
HTS   high-thoughput screening 
Hz   hertz 
IC50   half maximal inhibitory constant 
IL   interleukin 
JAK   janus kinase 
K   Kelvin 
k   kilo 
KD   dissocioation constant 
L   liter 
   wavelenght 
µ   mikro 
m   milli 
M   molarity 
m   multiplett 
MAP3K5  mitogen-activated protein kinase kinase kinase 5 
MAPKs  mitogen-activated protein kinases 
MeCN   acetonitrile 
MEK1   mitogen-activated protein kinase kinase 
MEK2   mitogen-activated protein kinase kinase 2 
MeOH   methanol 
min   minute 
mL   milli liter 
MPEOE  modified partial equalization of orbital electronegativity 
mTOR   mammalian target of rapamycin 
mTORC1  mammalian target of rapamycin complex 1 
mTORC2  mammalian target of rapamycin complex 2 
NH   number of hits 
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NMR   nuclear magnetic resonance 
ORTEP  oak ridge thermal ellipsoid plot program 
pAKT   phosphorylated protein kinase B 
PARP   poly (ADP-ribose) polymerase 
PDB   protein data bank 
PDGFR  platelet-derived growth factor receptors 
PDK1   pyruvate dehydrogenase lipoamide kinase isozyme 1 
PH   pleckstrin homology 
PhK   phosphorylase kinase 
PHLPP  PH domain and leucine rich repeat protein phosphatases 
PI3K   phosphatidylinositide-3-kinase 
PIM-1 proviral insertion in murine, proto-oncogene serine/threonine-protein ki-
nase isoform 1 
PIP3   phosphatidylinositol-3,4,5-trisphosphate  
PKA   protein kinase A 
POC   percent of control 
ppm   part per million 
PTEN   phosphate and tensine homologue 
q   quartett 
Quant.   quantitative 
RCC   renal cell carcinoma 
RGC kinases  receptor guanylate cyclase group 
r.m.s.d.  rout mean square deviation 
RSK   ribosomal S6 kinases 
RTK   receptor tyrosine kinases 
RUNX1  runt-related transcription factor 1 
RUNX3  runt-related transcription factor 3 
s   singulett 
S6K   S6 kinases 
SAR   structure-activity relationship 
SS   selectivity score 
SST   selectivity score types 
STE   homologues of yeast Sterile 7, Sterile 11, and Sterile 20 
t   triplett 
TBAF   tetra-n-butylammoniumfluoride 
TBSOTf  tert-butyldimethylsilyl trifluoromethanesulfonate 
TEC   terminal edge convention 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
TK   tyrosine kinases 
TKL   tyrosine-like kinases 
TLC   thin layer chromatography 
TPX2   targeting protein for Xklp2 
UV   ultra violet 
VdW   VAN-DER-WAALS 
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